Development of a non-viral gene therapy strategy for choroideremia by Ostad-Saffari, Elham
1 
 
 
 
 
 
 
DEVELOPMENT OF A NON-VIRAL 
GENE THERAPY STRATEGY FOR 
CHOROIDEREMIA 
 
 
 
ELHAM OSTAD-SAFFARI 
 
A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY FROM 
IMPERIAL COLLEGE LONDON 
2013 
2 
 
DECLARATION 
 
 
I, Elham Ostad-Saffari, hereby declare that this thesis submitted for the degree of Doctor in 
Philosophy is my own work and was carried out by myself unless otherwise stated. 
 
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, 
distribute or transmit the thesis on the condition that they attribute it, that they do not use 
it for commercial purposes and that they do not alter, transform or build upon it. For any 
reuse or redistribution, researchers must make clear to others the licence terms of this 
work. 
 
 
 
Elham Ostad-Saffari  
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
ABSTRACT 
____________________________________________________________________________ 
 
Non-viral plasmids harbouring scaffold matrix attachment regions (S/MARs) provide stable 
and functional episomal maintenance, resistance to epigenetic silencing and have been 
shown to be capable of sustained expression in murine tissues. S/MARs are an attractive 
alternative to conventional viral gene delivery vectors due to their low toxicity and reduced 
immunogenicity. This thesis documents the development of this novel non-viral episomal 
plasmid DNA (pDNA) expression system for persistently expressing vectors for 
Choroideremia (CHM) gene therapy. To this end, our goal was to analyse the ability of 
S/MAR plasmids to generate efficient and stable transgene expression in the mouse retina 
following subretinal injections. We generated and analysed a series of S/MAR constructs 
expressing either REP1 cDNA or the reporter enhanced green fluorescent protein (EGFP) or 
Luciferase (Luc) genes driven by the elongation factor-1 short (EFS) or cytomegalovirus 
(CMV) early enhancer/chicken beta actin (CAG) promoter. 
We demonstrate using the AtT20 cell line, the principle that S/MAR containing plasmids can 
provide long-term episomal EGFP and REP1 transgene expression in vitro. Furthermore, 
long-term REP1 expression was also analysed in CHM fibroblasts, where we showed in 
preliminary experiments that DNA constructs expressing REP1 were able to rescue CHM 
derived cells by rescue of their Rab27a prenylation defect and provide long-term expression 
of hREP1 after transfection of human and mouse CHM fibroblasts. 
We also developed an optimised method for delivering S/MAR containing plasmids in the 
eye via subretinal injections of complexed pDNAs, and provide evidence for the utility and 
versatility of S/MAR plasmids in ocular tissue. We show for the first time the longitudinal 
transgene expression of Luc in the retina as measured using bioluminescent imaging. Long- 
term maintenance and expression of EGFP and REP1 transgenes were also observed by  
PCR and Western blot analysis. Further analysis provided evidence for the long term 
episomal maintenance of these vectors in the eye as shown by Southern analysis. We 
provide evidence for the superiority of an S/MAR containing plasmid in providing long-term 
expression in the eye. All control pDNA constructs were shown to be incapable of sustaining 
significant transgene expression beyond one-month following pDNA delivery. We further 
demonstrate the lack of toxicity within the eye and show that fundus examinations as well 
as detailed histological examinations of retinal sections do not elicit an inflammatory 
response to our plasmids once subretinally injected in the eye.  
Finally, we explored the therapeutic potential of the REP1-S/MAR episome, by subretinally 
injecting mouse models of CHM. Further repeat experiments in CHM mouse models would 
add confidence to the overall experiments; however initial findings were encouraging where 
a partial correction of the REP1 protein and functional rescue in the eye was shown.  
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LIST OF ABBREVIATIONS 
_________________________________________________________________________ 
 
AAT  alpha-1 antitrypsin 
AAV  Adeno-associated virus 
AdV  Adenoviral virus 
AMD  age-related macular degeneration 
apoE  apoliprotein E 
BCA  bicinchonic acid  
 
Bcl-2  B cell lymphoma 2  
BLI  bioluminescent imaging  
BP  base pair 
BPV  bovine-papilloma virus  
BSA   bovine serum albumin  
CAG  CMV early enhancer/ chicken β-actin promoter 
CAT  chloramphenicol acetyltransferase  
cDNA  (First-strand) complementary DNA 
CFH  complement factor H  
CFTR  cystic fibrosis transmembrane conductance regulator 
CHM  choroideremia 
CMV  Cytomegalovirus 
CNV  choroidal neovascularisation  
DAPI  4’,6-diamidino-2-phenylindole  
DMEM  Dulbecco’s Modified Eagle’s Medium 
Dpf  days post-fertilisation  
dsOligo double stranded oligonucleotide  
EBV  Epstein-Barr Virus 
E. coli  Escherichia coli  
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EDTA  ethylenediaminetetraacetic acid 
EFS  elongation factor 1 short promoter (intronless version) 
EF1α  elongation factor 1-α promoter 
EGFP  enhanced green fluorescent protein  
ELISA  enzyme-linked immunosorbent assay 
ELOVL4 elongation of very long chain fatty acids-like 4  
ERG  electroretinography 
FACS   fluorescence activated cell sorting  
FTase  farnesyl transferase  
GAGs  glycosaminoglycans  
GAPs  GTPase activating proteins  
GCS  ganglion cell layer  
GDFs  GDI-displacement factors  
GEFs  guanine nucleotide exchange factors  
GGTase I geranylgeranyl transferase type I  
GTA  gene transfer agent 
HACs  human artificial chromosomes 
HCE  human corneal epithelial  
H&E  haematoxylin and eosin 
hREP1  human Rep1 protein  
HRP   horseradish peroxidase 
INL  inner nuclear layer  
IPL  inner plexiform layer 
IRES  internal ribosome entry site  
IS  inner segments 
KB  kilo bases 
KO  knock-out 
LCA  Leber congential amaurosis  
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LCR  locus control regions  
LDLR  low density lipoprotein receptor 
Lenti  Lentivirus  
LPS  lipopolysaccharides 
MACs  mammalian artificial chromosomes  
MSC  multiple cloning site 
N/P  nitrogen/phosphate 
NPC  nuclear pore complex  
NR  neural retina 
OCT  optimal cutting temperature compound/medium 
ONL  outer nuclear layer  
OPL  outer plexiform layer 
Ori  origin of replication  
OS  outer segments  
pA  polyadenylation  
PBS  phosphate buffered saline  
PCR  polymerase chain reaction  
pDNA  plasmid DNA 
PECS  pigment epithelium/choroid/sclera 
PEDF  pigment epithelium-derived factor 
PEG  polyethylene glycol 
PEI  polyethylenimine  
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PI  post injection  
PLA  polylactide  
PLGA  polylactide co-glycolide  
PLL  poly (l-lysine)  
PLRs  pupillary light responses  
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PMN  polymorphonuclear leukocytes 
 
PNS  post nuclear supernatant  
PVDF   polyvinylidene difluoride membrane 
RabGDI rab GDP-dissociation inhibitor  
RabGGTase rab geranylgeranyl transferase  
REP  rab escort proteins  
ROSs  rod outer segments  
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RPE  retinal pigment epithelium 
RT  room temperature 
rt-PCR  reverse transcription polymerase chain reaction  
SAF-A  scaffold attachment factor A  
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1 INTRODUCTION 
____________________________________________________________________________ 
 
1.1 Gene Therapy - designing the ideal vector 
 
Following the sequencing of the human genome and the concomitant understanding of 
genotype-phenotype relationships, increasing attention has been made to apply this 
knowledge to treating inherited diseases. As a first step numerous disease causing genes 
have been identified and studied. However the real therapeutic breakthroughs will depend 
on the development of gene therapy (for these specific diseases). Gene therapy can be 
defined as the treatment of a disease by the transfer and modification of genetic material 
within the cells of a patient, to correct or compensate for an abnormal or absent gene, by 
adding a functional copy of the gene to the appropriate cells. Ultimately, the goal of gene 
therapy is to correct gene functions, and result in the permanent correction of the genetic 
disorder, as well as to restore normal protein production back to physiologically regulated 
levels. If correction or compensation can be achieved through gene delivery, it is 
conceivable that monogenic disorders could be prevented and/or treated.  
An ideal gene delivery vehicle must be able to mediate long-term transgene expression as 
well as fulfil three key criteria: (i) protecting the transgene against degradation by nucleases 
in the nuclear matrix, (ii) delivery of the transgene across the plasma membrane and into 
the nucleus of target cells; within the nucleus it must be able to replicate and subsequently 
it must be passed on through cell divisions and finally, (iii) all these criteria must be met with 
no detrimental effect. To this end, the required transgene can be delivered to patients 
through the use of viral or non-viral vector gene delivery vehicles.  
The first clinical trial of gene therapy for the treatment of infants with X-linked severe 
combined immunodeficiency (X-SCID) was initiated in 1990 (Blaese, Culver et al. 1995). 
However, it was not until April 2000 that Cavazzana-Calvo et al. actually reported the first 
clinical success with gene therapy. In their report they showed that interleukin 2 receptor γ 
chain (IL2RG) transgene was able to successfully restore the humoral activity in 21 young 
patients (Cavazzana-Calvo, Hacein-Bey et al. 2000). Despite the initial optimism surrounding 
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this trial, these observations were overshadowed with considerable adverse events seen in 
5 treated children. In these cases, following the treatment, patients began to develop 
leukaemia which was later shown to be caused by the retrovirus integrating near the LMO2 
proto-oncogene promoter. This study was an unfortunate and grim reminder that 
insertional mutagenesis and its oncogenic consequences are a significant hindrance in the 
viral gene therapy approaches (Pike-Overzet, van der Burg et al. 2007). In another study, in 
1999, an 18 year old patient was treated with an adenovirus for a urea cycle metabolic 
disease called ornithine transcarbamylase deficiency (OTCD). Following treatment the virus 
induced a severe inflammatory response in the patient which ultimately led to death (Raper, 
Chirmule et al 2003). 
Viral vectors are unquestionably able to mediate high and efficient gene transfer. 
Furthermore they also provide the possibility of long-term gene expression and satisfying 2 
out of the 3 criteria of an ideal gene delivery vehicle. Despite these efficiencies, they are 
also coupled with safety concerns; particularly as viruses are inherently immunogenic and 
carry significant risks associated with insertional mutagenesis, which were uncovered in the 
gene therapy trials. While this still remains to be the case, at present due to their far 
superior efficiencies in vivo compared to non-viral vectors, in the field of gene therapy they 
are still the preferred vectors for gene delivery in clinical trials (Figure 1). Indeed there are 
currently over 1714 clinical trials which have been completed, are still running or have been 
approved, in more than 30 different countries, including at least one trial in every continent. 
These trials are in areas ranging from cancer, cardiovascular and ocular diseases; not 
surprisingly the majority of these cases apply to vectors of viral origin. 
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Figure 1: Current vectors used in gene therapy trials 
The majority of trials in 2011 involve the use of viral vectors due to their 
unquestionable high transfection efficiencies, however shortly following viral vectors is 
naked/pDNA signifying the emerging interest in alternative therapies 
(www.wiley.co.uk/genmed/clinical). 
 
In contrast to viruses, non-viral vectors have some key advantages, including safety as well 
as being relatively easy and cheap to produce. Despite this, the majority of non-viral vectors 
are still considerably less efficient than viral vectors, especially for in vivo gene delivery. Due 
to these constraints currently their successful applications in clinical trials have been limited 
to approximately 25% of the total clinical trials to date (Figure 1). Improvements in vector 
development, basic science of these vectors as well as gene transfer strategies may 
ultimately improve the preparation, delivery and expression of the current non-viral gene 
delivery vectors. Cumulatively this will lead to more efficient treatment of genetic disorders 
and much wider clinical applications.  
 
1.2 Overview of viral vectors 
 
Viruses provide a highly efficient vehicle for transferring genes to target cells or tissues 
where they mediate substantial expression in vitro, ex vivo as well as in vivo. They have 
evolved to develop highly efficient ways to enter target cells and facilitate their own 
expression. The viruses which have attracted the most attention of gene therapists are DNA-
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based adenoviruses (AdV) and adeno-associated (AAV) vectors, as well as the RNA-based 
retrovirus and lentiviruses. 
In spite of their high infection efficiency and successes, a number of worrying complications 
in early clinical trials resulting in oncogenesis or mortalities for OTCD (Raper, Chirmule et al 
2003) and X-linked SCID (Kohn, Sadelain et al 2003; Hacein-Bey-Abina, von Kalle et al. 
2003a) have been reported. These cases highlight the immunogenicity and cytotoxicity of 
viral vectors as gene transfer agents. Indeed the deaths of the X-SCID patients showed that 
following viral vector administration, insertional mutagenesis can occur. This is because the 
virus is able to integrate into the chromosomes of the patient receiving the gene therapy, 
leading to a disruption of tumour suppressor genes or the activation of oncogenes, which 
ultimately cause malignant transformation of cells. In contrast, the death of the OTCD 
patient was caused by an acute systemic inflammatory response to an adenovirus (AdV). 
Worryingly, numerous reports have also shown problems with persistence of viral vectors in 
the brain following ocular viral delivery (Provost, Le Meur et al. 2005; Stieger, Colle et al. 
2008). Furthermore, viral vectors can be hindered by the limited size of the expression 
cassette, difficulties in large scale production as well as safety issues resulting from repeat 
infections such as host immunity (Raper, Chirmule et al 2003; Thomas, Ehrhardt et al. 2003; 
Halbert, Miller et al. 2006; Baum, Kustikova et al. 2006). The advantages and disadvantages 
of the various types of viral vectors for gene therapy purposes are seen in Table 1. 
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Table 1: Typical viral vectors used in gene therapy as well as their advantages and 
disadvantages (O'Connor and Crystal 2006) 
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1.3 Overview of non-viral vectors 
 
The current gene delivery systems in use today are unquestionably gene therapy vectors 
based on modified viruses. However, recently crucial limitations including risks of insertional 
mutagenesis and adverse immune effects have been brought to light (Hacein-Bey-Abina, 
von Kalle et al. 2003a; Hacein-Bey-Abina, Von Kalle et al. 2003b; Thomas, Ehrhardt et al. 
2003). Due to a safety concern, non-viral vectors become an attractive alternative to viral 
gene delivery due to their ease of production in large scale at low costs as well as their low 
toxicity. Furthermore they provide greater versatility as any size of gene or regulatory 
sequence can be incorporated with relative ease.  
While non-viral vectors provide good levels of transgene expression in vitro, their 
efficiencies are still inadequate for realistic in vivo gene therapy as in vivo they still present 
poor transfection efficiencies. Ideally once a vector has been delivered to target cells it 
should also be maintained within the nucleus without disruption to the hosts’ gene 
expression or signaling pathways. Furthermore, they must be sufficiently stable to permit 
the delivery to target tissues. Hence they must be protected from potential problems during 
this initial stage including sheer forces from the blood stream and enzymatic degradation of 
the vector or gene product (Kircheis, Wightman et al. 2001). Once inside the target cell, for 
efficient transfection the vector must resist cytoplasmic degradation from enzymes such as 
nucleases and must be able to pass through the double membrane structure of the nuclear 
envelope which encapsulates the nucleus (Lyman, Guan et al. 2002; Jans, Xiao et al. 2000; 
Zelphati, Uyechi et al. 1998).  
In order to achieve some of these requirements and ultimately enhance non-viral gene 
expression, numerous methods to attempt to mimic the efficient gene delivery capacity of 
viruses have been utilised. Specifically these mechanisms include the nuclear maintenance 
and replication through: non-integrating episomes as well as artificial chromosomes.  
 
1.3.1 Persistent non-integrating episomal vectors 
 
Conventionally, genetic modification of cells has been done using potentially integrating 
viral vectors. An alternative is to utilise vectors which can replicate and segregate to 
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daughter cells (persist within the nucleus of cells) in an autonomous, extra-chromosomal 
and independent state. These vectors are particularly advantageous as they do not lead to 
cell transformation due to the inability of physical integration of these vectors into the host 
genome. Thus these vectors are devoid of problems associated with integration events, 
particularly, insertional mutagenesis, as seen with integrating viral vectors. If these vectors 
are based entirely on non-viral elements, they do not lead to immunological problems of the 
recipient organism or transformation of the cell caused by virally encoded proteins (Mazda, 
Satoh et al. 1997). Furthermore genes within such vectors cannot be interrupted or 
subjected to regulatory constraints which often occur from integration into cellular DNA. 
Additionally, episomal vectors persist in multiple copies in the nucleus, resulting in the high 
amplification of the gene of interest.    
These key advantages have led to increase efforts in developing vectors capable of extra-
chromosomal (episomal) replication that lack the ability of transgene integration events 
within the hosts’ chromosome.  
 
1.3.1.1 Episomal vectors based on replication deficient viruses 
 
One such class of episomal vector systems include viruses such as simian virus 40 (SV40),  
Epstein-Barr Virus (EBV) and bovine-papilloma virus (BPV). These viruses normally replicate 
episomally within mammalian cells by using the cellular replication machinery. However 
viral proteins are also essential for the initial replication at the viral origin of replication (ori). 
Within the SV40 viral plasmids, the region of this virus or the viral protein required for its 
cellular replication is the large T-antigen (Tag) (Li, Zhao et al. 2003), and for the EBV virus, 
the EBV Nuclear Antigen-1 (EBNA1) (Wu, Ceccarelli et al. 2000) is required. Furthermore, 
these viral proteins are required for the segregation of viral episomes to progeny cells 
during cell division. This is through a poorly understood ‘piggy-back’ mechanism following 
the association with a mitotic chromosome, origin of replication complex (ORC)(White, 
Wade-Martins et al. 2001). 
Importantly by including these viral ori sequences, episomal plasmids have been generated 
that can sustain expression of therapeutic transgenes. Studies have shown the development 
of an EBV-based episomal plasmid which contains the entire hypoxanthine phosphoribosyl 
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transferase (HPRT) locus. These studies also went onto show that this plasmid provided 
stable expression of HPRT at physiologically relevant levels for up to six months in vitro 
within HPRT-deficient human lung fibroblast cells (Wade-Martins, White et al. 2000). 
Despite these initial finding, the EBV-based episomes were gradually lost at a rate of 4% per 
cell division in the absence of antibiotic selection pressure. Furthermore the presence of a 
continuous selection pressure led to integration of the EBV plasmid into the host genome.  
In another report, EBV vectors were shown to enhance B-cell (lymphoma) immortalization 
several 1000-fold (Humme, Reisbach et al. 2003). While this highlights their potential use as 
a model for immune therapy of cancer, this was seen alongside humoral and cellular 
immune responses (Taylor, Haigh et al. 2004). Similar cellular transformations were also 
seen when using the Tag gene from the SV40 plasmid. At physiological levels, the Tag gene 
is shown to disable the p53 tumour-suppressor and retinoblastoma pathways. As p53 is 
significantly important for cell cycle arrest and apoptosis, this alters the function of other 
key host cell proteins which in turn cause numerous transformations to occur (Ali, Kasper et 
al. 2004). 
An alternative episomal viral vector system is based on replication deficient viruses or virus 
like particles (VLPs) such as AdVs and AAVs. These virus vectors are able to persist in the 
genome as a non-integrative state by utilising viral proteins. VLP based episomal systems 
are able to assemble as viral particles (virions) within producer systems unlike episomal 
systems based on EBV and SV40 replicons. Hence these VLP vectors are able to exhibit all 
viral functions; namely transduction of target cells and nuclear translocation of their 
genomes, however they importantly lack the ability to replicate and produce progeny. 
Despite this, reports have brought to light some considerable safety concerns. One such 
example is the induction of a host immune response following the leakage of viral products 
after the use of replication deficient AdVs. Furthermore low levels of integration and 
immunotoxicity, as well as high levels of multiplicities (which is a measure of the ratio of 
infectious virus particles to the number of target -host- cells) were observed against the viral 
capsid of AAV replication deficient viruses (Nakai, Montini et al. 2003). 
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1.3.2 Episomal vectors based entirely on chromosomal elements 
1.3.2.1 Mammalian Artificial Chromosomes 
 
Due to the safety concerns mentioned above for viral-based episomes, interest began on 
the development of episomal replicating vectors that were solely comprised of functional 
chromosomal elements – artificial chromosomes. These vectors have three main 
components: a centromere, two telomeres at both termini and several origins of replication. 
Artificial chromosomes have long been touted as an ideal vector for gene delivery; as such 
chromosomes would mimic the natural state of the DNA in the cell. This would mean 
essentially, unlimited amounts of DNA could be incorporated into such vectors. In the case 
of mammalian artificial chromosomes (MACs) such vectors could enable either whole genes 
or whole metabolic pathways with their entire natural genomic content containing all 
regulatory elements to be delivered. Furthermore these vectors would not integrate into 
the hosts’ genome. Despite this, the first human artificial chromosomes (HACs) were 
commonly unstable and integration events caused disruption of the host genome 
(Harrington, Van Bokkelen et al. 1997). One exception was circular HACs which were shown 
to be mitotically stable in the absence of selection (Ebersole, Ross et al. 2000). 
Human artificial chromosomes can be constructed either by the ‘bottom-down’ or ‘bottom-
up’ approach. In the ‘bottom-down’ approach minichromosomes are created, whereby 
existing chromosomes are truncated to a minimal length using irradiation or telomere 
fragmentation (Farr, Stevanovic et al. 1992). While the ‘bottom-up’ approach involves the 
assembly of centromeric DNA (such as long synthetic arrays of α-satellite DNA which are 
present at the centromeres of all normal human chromosomes), telomeric DNA and 
genomic DNA sequences to be delivered (Farr, Stevanovic et al. 1992). However, artificial 
chromosomes to-date require specialized delivery techniques including delivery to mice 
using microcell medicated chromosome transfer as well as pronuclear injections (Basu and 
Willard 2005; Jackson, Juranek et al. 2006). Several studies have utilised HACs to provide 
long-term therapeutically relevant levels of gene expression. One such study includes a HAC 
containing the entire 250 kb genomic cystic fibrosis gene, cystic fibrosis transmembrane 
conductance regulator (CFTR), including regulatory sequences. This HAC was shown to 
stably express CFTR protein as well as providing persistent chloride secretory response 
in vitro, showing the potential application for treatment of the disease (Auriche, Carpani et 
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al. 2002). Despite this, the use of MACs is plagued with numerous ethical and safety issues. 
This is primarily because they require chromosomal elements which are removed from 
animal cells; thus must be stringently controlled. 
 
1.3.2.2 Plasmid pEPI 
 
As an alternative, a plasmid called pEPI was generated in 1999. This plasmid contains an 
SV40-ori sequence, however does require transforming viral proteins for episomal 
maintenance (Figure 2).  
 
Figure 2: Schematic representation of pEPI-EGFP (or simplified pEPI) 
Plasmid pEPI is shown, including all necessary elements for replication and 
maintenance. 
 
Noteworthy is the study in haematopoietic stem cells, where this was the first application of 
S/MAR vectors in CD34+ stem cells (Papapetrou, Ziros et al. 2006). In this study, Papapetrou 
and colleagues showed that pEPI is maintained episomally for up to four weeks. However, 
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despite transgene silencing in the MEL cell line - as a result of histone deacetylation- pEPI 
continued to remain as an episome.  
In another study, S/MAR vectors were shown to episomally modify pluripotent p19 
embryonic cells (Sotirova, Calciano et al. 2006). Plasmid pEPI was modified slightly to 
express a short hairpin RNA (shRNA) against the endogenous proteins of β-tubulin III and 
cyclophilin A. Interestingly, when this vector was used together with a control non-S/MAR 
vector, it was shown that the S/MAR vectors were able to promote more efficient and 
sustained gene expression. In contrast the non-S/MAR vectors were not, while the episomal 
status of both vectors was also confirmed by Southern blot analysis. In an alternative study, 
S/MAR elements were included in a pDNA vector and were shown to restore functional 
levels of the human low density lipoprotein receptor (LDLR) in CHO ldlr-/- a7 cells. 
Importantly these were physiologically relevant levels and remained episomal for 11 weeks 
(Lufino, Manservigi et al. 2007). 
Significantly, pEPI has also been used to create genetically modified pigs following sperm-
mediated gene transfer of pEPI into oocytes. The vector was detected and retained as an 
episome in 12 out of 18 foetuses within different tissues analysed. Furthermore, strong 
reporter gene expression (of eGFP) was observed in 9 out of 12 episome-positive foetuses 
(Manzini, Vargiolu et al. 2006). While the foetuses were not brought to term due to legal 
reasons, this study highlights the ability of S/MAR plasmids in providing efficient and long-
term expression in vivo. 
Following this, pEPI vector was delivered to the mouse liver and lung. However in these 
studies, only transient expression was reported due to considerable silencing of the plasmid 
(Conese, Auriche et al. 2004; Argyros, Wong et al. 2008). To circumvent this problem 
Argyros et al. replaced the CMV promoter of pEPI with the liver-specific α1 antitrypsin 
promoter (AAT). This proved to be essential and led to the persistent transgene expression 
in the mouse liver for up to 6 months following a single vector administration (Argyros, 
Wong et al. 2008). Importantly, the removal of the S/MAR element from the vector resulted 
in silencing of pEPI within a week of administration. This was the first demonstration in vivo 
for persistent expression of S/MAR vectors with a tissue specific promoter. The authors 
showed that there appeared to be a synergistic relationship between the tissue-specific 
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promoter and pEPI. Furthermore they also showed that indeed this promoter was necessary 
for long-term transgene expression. Unfortunately the plasmid was not shown to be able to 
replicate in vivo, and following 70% partial hepatectomy, the CMV and AAT-based vectors 
failed to persist and expression was lost.  
In contrast, Wong et al. reported in 2011 the first episomal replication of an S/MAR plasmid 
in vivo following an initial period of selection pressure which was required to reveal 
episomal maintenance (Wong, Argyros et al. 2011). The authors showed an in vivo liver 
selection strategy. Liver cells were transfected with an S/MAR plasmid bearing the B cell 
lymphoma 2 (Bcl-2) gene. These cells were shown to have a survival advantage over non-
transfected cells after an initial selection pressure of the Fas anti-body Jo2. This is based on 
the induction of cell death by the Fas antigen, which induces apoptosis on engagement with 
its physiological ligand, FasL. Hence, in vivo this pathway can be activated following 
administration of an agonist Fas antibody, Jo2. Following hydrodynamic delivery to the livers 
of NOD/SCID mice and the twice weekly administration of Jo2, the authors showed that 
indeed the Bcl-2 S/MAR plasmid was able to provide long-term luciferase reporter gene 
expression despite constant Jo2 challenges. Furthermore the plasmid was also able to 
replicate as an episomal entity. While this approach is not clinically relevant, it shows that 
S/MAR vectors are capable of preventing transgene silencing, are resistant to integration 
and are capable of conferring mitotic stability in vivo provided with a selective advantage.   
 
1.3.2.3  Scaffold/Matrix Attachment Regions (S/MARs) 
 
S/MARs are genomic DNA sequences which were first described by Cockerill et al. in 1986 
while studying the organization of the nuclear matrix (Cockerill, Garrard et al. 1986). The 
organisation of the eukaryotic nucleus into chromosomal domains is thought to be 
mediated by the nuclear matrix or nuclear scaffold. It is composed of a highly proteinaceous 
intranuclear framework including branched core filaments. These filaments provide the 
supporting structure for the formation of DNA looped domains that participate in the 
numerous matrix-supported processes involving: DNA replication and transcription, RNA 
processing and transport, signal transduction and apoptosis. S/MARs are defined as the 
genomic DNA sequences which anchor the chromatin to the nuclear scaffold proteins (Heng, 
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Goetze et al. 2004; Mirkovitch, Mirault et al. 1984)(Figure 3). This binding then forms 
portioned looped domains that contribute structurally to the tight packaging of DNA in the 
nucleus - as described earlier - and functionally to the regulation of gene expression and 
replication of the genome. Hence S/MARs play a crucial role in chromatin structure, 
specifically in the organisation of eukaryotic genomes, particularly in maintaining the 
chromosome structure and function within the cell nucleus.  
It has been estimated that the human genome contains thousands of S/MAR elements. 
However some of the most commonly used S/MAR sequences have been: the Eµ SMAR in 
the immunoglobulin heavy chain enhancer locus (Wiersma, Ronai et al. 1999), the apoBMAR 
from the human apolipoprotein B locus (Attal, Cajero-Juarez et al. 1995), the Ch-LysSMAR 
from the chicken-lysozome locus (Makarova, Gorneva et al. 1996) and the huIFNβSMAR 
from the human β-interferon locus (Piechaczek, Fetzer et al. 1999). Despite being 
evolutionary conserved, S/MARs appear to show little sequence or organisation 
conservation; rather they contain several recognisable motifs within and between species  
(Girod, Nguyen et al. 2007). S/MARs have a range of between 300-5000 bp and are known 
for their high AT content, which is usually higher than 65% (Mirkovitch, Mirault et al. 1984; 
Bode, Benham et al. 2000). It is this high AT content which is believed to at least partially aid 
the unwinding and destabilization of the DNA double helix (Bode, Kohwi et al. 1992; Bode, 
Winkelmann et al. 2006) and the formation of secondary DNA loop structures (von Kries, 
Buhrmester et al. 1991). Thus, the affinity of an S/MAR to the nuclear matrix appears to be 
affected by the location and organisation of the AT-rich regions. However, being an AT-rich 
region alone does not make a DNA fragment an S/MAR (Benham, Kohwi-Shigematsu et al. 
1997). Indeed large S/MARs (of several kb) are found at borders of chromatin domains, 
while shorter S/MARs which have very similar physicochemical properties occur in close 
association with certain enhancers or introns. Therefore S/MARs are found either in non-
transcribed regions or within transcription units, but rarely in coding regions (Bode, Benham 
et al. 2000). This observation implies that each gene has its own S/MAR – the so called ‘one 
gene-one S/MAR’ hypothesis (Frisch, Frech et al. 2002). These unique properties 
differentiate S/MARs from standard promoters, enhancers and coding sequences. 
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Figure 3: The nuclear matrix – organisation of S/MARs 
DNA in eukaryotic genomes is organised in a complex structure within the nucleus. DNA 
in the nucleus interacts with histones and chromatin proteins to form a 30 nm fibre. The 
DNA is then condensed further and organised into chromatin loops. The formation of 
these chromatin loops is aided by the interaction of AT rich regions of the genome – 
S/MARs – with the nuclear matrix.  
(Image modified from: www.ghastlyfop.com/blog/2005_09_01_archive.html) 
 
1.3.2.4  S/MARs function as insulators 
 
As described earlier, the interaction of S/MARs with the nuclear matrix/scaffold is crucial for 
the organisation of chromatin loops, which define the boundaries of independent chromatin 
domains (Heng, Goetze et al. 2004). These boundary domains are commonly located near 
genes, thereby insulating their coding regions from stimulatory or recessive effects from 
their surroundings as well as to provide local assess of transcription factors to enhancers 
and promoters (Goetze, Gluch et al. 2003; Jenuwein, Forrester et al. 1997). Indeed the ‘one 
gene-one S/MAR’ hypothesis mentioned previously predicts that each active gene has its 
own S/MAR element (Bonifer, Vidal et al. 1990). Therefore S/MARs could effectively insulate 
transgenes from integration into the host chromosome by creating independent domains. 
 
Many genes are known to be shielded by so-called ‘insulator’ elements. Furthermore 
S/MARs have been commonly found in regions flanking genes, as well as colocalising with 
regions where such insulators are found. One such insulator is gypsy, which is a 
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retrotransposon in Drosophila melanogaster, suggesting that S/MARs indeed have an 
insulator function (Nabirochkin, Ossokina et al. 1998). In Drosophila, the nuclear matrix 
protein Su (Hw) binds to gypsy, creating a chromatin loop, however certain mutations in this 
protein disrupt the loop formation, rendering the gypsy insulator non-functional. This result 
suggests that the tethering of S/MARs to the nuclear matrix topologically constrains the 
DNA into looped structures, in turn protecting the DNA from regulatory elements outside 
the loop.  
Similarly, in vertebrates, CTCF, which is a ubiquitous nuclear matrix protein, binds to 
insulators and has also been shown to interact with S/MARs (Yusufzai, Felsenfeld et al. 
2004). While the mechanism whereby CTCF acts as an insulator remains largely unknown, it 
has been suggested that the binding of CTCF to S/MARs may block the interactions between 
promoters and unrelated enhancers. Furthermore this binding also creates loop structures 
which delimit different chromosome domains. Additionally as described previously, pEPI 
plasmid is able to mediate persistent transgene expression in a range of cells, however only 
transient expression is seen when transgenes lacking S/MARs were used. This indicates that 
in the pEPI plasmid, S/MARs are able to shield the transgene from the effects of the 
neighbouring host chromatin, hence enabling persistent and stable expression in vitro 
(Halweg, Thompson et al. 1999; Girod, Nguyen et al. 2007). 
Taken together, these examples support the view that S/MARs provide a crucial function as 
insulators in gene regulation. Following the attachment of S/MARs to the nuclear matrix (in 
the case of pEPI via interactions with the scaffold attachment factor A (SAF-A) protein), this 
interaction forms a complex higher-order nucleoprotein structure. This in turn insulates 
chromatin domains while also controlling gene expression by forming bridges between 
components of the transcriptional machinery and the regulatory elements (Ottaviani, 
Leveret al. 2008), as shown in Figure 4. 
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Figure 4: Schematic model depicting the function of S/MARs as insulators in gene 
regulation 
Activation of transcription is accompanied by the binding of the S/MARs to the nuclear 
matrix. This results in the formation of anchored chromatin loops which importantly 
are insulated from the stimulatory or repressive effects of flanking chromatin. The 
transcription machinery is assembled at the site of the S/MAR, which aids in bringing 
together the gene coding sequences and regulatory elements to allow the coordinated 
regulation of specific genes (Figure adapted from (Ottaviani, Lever et al. 2008)). 
 
1.3.2.5 S/MARs augment transcription 
 
Interestingly, S/MARs may also act in cis to increase the transcription rates, even in the 
absence of an enhancer.  Despite this, the precise mechanism of how S/MARs are able to 
switch on gene expression still remains largely unclear. Suggestions have indicated that the 
single chromatin loop which forms following the attachment of an S/MAR to chromatin is in 
fact not immobile. Therefore perhaps the changing of attachment points of the loops to 
different regions of the nuclear matrix many subsequently allow S/MARs to switch on gene 
expression (Kalos, Fournier et al. 2006). This implies that S/MARs are able to mediate 
successful transgene expression following its ability to change the structure of the 
chromatin in order to increase the likelihood of establishing an active locus (Ottaviani, Lever 
et al. 2008). 
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Interestingly, the binding of S/MARs to transcription factors may also influence transgene 
regulation. This is because following binding, this many allow the direct interaction of 
S/MAR elements with the components of the transcription machinery. Indeed S/MARs are 
also able to bind to nuclear matrix proteins such as the special AT-rich sequence-binding 
protein 1 - SATB1 (Galande, Purbey et al. 2007), SAF-B (Nayler, Stratling et al. 1998), 
topoisomerase II, histone H1 as well as acidic ribosomal protein PO, ARBP (Dickinson, Joh et 
al. 1992). Such binding allows the association of S/MARs with RNA polymerase; thus this 
increases the accessibility of an S/MAR containing plasmid to the transcription machinery of 
a cell and in turn influences gene expression. Interestingly, this is further confirmed 
following the fluorescence in situ hybridisation (FISH) analysis of the pEPI plasmid. These 
studies revealed areas of active sites which were present on the periphery of chromosome; 
implying that the chromatin is able to remain open for easy access to the transcription 
machinery.  
The actual replication of pEPI is dependent on the active transcription of a gene which is 
located upstream of the S/MAR, with transcription continuing past the gene of interest and 
extending part of the way into the S/MAR (Stehle, Scinteie et al. 2003). This has been 
demonstrated by the loss of episomal replication following the removal of the promoter – 
cytomegalovirus (CMV) – which drives transcription or the insertion of sequences which 
result in the termination of transcription ahead of the S/MAR element (Stehle, Scinteie et al. 
2003; Jenke, Stehle et al. 2004). This observation corroborates with the suggestions made 
previously, that transcription into the AT-rich S/MAR opens the surrounding chromatin 
structure of the plasmid, thus allowing access to the replication machinery (Schaarschmidt, 
Baltin et al. 2004; Stehle, Scinteie et al. 2003; Jenke, Stehle et al. 2004). 
 
1.3.2.6 Mitotic stability 
 
Plasmids harbouring S/MAR moieties are also believed to be mitotically stable, and several 
suggestions have been made to explain the molecular mechanism. Stehle et al. have shown 
that once the pEPI plasmid is established as an episome in vitro, it is then able to be 
maintained efficiently in active chromatin and importantly associate with early replicating 
chromosome sequences (Jenke, Scinteie et al. 2004). Noteworthy is the fact that vectors 
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without S/MAR or vectors in which the transcription was terminated before the S/MAR 
resulted in integration and loss of transgene expression – due to the silencing by promoter 
methylation (Jenke, Scinteie et al. 2004). 
Interestingly, pEPI has also been shown to interact with mitotic chromosomes (Baiker, 
Maercker et al. 2000). This is thought to be mediated through the binding of the S/MAR 
element within this plasmid with the scaffold attachment factor A (SAF-A) protein (Jenke, 
Fetzer et al. 2002; Mearini, Nielsenet al. 2004), which is a principle component of cellular 
chromatin and chromosomes (Kipp, Gohring et al. 2000). This interaction most likely brings 
pEPI into contact with the host replication machinery, which is located on the nuclear 
matrix, hence facilitating pEPI replication once per cell cycle.  
In another study, Jenke et al. showed that the pEPI plasmid is segregated to daughter cells. 
They showed that the S/MAR element within this plasmid is able to bind to a range of 
nuclear matrix proteins as mentioned previously. In particular, the S/MAR element was 
found to preferentially associate with the SAF-A protein (Jenke, Fetzer et al. 2002; Mearini, 
Nielsen et al. 2004). This suggests that during mitosis, pEPI is able to interact with mitotic 
chromosomes, following the interaction between the S/MAR element and SAF-A, this then 
allows the co-segregation of pEPI with the chromosomes during mitotic division (Jenke, 
Fetzer et al. 2002; Mearini, Nielsen et al. 2004). Therefore the S/MAR moiety of the pEPI 
plasmid performs a similar function to virally encoded proteins such as Tag and EBNA-1 of 
SV40 and EBV respectively (White, Wade-Martins et al. 2001, Wade-Martins, White et al. 
2000) by allowing replication to occur through chromosome associations. Thus this 
association leads to helix destabilisation forming an open chromatin domain which mediates 
the assembly of the replication machinery and subsequent co-segregation of pEPI with 
chromosomes during mitosis (White, Wade-Martins et al. 2001; Baiker, Maercker et al. 
2000).  
While S/MARs have been shown to modulate transcription levels, other elements also have 
this same ability including: insulators, locus control regions (LCR) and ubiquitous chromatin 
opening elements (UCOE).  Insulators are sequences of DNA which protect the integration of 
a transgene into the host genome, a phenomenon known as position effect variegation. 
They function by partitioning the genome into discrete functional domains which allows 
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independent regulation to occur preventing the overlap of promoter or enhancer signals at 
different loci (Kellum andSchedl 1992). Indeed, in studies involving adenoviral (Steinwaerder 
and Lieber 2000) and AAV vectors (Fitzsimons, Mckenzie et al. 2001), the presence of an 
insulator on the chicken β-locus in these vectors was shown is shield transgenes from the 
effects of flanking viral sequences. Similarly in pDNA vectors, increased reporter gene 
expression has been shown (Johansen, Tornoe et al. 2003). 
Alternatively LCRs are long range transcriptional enhancers which provide strong chromatin 
opening abilities. While the majority of LCRs are tissue specific, some ubiquitous chromatin 
opening elements - UCOEs - have been identified in regions surrounding promoters of 
certain housekeeping genes (Antoniou, Harland et al. 2003). In an example Miao et al 
showed that the enhancement of human factor VIII and IX transgenes in liver tissues was 
achieved following the inclusion of a hepatocyte specific LCR derived from the 
apolipoprotein E (apoE) locus in pDNA (Miao, Ye et al. 2003). 
It is important to remember that these elements provide a singular function - modulating 
transcription - however S/MARs have been shown to be extremely versatile and have the 
ability to provide numerous functions. Indeed similar to insulators, upon inclusion in a 
plasmid, S/MARs are able to shield a plasmid from the recessive or stimulatory effects 
within their surroundings. The important difference between insulators and S/MARs are 
that within a chromosome insulators mark the boundaries of active domains, in contrast, 
S/MARs are the boundaries by which chromatin is physically constrained into loops. 
Furthermore, it is this linkage with the nuclear matrix which provides S/MAR containing 
plasmids mitotic stability as well as segregation into daughter cells. Additionally, like LCRs 
and UCOEs, S/MARs are able to mediate domain opening. This in turn brings the transgene 
into close contact with promoters and other transcription factors, increasing the chances of 
possible interactions and hence potentially facilitating with transcription.  
 
1.4 Non-viral gene delivery techniques 
 
DNA does not require a vehicle to enter a cell. In fact most cells are able to take up DNA on 
their own, albeit at a very low efficiency. Systemic delivery of naked DNA is highly inefficient 
due to the rapid degradation by nucleases and clearance by the monocular phagocyte 
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system (Mahato, Takakura et al. 1997). Furthermore the phosphate group on the 
deoxyribose rings of DNA confer a negative charge to DNA molecules, which results in a low 
electrostatic interaction with anionic lipids in the cell membrane. Indeed direct injections of 
DNA into tissue may significantly increase the concentration of the vector in proximity to 
the target cell. For example with pulmonary administration for lung gene transfer, hepatic 
vein injections for liver gene transfer or subretinal and intravitreal injections for ocular gene 
transfer. Noteworthy is that this is not always possible due to the access of some tissues. 
Despite this, low levels of injected DNA may be taken up by target cells (Wolff, Williams et 
al. 1991). Therefore the main aim of non-viral gene delivery is to improve the efficiency of 
DNA uptake and prevent degradation outside the cell.  
Commonly this is achieved by coating naked plasmid DNA (pDNA) with a positively charged 
lipid (cationic lipid) or cationic polymer, forming a gene transfer agent (GTA). These cationic 
lipids/polymers surround DNA such that the positive charge of the lipid/polymer is attracted 
to the negatively charged DNA, forming a complex called a lipoplex/polyplex. Within these 
complexes, the hydrophobic ends of lipids remain free and interact with the cell membrane 
facilitating entry into the cytoplasm of cells. Once within the cell, the entry of the DNA into 
the nucleus and subsequent expression of transgenes is not well understood.  
In an alternative method, DNA can be administered directly to the required cells or tissues 
via physical methods such as ultrasound and electroporation. Furthermore, for specific 
routes for specialised tissues such as the eye more specialised routes may be required (as 
described in section 1.7.1).  
 
1.4.1 Gene transfer by chemical carriers 
1.4.1.1 Cationic Liposomes 
 
The use of cationic lipids for gene delivery was first reported by Felgner et al. in 1987. 
Felgner and colleagues described a chemical carrier which was effective at binding and 
delivering DNA to cultured cells following a cationic liposome formulation, called Lipofectin 
(DOTM/DOPE)(Felgner, Gadek et al. 1987). This was quickly followed in 1989 by the first 
reports of in vivo transgene administration. In these studies gene expression of 
chloramphenicol acetyltransferase (CAT) in the lungs and liver of mice was reported for up 
41 
 
to 7 days following intravenous and/or intratracheal administrations of plasmid DNA 
complexed with Lipofectin (Brigham, Meyrick et al. 1989). Typically cationic lipids are 
comprised of a cationic head group, a hydrophobic lipid anchor and a linker bond between 
the two domains (Mintzer and Simanek 2009). A lipid anchor is normally comprised of a 
fatty acid chain or cholesterol ring group and determines the physical properties of a lipid 
bilayer such as membrane rigidity. The linker bond determines a cationic lipids stability and 
biodegradability. Finally the cationic head group is crucial for the transfection activity and 
toxicity following formulations. Since the initial studies involving Lipofectin, numerous other 
cationic lipids have been developed, differing mainly in the charge of their cationic head 
group as well as the detailed structure of their hydrophobic portion. Some of the most 
commonly used liposome formulations include: DOGS, DOTAP, DOTMA, CDAN and DOSPA.  
The phosphate backbone of all nucleic acids has a single negative charge on it per base. In 
general, the formation of lipoplexes relays on the ionic interaction between the negatively 
charged phosphate backbone of the nucleic acid and that of the positive charge on the 
amino groups of lipids. Hence lipoplexes form instantly when cationic lipids are combined 
with DNA, through the electrostatic association of the polycationic liposome and 
polyanionic DNA. In general, when a low cationic liposome-to-DNA mole ratio is used, where 
the positive/negative charge ratio is less than 1, this results in small (< 40 nm) 
liposome/DNA complexes, which coexist as free or loosely bound DNA. In contrast, when a 
liposome-to-DNA mole ratio in excess of the neutral charge ratio is used, large (> 100 nm) 
complexes are formed. These complexes appear to encapsulate DNA within multilamellar 
lipid structures (Wasan, Reimer et al. 1996), where the DNA is sandwiched between the 
cationic lipid (Radler, Koltover et al. 1997). In these conditions, the large liposome/DNA 
complexes (lipoplexes) are most likely in dynamic equilibrium with smaller clusters, thinly 
lipid-coated DNA strands and free DNA. Therefore one can say that optimal gene delivery is 
achieved when the lipoplexes are at their most heterogeneous; for in vivo studies this 
appears to be when the positive/negative charge ratio is in excess of 1 (or neutral charge), 
while in some circumstances this may be higher (Miller 1998). 
Following successful formation of a lipoplexes, this is then delivered to a cell surface and the 
‘lipofection’ process occurs. During this process the complex fuses with the cell membrane 
and becomes internalised (by endocytosis) to form an endosome (Monkkonen and Urtti  
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1998). During the process of maturation, the endosomal walls begin to rupture allowing the 
DNA to be released into the cytoplasm. From here the DNA can then move towards the 
nucleus, cross the nuclear membrane and potentially result in gene expression. Alternatively 
limited expression may be observed because the DNA may not reach the nucleus due to it 
being degraded within the cytoplasm by lysosomes. A simplified version of this process is 
shown in Figure 5. 
 
Figure 5: Liposome mediated transfection of DNA to form a lipoplex and the 
internalisation at the cell surface by endocytosis 
Initially the liposome is complexed with DNA to form a liposome/DNA complex 
otherwise known as a lipoplex. This lipoplex is then added to cells in culture where it 
attaches to the cell membrane and becomes internalised by endocytosis. At this stage 
the DNA can be released and subsequently reaches the nucleus to allow successful gene 
expression, or it may become degraded by lysosomes within the cytoplasm  
(Parker, Newmanet al. 2003). 
 
While lipoplexes show good levels of transgene expression in vitro, this is often not the case 
when applied to in vivo studies, where transgene levels are often very low or transient. 
Factors which may hinder the utility of liposomes in vivo could be the lack of stability and 
survival in the blood stream, as well as the size of the complex and electric charge (Smyth 
Templeton 2001). Furthermore serum proteins such as albumin which are negatively 
charged can also bind to the lipoplexes, causing a loss of cationic charge on the lipoplexes 
and in turn interfering with liposome-cell membrane associations. This can cause aggregates 
43 
 
to form which can lead to rapid clearance of these complexes by phagocytic cells. Ultimately 
these complexes disintegrate and the DNA becomes degraded preventing them from 
reaching the intended target cells.  
Interestingly, modification of lipid and polymer complexes with hydrophilic polymers such 
as polyethylene glycol (PEG) can stabilise polyplexes against such inactivation. It is believed 
that PEG being hydrophilic is unable to interact with either DNA or cationic lipids. Therefore 
it provides longer circulation times of liposomes in blood circulation by minimising the 
binding of blood components and lipoplexes. However, this modification (PEGylation) has 
also been shown to cause an (dose-dependent) inhibition of transfection activity; in turn 
reducing the internalisation of untargeted polyplexes (Mishra, Webster et al. 2004). 
Furthermore PEGylated lipids are unable to efficiently condense DNA causing low stability of 
complexes in solution. Lipoplexes also appear to induce immune responses – albeit at a 
lesser extent than viral vectors – through the toll-like receptor 9 (TLR9) pathway which 
causes an increase of proinflammatory cytokines (Hemmi, Takeuchi et al. 2000; Ito, 
Kawakami et al. 2009). This has been shown to lead to vector-associated toxicity as well as 
the elimination of transfected cells and gene expression (Niidome and Huang 2002).  
Due to these limitations in vivo, cationic lipids such as LipofectAMINE and  
LipofectAMINE 2000 (DOSPA/DOPE) are more readily only used for in vitro studies where 
they show good transfection efficiencies in many cell lines. 
 
1.4.1.2 Cationic polymers (Polyplexes) 
 
Cationic polymers constitute another category of DNA carriers that have been widely used 
for gene delivery. Cationic polymers - also known as polyplexes - are able to complex DNA in 
a similar way utilised by cationic liposomes mentioned previously, however they are able to 
condense DNA much more efficiently compared to lipid polymers. Many different types of 
polymers have been utilised for gene delivery including poly (L-lysine) (PLL) and 
polyethylenimine (PEI). 
Poly-(L-lysine) (PLL) was one of the first class of cationic polymers used for gene transfer  
in vivo (Wu, Wilson et al. 1989). It is typically a polypeptide, composed of approximately 25-
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30 amino acid lysine molecules, which possess a biodegradable nature making it highly 
desirable for in vivo studies. Despite this, PLL polyplexes rapidly bind plasma proteins and 
are cleared from the circulation in a similar way to liposomes (Ward, Read et al. 2001). 
Furthermore, PPL polyplexes alone have poor transfection abilities, and require the addition 
of chloroquine. Chloroquine is a lysosomotropic agent which reduces the lysosomal 
degradation of these lipoplexes; however, this still only results in moderate levels 
transfection. This is accepted to be the result of poor escape from the endocytic pathway. In 
general only PLL polymers with high molecular weights (> 3000 Da) are able to effectively 
condense DNA to form stable complexes (Kwoh, Coffin et al. 1999). Despite the effective 
condensing ability of high molecular weight PPL polyplexes, these compounds also exhibited 
relatively high cytotoxicity (Choi, Liu et al. 1998). Furthermore the heterogeneity in the 
chain length of commercially available PPL also results in inaccurate formulations. While the 
early studies on PPL were promising, their relatively low efficiency and high toxicity render 
them unfavourable for in vivo applications. 
Contrary to PPL, polyethylenimine (PEI) is perhaps the most prominent example of a cationic 
polymer capable of efficient gene-delivery in vivo. Jean Paul Behr’s group first introduced 
PEI in 1995 as an efficient and economical synthetic polymeric gene transfer agent (Boussif, 
Lezoualc'h et al. 1995). Importantly unlike PPL, PEI is able to mediate efficient levels of gene 
delivery in the absence of an exogenous endosomolytic agent. PEI exists as both a branched 
and linear structure differing in their structure and molecular weight (Figure 6). Several 
linear PEI transfection agents have been made commercially available, including ExGen500 
and jetPEI, which are both linear derivatives of PEI (Ferrari, Moro et al. 1997). Linear PEI has 
been shown to mediate successful gene delivery in vivo into a wide variety of tissues, 
including the liver (Argyros, Wong et al. 2008; Wong, Argyros et al. 2011), lung (Wiseman, 
Goddard et al. 2003; Dif, Djediat et al. 2006), brain (Goula, Remy et al. 1998; Hassani, 
Franois et al. 2007), bladder (Ohana, Schachter et al. 2005) as well as the retina (Liao and 
Yau 2007).  Furthermore the first used of jetPEI in a clinical trial included its use for complex 
formation with plasmid DNA (pDNA) and the successful transfection of tumour tissues 
(Ohana, Gofrit et al. 2004). 
45 
 
 
Figure 6: Structures of PEI 
Cationic polymers can have a linear form such as Poly-(L-lysine) or a branched form 
such as PEI (Lavigne and Gorecki 2006). 
 
Chemically, PEI is one of the most densely charged polymers; one third of the atoms are 
nitrogen and one sixth of the nitrogen atoms carry a positive charge at physiological pH. For 
PEI-mediated transfection, numerous factors determine the physical properties of PEI/DNA 
complexes (polyplexes) and their transfection activity. These can include: DNA-to-PEI ratios 
(the ratio between the amine groups from the PEI backbone (+) and the phosphate groups  
(-) of the nucleic acids – N/P ratio). Furthermore the molecular weight and configuration of 
PEI, the concentration of DNA as well as the polymer and the ionic strength of the solvent 
for preparation can also affect the properties of PEI/DNA polyplexes. Both linear PEI (L-PEI) 
and branched PEI (B-PEI) have excellent transfection efficiencies in vitro. However L-PEI is 
reportedly less toxic than its branched counterpart following systemic administration. This 
coincides with the fact that LPEI/DNA complexes are less condensed and are able to 
dissociate more efficiently than BPEI/DNA complexes. Studies have also revealed that 
LPEI/DNA complexes enter the nucleus more readily than branched complexes (Wightman, 
Kircheis et al. 2001). 
Cellular trafficking usually directs the endocytosis of particles into lysosomes for 
degradation. Endosomes mature from an ‘early’ to ‘late’ stage when the pH drops from ~6 
to ~5 via the active import of H+ ions, and subsequently the endosomes fuse with lysosomes 
for degradation (Luzio, Mullocket al. 2001). Thus, the accumulation of polyplexes in 
endosomes would eventually lead to their degradation by the lysosomal enzymes and 
subsequently strongly limit gene transfer. Therefore gene transfer agents which possess 
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endosomolytic components should ensure early escape of polyplexes from lysosomes, 
resulting in enhanced transfection efficiency. Indeed, it has been proposed that the high 
gene transfer efficiency of PEI and its derivatives is due, at least in part, to their capacity to 
efficiently escape from the intracellular endocytic pathway through the ‘proton-sponge’ 
mechanism (Boussif, Lezoualc'h et al. 1995; Behr 1997) (Figure 7). 
 
Figure 7: Schematic of the proton-sponge mechanism 
Following the efficient condensation of DNA with PEI, PEI/DNA complexes interact with 
the cell membranes allowing the binding of complexes to anionic proteoglycans present 
at the cell surface, which facilitate entry into cells via endocytosis (left image). Within 
the cytoplasm, endosomes begin to mature following the activity of ATPase enzymes 
which actively transport protons (H+ ions) from the cytosol into the endosomes causing 
a gradual decrease in the pH of the endosomes. As PEI contains 1 in 3 nitrogen atoms 
which are unprotonated/cationic, PEI lends itself to protonation during endocytic 
trafficking (middle image). The accumulation of protons in the endosomes must be 
balanced by an influx of counter ions (Cl- ions). This increased ion concentration 
ultimately causes osmotic swelling and rupture of the endosomes membrane, which 
releases the polyplex into the cytosol (right image). Hence PEI is able to destabilise the 
endosomes by the ‘proton-sponge’ effect resulting in the escape of the polyplex from the 
endosomes (Pack, Hoffman et al. 2005). 
 
At neutral or physiological pH, PEI is only partially protonated, with approximately one in 
three nitrogen atoms within the PEI remaining unprotonated/cationic. Hence due to this PEI 
lends itself to protonation. Therefore, within the endosome PEI acts as a ‘proton-sponge’ 
whereby continuous protonation of the remaining nitrogen atoms causes an influx of 
protons/chloride ions into the endocytic vesicles. This ultimately causes osmotic swelling 
and rupture of vesicles and the release of polyplexes into the cytoplasm (Boussif, Lezoualc'h 
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et al. 1995; Behr 1997). Complexes are then translocated into the nucleus followed by 
separation of DNA from the delivery vehicle PEI. The released DNA is then able to undergo 
transcription and translation; giving rise to protein production and gene expression (Thomas 
and Klibanov 2003). The presence of nitrogen atoms which are protonatable at low pH is a 
prerequisite for this ‘proton-sponge’ effect; indeed PLL, which possesses only primary amino 
groups and hence is incapable of further protonation, is a much less efficient gene transfer 
agent than PEI. Therefore PEI represents a versatile and promising approach to deliver 
naked DNA in vitro as well as in vivo. 
 
1.4.1.3 Nanoparticles 
 
A newer type of lipid based gene carrier is a solid-lipid nanoparticle and compared to 
traditional liposomes, these particles are reportedly easier to make as well as having a 
diameter of approximately 200 nm in diameter (Bondi, Azzolina et al. 2007). Nanoparticles 
can take many forms, and generally smaller particles (<25 nm) are considered to be more 
efficient at passing through the pores in the nuclear membrane, thus overcoming one of the 
significant barriers for successful transfection (Liu, Zhang et al. 2001). Gene delivery 
nanoparticles usually consist of a peptide of polymer base that condenses or encapsulates 
DNA. Some of the most commonly used nanoparticles include polylactide (PLA) - and 
polylactide co-glycolide (PLGA) - based particles and particles condensed with cationic 
polypeptides such as Poly-(L-lysine) (PLL).    
The formation of polypeptide-based nanoparticles relies on the principle of DNA 
condensation. This principle relays on the idea that cells expand a significant amount of 
energy to keep DNA condensed enough to fit inside the nucleus, however importantly under 
specific conditions DNA is able to be condensed or compacted easier (Bloomfield 1997). 
Infact, a requirement for this to occur is the inclusion of a multivalent cation condensing 
agent, particularly because of the highly negative charge of the DNA backbone. These 
agents can vary from organic polyamines to inorganic polycations to polypeptides such as 
PLL. Ultimately, such condensing agents neutralize the negative charge on the DNA 
phosphate molecules, thus making the interactions between DNA and solvent less 
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favourable. This also enhances the attractive molecular forces and finally causes localised 
DNA bending which can encourage condensation to occur more readily (Bloomfield 1997). 
The first case of utilising DNA compaction to generate gene therapy vectors was shown in 
1979 by Wilson et al., where they characterised a compact DNA particle of approximately  
50 nm (Wilson and Bloomfield 1979). PLL has been used for nanoparticle compaction, 
however early studies involving compaction used high salt concentrations (~ 1M). This 
resulted in large variations in sizes of the condensed particles formed (ranging from 15-100 
nm) (Perales, Ferkol et al. 1994; Perales, Grossmann et al. 1997). 
In order to overcome the limitations of these high-salt particles, DNA was added in aliquots 
to a solution of lysine peptides, which were also sometimes coupled to PEG (Liu, Li et al. 
2003). Following the addition of PEGylated PLL, these particles were observed to be of a 
neutral charge, homogenous in size and shape and consisted of only compact DNA. 
Importantly these DNA nanoparticles were observed to show limited aggregates hence were 
stable in physiological salt concentrations. The process of PEGylation involves the addition 
of repeat PEG molecules to proteins or polymers which ultimately increase the 
hydrophilicity and electrostatic binding properties as mentioned previously, as well as 
protecting compounds from degradation by cellular enzymes, thus increasing complex 
stability. 
Current techniques in the PEGylation of PLL for the generation of nanoparticles involve 
mixing a purified 30-mer of PLL terminating with a single cysteine (CK30) and a methoxy-
PEG10K-maleimide to create a covalently modified PEGylated CK30 peptide (CK30-PEG) (Liu, 
et Li al. 2003). These nanoparticles were shown to efficiently deliver genes to dividing as 
well as post-mitotic cells and have a plasmid capacity of at least 20 kb which is considerably 
more than that of viruses (~8 kb for Lenti and ~4.5 kb for AAV viruses)(Fink, Klepcyk et al. 
2006; Liu, Li et al. 2003). Initial studies involved both CK30 and CK30-PEG nanoparticles 
carrying the luciferase gene under the control of the CMV promoter which were 
administered intranasally or intratracheally into the murine lung. Interestingly, when the 
CK30 compacted nanoparticles were delivered to the murine lung, no gene expression was 
observed in the airway tissue. However when CK30-PEG was used for compaction, efficient 
luciferase activity was observed in the airway. These results highlighted the importance of 
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PEGylation to improve transfection efficiency in vivo (Ziady, Gedeon et al. 2003). 
Furthermore these nanoparticles have also been used in clinical trials to deliver the cystic 
fibrosis transmembrane regulator (CFTR) gene to cystic fibrosis (CF) patients (Konstan, Davis 
et al. 2004) and are also being developed for the treatment of genetic brain diseases (Yurek, 
Flectcher et al. 2009). 
Recently the same CK30-PEG nanoparticles were also shown to efficiently condense a CMV-
EGFP containing plasmid vector (pZEOGFP5.1) for successful delivery to the eye (Farjo, 
Skaggs et al. 2006). Interestingly, the nanoparticles were able target most tissues within the 
eye by varying the site of injection (these will be described further in section 1.7.1). 
Following intravitreal injections, high levels of gene expression were observed in the lens of 
mice, while only moderate expression were found in the retina and little to no expression in 
the pigment epithelium/choroid/sclera (PECS). In contrast, after subretinal injection, 
expression in the retina and PECS was substantially higher than the lens. Furthermore gene 
expression was also observed in the outer nuclear layer (ONL) of photoreceptor cells, optic 
nerve head as well as in the extra-ocular muscle.  Subsequently, nanoparticles were also 
used for the treatment of an inherited retinal degeneration - retinitis pigmentosa (rd - which 
is characterised as a progressive degeneration of the photoreceptor cells within the retina). 
Mice with rds were subretinally injected with nanoparticles containing the normal murine 
RDS cDNA driven by 1 of 3 promoters. Excitingly Cai et al. showed that following the 
subretinal delivery of these nanoparticles to the diseased mouse eye, nearly all 
photoreceptors were able to be transfected, resulting in a partial functional rescue of the 
retinitis pigmentosa disease phenotype (Cai, Nash et al. 2009).  
These results highlight the utility of nanoparticles for in vivo studies, and current successes 
of nanoparticles for therapeutic gene therapy make this approach particular attractive for 
future clinical applications.  
 
1.4.2 Barriers for non-viral delivery 
 
For the non-targeted gene delivery of non-viral vectors using cationic liposomes or 
polyplexes, one of the first obstacles for efficient gene delivery is the extracellular 
membrane. Naked DNA is readily degraded by nucleases while transfection with cationic 
50 
 
lipids and polymers are often also hindered by hydrophobic negatively charged proteins 
such as albumin. The coating of the surface of liposomes with polyethylene glycol (PEG) has 
been shown to extend the circulation lifetime of vectors, due to the hydrophilic nature of 
PEG and its high ability to compact such polymers. However as mentioned before, 
PEGylated lipids are less efficient at condensing DNA, hindering ionic strength interactions 
and in turn reduce the internalisation of complexes into target cells (Mishra, Webster et al.  
2004). 
Non-viral gene delivery vehicles next face another barrier, the cell plasma membrane. The 
plasma membrane is composed of impermeable phospholipid glycoproteins that are crucial 
for the integrity of the cell as well as its contents. Apart from reducing in size, binding of 
cationic liposomes or polyplexes to DNA also imparts excessive positive charge. The 
positively charged polyplexes electrostatically interact with the cell membrane. This process 
is then followed by endocytosis, whereby localised regions of the plasma membrane 
invaginate and pinch off to form an endocytic vesicle. This can be a non-targeted charge-
mediated step, or alternatively, depending on the size of complexes and the nature of the 
target cells, phagocytosis or receptor mediated endocytosis may be operational instead. 
Once in the cytoplasm, normal cellular trafficking usually directs endocytosed particles to 
lysosomes for degradation. Hence gene delivery agents must incorporate a mechanism of 
endosomal escape. Indeed, as mentioned previously, chloroquine is used alongside 
lipoplexes due to its ability to reduced lysosomal degradation, while PEI-based polyplexes 
are able to destabilise endosomal membranes and escape the endocytic pathway through 
the ‘proton-sponge’ mechanism.   
Following endosomal escape, lipoplexes/polyplexes are then placed in the cytoplasm where 
they meet the next barrier. The cytoplasm is composed of a complex network of 
microfilament and microtubule systems as well as a variety of subcellular organelles. Within 
the cytoplasm the mobility of pDNA is severely impeded due to molecular crowding, 
immobile cytoplasmic obstacles as well as the association of pDNA with cytosolic DNA 
binding proteins.  Indeed the lateral diffusion of macromolecules with comparable sizes to 
expression cassettes suggests that the mobility of pDNA is severely impeded in the 
cytoplasm, due to its large size (Dowty, Williams et al. 1995). 
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The nuclear envelope is the final and perhaps most challenging obstacle along the delivery 
pathway of pDNA. The trafficking and control of proteins and ribonucleoproteins to and 
from the nucleus is controlled by the nuclear pore complex (NPC), which forms an aqueous 
channel through the nuclear envelope. The size of the NPC channel is 25-30 nm and allows 
the passive diffusion of molecules below 40 kDa. In contrast molecules larger than 60 kDa 
usually contain a specific targeting signal (the nuclear localization sequence (NLS)) or 
associate with other polypeptides to pass through the NPC. Due to the size of pDNA, 
accumulating evidence suggests that pDNA is able to pass through the NPC via a mechanism 
reminiscent of the active transport of molecules larger than 60 kDa. Furthermore, the 
incorporation of a NLS to a vector may aid nuclear entry of pDNA into the nucleus by active 
transport (Lechardeur, Verkman et al. 2005; Clever, Yamada et al. 1991). 
Once within the nucleus, the vector must provide sustainable transgene expression which 
will be discussed in section 1.5. 
 
1.4.3 Gene transfer by physical methods 
 
As an alternative to chemical gene delivery described in the earlier section, a physical 
approach can also be utilised. In such instances naked DNA (such as pDNA) can be delivered 
directly into the cytoplasm and thus bypassing the endosome and lysosomal degradation. 
The most common physical methods available include: direct injection, electroporation, 
sonication and gene gun.  
 
1.4.3.1 Direct injection  
 
The simple injection of pDNA directly into tissue without additional help from either 
chemical agent or physical force is the simplest approach one could use for gene transfer  
in vivo. This was discovered by chance by Wolff et al. in 1990, where they injected mouse 
skeletal muscle as a negative control for a gene delivery experiment with naked RNA and 
pDNA. To their surprise they observed expression for up to 2 months following injection 
(Wolff, Malone et al. 1990; Wolff, Williams et al. 1991). Since those initial studies, gene 
transfer with naked pDNA has been applied to the liver through direct intraportal injections 
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(Hickman, Malone et al. 1994; Budker, Zhang et al. 1996), to the skin through cutaneous 
injections (Choate and Khavari 1997) and to the lungs through airway instillations (Meyer, 
Thompson et al. 1995). Despite the broad applications of naked pDNA-mediated gene 
transfer, delivery by this method is highly inefficient and only 1% of injected DNA is taken 
up. Furthermore gene transfer is almost always limited to cells adjacent to the site of 
injection (Wolff, Williams et al. 1991). 
 
1.4.3.2 Gene gun 
 
Particle bombardment through a gene gun is an ideal method for gene transfer to skin, as 
well as tissues such as skeletal muscle that can be surgically exposed within a confined area. 
Naked DNA is deposited on the surface of gold particles, which are then accelerated by 
pressurised gas and expelled allowing direct penetration of cell membranes. However, the 
momentum only allows a short depth of the gold particle penetration, indeed in skeletal 
tissue this is less than 0.5 mm (Zelenin, Kolesnikov et al. 1997). Improvements to this 
approach include the chemical modification of the surface of gold particles to allow higher 
capacity and better consistency for DNA coating. Alternatively the fine tuning of the 
expelled force from the gene gun to control the final DNA distribution can also be utilised 
(O’Brien and Lummis 2002). 
 
1.4.3.3 Ultrasound mediated permeabilisation 
 
Another method for plasma membrane permeabilisation involves the application of focused 
ultrasound pulses at a specific site at which gene transfer is required. Ultrasound mediated 
permeabilisation was found to enhance reporter gene expression over that of naked DNA by 
up to 10-20 fold (Gao, Kim et al. 2007).The technique works on the principle that a medium 
such as naked DNA exposed to ultrasound experiences periodic pressure oscillations at the 
frequency and amplitude determined by an ultrasound source (Mitragotri 2005). However 
besides pressure oscillations, the most significant secondary effect of ultrasound 
application, namely cavitation (formation of gas bubbles in liquid due to ultrasonic pressure 
waves), can also induce fluid velocities, sheer forces and shock waves in surrounding tissues 
(Pecha and Gompf 2000). All of these effects cause a transient compromise of cell 
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membrane or tissue integrity, thereby achieving an enhanced uptake of applied naked DNA 
(Mitragotri 2005). Thus cavitation is believed to cause cell membrane permeabilisation, 
where application of ultrasound have been shown to enhance the transport and gene 
expression of naked DNA to cells (Fechheimer, Boylan et al. 1987; Liu, Lewis et al. 1998), as 
well as the skin (Mitragotri 2005), skeletal muscle (Taniyama, Tachibana et al. 2002a) and 
carotid artery (Taniyama, Tachibana et al. 2002b). 
The transfection efficiency of this system is determined by several factors, including the 
frequency and output strength of the ultrasound applied, the duration of the treatment and 
the amount of pDNA used. To further enhance gene delivery, contrast agents such as air-
filled microbubbles can be used, generating local shockwaves that transiently permeate 
surrounding cell membranes. Indeed studies have shown in vitro the combination of 
ultrasound exposure and microbubble-mediated gene delivery of DNA polyplexes can lead 
to a 300-fold increase in gene expression compared to that of naked DNA alone (Lawrie, 
Brisken et al. 2000). 
Interestingly, focused ultrasound has also been shown to induce reversible and non-
destructive disruptions of the blood-brain barrier which may facilitate drug delivery to the 
brain (Mesiwala and Mourad 2002). Moreover, ultrasound has also been utilised to enhance 
solute transport into the eye, where drug delivery was improved to the cornea with minimal 
changes to the corneal epithelium (Zderic, Clark et al. 2004), as well as ocular drug delivery 
for glaucoma (Zderic, Vaezy et al. 2002). While most studies utilising this technique have 
involved in vitro as well as ex vivo transfection, uses of ultrasound delivery in vivo are also 
slowly becoming more prevalent. The ability to precisely focus the required ultrasound 
beams within any tissue as well as the safety and possibility of repeat administrations makes 
this technique particularly promising for future clinical applications.  
 
1.4.3.4 Electroporation 
 
An alternative physical method for gene transfer includes electroporation which involved 
gene transfer based on the application of controlled electrical pulses. The principle being 
that the application of the electric field alters the structure of cell membranes such that 
transient pores are created through which large molecules like DNA - which normally cannot 
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permeate the membrane - can enter the cytoplasm (Andre and Mir 2004). Initially this 
technique was used in vivo in superficial tissues such as the skin and muscle, where long 
term episomal expression of pDNA expressing a dystrophin gene was observed in a mdx 
mouse model of Duchenne muscular dystrophy (Wolff, Williams et al. 1991; Wells 2004). 
Other examples include the pDNA administration through the portal vein followed by 
localised electroporation of rat liver. The results of this were widespread transfection of 
hepatocytes in the treated lobe but not in the surrounding lobes (Sakai, Nishikawa et al. 
2005). 
This raised the possibility that applied electroporation to selected areas can achieve 
localized gene transfer to specialised tissues and cells. Indeed electroporation has been 
successfully used in the eye, initially applied to the most accessible structure, the cornea 
(Oshima, Sakamoto et al. 1998, Oshima, Sakamoto et al. 2002). However it has also been 
used to deliver genes to the retinal ganglion cells in the adult rat retina following an 
intravitreous injection of pDNA (Dezawa, Takano et al. 2002; Mo, Yokoyama et al. 2002). 
Excitingly, subretinal injections of pDNA condensed with lipoplexes as well as naked pDNA 
alone following electroporation resulted in efficient transfection of the retinal pigment 
epithelial (RPE) cells in adult mice (Kachi, Oshima et al. 2005; Johnson, Berglin et al. 2008). 
Similarly, electroporation coupled with subretinal injections in adult mice have also 
facilitated the efficient gene transfer of non-viral nanoparticles into the RPE cells of the 
retina.  
The utility of this technique is dependent on the accessibility of the target tissue to the DNA 
injection as well as the placement of the electrode. Thus, the protocol and highly skilled 
technique requires considerable adaptation for targeting different tissues, accounting for 
the differences in tissue densities and extracellular matrix compositions (Trezise 2002). 
Furthermore, substantial tissue damage and inflammation can occur if incorrect electric 
fields are applied. Considering these limitations, this approach is limited to broad clinical 
applications. 
 
For delivery in specialised organs, such as the eye, specific routes of injection may be 
utilized. This would allow the delivery of pDNA and transfection of different tissues within 
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the eye by varying the site of injection. This will be described in more detail in section 1.7. 
 
1.5 Regulation of transgene expression 
 
In gene therapy, the amount of therapeutic correction one sees is dictated by the success of 
gene transfer one can achieve. Therefore following the successful delivery of genetic 
material to the target cells of interest, successful protein expression is required for a 
therapeutic benefit. This can be done by increasing the amount of protein produced by cells, 
or by increasing the number of transfected cells. As non-viral vectors may have limited 
transfection efficiencies, the need to have an optimal expression cassette which yields 
maximum therapeutic protein levels is essential. Currently, gene therapy vectors have 
common expression cassettes under the control of a promoter. The simplest approach 
would be to change the expression of a transgene cassette with the addition of an S/MAR 
moiety as well as a promoter to drive the strongest expression specific to target cells.  
 
1.5.1 Choice of promoter 
 
The promoter is a stretch of DNA which contains specific DNA sequences recognised by 
proteins as transcription factors. Arguably it is the key regulatory element which determines 
the strength of transgene expression from a pDNA vector. Transcription factors are able to 
bind to promoter sequences and in turn recruit RNA polymerase, the enzyme which is 
required for the synthesis of RNA from the coding region of a gene. Eukaryotic promoters 
are often diverse however typically they lie upstream of genes and have regulatory 
elements which can be as much as several kilobases away from the transcriptional start site. 
Promoters can be ubiquitously active or have specific tissue restricted activity, depending on 
the expression profile of the transcription factors which bind to them and are crucial for 
their activity.  
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1.5.1.1 The CMV promoter  
 
One of the most commonly used promoters for gene therapy includes the promoter from 
the immediate early gene of the human cytomegalovirus (CMV). Its popularity rose from the 
extremely strong expression it confers in most cell types tested in vitro (Boshart, Weber et 
al. 1985). Since the CMV promoter was considered as one of the strongest promoters in 
vitro, it has also been utilised for many studies in vivo to show strong expression of reporter 
and therapeutic genes. However one of the drawbacks in using promoters of viral origin - 
including the CMV promoter as well as others such as the simian virus 40 early promoter 
(SV40) - is that eukaryotic organisms have evolved strategies in defence of viral pathogens. 
Indeed they are efficiently able to detect and subsequently stop the transcription of the viral 
genes. Thus strong expression in vivo is only short-term, where peak transgene expression 
typically is either 1 or 2 days following vector delivery. Importantly however within weeks of 
transfection, transgene expression is barely detectable or above background activity in 
many animal studies. This silencing of the CMV promoter has been attributable to the 
elimination of transduced cells extracellularly by the immune system through cytokine 
inhibition (Zhang, Ni et al. 1995) as well as the activation of repressor proteins that can 
cause methylation (Zhang, Ni et al. 1995; Sinclair, Baillie et al. 1992). 
Alternatively a wide variety of ubiquitously expressed eukaryotic promoters have also been 
described which unlike viral promoters do not invoke such defensive responses from 
transduced cells or the host immune system. While most eukaryotic promoters are typically 
not as strong as their viral counterparts, they have the advantage of providing more 
sustainable transgene expression.  
 
1.5.1.2 The CAG promoter 
 
The CMV early enhancer/ chicken β-actin promoter (CAG or CBA) is 1.7 kb and is composed 
of: a CMV enhancer and a chicken β-actin promoter fused to 90 nucleotides of exon one of 
the chicken β-actin gene, 917 nucleotides of a hybrid chicken β-actin/ rabbit β-globin intron 
and 55 nucleotides of rabbit β-globin exon. This promoter is ubiquitously expressed and was 
first used to facilitate high levels of AAV-mediated gene expression in the brain 
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(Kaemmerer, Reddy et al. 2000). Furthermore this promoter has also been successfully used 
for retinal transduction, where successful long-term expression in the mouse RPE and 
photoreceptor cells have been observed following the subretinal injection of an Ad virus 
(Cashman, McCullough et al. 2007). Following this, similar successes were also observed 
using AAV-vector mediated gene replacement (by the CAG promoter) of the RPE65 gene in a 
canine model of childhood blindness, Leber congenital amaurosis (LCA). This study showed 
long-term restoration of photoreceptor cell function in the treated dogs (Acland, Aguirre et 
al. 2005). Following these significant results with the CAG promoter and lack of toxicity or 
immune response in vivo, this paved the way for three clinical trials for RPE65 gene-
replacement in patients with LCA (Cideciyan, Aleman et al. 2008; Hauswirth, Aleman et al. 
2008; Maguire, Simonelli et al. 2008). These studies validate the clinical significance and 
importance of this promoter in the use of non-viral vectors for ocular gene therapy. 
 
1.5.1.3 The EFS and EF1α promoter 
 
Most eukaryotic cells express the polypeptide chain elongation factor-1α (EF1-α) which is 
responsible for the enzymatic deliver of GTP-dependent binding of aminoacyl-tRNA to 
ribosomes. Hence the gene has a house keeping function in all cells and is expressed in high 
level. Most importantly, due to its indispensible housekeeping function in all cells, EF1-α 
promoter expression is consistent and relatively insulated from changes in cell physiology 
and is cell type independent (Kim, Uetsuki et al. 1990; Wakabayashi-Ito and Nagata 1994; 
Goldman, Cutrone et al. 1996). An intronless version of this promoter also exists and is 
called the elongation factor 1 short (EFS), corresponding to the nucleotides 378-610 of the 
EF1-α gene. Expression from the EF1-α promoter has been shown to result in 10-fold lower 
expression compare to the CMV promoter following instillation to the lungs. However 
perhaps more importantly, transgene expression conferred by the CMV promoter was 
rapidly lost, while that of the EF1-α promoter was still detectable at 4 weeks post 
administration (Gill, Smyth et al. 2001). Furthermore the intronless version of this promoter, 
EFS has been shown to ubiquitously express transgenes broadly throughout the entire 
retina. This includes EFS facilitating GFP transgene expression in RPE cells, inner nuclear 
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layer (INL) cells of the photoreceptors as well as glial cells of the retina (Kostic, Chiodini et al. 
2003).  
 
1.5.1.4 The Ubiquitin C promoter 
 
The ubiquitin C (UbC) promoter drives the expression of three known human ubiquitin 
genes, UbA-C. Ubiquitin is abundantly expressed in all eukaryotic cells and is responsible for 
marking proteins for destruction by attaching covalently to abnormal, misfolded or short-
lived proteins. Importantly, in transgenic mice, the UbC promoter has been shown to 
facilitate strong ubiquitous expression (Schorpp, Jager et al. 1996). Furthermore, when 
contained in a pDNA, UbC is able to mediate high-levels of reporter gene expression for up 
to two months following delivery to the lungs. However expression was seen to gradually 
decline and by 6 months following administration expression was lost (Gill, Smyth et al. 
2001). 
 
1.6 The eye as a target organ 
1.6.1 The retina 
 
The retina is the most metabolically active tissue within the body and is the primary light 
sensing organ in vertebrates. In humans it is approximately 0.5 mm thick and lines the 
interior surface at the back of the eye. The light is it initially focused through the lens and 
then detected by the retina, where it is converted into signals that reach the brain through 
the optic nerve. The eye contains three chambers of fluid: the anterior, posterior and 
vitreous chambers. A radial section of a portion of the retina reveals that the ganglion cells 
are found on the inner most layer closest to the lens and the front of the eye. The ganglion 
cells function as the output neurons of the retina, forming long axons that extend into the 
brain together allowing the transmission of visual information from the retina to the brain. 
Collectively the axons of the ganglion cells make up the optic nerve. The other layer is the 
neural sensory retina which is composed of the photoreceptor cells, of which there are two 
types: rods and cones. These are the crucial photosensory cells which detect a photon of 
light and subsequently create the electrical signal that is crucial for vision. Photoreceptors 
lie against a monolayer of specialised epithelial cells called the retinal pigment epithelium 
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(RPE). RPE cells are the highly pigmented cells that firmly attach to the underlying choroid. 
The choroid contains the blood vessels that supply the retina with nutrients and oxygen as 
well as removing its waste products. 
Between the photoreceptors and the ganglion cells there are many interneurons found 
within this region of the retina. All vertebrate retinas are composed of three further layers 
of nerve cell bodies and two of synapses. The three nerve layers are: (i) the outer nuclear 
layer (ONL) comprising of the rod and cone photoreceptors, (ii) the inner nuclear layer (INL) 
contains cell bodies of the bipolar cells, horizontal and Amacrine cells and (iii) the ganglion 
cell layer which contains cell bodies of ganglion cells and displaced Amacrine cells. The 
horizontal cells relay messages back and forth between the photoreceptor cells, the bipolar 
cells and each other. While the Amacrine cells are interconnected with the bipolar cells, the 
ganglion cells as well as each other. Both these types of interneuron cells play a major role 
in the processing of visual information at the level of the retina before it is passed to the 
brain for interpretation. The retina also has two layers of neuronal interconnections dividing 
these nerve cell layers: the outer plexiform layer (OPL) and the inner plexiform layer (IPL). 
At the center of the retina is a region of approximately 5mm in diameter called the macula. 
Near the center of this is the fovea, a small region which contains the highest concentration 
of cone cells in the eye and is responsible for central and high acuity vision. This is evident 
by the fact that loss of peripheral vision may go unnoticed for some time, however damage 
to the macular causes loss of central vision which is usually immediately obvious.  The 
progressive deterioration and loss of the macula is the primary consequence of age-related 
macular degeneration. The summary of the anatomy of the eye and the retinal architecture 
are shown in Figure 8.  
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Figure 8: Anatomy of the eye and enlargement showing the organisation of the 
retinal architecture 
The process of light detection and visual cycle occurs in the photoreceptors 
(constituting rod (r) and cone (c) cells) and retinal pigment epithelium (RPE) of the 
retina. Specifically, light is detected in the photoreceptor outer segments (OS). 
Photoreceptor outer and inner segments (IS) constitute the outer nuclear layer (ONL). 
Photoreceptor synapses with horizontal cells (hc) and bipolar cells (bc) constitute the 
outer plexiform layer (OPL). Horizontal, bipolar and Amacrine cells (ac) constitute the 
inner nuclear layer (INL). Bipolar and Amacrine cells synapse with ganglion cells (gc) of 
the ganglion cell layer (GCS) in the inner plexiform layer (IPL). Blood vessels (bv) as 
well as glial Müller cells (m) are seen throughout the neural retina. The nerve fiber layer 
(NFL) is formed by the expansion of the axons from ganglion cells which make up the 
the optic nerve (Figure adapted from (Kolb 2003)). 
 
 
1.6.1.1 Retinal cycle 
 
The human eye constantly metabolises vitamin A to function properly in a process known as 
the visual/retinal cycle. This process takes place in the photoreceptors and RPE of the retina 
and involves a series of enzymatic reactions. One particular enzyme, RPE65 which is the 
most abundant protein in the RPE, is crucial for the conversion of dietary vitamin A all-trans 
retinol into its derivative form 11-cis-retinol, which is taken up by the photoreceptor cells 
for processing of vision. In vertebrates, light detection is mediated by the photoreceptor 
cells, specifically within the rod and cone cells. Both cells consist of the two parts: the outer 
segments and inner segments. It is the outer segments which contain the machinery 
responsible for the biological conversion of a photon of light into an electrical signal (within 
the retina) – this process is referred to as visual phototransduction. 
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The sequence of events to generate signal to the brain for twilight (scotopic) and 
monochrome vision occurs in the rod cells, while for daylight (photopic) and colour vision 
this occurs in the cone cells (Shichida and Imai 1998). Both rod and cone cells consist of two 
parts, the outer segment (OS) and inner segment (IS). The OS contains the machinery 
responsible for this process, namely the light-absorbing pigment, opsin, which also contains 
the retinal chromophore 11-cis-retinal. Upon absorption of light by the pigment cells, the 
chromophore undergoes a photoisomerisation, or change in molecular arrangement, from 
11-cis-retinal to all-trans-retinal. Following this isomerisation, this induces a conformational 
change in the photo-bleached opsin pigment which leads to the activation of an enzyme 
cascade to evoke a light response leading to vision (Lamb and Pugh 2006; Fu and Yau 2007). 
The product formed after light induction, all-trans-retinal, is then released from the opsin 
protein into the cytoplasm (Liu, Itagaki et al. 2000). Once in the cytoplasm, all-trans-retinal 
is reduced to all-trans-retinol (Vitamin A). This form of retinol then exits the photoreceptors, 
crosses the subretinal space bound to the interphotoreceptor retinoid binding protein 
(IRBP), and enters the RPE (Bunt-Milam and Saari 1983; Ala-Laurila, Crouch et al. 2006; Wu, 
Blakeley et al. 2007) .  
In the RPE, all-trans-retinol is first esterified by lecithin-retinol acyltransferase (LRAT) (Saari 
and Bredberg 1989) and then simultaneous hydrolysis and isomerisation of all-trans esters 
yields 11-cis-retinol. This coupling of isomerisation and hydrolysis is facilitated by a single 
enzyme, the isomerohydrolase enzyme RPE65 (Redmond, Yu et al. 1998; Moiseyev, Chen et 
al. 2005). Indeed, RPE65 is essential for the regeneration of 11-cis retinoids, and there is no 
isomerohydrolase activity in its absence (Redmond, Poliakov et al. 2005). Finally, 11-cis-
retinol from the isomerohydrolase reaction is oxidised to 11-cis-retinal (Simon, Hellman et 
al. 1995). The newly generated 11-cis-retinal is then transferred back to the outer segments 
where it can again be conjugated to an opsin protein; restore the light sensitivity of this 
protein and in turn regenerating the visual pigment to complete the cycle. It is this cycle of 
generation of 11-cis-retinal from all-trans-retinol and regeneration of all-trans-retinol from 
11-cis-retinal which is known as the visual cycle (Figure 9A) and is essential for the 
continuous processing of vision.  
Our current understanding of the visual cycle is largely based on studies from the rod 
photoreceptors (McBee, Palczewski et al. 2001). Cone photoreceptors are believed to rely 
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upon this same system; however they are also thought to have privilege to an alternative 
visual cycle pathway within the inner retina. Indeed there is growing evidence for a cone 
specific pathway involving the cone photoreceptors and the Müller glial cells of the inner 
retina (Znoiko, Crouch et al. 2002)(Figure 9B). Central to this theory is the ability of cone 
cells to regenerate 11-cis retinal from 11-cis retinol supplied to the inner segments (Jones, 
Crouch et al. 1989). In this proposed cone visual cycle, it has been suggested that that the 
all-trans-retinol generated in the photoreceptors is transported to the Müller cells and 
isomerized to 11-cis retinol by an unidentified isomerise. Following this, 11-cis retinol from 
the Müller cells then enters the inner segments of the cone photoreceptors and is oxidised 
to 11-cis retinal for visual pigment formation. Interestingly, the cone inner segments are in 
close proximity to the apical microvilli of Müller cells. These microvilli contain a retinoid 
binding protein which has a high affinity for 11-cis retinoids; cellular retinoid binding protein 
(CRALBP) (Bunt-Milam and Saari 1983). Furthermore, Müller cells have the ability to 
generate 11-cis retinol from all-trans-retinol (Das, Bhardwaj et al. 1992). Finally, IRBP which 
acts as a transporter in the visual cycle discussed earlier, appears to co-localise with the 
microvilli and is found in high concentrations around cone photoreceptors (Carter-Dawson 
and Burroughs 1992; Gonzalez-Fernandez, Baer et al. 2003). While the relationship between 
IRBP, Müller cells and cone inner segments in the cone-specific pathway still remains 
unproven, it may explain the ability of cone cells to function and efficiently regenerate visual 
pigment in conditions of constant light/daylight.  
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Figure 9: The rod and cone visual cycle 
Shown is a scheme to show the current supported visual cycle of (A) rod and (B) cone 
photoreceptor cells. After absorption of light by the photoreceptor outer segments (OS), 
the visual pigment chromophore, 11-cis retinal, is isomerized to all-trans retinal. 
Following this all-trans retinal is detached from the opsin and reduced by the enzyme 
retinol dehydrogenase 8 (RDH8) to all-trans retinol. This reduced retinol is then 
transferred to the RPE where the all-trans from is isomerized into 11-cis form and is 
subsequently oxidised to 11-cis retinal. Following this 11-cis retinal is transferred back 
to the OS of rod cells to regenerate visual pigment. (B) A similar pathway of the visual 
cycle for cones is seen. However, in cones an additional pathway for the production of 
11-cis retinal is present. In this alternative pathway, 11-cis retinol supplied from Müller 
cells is converted to 11-cis retinal (Miyazono, Shimauchi-Matsukawa et al. 2008). 
 
1.6.1.2 The Photoreceptors 
 
There are two types of photoreceptors, the rods and cones, each having a distinctive 
morphology, indeed the names of the respective cells come from their shapes (Figure 10). 
They are comprised of an outer segment, which contains membrane disks filled with 
photosensitive pigments called opsin proteins. The outer segment is connected through a 
cilium to the inner segment which contains mitochondria. Following this is the main cell 
body which contains all the organelles, and finally the synaptic endings where release of 
neurotransmitters occurs.  
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Figure 10: Generalised picture representing the structure of a vertebrate rod and 
cone photoreceptor 
A schematic showing the structure of a vertebrate rod (left) and cone (right) 
photoreceptor. In rod photoreceptor cells opsins and photopigments are embedded in 
membranous disks of the outer segments. Distal tips of the outer segments are shed 
daily and phagocytosed by RPE cells before being recycled back to the photoreceptors. 
Cone photoreceptor cells have a similar cell body structure with the exception that 
outer segments appear shorter with a more conical morphology (Figure adapted from 
(Colella, Cotugno et al. 2009)). 
 
Rod cells are concentrated at the outer edges of the retina and are used for peripheral 
vision. They are able to function under scotopic conditions (dim light) and are almost 
entirely responsible for night vision. This ability come from the fact that they are structurally 
narrower than cone cells as they have a higher area for visual pigment thus a substantial 
higher efficiency of light absorption in the retina. As vertebrates only possess light-sensitive 
pigment, rods have little if any role in colour vision. 
Cone cells in contrast sense light under photopic (bright light) conditions. They are densely 
localised in the fovea, and gradually become sparser towards the periphery of the retina. 
While cone cells are less sensitive to light than rod cells (which detect low levels of light), 
they allow the perception of colour. In humans, there are three types of pigmented cells in 
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cone cells which provide basic colour vision. Each type of pigmented cell responds and has 
the greatest sensitivity to light from a different portion of the spectrum of visible light. 
These include sensitivities to short (S,~ 430nm, blue light), medium (M, ~ 530nm, green 
light) and long (L, ~ 560nm, red light) wavelengths of light (Terakita 2005). Hence colour 
vision is achieved with these cone-opsin based pigments with different colour sensitivities. 
Visual transduction occurs in photoreceptor outer segments, with the photo-isomerisation 
of opsin bound 11-cis retinal (chromophore), as described earlier in section 1.6.1.1. The 
outer segments contain stacks of membranes/disks in which the opsin and chromophore 
complexes are embedded. 
 
1.6.1.3 The Retinal Pigment Epithelium 
 
The RPE is a pigmented layer that is found just after the neurosensory photoreceptor cells 
within the retina. It is an apically polarised monolayer which is essential for the function of 
photoreceptor cells and forms a part of the blood-brain barrier. The apical membranes of 
the RPE are lined with long microvilli which extend into the inter-photoreceptor space 
allowing the continual contact between the photoreceptor outer segments and the RPE. 
Indeed, each RPE cell is in contact with between fifty and one hundred photoreceptors, thus 
allowing the synergistic interaction of these tissues (Strauss 2005). Such integrations include 
the visual cycle, in which following light transduction retinal cycles between the 
photoreceptors (from all-cis- to all-trans retinal) and RPE (from all-trans- to all-cis retinal), a 
process essential for maintaining photoreceptor excitability. Another example is the 
phagocytosis of shed photoreceptor outer segments by RPE cells and the recycling of 
essential substances to be returned to the photoreceptors to rebuild light-sensitive outer 
segments from the base of the photoreceptors. As shown in Figure 11, the RPE performs 
multiple functions within the retina, many of which are also essential for the normal 
function of photoreceptor cells.    
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Figure 11: Functions of the Retinal Pigment Epithelium 
The RPE performs numerous functions in supporting and maintaining the 
photoreceptor cells. Apical microvilli (MV) from the RPE extend into the photoreceptor 
outer segments (OS). The choroidal capillaries lie underneath the RPE and provide 
circulation for the retina. VEGF, vascular epithelium growth factor, PEDF, pigment 
epithelium derived growth factor (Figure adapted from (Strauss 2005)). 
 
The RPE takes up nutrients such as oxygen, glucose, retinol (vitamin A) and fatty acids from 
the choroidal blood flow and delivers these to the photoreceptors. At the same time 
metabolic end products from the photoreceptors are removed from the inter-
photoreceptor space for recycling via the RPE.  The RPE is also able to secrete a variety of 
growth factors to help promote the survival, proliferation and differentiation of retinal cells.   
With these complex different functions, the RPE is essential for visual function and a failure 
of any of these functions can lead to retinal degeneration, loss of visual function and 
blindness.  
 
1.6.1.4 The Choroid 
 
Encompassing the outer retina is a network of capillary vessels called the choriocapillaris, or 
better known as the choroid. The choroid receives the greatest blood flow (65-85%) 
(Henkind, Hansen et al. 1979) and is vital for the maintenance, supply of oxygen and 
nutrients to the outer retina particularly the RPE and photoreceptor cells. The remaining 20-
30% of intra-ocular blood vessels support and nourish the inner retinal layers such as the 
neurons apical to the ONL. The choroid lies beneath the Bruch’s membrane and the RPE, 
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and similar to the RPE, the choroid also contains pigmented cells to prevent damage from 
light to surrounding tissue.   A range of retinopathies have been well characterised in recent 
years, all of which arise due to problems and deterioration within any of the three key cell 
layers of the retina described above (choroid, photoreceptors and RPE). These diseases as 
well as the delivery routes used will be highlighted in more detail in the following sections.   
 
1.7 Goals of Gene therapy – targeting eye disease 
 
Gene therapy holds great promise for the treatment of eye diseases, and proof-of-principle 
as well as its efficacy have been provided by viral vectors and will be discussed in the 
following sections. 
The eye is an excellent target for gene therapy due to its high accessibility and its unique 
compartmentalisation, allowing various routes of gene delivery to target different cell layers 
or cell types within the eye. Furthermore, the small tissue volume and size allow for low 
vector and/or gene doses in the eye. Unique to the eye is the presence of a blood-retina 
barrier which limits vector and/or gene leakage into the circulation and gives the eye a 
useful immune privileged status. This is highly advantageous as this significantly limits the 
immune response to vector components as well a transgenes. Furthermore many disease 
causing genes which lead to retinal degenerations have been identified. The availability of 
numerous animal models which have been created that showing considerable resemblance 
to the specific human pathologies is also an invaluable tool. This is particularly necessary for 
the validation and functional examinations in therapeutic gene therapy studies. 
Furthermore such models also enable clinical applications to be possible. The contralateral 
eye is also an invaluable control within ocular gene therapy, as this eye can either remain 
untreated or is treated with vehicle alone, while the other eye is subjected to the required 
treatment. Finally, the external layers of the retina (in vivo) can be easily monitored for 
function, morphology and retinal integrity using techniques such as scanning laser 
ophthalmoscopy (SLO) and electroretinography (ERG) as well more complex tests such as 
afferent pupillary light responses (PLRs). 
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1.7.1 Barriers for retinal gene delivery using non-viral vectors 
1.7.1.1 Delivery routes for ocular gene therapy 
 
Gene delivery to ocular tissues can commonly be performed through topical applications 
(via eye drops) and injections including: intracameral injections, subconjunctival injections, 
intravitreous injections as well as subretinal injections (Figure 12). Each technique allows 
different regions of the eye to be transfected and these methods will be discussed in the 
next section.  
 
Figure 12: Delivery routes for ocular gene therapy 
Gene delivery to the eye can be performed through several routes depending on the cell 
to be targeted and the specific features of the vector used for gene delivery:  
(A) Topical applications, (B) Intracameral injections, (C) Subconjunctival injections,  
(D) Intravitreal injections and (E) Subretinal injections (Figure adapted from (Colella, 
Cotugno et al. 2009)). 
 
1.7.1.2 Topical applications and intracameral injections 
 
Topical applications are the primary route of drug delivery to the anterior segment of the 
eye. This route is relatively non-invasive, free from systemic side effects and easy to apply, 
with either a punctal occlusion or gentle lid closure to minimise systemic drug absorption 
(Figure 12A). A puncal occlusion is a procedure where some or all of the puncta in the eyes 
are blocked. Puncta are small openings located on the nasal part of the inner eye lids, 
through which tears drain. By blocking these openings, the surface of the eye becomes 
more lubricated as the drainage of tears slows down.   
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To determine the most appropriate route of delivery in the eye, specifically to the retina and 
RPE, topical instillations as well as systemic administration are not a practical choice in gene 
delivery. The lack of extravasations into the eye after intravenous administration due to the 
presence of the tight blood-retina barrier (Duvvuri, Majumdar et al. 2003), means that 
systemic administration is not a practical choice in retinal gene delivery. Similarly, many 
features of the cornea, such as the topical ocular administration of small-molecular-weight 
compounds show limited diffusion across the large corneal surface to the retina (Tonjum 
1974; Tonjum 1977; Maurice and Mishima 1984; Weinreb 2001). This is mainly due to the 
cornea being protected from environmental substances by rapidly secreted tears to flush its 
surface as well as the corneal epithelium being highly impermeable with tight junctions 
between cells (Maurice and Mishima 1984; Weinreb 2001; Rosenblatt and Azar 2004). 
Despite this, previous reports show expression (of β-galactosidase (β-gal)) in various ocular 
tissues including anterior chamber, cornea, iris, choroid sclera, conjunctiva, RPE and the 
vitreous body after topical administration of (non-ionic PEO-PPO-PEO) polymer micelles 
(PM) with pDNA (pCMV-Lac Z pDNA) via eye drop delivery (Liaw, Chang et al. 2001). 
Expression was shown to be enhanced when pretreatment was carried out with 
cytochalasin B and ethylenediaminetetraacetic acid (EDTA), which are both known to open 
tight junctions of the corneal epithelium. This in turn enhances paracellular transport of 
formulated genes for further penetration of DNA to tissues other than the cornea (Madara, 
Barenberg et al. 1986). Furthermore, increases in intracellular calcium levels can also lead to 
increases in endocytosis which also help encourage complex uptake (Lam and Cullis 2000). 
While the mechanism of EDTA transport, whereby calcium can stimulate uptake of pDNA is 
not clear in the cornea, it appears that the internalisation and the transport mechanism of 
pDNA in the cornea may be influenced by endocytosis and enhanced (penetration) through 
the opening of tight junctions in the corneal epithelium.  
As an alternative to topical instillations, direct injection into the anterior chamber of the 
retina - via an intracameral injection - can also be utilised to allow the transfection of 
anterior eye segment tissues (Figure 12B). This approach has been particularly useful for the 
delivery of secreted anti-inflammatory molecules to reduce inflammation after corneal 
transplantation. However, similar to the topical route, intracameral injections although 
effective for anterior segment disorders, this technique does not result in significant retinal 
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concentrations of most molecules (Maurice 2002). 
 
1.7.1.3 Subconjunctival injections 
 
Periocular routes of delivery are another method considered less invasive than direct 
injection into the retina and one such route includes the subconjunctival route. This route is 
performed by injecting vectors directly under the conjunctival membranes of the eye (Figure 
12C). This route for delivery has been particularly useful for vector-mediated delivery of 
secreted antiangiogenic proteins that are able to enter the eye from the periocular space for 
treatment of neovascular diseases (Gehlbach, Demetriades et al. 2003). Periocular routes 
exploit the permeability of sclera for retinal drug delivery, as well as being particularly useful 
for the administration of sustained-release systems of potent drugs. While this route 
appears to be most suitable for the treatment of posterior segment ocular disorders, limited 
transfection of the retina has been observed; most likely due to the clearance of drugs via 
the choroidal circulation. 
 
1.7.1.4 Intravitreous injections 
 
Contrary to the methods described earlier, direct injection into the vitreal space / vitreous 
body is another route of delivery in the eye (Figure 12D). This route allows the transfection 
of the inner most cell layers of the retina. In particular this method has been useful for the 
treatment of inner retinal neovascularisation as well as glaucoma (Murata 2001; Gehlbach, 
Demetriades et al. 2003; Shahar 2006).  
Importantly intravitreous injections are not suitable for delivery to photoreceptors in the 
outer retina because, injected vectors would need to diffuse through the vitreous – which 
functions as a molecular sieve restricting the diffusion of large molecules – as well as the 
neural retina before reaching the RPE (Maurice and Mishima 1984; Bishop 2000).The 
vitreous is made up of water (98%) and colloids (0.1%), with the rest of the solid material 
being ions and low-molecular-weight solutes (Pitkanen, Ruponen et al. 2003). The two 
major structural components of the vitreous are collagen (40-120 µg/ml) and hyaluronic 
acid (100-400 µg/ml) (Pitkanen, Ruponen et al. 2003). Hyaluronan is the most common 
71 
 
negatively charged glycosaminoglycan (GAG) in human vitreous and is known to interact 
with complexed polymeric and liposomal DNA (Ruponen, Ylä-Herttuala et al. 1999). Thus the 
vitreous is built up of a complex network of collagens, negatively charged GAGs and non-
collagenous structural proteins. Within such a network, collagen fibrils are bridged by 
proteoglycan filaments which contain negatively charged GAGs (Bishop 2000). Furthermore 
the interfibrillar spaces of this network are also filled by a dense network of hyaluronan. 
This complex network within the vitreous has been shown to immobilize non-viral 
complexes, including nanoparticles composed of plasmid DNA and cationic lipids. 
Specifically, aggregations of lipoplexes within the vitreous have been shown to be caused by 
the binding of the negatively charged GAGs within the vitreous to the positively charged 
complexes (Pitkanen, Ruponen et al. 2003; Peeters, Sanders et al. 2005). Interestingly, this 
problem of aggregation can be overcome. Studies have shown that nanoparticles within the 
vitreous can be protected from aggregation by shielding their surface with polyethylene 
glycol (PEG); through a process named ‘pegylation’ (Pitkanen, Ruponen et al. 2003; Peeters, 
Sanders et al. 2005).  
While pegylation can be used to avoid aggregation within the vitreous, vectors delivered to 
the vitreous must also be able to penetrate through the neural retina before reaching the 
RPE cells. However, the retina is also inefficiently permeable to non-pegylated liposomal 
(and polymeric) gene complexes (Pitkanen, Ruponen et al. 2003). Further to this, it has been 
shown that the strongest barrier in the neural retina is the inner limiting membrane (ILM) 
(Pitkanen, Ruponen et al. 2003). The ILM is the boundary region between the vitreous space 
in the posterior chamber and the retina. This ILM has been shown to restrict the 
penetration of polyethylenimine (PEI) polyplexes, (polyplexes, poly-L-lysine polyplexes and 
DOTAP liposomes) through the neural retina (Pitkanen, Ruponen et al. 2004). 
 
1.7.1.5 Subretinal injections 
 
Finally, subretinal injections deliver injected vectors between the distal tip of the outer 
segments of the photoreceptor, causing an initial subretinal bleb that usually is seen to 
regress quickly (Figure 12E and Figure 13). Hence this technique allows the targeting of the 
cells in the outer retina and the RPE cells.  
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Subretinal injections have been successfully used in many experimental models of ocular 
diseases including: Retinitis pigmentosa (RP)(Takahashi, Miyoshi et al. 1999; Chen, Moiseyev 
et al. 2006), Age Related Macular Degeneration (AMD)(Lai, Wu et al. 2001; Campochiaro, 
Nguyen et al. 2006) as well as diabetic retinopathy (Ideno J 2007). Furthermore, this 
technique has also been utilised in three recent ocular clinical trials for Leber congential 
amaurosis (LCA)(Bainbridge 2008; Bainbridge, Smith et al. 2008; Bainbridge and Ali 2008; 
Cideciyan, Aleman et al. 2008; Maguire, Simonelli et al. 2008). 
Despite subretinal injections being very efficient, some major drawbacks include that it is 
relatively invasive but more importantly it is also a technically demanding procedure. 
However numerous approaches to the injection technique have been proposed including via 
a transcorneal/transvitreal route (Johnson, Berglin et al. 2008; Timmers, Zhang et al. 2001), 
transscleral route (Price, Turner et al. 1987) as well as transscleral-transchoroidal-Bruch’s 
membrane route (Gekeler, Kobuch et al. 2004; Gerding 2007). 
 
 
Figure 13: Schematic showing the subretinal injection procedure 
A needle containing the required vector is inserted into the retina within the subretinal 
space – located between the plasma membrane of the photoreceptor and RPE cells of 
the retina. Upon injection of the vector into the subretinal space, a bleb occurs causing 
the two layers (photoreceptor and RPE cells) to become separated and the vector is able 
to spread along the retina. This usually regresses back quickly and the treated area 
including the pigmented RPE cells are able to rejuvenate within the treated area  
(Figure from Moorefield Eye Hospital). 
 
73 
 
1.7.2 Eye disorders 
1.7.2.1  Macular Degeneration -Age related Macular Degeneration (AMD) 
 
Macular degeneration is one of the most common causes of severe vision loss within the 
Western world, indiscriminately affecting the young and old. The most common subtype is 
age-related macular degeneration (AMD) affecting more than 8 million people worldwide, 
including 75% of age-related blindness in the Western world. It is a complex disorder in 
which depositions of material in and around the Bruch’s membrane lead to dysfunction and 
death of the photoreceptors and RPE cells, as well as the eventual choroidal 
neovascularisation (CNV) which grows beneath the RPE and photoreceptors. 
AMD occurs in two forms, dry and wet. In the dry form, patients often manifest deposits 
beneath the RPE, called drusen. Pigmentary changes are also seen in the retina, which 
indicates death of photoreceptors and RPE, for years before the onset of CNV. This stage of 
the disease is referred to as atrophic or non-neovascular AMD, often accompanied by mild 
visual dysfunction, particularly loss of photoreceptors in the central part of the eye. 
In the wet form, visual prognosis becomes considerably worse by the conversion of the 
disease from non-neovascular to neovascular AMD. Initially, visual loss is caused by pockets 
of fluid seen beneath and within the retina, due to the leakage of the plasma membrane 
from abnormal growth of new choroidal blood vessels. During this stage of the disease, 
visual loss is reversible if the resorption of fluid occurs. Following this, choroidal blood 
vessels often haemorrhage which leads to blood entering the subretinal space (below the 
macula) resulting in loss of vision. However, again at this stage, vision can be improved with 
the resorption of the blood. The subsequent formation of new choroidal vessels, blood and 
plasma within the eye ultimately stimulates the migration and proliferation of RPE and glial 
cells, causing irreversible scaring that permanently destroys vision (de Jong 2006; Zarbin 
2004). 
To date, no effective treatments had been available for wet-AMD patients. However, 
recently a number of factors were shown to be responsible for the conversion from non-
neovascular AMD to neovascular AMD. These include the vascular endothelial growth factor 
(VEGF) as well as the pigment epithelium-derived factor (PEDF)(Kwak, Okamoto et al. 2000). 
Studies have shown that neovascularisation results from unbalanced production of factors 
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such as VEGF or PEDF which result in the growth of abnormal blood vessels in the choroid 
and retina (Allocca, Tessitore et al. 2006). Studies in animal models showed that blocking 
VEGF or its signalling suppresses CNV (Kwak, Okamoto et al. 2000; Krzystolik, Afshari et al. 
2002). This finding led to the prediction that VEGF antagonists could prevent the 
neovascularisation observed in AMD. This prediction was confirmed following two large 
scale clinical trials in which patients with neovascular AMD received repeat intravitreal 
injections of VEGF antagonists. In one trial this was pegaptanib, an aptamer which binds 
VEGF (Gragoudas, Adamis et al. 2004). In another trial, this was ranibizumab, which is a Fab 
fragment of an antibody that binds to all isoforms of VEGF-A. Results from the first trial 
showed the percentage of patients who experienced severe loss was reduced by 15% during 
the course of the 1 year trial. However results from the second trial were considerably 
better, where substantial improvement in patients’ vision was increased from 4.6% to 34%.  
PEDF is an anti-angiogenic molecule which is responsible for inducing and maintaining the 
avascularity of the cornea and vitreous compartments in physiological conditions (Allocca, 
Tessitore et al. 2006). PEDF gene transfer inhibits both retinal and choroidal 
neovascularisation. Intravitreal, subretinal and periocular administration of Adenoviral (Ad) 
or Adeno-associated (AAV) vectors encoding PEDF results in reduction of neovascularisation 
in various animal models (Gehlbach, Demetriades et al. 2003; Allocca, Tessitore et al. 2006). 
Following this, in a phase I clinical trial, patients with neovascular AMD received intravitreal 
injections of Ad-PEDF vectors (Campochiaro, Nguyen et al. 2006). Therapeutic efficacy was 
reported, where 94-71% of patients treated with the highest vector dose had a reduction in 
the size of CNV lesions within the retina (Campochiaro, Nguyen et al. 2006). 
AMD is classed as a complex genetic trait, and suggestions have been made that an 
immunological contribution many lead to AMD pathogenesis. A common single nucleotide 
polymorphism in Complement Factor H (CFH), His402, has been associated with AMD. 
Homozygous individuals have been shown to be at a substantially higher risk of developing 
AMD compared to the homozygotes for the normal Tyr402 haplotype, while heterozygotes 
showed an intermediate risk (Edwards, Ritter et al. 2005; Klein, Zeiss et al. 2005). CFH has 
been shown to be a key component of the alterative complement pathway, where it is a 
negative regulator of the complement cascade. CFH binds activated Complement Factor 3 
(known as C3b in its active state) and this promotes its digestion by Complement Factor I. 
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The mutation in CFH (His402) reduces the ability of CFH to recognise surface markers such 
as glycosaminoglycans. Hence this change reduces the ability of CFH to regulate 
complement in critical surfaces such as the specialised membrane at the back of the eye. 
Subsequently this leads to an increased inflammatory response within the macula. 
Interestingly, 20 out of the 84 CFH gene polymorphisms have been associated with an 
increased risk of developing AMD (Li, Atmaca-Sonmez et al. 2006); implying that CFH 
expression could determine AMD risk.    
Another susceptibility locus has been mapped to chromosome 10q26; the causative 
variation has been shown to lie in a ‘hypothetical gene’ called LOC387715 or in the 
promoter of the neighbouring gene HTRA1 (Rivera, Fisher et al. 2005; Schmidt, Hauser et al. 
2006).Two further complement regulatory proteins, complement factor B (CFB) and 
complement component protein C3 (C3) have also been shown to possess sequence 
variants which strongly associate with the occurrence of AMD (Maller, Fagerness et al. 2007; 
Yates, Sepp et al. 2007). 
Indeed population attributable risks of AMD associated with variants in CFH, CFB and 
LOC387715/HTRA1 have been shown to be at least 50% (Maller, George et al. 2006). These 
finding suggest that AMD is caused by aberrant complement activation, which causes a 
positive feedback loop of activated complement and pro-inflammatory peptides within the 
retina (Rattner and Nathans 2006). 
 
1.7.2.2 Stargardt disease 
 
Stargardt disease is the most common form of juvenile macular degeneration. It is inherited 
as an autosomal recessive trait, showing severe juvenile macular degeneration and has an 
incidence of 1 in 10,000. Disease progression usually starts between the ages of 6-12 years 
leading to rapid reduction in visual acuity. It is characterised by the appearance of 
lipofuscin-like protein deposits in the RPE underlying the macula, which cause atrophy of 
the macula and underlying RPE resulting in the loss of vision. The disease is caused by 
mutations in the ABCA4 gene at the locus 1p13-p21 (Arnell, Mantyjarvi et al. 1998). The 
ABC4A gene is expressed exclusively and at high levels in the retina. Specifically it is localised 
to the photoreceptor outer segments, where it translocates all-trans retinal 
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phosphatidylethanolamine from the outer segment disc lumen to the cytosol (Molday, 
Rabin et al. 2000). Failure of this process causes an accumulation of all-trans-retinal in the 
photoreceptor outer segments, which progressively causes the accumulation of a toxic 
compound called A2E which can induce apoptosis and dissolve cell membranes.  
Stargardt disease also has a rare dominant form called Stargardt-disease 3 (STGD3) or 
Stargardt-like dominant macular dystrophy. This form of the disease is thought to be caused 
by mutations in the elongation of very long chain fatty acids-like 4 (ELOVL4) gene found on 
chromosome 6q14. The ELOVL4 gene is involved in the production of long-chain fatty acids, 
(via the fatty acid elongation pathway) which occurs exclusively in the photoreceptors 
(Edwards, Donoso et al. 2001). To date all types of mutations found in the ELOVL4 gene 
result in C-terminal truncated versions of the protein. As a result the protein cannot be 
retained in the endoplasmic reticulum of photoreceptor cells. Instead, the ELOVL4 protein 
forms clumps or aggregates adjacent to the nucleus (Grayson and Molday 2005). Since these 
aggregates cannot make long-chain fatty acids they may interfere with cell functions, 
ultimately leading to photoreceptor cell death. These findings suggest that aberrant 
subcellular localisation of wild-type ELOVL4 protein may contribute to STGD3 disease 
development.  
 
1.7.2.3 LCA 
 
One of the most clinically severe retinal degenerations is Leber congenital amaurosis (LCA). 
It is an early-onset inherited retinopathy as rods and cones are completely non-functional 
from birth and can be lost within the first few years of life (Cremers, van den Hurk et al. 
2002; Ahmed and Loewenstein 2008). LCA is inherited in an autosomal recessive manner, 
where the incidence is 1:50 000-100 000, despite being a rare disorder it is the most 
common cause of infant blindness in schools for the blind. Patients possess a variety of eye-
related abnormalities including roving eye movements where the eyes appear to slowly 
wander around not fixing or staying still on objects. Furthermore patients have deep-set 
eyes, fast to-and-fro movements of the eyes called Nystagmus and sensitivity to bright light.  
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To-date mutations in 14 genes are known to be associated with LCA and the mutations in 
these genes account for approximately 60% of all LCA cases (Koenekoop 2004). The 14 LCA 
genes identified encode retinal proteins which are necessary for normal vision. They play a 
variety of roles in the development and function of the retina. For example some of the 
genes associated with this disorder are necessary for normal photoreceptor development 
and vitamin A cycling, while others are involved in phototransduction, the process by which 
light enters the eye and is converted into electrical signals that are then transmitted to the 
brain (Koenekoop 2008). The genes have also been shown to participate in a wide variety of 
retinal pathways: retinoid metabolism (RPE65), phototransduction (GUCY2D), 
photoreceptor outer segment development (CRX). Mutations in the CEP290, CRB1, GUCY2D 
and RPE65 genes are the most common causes of the disorder. Currently the most 
successful example of gene therapy for an ocular disease is gene therapy for LCA arising 
from mutations in the RPE65 gene. These mutations account for 10% of all LCA cases and 
this will be the main mutation of focus for this section. 
The first RPE65 mutations were identified in humans with LCA by Marlhens et al. in 1997 
(Marlhens, Bareil et al. 1997). The RPE65 gene is expressed in the RPE -found in the smooth 
endoplasmic reticulum of the RPE cells - and encodes a 65-kDa protein that is a key 
component of the visual cycle. It is important for the regeneration of visual pigment after 
exposure to light as described previously in section 1.6.1.1. Specifically, RPE65 encodes a 
protein requisite for the isomerohydrolase activity of the RPE; this activity produces 11-cis-
retinal from all-trans-retinyl esters (Moiseyev, Chen et al. 2005). In RPE65 deficiency, 
photoreceptor cells do not regenerate their visual pigment and vision is not sustained 
(Perrault, Rozet et al. 1999; Moiseyev, Chen et al. 2005). Despite this, cone photoreceptors 
may have access to 11-cis-retinal chromophore through an alternative pathway which is 
independent of RPE-derived RPE65 (Znoiko, Crouch et al. 2002). Thus children with LCA 
often have cone mediated vision; however, progressive degeneration of the cone 
photoreceptors leads to the ultimate loss of this vision. 
Dramatic restoration of vision with gene therapy was first reported in the Swedish Briard 
(RPE65-/-) dog, a naturally occurring animal model with mutated RPE65 (Acland, Aguirre et 
al. 2001). Visual impairment in the RPE65-/- dogs is caused by a homozygous 4-bp deletion in 
the RPE65. This results in a frameshift mutation and formation of a premature stop codon 
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which truncates the protein in these dogs (Aguirre, Baldwin 1998). (Three) Homozygous 
RPE65-/- affected dogs each received a single subretinal injection of AAV virus serotype 2 
(AAV2/2) carrying a chicken β-actin-promoter/CMV enhancer-driven wild-type canine RPE65 
cDNA. At 4-months following injection, RPE65-/- dogs showed elevated ERG response/signal. 
This measures retinal function, specifically the activation of photoreceptors, primarily the 
rod cells. ERG analysis also measures the function of the inner retinal neuronal/bipolar cells, 
showing an improved retinal function. Furthermore qualitative visual assessment showed 
that under dim light dogs were able to constantly avoid objects directly in front of them and 
on the right (the side injected subretinally), while constantly failing to avoid objects on the 
left (injected intravitreally). In contrast, untreated affected dogs displayed no avoidance 
behaviour in any direction. This further showed that the RPE65-/- dogs had improved vision 
as determined by visual motility. Excitingly, over eight years after the AAV vector 
administration, the RPE65-/- dogs still maintained stable vision improvements (Narfstrom, 
Katz et al. 2003; Acland, Aguirre et al. 2005). 
Studies involving AAV-vector mediated RPE65 gene therapy have also been described in 
murine models with RPE65 deficiency which has led to rescued morphological, biochemical 
and electrophysiological abnormalities (Dejneka, Surace et al. 2004; Pang, Chang et al. 
2006). 
 
1.7.2.3.1 Human Gene Therapy trials for LCA 
 
Following the successful replacement of RPE65 in mice and canine models of LCA and the 
encouraging improvements in visual function, these results provided the impetus for three 
ongoing phase I clinical trials. These trials all used AAV2/2 vectors for gene-therapy in 
patients affected by LCA due to RPE65 mutations. 
From the three studies, one has been conducted in London based at Moorfields Eye 
Hospital, led by Dr. Robin Ali as well as two others in the USA, conducted at the University of 
Pennsylvania, Philadelphia and the University of Florida, Gainesville, as well as another 
conducted at the Children’s Hospital in Philadelphia. 
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In the first Philadelphia study, Maguire and colleagues used 1.5 x 1010 AAV particles 
containing recombinant AAV2.hRrpe65v2  – which is a replication deficient AAV – carrying 
the chicken-β-actin (CBA) promoter (Maguire, Simonelli et al. 2008). The 150 µl solution was 
injected into the subretinal space of three LCA patients aged between 19-26 years old. Two 
subjects carried the homozygous missense (p.Glu106Lys) and one a predicted null mutation 
(p.Arg234Ter) in the RPE65 gene. No local - retinal and vitreous - or systemic adverse effects 
were observed. Following this lack of toxicity the Maguire group also performed functional 
analyses on their patients. They used pupillometry, which measures retinal sensitivity from 
the retina to the brainstream and nystagmus frequency which is an indirect measure of 
fixing ability. Additional measures included Early Treatment Diabetic Retinopathy Study - 
ETDRS - visual acuities, which are the gold standard of visual acuity measurements using 
chart and letter counts, as well as the ability to navigate an obstacle course before and after 
surgery. Measurements by electroretinography (ERG), which measures cone and rod 
photoreceptor responses in a-waves, as well as bipolar and Müller cell responses in  
b-waves, were not reported. 
All three patients with LCA who received AAV2.hRrpe65v2 by subretinal injection showed 
evidence of improvement in retinal function. Improvements in ETDRS acuities where 
considerable, ranging from 3 to 4.5 lines. On average before surgery, patients had an 80° 
visual field width; however after surgery this was significantly increased to 200°. Obstacle 
course videos showed improvements in the confidence and time in all subjects. The 
frequency of nystagmus was improved as well as the significant improvements seen in the 
pupillometry studies which reflected enhanced sensitivity of the retina as well as better 
transmission to the brainstem. 
In the London study, Bainbridge et al.used AAV 2/2.hRrpe65 carrying the human RPE65 
promoter (Bainbridge, Smith et al. 2008). Three LCA patients were used in this study ranging 
from 17-23 years of age, with RPE65 mutations, while RPE65 null mutations were excluded. 
A volume of 1 x 1011 viral particles was injected via a single subretinal injection into the 
retinas of the patients. After injections, no evidence of disseminated virus or adverse ocular 
or systemic effect was observed. Furthermore, measurements included: ERG, ETDRS charts 
as well as mobility tests through an obstacle course. 
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Overall the visual acuities of the patients in the Bainbridge group were slightly better than 
those of the Maguire group. Indeed one patient’s ETDRS acuities improved from 20/286 to 
20/145 by 12 months. However, the investigators did not feel this improvement was 
significant as the control eye had also improved from 20/150 to 20/120. Bainbridge et al. 
suggested that due to the improvements in the frequency of nystagmus, this may have also 
improved the visual acuities in the control eye (Bainbridge, Smith et al. 2008). An alternative 
suggestion has been that the RPE65 protein was able to find its way to the control eye 
(Narfstrom, Katz et al. 2003). However this may be doubtful, as the other two patients 
showed no significant improvements in visual acuity, unlike the Maguire group. In another 
analysis, at 6 months following surgery, 1 of the 3 patients observed a highly significant  
14 dB (25 fold) improvement in the sensitivity of the retina following microperimetry 
studies. Furthermore a significant enhancement of dark adapted perimetry was also 
observed in this patient, no improvement was seen in the control eye. Interestingly, this 
patient also showed significant improvements in mobility. This was assessed by the amount 
of time the patient took to go through an obstacle course before and after surgery, where 
the walking time through the course was reduced from 77 seconds to 14 seconds. 
In the final study, Cideciyan and associates used a similar vector to the Maguire group, 
AAV2.hRPE65 carrying the CBA promoter (Cideciyan, Aleman et al. 2008). Three patients 
were also included in this study, all with various RPE65 mutations which were reported to 
have less than 3% isomerisation activity in vitro compared with wild-type. After injections, 
as with the other two trials, no signs of inflammation were observed. However, the 
investigators in this trial were considerably interested in not only showing retinal function 
and visual acuity, but specifically dissecting the precise location of correction and the cell 
types sub-serving any visual phenotype. They were eager to see whether a response was 
observed specifically within the rod or cone cells of injected subjects. Such an approach was 
not utilised in the previous two trials. 
Retinal examinations to analyse the photoreceptor cell ONL thickness topography prior to 
treatment showed that all three patients had significantly reduced ONL thickness. However 
thickness remained significantly detectable to warrant treatment. Patients were aged 
between 21-24 years old and all had experienced severe visual disturbances since 
childhood. Patients received 1 single subretinal injection of 5.96 x 1010 viral particles in  
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150 µl solution, and their vision was analysed up to 90 days following surgery. In all three 
patients, the light sensitivity of the retina was measured before and after surgery. This 
showed that there was a statistically significant increase in the visual sensitivity localised to 
the areas that had received the vector at 30 days following treatment. However no further 
changes were seen between 30 and 90 days. 
All patients were observed to have extended dark adaptation times. Normal human vision 
becomes more sensitive to light after an instantaneous decrease in ambient illumination – a 
process known as dark adaptation and this can take up to 1 hour in normal vision. However 
in the three patients this was considerably higher between 3-8 hours. The investigators 
suggested that this may be an indication that the kinetics of the reconstituted visual cycle in 
the study eyes may be abnormally slow. In order to define the kinetics of the dark 
adaptation, specifically to differentiate rod and cone kinetics, chromatic sensitivity was 
measured before and after desensitizing light flash. Both rod- and cone-photoreceptor-
based vision was demonstrated in treated areas of all three patients, with an increase of 50 
fold in cone cells, while for rod cells this increased by 63,000 fold. The group suggested that 
this considerable increase in rod sensitivity was likely to be driven by the increase in  
11-cis-retinal chromophore from the wild-type protein that was introduced to the RPE by 
expression from the AAV vector. Importantly, the group argued that the magnitude of the 
increase observed as well as the lack of a visual function increase in the control sham 
injected eyes rules out these visual gains involving neurotrophic factors (Wen, Song et al. 
1995) or secondary gains due to the actual subretinal injection procedure (Del Priore 2005) 
as suggested in previous studies. 
The Cideciyan group also accessed what fraction of full vision potential was restored 
following the injection procedure. In order to achieve this, the group related the areas of 
light sensitivity to the level of remaining photoreceptors within the treated areas of the 
retina. They observed that the gene therapy could overcome nearly all the loss of sensitivity 
in the patients. However the group highlight that this resulted in a reconstituted visual cycle 
that was not completely normal. This is because despite cone-sensitivity recovery time 
being rapid, the kinetics of the newly treated rod cells in the patients required up to 8 hours 
or more for the attainment of full sensitivity. 
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Upon analysis of these three clinical trials for LCA, the differences in each trial included: the 
vector manufacturing procedures and the RPE65 expression cassette which contained either 
the CBA promoter (Cideciyan, Aleman et al. 2008; Hauswirth, Aleman et al. 2008; Maguire, 
Simonelli et al. 2008) or the RPE specific RPE65 promoter (Bainbridge, Smith et al. 2008). 
Additionally the AAV vector injection volumes, as well as patients’ baseline acuities 
(patients’ visual function) were all different in each trial. Despite these differences, some 
important conclusions can also be made. No improvements were observed by ERG 
parameters in either the Maguire or Bainbridge lead trials (Bainbridge, Smith et al. 2008; 
Maguire, Simonelli et al. 2008). This may be due to the initially low ERG testing which is 
characteristic of LCA patients. Regardless of this, all the studies showed safety of the 
procedure and no reports of systemic toxicity or immune responses to the therapy were 
made. Furthermore each group showed significant efficacy of the various techniques 
adapted to measure visual function. These included the use of micro-perimetry to show 
visual field extension (Bainbridge, Smith et al. 2008) and navigation tests to indicate 
improvement of visual function (Bainbridge, Smith et al. 2008; Maguire, Simonelli et al. 
2008). 
Both the Maguire and Bainbridge groups (Bainbridge, Smith et al. 2008; Maguire, Simonelli 
et al. 2008) showed significant improvements in the papillary reflex and in turn enhanced 
sensitivity of the retina by pupillometry and microperimetry studies respectively. However 
Cideciyan and colleagues (Cideciyan, Aleman et al. 2008) took their analyses one step 
further and reported significant increases in visual sensitises, with evidence for both cone- 
and rod-based vision. 
 
Overall these studies reflect some of the most profound advances in gene therapy to date, 
and highlight the possibilities for additional studies, including our disease of interest, 
Choroideremia, to take this route from bench to bedside. 
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1.7.3 Choroideremia (CHM) 
 
Choroideremia (CHM) was originally described in 1872 in an Irish pig farmer who had 
emigrated to Canada. His family tree was analysed and it was found that all his children 
appeared unaffected and showed no signs of blindness, including all his sons and their 
descendants. However when the male descendants from his daughters lineage were 
analysed, they appeared to go blind over subsequent generations (McCulloch 1969). 
Following this, CHM was described as a progressive retinopathy that was exhibited as an  
X-linked recessive condition. Mutations in the Rab Escort Protein 1 (REP1) gene were found 
to underlie this condition (Seabra, Brown et al. 1992; Andres, Seabra et al. 1993; Seabra, 
Brown et al. 1993). However, to date, there is still no effective treatment for affected 
individuals although the first UK Phase 1 clinical tiral for choroidermia using AAV vectors has 
just started. 
 
1.7.3.1 Clinical features of Choroideremia 
 
Affected male patients begin to develop pathological changes gradually, often starting with 
night blindness and tunnel vision in their teens. Subsequently, visual loss progresses to the 
mid-periphery, with central vision preserved until complete loss of vision in the final stages 
of the disease 2-3 decades following onset.  
Associated retina changes are evident as early as childhood, were CHM patients display 
spotted areas of depigmentation of the fundus, which reflect degeneration of the RPE. 
Furthermore, atrophy of choroidal vessels and sclera occurs around the optic disc in 
adolescence (Figure 14B). In the intermediate stages of the disease, the pattern of RPE and 
choroidal atrophy spreads even further within the retina. Furthermore, all sizes of choroidal 
vessels are affected, with the exception of those underlying the far periphery and macula; in 
turn the fundus appears off-white to yellow-white in colour (Figure 14C). Heterozygous 
female carriers usually retain normal/good visual function, but subtle changes in the fundus 
are evident, with patchy areas of depigmentation and chorioretinal degeneration due to 
random X-inactivation (Figure 14D)(MacDonald, Mah et al. 1998). 
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Figure 14: Fundus photographs of normal and choroideremia retinas 
The fundus showing (A) normal human retina, (B) early and (C) late changes in the 
retinas of choroideremia patients (D) X-linked female choroideremia carrier retina. The 
fundus of choroideremia patients is off-white/yellow compared to a normal fundus. 
Choroideremia retinas show areas of depigmentation as well as islands of choroid, 
where widespread choroidal atrophy is prominent as opposed to an even distribution of 
the choroid. Asymptomatic carriers show more subtle fundus changes with patchy areas 
of depigmentation  
(Images taken from http://webvision.med.utah.edu/ClinicalERG.html). 
 
A study of CHM patients in 2006 measured the thickness of retinal laminae using in vivo high 
resolution optical imaging and describes the remodelling which occurs within the retina 
over several decades of the disease. This study suggests four stages of the CHM disease as 
shown in Figure 15 (Jacobson, Cideciyan et al. 2006). Young affected males (7-12 years of 
age) had small areas of photoreceptor abnormalities which co-localise with normal and 
abnormal RPE. Interestingly however, no abnormal RPE were seen in association with 
normal photoreceptors, thus photoreceptor loss was found to precede RPE depigmentation. 
In the peripheral rod-rich retina, normal thickness was maintained for approximately twenty 
years. After this time, a slow degeneration was seen which lead to a thinner, disorganised, 
bilaminar retina seen in 34 and 56 year old patients. The cone-rich fovea became thicken 
decades before cone dysfunction was apparent, measured by visual acuity. Patients from 
the age of 13 through to 40 displayed thickening of the fovea, followed by photoreceptor 
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degeneration, RPE depigmentation and finally loss of lamination. All these progressions 
result in a subnormal thinning of the retina from approximately the fifth decade of life.  
 
Figure 15: Schematic model of retinal remodelling in human choroideremia 
disease progression 
The earliest detectable stage is the thickening of the retina, with otherwise normal 
lamination (Stage I). The next stages show clinical signs of disease progression 
characterised by loss of photoreceptor nuclei, inner and outer photoreceptor segment 
thinning and depigmentation of RPE cells (Stage II and III). The end stage of disease 
progression is further thinning of the retina, disorganisation of all retinal cell layers and 
loss of lamination (IV). Throughout the stages of disease, Müller cells filled in pink 
indicate progressive gliosis.   
MC, Müller cells; RPE, retinal pigment epithelium; PS, photoreceptor outer and inner 
segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; 
IPL, inner plexiform layer; GCL, ganglion cell layer (Figure adapted from (Jacobson, 
Cideciyan et al. 2006)). 
 
Jacobson et al speculated that the initial thickening of the retina seen in stage I of CHM 
disease progression was caused by Müller cell activation, hypertrophy or even proliferation 
in response to photoreceptor stress and damage (Jacobson, Cideciyan et al. 2006). This 
speculation was based on studies in aging rats with retinal degeneration, where Müller cells 
were found to be stimulated prior to photoreceptor loss (DiLoreto, Martzen et al. 1995). 
Furthermore glial cells are commonly activated after trauma or neuronal injury (Rattner and 
Nathans 2005). 
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There is considerable phenotypic variation seen between CHM members within the same 
family as well as members of different CHM families, specifically age of symptom onset as 
well as the subsequent rate of disease progression and severity (Jacobson, Cideciyan et al. 
2006). In extreme cases, the earliest detectable retinal changes (stage I) have been seen in 
boys younger than four years of age, where they were reported to have developed night 
blindness. In comparison a 45 year old affected male had reported to have only slight visual 
changes and abnormalities (Ponjavic, Abrahamson et al. 1995; Mura, Sereda et al. 2007). In 
contrast, variation within female carriers is often the result of random X-inactivation.  
A heterozygous female carrier was reported to have abnormal RPE depigmentation of 
irregular thickness as well as abrupt transitions between areas of normal and absent 
photoreceptors (Flannery, Bird et al. 1990). Photoreceptor loss was seen in areas of normal 
RPE, while abnormal RPE were also seen in association with areas of normal 
photoreceptors. Autofluorescent particles, presumably lipofuscin, were seen in pigmented 
RPE cells. In areas of complete atrophy, choroidal capillaries and photoreceptors were 
completely absent, while mild atrophy was coupled with reduced capillaries and abnormal 
photoreceptors. Areas of normal photoreceptors where always seen with normal choroid. 
Finally, deposits seen on the Bruch’s membrane showed that the RPE had been functioning 
previously, but had stopped phagocytising outer photoreceptor segments. From these 
finding, the authors proposed that the CHM disease is primarily associated with RPE 
degeneration. However they also highlighted that they lacked to show evidence for the root 
and cause of the disease. 
In another study of a female carrier, survival of photoreceptor cells neighbouring severely 
abnormal RPE cells was observed (Syed, Smith et al. 2001). Furthermore, minimal changes 
were seen in the choroid as well as normal pigmentation of RPE cells. However, lipofuscin 
accumulation was also seen in the RPE cells, and the preferential loss of rod photoreceptors 
was also observed. Interestingly, the end stage of the disease was characterised by the loss 
of all photoreceptor cells as well as pronounced damage of the choroidal capillaries. This 
suggested that the photoreceptor and RPE degenerations seen in association with CHM are 
independent. Furthermore, immunostaining of retinal sections showed REP1 staining in 
normal areas of rod inner segments and synapses, while an absence of staining was 
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observed in rod outer segments or cones. These authors suggested the rod cells are the 
primary site of disease in CHM, and importantly, that the disease is independent of the RPE. 
While the pathogenesis and cellular origin of CHM remains complex and debatable, three 
areas of the retina have been implicated with the disease. These include the choroid, 
particularly in the late stages of the disease, as well as the RPE and photoreceptors. The 
latter two appear to be more associated with the early stages of CHM, where the 
degenerative process is believed to be cell autonomous - self directed- and develops 
independently in both these key affected layers (Syed, Smith et al. 2001; Tolmachova, 
Anders et al. 2006; Krock, Bilotta et al. 2007). 
 
1.7.3.2 Genetic basis of choroideremia  
 
The X-linked recessive pattern of inheritance was first noted by two independent authors in 
1942. Estimates of incidence range from 1 in 50000 to 1 in 100000, classifying CHM as a rare 
disorder. CHM has been linked to the chromosome Xq21.2 (Cremers, van de Pol et al. 1990) 
and the causative gene responsible identified as the REP1 gene (Seabra, Brown et al. 1992; 
Andres, Seabra et al. 1993; Seabra, Brown et al. 1993). The REP1 gene spans 150 kb of 
chromosome Xq21.2, contains 15 exons and encodes a 653 amino acid protein (van 
Bokhoven, van den Hurk et al. 1994; van den Hurk, Hendriks et al. 1997). The gene is also 
flanked by genes associated with mental retardation and deafness type 3; hence these 
syndromes are also seen in CHM patients that have large deletions in this region.  
Over 100 mutations have been detected in REP1, however these only represent 60% of 
familial cases and 30% of sporadic cases, showing the genetic heterogeneity of this disease 
(Preising and Ayuso 2004). Mutations in the REP1 gene have been reported ranging in size 
from a few kilobases, removing of single exons, to those which encompass the entire REP1 
gene and most of the Xq21 band (van den Hurk, Schwartz et al. 1997; Fujiki, Hotta et al. 
1999; McTaggart, Tran et al. 2002; van den Hurk, van de Pol et al. 2003). Furthermore 
translocations disrupting REP1 have also been detected in female carriers, with autosomal 
breakpoints at 7p14 (X breakpoint in REP1 exon 3 or 4; t(X;7)(q21;p14) ), 13p12 (X 
breakpoint in REP1 exon 12; t(X;13)(q21;p12) ) and 4p16 (X breakpoint in REP1 intron 8; 46, 
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X, t(X;4)(q21;p16))(Cremers, van de Pol et al. 1990; van Bokhoven, van den Hurk et al. 1994; 
Lorda-Sanchez, Ibanez et al. 2000; Garca-Hoyos, Sanz et al. 2005). 
Furthermore a variety of nonsense, frameshift, missense and splice-site mutations have also 
been identified and until recently all mutations were thought to cause the protein to 
become truncated due to an early stop codon or absent (Seabra 1996; van den Hurk, van de 
Pol et al. 2003). However, recently new cases of missense mutations have also been 
observed in some CHM patients (Sergeev, Smaoui et al. 2009; Jung, Huh et al. 2011). 
Furthermore, Garcia et al. reported a novel mutation in three CHM families which did not 
result in a truncation or loss of REP1 protein. Instead this mutation caused the loss of 
various parts of the REP1 mRNA in-frame which all encoded conserved regions of the 
protein implicated in the interaction of Rab proteins (Garcia-Hoyos, Lorda-Sanchez et al. 
2008). 
No phenotypic correlations between the various types of mutations have been detected. 
Interestingly, recombinant REP1 lacking only the C-terminal end 49 amino acids results in 
defective REP1 that is unable to interact with RabGGTase in vitro. This highlights the 
importance of full-length protein production to avoid loss of function (van den Hurk, 
Schwartz et al. 1997; Fujiki, Hotta et al. 1999; McTaggart, Tran et al. 2002; van den Hurk, van 
de Pol et al. 2003). 
Furthermore, as over one third of all mutations have been identified as nonsense mutations 
(van den Hurk, Schwartz et al. 1997; Fujiki, Hotta et al. 1999; McTaggart, Tran et al. 2002; 
van den Hurk, van de Pol et al. 2003), this brings to light CHM as an excellent the disease 
candidate for (translational) gene therapy. 
 
1.7.3.3 Functionality of Rab Escort Proteins 
1.7.3.3.1 Rabs as cellular membrane organisers 
 
The Rab proteins are the largest subfamily of small GTPases, with over 60 different 
members identified in mammals since their discovery in the 1980’s. Rab proteins are key 
regulators of intracellular membrane trafficking and vesicular transport in both endocytic 
and secretory pathways. This includes the regulation of vesicular budding from donor 
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membranes, organelle transport along microtubules and actin filaments, vesicle 
tethering/docking to acceptor membranes and fusion of vesicles with the membrane of 
acceptor compartments in vesicular transport (Zerial and McBride 2001; Seabra, Mules et al. 
2002; Barral and Seabra 2004; Seabra and Wasmeier 2004). Rabs are cytosolic proteins 
which localise to distinct intracellular membranes, in an organelle specific manner. 
Therefore they display localisation to particular sub-cellular membranes and this may 
determine a Rabs involvement in a specific transport step as well as contribute to defining 
organelle identity (Pfeffer 2001; Zerial and McBride 2001; Seabra, Mules et al. 2002; Barral 
and Seabra 2004; Seabra and Wasmeier 2004). Many Rabs are ubiquitously expressed; 
however others are highly tissue specific indicating specialised roles (Pfeffer 2005), this is 
illustrated in Figure 16. For example Rab 1 is involved in the regulation of transport between 
the endoplasmic reticulum (ER) and Golgi complex in cells, while Rab 5 is involved in the 
regulation of early endosome transport and motility from the plasma membrane to the ER. 
Cumulatively, both are ubiquitously expressed and common to stages of the exocytic and 
endocytic pathways respectively. In contrast Rab27a is involved in the capture and 
movement of melanosomes at the cell periphery and so is primarily found on melanosomes 
within highly pigmented cells called melanocytes. 
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Figure 16: Intracellular vesicular transport and localisation of a selection of 
selected Rab proteins 
In the endocytic pathway, phagocytosed material reaches early endosomes (EE). From 
here they can be recycled back to the surface of the plasma membrane either directly or 
via perinuclear recycling endosomes (RE), or transport to late endosomes (LE) and 
lysosomes. In the exocytic pathway, proteins are transported from the endoplasmic 
reticulum (ER) through the Golgi complex and to the plasma membrane/cell surface. In 
the trans-Golgi network (TGN), molecules enter either constitutive secretory vesicles 
(CV) or regulated secretory vesicles (RV). In specialise cell types, such as melanocytes, 
melanosomes (M) move to the cell periphery via actin and myosin interactions. Rab 
proteins regulate discrete steps in all these pathways (Stenmark and Olkkonen 2001). 
 
The regulatory ability of Rab proteins is based on a conformational switch between 
‘inactive’ GDP-bound and ‘active’ GTP-bound states (Takai, Sasaki et al. 2001). Furthermore, 
Rabs also cycle between membrane and cytosol.  Hence, to be functionally active, a Rab 
protein must not only be GTP-bound but also membrane associated (Pfeffer 2001; Zerial 
and McBride 2001; Seabra, Mules et al. 2002; Barral and Seabra 2004; Seabra and Wasmeier 
2004).  When activated Rabs bind to a wide variety of Rab-specific effector proteins that 
mediate their downstream functions (Jordens, Marsman et al. 2005; Grosshans, Ortiz et al. 
2006). 
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1.7.3.3.2 Lipid Modification of Rab Proteins – Prenylation 
 
Rab proteins are intrinsically soluble proteins. In order to bind to intracellular membranes 
and in turn become functional, all Rab proteins must undergo post-translational lipid 
modification, termed prenylation.  Prenylation involves formation of a covalent thioester 
bond between a farnesyl (15-carbon) or geranylgeranyl (20-carbon) lipid group and a  
C-terminal residue of newly synthesised Rab proteins. Prenylation is catalysed by one of 
three protein prenyltransferases: farnesyl transferase (FTase), geranylgeranyl transferase 
type I (GGTase I) or Rab geranylgeranyl transferase (RabGGTase)(Casey and Seabra 1996; 
Leung, Baron et al. 2007). Interestingly, RabGGTase, unlike the other prenyltransferases, 
cannot bind to its substrate protein directly, instead it requires association with Rab Escort 
Protein (Andres, Seabra et al. 1993; Shen and Seabra 1996). Rabs are either singly or 
predominately (87%) doubly prenylated, depending of the C-terminal cysteine motif they 
possess (Farnsworth, Seabra et al. 1994; Shen and Seabra 1996; Thoma, Iakovenko et al. 
2001). The correct prenylation of Rab proteins is crucial for accurate membrane targeting 
and subsequently is essential for the correct function and membrane transport of Rabs 
(Calero, Chen et al. 2003; Gomes, Ali et al. 2003). 
 
1.7.3.4 Rab Escort Proteins in disease – CHM 
Rab escort proteins (REP) are accessory proteins involved in the prenylation of Rab proteins, 
described earlier. Two REP homologues are known to exist in mammals, REP1 and REP2.  
REP1 was first purified as “component A” of RabGGTase, when RabGGTase was thought to 
be composed of two loosely associated components that were able to attach prenyl 
groups/lipids to Rab proteins (Seabra, Brown et al. 1992). The second component, 
“component B” was then presented as the catalytic subunit, but has now become known as 
RabGGTase (Seabra, Goldstein et al. 1992). Interestingly, lymphoblasts isolated from CHM 
patients showed a deficiency of component A (Seabra, Brown et al. 1993). Furthermore, the 
authors found that the deficiency was less pronounced when Rab1a was used as a 
substrate, resulting in 70-80% of normal prenylation levels in these cells. In contrast, when 
Rab3a was the substrate, only 20-25% normal levels were achieved. This lead to the 
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suggestion that there must be a second REP present and active in CHM cells, which is 
potentially acting as a compensatory protein, displaying some levels of substrate specificity.  
Following on from this, during the stage of cloning the 5’ end of REP1 cDNA, an autosomal 
homologue, named choroideremia-like (CHML), and later renamed Rab Escort Protein 2 
(REP2), was found and was shown to functionally replace REP1 in vitro (Cremers, Armstrong 
et al. 1994). REP-2 is encoded by an intronless gene which spans 2.3 kb of chromosome 
1p42 (Cremers, Molloy et al. 1992), where it is found in the panopsin gene (Halford, 
Freedman et al. 2001). This gene has been shown to be linked to Usher Syndrome Type 2 
(USH2) which is an autosomal recessive disease leading to deafness and progressive visual 
loss (Cremers, van de Pol et al. 1990; van Bokhoven, van den Hurk et al. 1994; Lorda-
Sanchez, Ibanez et al. 2000; Garca-Hoyos, Sanz et al. 2005). However no disease specific 
mutations were observed when USH2 patients were analysed for REP2 (Eudy, Weston et al. 
1998). 
The REP1 and REP2 proteins share 71% sequence identity (Cremers, Molloy et al. 1992). 
They are also both ubiquitously expressed, although some tissues express higher amounts 
than others. For example REP1 is highly expressed in tissues of the eye, brain and kidney 
(Desnoyers, Anant et al. 1996; Tolmachova, Anders et al. 2006). Interestingly, it has been 
suggested that in CHM, REP1 deficiency can be overcome and compensated for by REP2 
activity. In turn REP2 can partly substitute the prenylation of Rabs, in all tissues expect the 
eye, were this leads to the subsequent onset of retinal degeneration and ultimately 
blindness (Seabra 1996). 
 
1.7.3.5 Rab Escort Protein function 
 
The function of REP proteins can be divided into three key areas. Firstly they bind newly 
synthesised Rab proteins, secondly they present the Rabs to RabGGTase for prenylation and 
finally they deliver each Rab to its target membrane. 
In the initial stages, REP forms a stable complex between itself and newly synthesised 
unprenylated Rabs (at a 1:1 ratio) (Anant, Desnoyers et al. 1998). REP then presents itself to 
RabGGTase for prenylation. RabGGTase itself does not bind to REP but only interacts with 
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REP to form a REP:RabGGTase complex (Andres, Seabra et al. 1993; Shen and Seabra 1996). 
Interestingly, the efficiency of Rab prenylation is not determined by the binding affinity of 
Rabs to REP, but rather seems to arise due to variations in the catalytic efficiency of the 
REP:RabGGTase complex. Both REP1 and REP2 show equivalent binding affinity (and 
activity) to Rab27a (Larijani, Hume et al. 2003). However REP1:Rab27a complex has a higher 
affinity for RabGGTase compared to REP2:Rab27a complex, resulting in twice as much 
prenylation of Rab27a (Rak, Pylypenko et al. 2004). This implies that substrate selectivity 
occurs during the formation of the RabGGTase:REP:Rab complex. 
Once the REP:RabGGTase complex has been formed, RabGGTase then catalyses the 
prenylation reaction by the addition of prenyl lipid groups to the C-terminal cysteine 
residues of Rabs (Andres, Seabra et al. 1993). Following this, RabGGTase dissociates from 
the complex, leaving REP to escort the prenylated Rab to their target membrane 
(Alexandrov, Horiuchi et al. 1994). The actual mechanism of membrane delivery is still 
unclear. However factors thought to be involved include: RabGEFs (Rab guanine nucleotide 
exchange factors), specific targeting proteins or specialised GDI-displacement factors 
(GDFs). GDFs allow the Rab:REP complex to dissociate as well as facilitating in the insertion 
of the prenylated Rab to the membrane (Pfeffer 2001; Zerial and McBride 2001; Seabra, 
Mules et al. 2002; Barral and Seabra 2004; Seabra and Wasmeier 2004).These stages are 
summarised in Figure 17.  
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Figure 17: The role and function of REP in the Rab cycle 
(1) Newly synthesised Rab proteins in the cytosol are inactive and become GDP-bound 
by association with Rab Escort Protein (REP) (2) REP then presents the Rab to 
RabGGTase which catalyses the prenylation reaction. After prenylation, REP remains 
bound to the prenylated Rab and escorts it to its target membrane.  REP then 
dissociates from the Rab and assists with the prenylation of other newly synthesised 
Rabs, while the guanine nucleotide exchange factors (GEFs) replace GDP with GTP 
resulting in an activated Rab (3) This activated GTP-bound Rab protein is then able to 
become membrane associated, as well as able to recruit effectors (4) GTP hydrolysis is 
catalysed by GTPase activating proteins (GAPs) which remove Rabs from the membrane 
into the cytosol again (Figure adapted from (Stenmark and Olkkonen 2001)). 
 
1.7.3.6 A subset of Rabs remain unprenylated in Choroideremia 
 
In CHM, loss of REP1 activity gives rise to progressive retina degeneration, as demonstrated 
by the restoration of RabGGTase activity in CHM lymphoblasts following the addition of 
purified REP1 (Seabra, Brown et al. 1993). Indeed it has been suggested that the lack of a 
generalised phenotype and severity of the CHM disease limited to the eye alone in patients 
is due to REP2 which is able to partly compensate for this activity in all other tissue except 
the eye (Seabra 1996). In the eye, REP2 function is not able to fully compensate the lack of 
correct REP1 activity. This leads to a subset of Rab proteins, including Rab27a, to 
accumulate within the cytosol, as they are unable to be correctly prenylated and in turn also 
unable to function correctly (Seabra, Ho et al. 1995; Alory and Balch 2000; Tolmachova, 
Anders et al. 2006). 
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Indeed, Rab27a is highly expressed in the RPE cells and choriocapillaris, while no significant 
expression is observed in the photoreceptors. Despite being one of the Rabs that is affected 
in CHM, Rab27a is unlikely to be the only Rab responsible for the disease. In fact CHM 
patients do not develop symptoms of pigmentary dilution of the hair and skin - caused by 
the accumulation of pigmented melanosomes in melanocytes. Furthermore, CHM patients 
do not possess immune deficiencies - caused by uncontrolled T lymphocyte and 
macrophage activation - characteristic of Griscelli syndrome; a rare autosomal recessive 
disorder caused by mutations in the human Rab27a gene.  Similarly, Griscelli syndrome 
patients do not develop retinal degeneration; however the early death of patients may 
prevent the manifestation of retina disease. Rab27a deficiency in ashen mice, results in 
ablation of melanosomes in the apical processes of RPE cells (Pereira-Leal, Hume et al. 
2001), which has also been shown in a conditional knock-out mouse model of CHM 
(Tolmachova, Anders et al. 2006). However it should be mentioned that the ashen mouse 
does not show signs of retinal degeneration (Gibbs, Azarian et al. 2004).  
As mentioned previously, the severity of CHM is limited as a retina phenotype due to REP2 
which is able to compensate for the lack of REP1 function. However, REP2 displays varying 
substrate specificity, indeed REP2 has been shown to prenylate Rab3a at only 25% of normal 
levels in CHM lymphoblasts (Seabra, Ho et al. 1995). Rab3a is a component of the 
neurological synaptic vesicles and regulates a late step in the synaptic vesicle fusion. 
However, the absence of a neurological phenotype in CHM is observed; implying that only 
25% of normal Rab3a prenylation is sufficient for synaptic vesicle function. 
Taken together, in CHM, the slow clinical development and combined genetic diagnosis 
makes CHM an attractive candidate for ocular gene therapy. As virtually no functional REP1 
is produced, the presence of a low level of functional REP1 protein localised within the eye, 
could prove advantageous. This could potentially prenylate enough critical Rab proteins 
within the eye, resulting in the normal function and in turn potentially also preventing or 
arresting disease development and progression. While speculation and a full understanding 
of the molecular mechanisms underlying CHM still remain unclear, the potential of non-viral 
gene therapy for the CHM is an exciting route we hoped to explore during this study. 
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1.7.3.7 Animal models of choroideremia 
 
The pathogenesis of CHM remains largely unclear. There are three affected areas (choroid, 
RPE and photoreceptors) within the retina which appear interdependent on one another 
causing progressive retinopathy. Certain questions still remain outstanding including where 
the primary site of degeneration is or where CHM originates in, which in turn leads to the 
demise of the other two layers. The RPE is the most likely candidate for the primary site of 
degeneration due to it close proximity and position between the other two degenerating 
layers (Krock, Bilotta et al. 2007). An alternative hypothesis could be that the degeneration 
of the RPE and photoreceptors within the retinas of CHM patients occur simultaneously; i.e. 
cell autonomously. In order to explore these ideas animal models of CHM were created and 
analysed. A summary of these studies and implications in understanding further the CHM 
disease pathogenesis and progression are discussed forthwith.  
 
1.7.3.7.1 The Choroideremia Zebrafish 
 
The CHM mutant zebrafish (CHMru848) was generated following random chemical 
mutagenesis with N-ethyl-N-nitrosourea (ENU) and was subsequently identified in a screen 
for balance and hearing defects (Starr, Kappler et al. 2004). Positional cloning revealed the 
CHM mutation in zebrafish was on a gene homologous to human REP1. This caused a 
nonsense mutation (C→T) and a premature stop codon, truncating the REP1 protein at 
amino acid position 33 of a 666 amino acid protein.  
At 5 days post-fertilisation (dpf), mutants have defective swimming behaviour - moving in 
circles – showed absence of functional swim bladder (uninflated), reduced body length, 
curvature of the spin and increased pigmentation. Ocular features included noticeably 
smaller eyes and irregular eye pigmentation. Electron microscopic analysis showed that the 
retinal layers were disrupted in mutants (Starr, Kappler et al. 2004). The RPE were clearly 
disorganised, where some RPE were seen invading the ONL. Furthermore within the RPE 
layer, large vacuoles and undigested outer segments were observed. However, the REP1 
null mutation in zebrafish is embryonically lethal by 6 dpf. While the uninflated swim 
bladder seen in mutants prevents larvae from reaching the surface of the water to feed, lack 
of nutrition was not considered to be the cause of death. This was because wild-type larvae 
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are known to survive until 10 dpf without food (Starr, Kappler et al. 2004). As zebrafish do 
not possess a choroideremia–like gene (CHML/REP2), the CHM knock-out (KO) mutants 
manifest extremely severe systemic abnormalities that ultimately lead to lethality at 6 dpf 
(Starr, Kappler et al. 2004; Moosajee, Tulloch et al. 2009). Due to this extremely short 
survival rate, the use of the zebrafish KO model for CHM is limited.  
 
1.7.3.7.2 The Choroideremia Mouse 
 
Initial attempts to generate a REP1 knock-out (KO) mouse surprisingly showed that null 
mutations were embryonically lethal in males and in heterozygous females when the 
mutation was transmitted through the female germline (van den Hurk, Hendriks et al. 1997). 
Death occurred in utero by E11.5 and it was suggested to be due to the lack of REP1 in extra-
embryonic tissues which was specifically seen to cause defects in trophoblast development 
and vascularisation of the yolk sac and placenta (Shi, van den Hurk et al. 2004). Lethality in 
the heterozygous female carriers was suggested to be due to the preferential inactivation of 
the paternal wild-type X chromosome in the extra-embryonic tissues, resulting in the 
expression of the mutant maternal allele (van den Hurk, Hendriks et al. 1997). Interestingly, 
histological analysis of carrier females (from chimeric males that had developed and 
transmitted the mutant REP1 gene to female offspring) showed that these mice developed 
mild photoreceptor cell degeneration. While this model showed that murine REP1 did 
indeed cause retinal changes, the mouse line was not possible to maintain as neither 
chimeric males nor carrier females could transmit the null alleles. Therefore further 
attempts to generate a mouse KO of REP1 were warranted. 
The process of generating mice with KO CHM alleles was described by Tolmachova et al. 
(Tolmachova, Anders et al. 2006) and is summarised in Figure 18. 
 
The CHM mouse model was created using the Cre/loxP system of site specific 
recombination. For the initial stages, the targeting vector pTT55 (Figure 18B) which contains 
exons 3 and 4 of the murine CHM gene, as well as the neomycin and spectinomycin 
resistance cassette was generated. Two loxP sites were located either side of the resistance 
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cassette, positioned downstream from the 3’ end of exon 4, while a third loxP site was 
inserted upstream from the 5’ end of exon 4. Hence, two loxP sites where inserted either 
side of exon 4 in the murine CHM gene - as well as the resistance cassette. This allows for 
the conditional deletion of exon 4, which in turn causes a frameshift mutation leading to an 
early stop codon that results in the lack of a functional CHM gene in these mice. Targeting of 
ES cells with pTT55 and subsequent blastocyst injections resulted in the generation of 
CHM3lox mice (Figure 18C).   
These CHM3lox mice were mated with the mouse line βMCM70, which expressed Cre protein 
as a fusion protein with 2 copies of the tamoxifen responsive (TM -responsive) estrogen 
receptor (MerCreMer) under the control of the ubiquitous CMV-enhanced chicken β-actin 
(CAG) promoter. When TM is bound to the MerCreMer receptor, this induces a nuclear 
translocation of the receptor which in turn catalyses the recombination event between the 
loxP sites. In this case, the recombination event between the two loxP sites both side of 
exon 4 and the subsequent KO of the CHM gene.  
Male mice with an inducible CHM allele (MerCreMer+ CHM3loxmales) were treated with TM 
which was administered to 6-8 week old mice by 5 intraperitoneal (i.p.) injections on 5 
consecutive days (1 mg of TM per injection). This induced the recombination of the CHM 
floxed alleles and subsequent mutation in the germline in adulthood. When these mice 
were mated with WT females, the viable offspring carried the CHMWT allele from the 
mother, and either the CHM3loxor 1 of 3 possible deleted alleles, CHMFlox, CHMnull+Neo or 
CHMnull from the father (corresponding to Figure 18D, E, F). In the case where CHMnull+Neo or 
CHMnull were transmitted, both are null alleles, while CHMFlox is similar to wild-type, with the 
exception of two loxP sites on both side of exon 4.  
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Figure 18: Summary of the generation of several CHM conditional and KO mice 
Shown is the generation of mice carrying the conditional and KO CHM alleles. Several 
CHM mouse models were created using the Cre/loxP system of site specific 
recombination. (A) Initially the murine CHM gene was inserted into wild-type (WT) 
mice from (B) the targeting vector pTT55 which carries 3 loxP sites (indicated as white 
triangles), a neomycin and spectinomycin resistance cassette (indicated as grey box - 
Neor, Spr) and exons 3 and 4 of the murine CHM gene. The targeting vector was initially 
linearised and used for electroporation of GSI-1 embryonic stem (ES) cells in vitro. 
Followed this, isolated clones were then screening for correct integration of the vector 
using Southern blot analysis. Blastocyst injections of ES cells and subsequent 
homologous recombination in ES cells resulted in the transmission of the (C) CHM3lox 
allele through the germ line. Cre-mediated recombination between the three loxP sites 
within the CHM3lox allele resulted in three possible allele outcomes: (D) CHMFlox  
(E) CHMnull+Neo (F)CHMnull (Figure adapted from (Tolmachova, Anders et al. 2006)). 
 
This sophisticated approach ultimately produced heterozygous CHMnull/WT females that were 
viable carriers created to avoid the transmission of the CHM-null allele through the maternal 
germline. The CHMnull/WT females are mosaic for cells with normal REP1 function or no REP1 
function. Hence approximately 50% of the cells are CHM KO cells. While this ratio may vary 
from one CHMnull/WT female mouse to another due to random X-inactivation, the analysis of 
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REP1 deficiency in these KO mice is highly valuable and can be used to understand and 
decipher the pathogenesis and disease progression of CHM further. 
The first defects that were observed in the CHMnull/WT females were RPE depigmentation by 
post-natal day (P) 7, as well as noticeable delays in the formation of photoreceptor outer 
segments and reduced thickness of the outer nuclear layer (ONL) by P17. By four months of 
age, retinal changes were more evident by areas of severe RPE depigmentation. This was 
accompanied by abnormal electroretinogram (ERG) readings. In these analyses white 
autofluorescent flecks were evident in some areas of intact retina. These most likely 
represent RPE depigmentation and lipid accumulation as a result of the photoreceptor outer 
segments not being digested normally by the RPE cells within the retina.  
Histological analysis of older CHMnull/WT mice (Figure 19) showed the late onset of 
photoreceptor degeneration. This was determined by counting the rows of nuclei in the 
ONL. It was observed that 2-month old female carriers showed a small reduction in ONL 
thickness from 10-12 to 8-10 nuclei. This was further reduced at 7 months where on average 
7-8 nuclei were observed and by eight months only 5-6 nuclei were seen. Interestingly, the 
phenotype in the 8 month old carriers was variable between mildly affected areas and areas 
of severe degeneration where only 1-2 nuclei were seen. Furthermore mice also showed 
progressive degeneration of RPE cells resulting in patchy RPE depigmentation, RPE thinning 
and the occurrence of abnormal cells close to RPE cells. Indeed thinning of the RPE layer has 
also been characterised in human CHM patients (Syed, Smith et al. 2001).   
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Figure 19: Histological analysis of eye sections from CHMnull/WT retinas at various 
time points 
Shown are representative haematoxylin and eosin (H&E) stained retinal sections of 
CHMnull/WT mice at 2 (A), 4 (B), 8 (C) and 16 (D) months (mo), and CHMWT/WT mice at 10 
months (E).  The retinas of CHMnull/WT mice shows the progressive photoreceptor 
degeneration with reduction of outer nuclear layer (ONL) thickness from 10-12 nuclei 
thick at 2 mo, to 5-6 nuclei at 8 mo and considerably less by 16 mo. This phenotype is 
also accompanied by RPE defects including patchy areas of RPE depigmentation as well 
as thinning. Furthermore occasionally abnormal cells were also seen in close proximity 
to the RPE cells (A, inset). CH, choroid; RPE, retinal pigment epithelium; OS, outer 
segments; ONL, outer nuclear layer; INL, inner nuclear layer; IPL, inner plexiform layer; 
GCL, ganglion cell layer (Figure adapted from (Tolmachova, Anders et al. 2006)). 
 
Electron microscopy analysis of 9-month old CHMnull/WT mice (Figure 20) also showed 
considerable phenotypic variation. Some regions of the retina appeared normal, while 
others showed areas of depigmentation and the redistribution of pigment granules to the 
basal area of the RPE cells accompanied by normal rod outer segments (ROSs).  Conversely, 
other areas of the retina showed severely depigmented RPE cells adjacent to shortened and 
structurally altered ROS. While in extreme cases severely degenerated photoreceptor cells 
were also seen.  
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Figure 20: Electron microscopic analysis of a CHMnull/WT retina at 9 months old 
Shown are representative electron micrographs of different regions from the same eye 
of a 9-month- old CHMnull/WT female mouse (A-D). (A) An area of the retina where the 
RPE and rod outer segments (ROSs) appear normal. (B) A region showing depigmented 
RPE cells with redistributed pigment granules in the basal area of the RPE cell, while 
ROSs are normal. (C) Another region of the retina shows severely depigmented RPE 
cells (highlighted by an asterisk) in close proximity to shortened and structurally 
altered ROSs. An abnormal cell close to the RPE is also seen (highlighted by an arrow 
head). (D) The final region highlights pigmented RPE cells which are adjacent to 
severely degenerated photoreceptors, where most of the ROSs have disappeared, 
resulting in photoreceptor nuclei (highlighted by an arrows) approaching the RPE cells 
(Figure adapted from (Tolmachova, Anders et al. 2006)). 
 
Cumulatively, these data suggested that there was no direct correlation between 
depigmentation of the RPE and degeneration of the photoreceptors. Hence these two 
processes of degeneration in the photoreceptor and RPE cell layers may be independent. In 
order to investigate this further, a tissue-restricted CHM KO mouse was generated using the 
conditional alleles CHM3lox and CHMFlox. In the first model, MerCreMer+ CHM3lox /Y (and 
CHM3lox/3lox) animals were induced with TM at 6-8 weeks of age as described earlier. These 
induced KO mice subsequently showed RPE degeneration which was also observed up to 14 
months following induction with no effects on the photoreceptors.  
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An alternative model was also produced following the breeding of CHMFlox mice with mice 
carrying a six3-Cre transgene (Furuta, Lagutin et al. 2000). Six3 is a transcription factor which 
is expressed in the neural retina during eye development (Bovolenta, Mallamaci et al. 1998; 
Hsieh, Zhang et al. 2002). Consistent with this, 2 months following TM induction these mice 
showed restricted KO in the neural retina, specifically prominent degeneration was 
observed in the photoreceptors where they showed shorter outer segments and a thinner 
ONL nuclei. Only mild RPE defects were observed including visible patchy RPE layer 
abnormalities. However these defects were attributed to the secondary changes observed 
due to the supportive role the RPE has towards the photoreceptors (Jaissle 2004). 
Interestingly, in vitro prenylation reactions were performed on eye extracts from both 
tissue-restricted KO mouse models. The pattern of unprenylated Rabs in the eyes of the TM-
induced CHM3lox/Y MerCreMer+ mice were significantly different from that of the CHMFlox/Y 
six3-Cre+ mice. This shows that in the RPE and neural retina, different subsets of Rabs are 
under-prenylated in the absence of REP1 transgene. This implies both layers have intrinsic 
prenylation defects that ultimately lead to degeneration. Taken together, these results 
reflect independent degeneration of the photoreceptors and RPE cells in CHM.  
To investigate the pathogenesis of the disease further, Tolmachova et al. recently showed 
the generation of three new CHM mouse models. These mice showed KO specifically seen in 
the photoreceptors, RPE cells or both layers and were called: CHMFlox, IRBP-Cre+, CHMFlox, 
Tyr-Cre+ or CHMFlox, IRBP-Cre+,Tyr-Cre+ mice respectively (Tolmachova, Wavre-Shapton et al. 
2010). Analysis of these mouse models was hoped to elucidate whether the CHM KO in one 
layer (either photoreceptors or RPE), could initiate or indeed affect the degeneration of the 
other layer. A summary of the histology analysis and main differences observed in these 
three CHM KO models is shown in Figure 21.    
To achieve photoreceptor-specific CHM KO (CHMFlox, IRBP-Cre+), mice carrying the 
conditional allele CHMFlox were crossed with the transgenic interphotoreceptor retinol 
binding protein (IRBP-Cre) mouse line. These mice express the Cre-transgene under the 
control of a tyrosinase promoter (as described previously in (Vooijs, te Riele et al. 2002). As 
described earlier, the CHMFlox allele is a conditional allele that carries two loxP sites flanking 
exon 4 of the CHM gene. Thus recombination between these two sites leads to a frameshift 
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and early stop codon appearance (Tolmachova, Anders et al. 2006). Therefore  
CHMFlox, IRBP-Cre+ mice have CHM KO specifically in the photoreceptors.  
To create RPE specific CHM KO (CHMFlox, Tyr-Cre+), CHMFlox mice were crossed with the 
transgenic Tyr-Cre mouse line (Tyr::CreB). These mice express the Cre-recombinase gene 
under the control of an artificial tyrosinase promoter (as described previously in (Delmas, 
Martinozzi et al. 2003)). This promoter is active in pigmented cells, including RPE and skin 
melanocytes. Therefore CHMFlox, Tyr-Cre+ mice have CHM KO specifically in the RPE cells. 
Finally to produce mice with CHM KO in both cell layers (CHMFlox, IRBP-Cre+, Tyr-Cre+), the 
CHMFlox, Tyr-Cre+ and the CHMFlox, IRBP-Cre+ mice were mated together.  
The histological analysis of CHMFlox, IRBP-Cre+ mice showed slow progressive photoreceptor 
degeneration. Normal thickness in the ONL was observed at 6 months where approximately 
8-10 nuclei were observed (Figure 21C & H). In contrast, by 12 months the ONL was reduced 
by as much as 30% showing only 7-8 rows of nuclei compared to control mice - CHMFlox - 
which showed 10-12 nuclei at the same time point (Figure 21G & H). Conversely, the RPE 
cells retained a normal morphology with normal pigmentation and melanosome 
distribution.  
Together, these date show that CHMFlox, IRBP-Cre+ mice have late onset photoreceptor 
degeneration (due to the KO of functional REP1 in these cells), in the presence of normal 
RPE, implying that photoreceptors are an independent site of the CHM disease.  
In contrast, CHMFlox, Tyr-Cre+ mice exhibited coat colour dilution. These mice were lighter 
(chocolate rather than black) coat colour compared to the CHMFlox animals on the same 
C57BL/6 genetic background. This lightness is presumably is a result of the CHM deletion 
within the melanocytes, which in turn affects the biogenesis and transport of melanosomes 
within the skin cells - melanocytes - of these mice (Wasmeier, Hume et al. 2008).  
 
Electron microscopy of these mice further confirmed the disruption of melanosomes 
distribution within the RPE. Areas of melanosomes remained in the main body of the cell 
and did not enter the apical processes as seen in wild-type mice. This phenotype is also 
observed in Rab27a mutant mice (Lopes, Ramalho et al. 2007); hence these changes may be 
caused by Rab27a dysfunction.  
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Histological analysis revealed normal photoreceptors and intact ONL, with no reduction in 
the number of cells. In contrast pigment/melanosome abnormalities were observed. 
Specifically, homogenous melanosomes distribution was not observed as seen in wild-type 
mice (Figure 21B & F). The analysis of this RPE specific KO model confirmed previous finding 
that the degeneration of the RPE and photoreceptors in CHM disease is caused by intrinsic 
events which occur within each layer. This is contrary to assumptions that the degeneration 
of one layer leads to secondary degeneration of the other layer. Thus both layers could be 
considered as the primarily sites in CHM.  
 
In the final effort to understand whether one layer could influence the adjacent layer within 
the retina, CHM KO in all both photoreceptors and RPE cells was established and 
CHMFlox, IRBP-Cre+, Tyr-Cre+ mice were examined. Interestingly, histopathologic studies of  
6-month-old mice showed normal morphology of RPE cells. In contrast photoreceptor 
degeneration was considerably enhanced. A dramatic decline in the number of ONL nuclei 
was observed compared to the control mice as well as the single-layered KO mice (Figure 
21D & H). Despite this clear initial enhancement of photoreceptor degenerationat 6 months, 
the progression of degeneration remained steady and did not continuing to deteriorate at a 
rate higher than the single-layered KO mice. Indeed by 12 months, the level of 
photoreceptor degeneration in these mice was comparable to that of single-layered KO 
mice (Figure 21 H & I). This data suggests that the degeneration of the photoreceptors in 
this double KO CHM model is enhanced in the presence of normal RPE cells in younger mice. 
However this appears to level and in older mice this degeneration approaches that seen in 
the single layered KO mice. 
Overall one can say that the combination of photoreceptor and RPE disease (observed in the 
double-layered KO mice) is not equal to the sum of the effects seen in each individual cell 
type (observed in the single-layered KO mice). 
Interestingly, electroretinograms (ERGs) and scanning laser ophthalmoscopy (SLO) analysis 
were carried out on all three CHM mouse strains. Both analyses supported the 
histopathological findings seen in all three groups of mice. Noticeable abnormal 
autofluorescent mottling of the retina was seen in 8- and 14-month-old CHMFlox, Tyr-Cre+ 
and CHMFlox mice. Levels of autofluorescence were consistent and equally obvious at both 
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time points. This is consistent with pigment irregularities seen in these mice following 
electron microscopy analysis. The retinas of CHMFlox, IRBP-Cre+, mice showed normal 
autofluorescence levels at 8 months; while considerable multiple dot-shaped 
autofluorescence was observed in mice older mice presumably due to physiological aging of 
the RPE. Interestingly, in the double-layered KO mice, 8- and 14- month old mice presented 
abundant autofluorescence of both types (mottled and dot-like specks).  
White autofluorescent mottled specks/flecks were observed which were dim in colour and 
irregular in appearance. These specks most probably represent areas of RPE 
depigmentation, while dot-like specks, which were round and regular in appearance, usually 
represent intraretinal changes. Analysis of the dot-like specs was carried out. This was done 
by staining of whole mounts for the ionized calcium adaptor molecule (Iba-1), which is a 
marker for cells of microglia origin. Following staining, significantly higher levels of Iba-1-
positive structures where seen in the retinas of the double-layered KO, compared with both 
single-layered KO mice (Figure 21J). Microglia cells are scavenging cells presumably 
recruited to the retina to clear debris produced by dying photoreceptors. Indeed this is in 
agreement with the increase degeneration seen in these mice. Interestingly, this increased 
microglia phenotype is consistent with the retinal remodelling theory proposed previously 
to explain the various changes in the retinas of CHM patients (Jacobson, Cideciyan et al. 
2006). In the early stages of CHM disease, retinal thickening is observed which has been 
shown to be one of the stages involved in retinal remodelling through Müller (microglia) cell 
hypertrophy. 
If one takes the enhanced functional and photoreceptor defects seen in the younger 
double-layered KO mice, this implies that the presence of a diseased RPE considerably 
effects the rate of photoreceptor degeneration. Both these results highlight the significant 
interactions present between these adjacent cell layers and the influence that this has on 
the degeneration of the retina in CHM. 
Interestingly, in older mice, the levels of photoreceptor degeneration appear to reach 
similar levels between the single layered photoreceptor CHM KO mice, and the double CHM 
KO mice. This suggests that the RPE disease does not negatively affect the ultimate fate of 
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the CHM KO photoreceptor survival. Taken further, the CHM RPE may be behaving similar to 
a prematurely aged RPE. 
Other results also appear consistent with previous findings that both layers are the primary 
sites of CHM disease (Tolmachova, Anders et al. 2006). Indeed RPE abnormalities and 
normal photoreceptors were seen in the RPE-specific KO mice. Similarly, slow degeneration 
of the photoreceptors and normal RPE were seen in the photoreceptor-specific KO mice. 
Cumulatively the histological and functional studies show a complex relationship between 
the survival and function of photoreceptors, RPE status and aging.   
 
Indeed the single-layered REP CHM KO mice show morphologically normal photoreceptor 
cells, however, upon functional ERG studies, the mice showed mild functional impairments 
of these photoreceptor cells. This supports the idea that CHM is a retinal disease that is 
initially manifested as sight impairment due to the functional defects within the cell layers 
affected in the disease. However this then leads to progressive cell death. This is potentially 
very important for future gene therapy of CHM, as functional deficit may potentially be 
overcome if the expression of REP1 transgene is targeted to both RPE and photoreceptor 
cells.    
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Figure 21: A summary of the main differences in the CHM KO mouse models 
Histological analysis of sections of eyes from (A and E) CHMFlox (Flox (control) mice,  
(B and F) CHMFlox, Tyr-Cre+ (Flox, Tyr) mice, (C and G) CHMFlox, IRBP-Cre+ (Flox, IRBP) 
mice, (D) CHMFlox, IRBP-Cre+, Tyr-Cre+ (Flox, IRBP, Tyr) mice at 6 and 12 months 
respectively.  
(H) Morphometric analysis of the photoreceptor rows in the central retina in the Flox, 
IRBP (purple bars) and Flox, IRBP, Tyr (blue bars). (I) Quantitative data of the number 
of Iba1-positive cells per eye cup from 11-to 12-month-old Flox (gray bar), Flox, IRBP 
(closed bar), Flox, Tyr (open bar) and Flox, IRBP,Tyr (hatched bar) mice  
(Figure adapted from (Tolmachova, Wavre-Shapton et al. 2010)). 
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1.8 Summary and Project Aims 
 
Many efforts for ocular gene therapy are based on viral vectors, however currently there is 
neither a treatment nor cure for CHM patients. There are numerous reasons why CHM is a 
suitable candidate for local gene therapy:  
(1) The complete human cDNA, which encodes the REP-1 gene has been identified and 
cloned.  
(2) CHM patients have mutations in the REP-1 gene, which cause the loss of function of 
the REP-1 gene in majority of cases.  
(3) A mouse model of CHM was recently created (Tolmachova, Anders et al. 2006; 
Tolmachova, Wavre-Shapton et al. 2010), which has all the characteristic hallmarks 
of CHM: progressive degeneration of photoreceptors, patchy depigmentation of the 
RPE and defects in Rab prenylation.    
(4) CHM is particularly suitable for gene therapy due to the slow rate of degeneration, 
as well as the possibility of early diagnosis before the onset of detrimental changes 
occurs.  
(5) The small size and the high degree of compartmentalisation of the eye allows 
accurate delivery of vector suspensions to necessary tissues. Specifically subretinal 
injections enable the delivery of vector suspensions into the potential space 
between the photoreceptors and the RPE (Bainbridge, Tan et al. 2006), key areas 
affected in CHM. 
 
Our hypothesis is that S/MAR based vectors are suitable gene delivery plasmids for CHM, 
due to their non-viral nature and the fact that CHM is not a life threatening disease. 
Currently non-viral vectors face two main problems when compared to the efficient viral 
gene therapy alternatives. These include: delivery of the vector and the maintenance of the 
transgene. Hence we will endeavour to utilise techniques currently being used by our group 
for viral vector administration.  
For efficient delivery of S/MAR vector chemical formulations combined with direct 
subretinal injections will be used, thus we will overcome these hurdles and establish a long- 
term transgene expression within the eye.  
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We aim to utilise S/MAR based vectors for the development of a persistently expressing 
vector for CHM. In particular the aims of this project are:   
 Demonstrate the potential of S/MAR sequences to drive long-term transgene 
expression in vitro to verify and extend previous observations reported in the 
literature. 
 Development of a novel non-viral S/MAR vector for the therapeutic purposes of 
CHM gene therapy, specifically the development of an S/MAR based vector 
containing REP1.  
 Development of proof-of-principle experiments validating novel non-viral S/MAR 
vectors in vitro, including the introduction of the S/MAR vectors containing REP1 into 
CHM derived cells as well as the analysis of phenotypic correction/rescue. 
 Development of S/MAR vectors for long-term gene delivery in the mouse retina, 
including delivery optimisation and plasmid safety validation in vivo.  
 Delivery of novel S/MAR vectors in CHM mice, the analysis of long-term gene 
expression in the mouse retina of CHM disease as well as the analysis of phenotypic 
and functional rescue/correction.  
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2 MATERIALS &METHODS 
____________________________________________________________________________ 
2.1 Materials 
2.1.1 General Chemicals 
 
Agarose electrophoresis grade   Invitrogen (UK) 
Ampicillin      Sigma-Aldrich (USA) 
Bovine Serum Albumin (BSA)    New England Biolabs 
2’-desoxynucleotide 5’-triphosphate mix (dNTPs) Invitrogen 
EDTA (ethylenediaminetetraacetic acid)  BDH (UK) 
Ethanol      BDH 
Ethidium bromide     Sigma-Aldrich 
Formaldehyde      BDH 
Glucose      BDH 
Glycerol      BDH 
Isopropanol      Sigma-Aldrich 
Kanamycin      Sigma-Aldrich 
LB broth      Invitrogen  
Luciferin      Gold Biotechnology (USA) 
Molecular weight DNA markers   Invitrogen and Bioline (USA) 
Paraformaldehyde Invitrogen    Sigma-Aldrich 
Sodium dodecyl sulphate (SDS)   Sigma-Aldrich    
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2.1.2 Enzymes and molecular biology reagents 
 
All restriction enzymes were from NEB Biolabs (New England Biolabs, Hitchin, UK) and were 
used with the appropriate buffer. 
 
2.1.2.1 Enzymes for DNA manipulation 
 
Klenow large DNA polymerase I   Invitrogen 
T4 DNA ligase       Invitrogen 
 
2.1.2.2 PCR reagents and DNA size markers  
 
DNA Ladders (100 bp and 1 kb)   Invitrogen 
dNTPs       Invitrogen 
Taq DNA polymerase      Invitrogen 
 
2.1.2.3 Buffers, Solutions and Media 
 
DNA Loading Buffer 6x   5 Mm EDTA 
      40% (v/v) Glycerol in ddH20 
      0.25% (w/v) Bromophenol Blue  
       
SSC 20 x     3M NaCl 
0.3M Sodium Citrate, pH 7.0 
Luria Broth - LB medium    12.5 g / 500 ml of LB 
(1x concentration)    + 500 ml sterile H20 
LB + Agar      12.5 g / 500 ml of LB 
(1x concentration)    7.5 g / 500 ml of Agar  
      + 500 ml sterile H20 
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2.1.3 Tissue culture reagents 
 
Dulbecco’s Modified Eagle medium (DMEM)  Invitrogen  
RPMI 1640       Invitrogen  
DMEM:F-12       Invitrogen 
OPTIMEM serum-free medium    Invitrogen 
1 x PBS        Invitrogen 
Trypsin-EDTA solution      Invitrogen 
Penicillin/streptomycin reagent     Invitrogen 
Lipofectamine 2000 reagent      Invitrogen 
Lipofectin       Invitrogen 
Fetal Calf Serum (FCS)      Invitrogen 
Geneticin (G418)      Invitrogen 
Antibiotic-Antimycotic      Invitrogen 
Dispase        Sigma-Aldrich 
 
2.1.4 Antibiotics 
 
Stocks solutions of antibiotics were prepared at working concentrations below and stored at 
-20°C. 
Ampicillin (Amp)  100 mg/ml   Sigma-Aldrich  
Kanamycin (Km)  50 mg/ml   Sigma-Aldrich 
 
2.1.5 DNA extraction and purification kits 
 
QIAGEN Endotoxin Free Plasmid kit    Qiagen Ltd (UK) 
QIAquick PCR Purification Kit      Qiagen Ltd  
QIAquick Gel Extraction Kit     Qiagen Ltd 
Sigma GenElute Mammalian Genomic DNA   Sigma-Aldrich 
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2.1.6 Plasmids 
 
Plasmids Size (bp) Original source (group) Resistance  
pEOS 5084 Personal Efforts  Kanamycin 
pEFS-EGFP 6184 Personal Efforts Kanamycin 
pEFS-EGFP-Control 4184 Personal Efforts Kanamycin 
pEOS-CAG-S/MAR 6810 Personal Efforts Kanamycin 
pEOS-CAG-MCS-S/MAR 6838 Personal Efforts Kanamycin 
pCAG-EGFP 7691 Personal Efforts Kanamycin 
pCAG-EGFP-Control 5691 Personal Efforts Kanamycin 
pEOS-EFS-S/MAR  5384 Personal Efforts Kanamycin 
pEFS-REP1 7352 Personal Efforts Kanamycin 
pEFS-REP1-Control 5352 Personal Efforts Kanamycin 
pCAG-REP1 8830 Personal Efforts Kanamycin 
pCAG-REP1-Control 6830 Personal Efforts Kanamycin 
pEPI-MCS1 5366 Ms. Azadeh Cheraghchi 
Bashi (Masters Student – 
Imperial College London) 
Kanamycin 
pEPI-EGFP 6695 Prof. Hans Lipps,  
Witten, Germany 
Kanamycin 
pEPI-Luc 7611 Prof. Hans Lipps,  
Witten, Germany 
Kanamycin 
pUbqC-Luc 7619 Prof. Hans Lipps,  
Witten, Germany 
Kanamycin 
pWPT-GFP  Dr D. Trono, University of 
Geneva, Switzerland and/or 
Addgene 
Ampicillin 
pBC SK + 3400 Commercial - Stratagene Chloramphenicol 
pWPI-REP1 13101 Dr D. Trono, University of 
Geneva, Switzerland  
Ampicillin 
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2.2 Methods 
2.2.1 Growth and Maintenance of Cells 
2.2.1.1  Mammalian cells 
 
Mouse anterior pituitary cells (AtT20 cells) were maintained in a 3:1 ratio of Dulbecco’s 
Modified Eagle’s Medium (DMEM):F-12 (Invitrogen, UK), supplemented with 25 mM 
glucose, 15% fetal bovine serum (FBS), 100 U/ ml penicillin and streptomycin 100 U/mL 
penicillin. Mouse RPE cells were maintained in RPMI 1640 (Invitrogen), while Porcine RPE 
were maintained in DMEM supplemented with 10% FBS, 100 U/ ml penicillin and 
streptomycin 100 µg/mL. All cells were grown at 37°C in a humidified incubator with 10% 
CO2. All cells were allowed to reach 80-90% confluency before being split by aspirating the 
growth medium, washing with phosphate buffered saline (PBS) to remove the remaining 
medium, adding Trypsin-EDTA and incubating at 37°C until all the cells had begun to detach. 
Media was then added to neutralise the trypsin solution. Cells were then pelleted by 
centrifugation at 1000 g for 5 mins. An aliquot of these cells were then seeded into a new 
flask. 
2.2.1.2 Long-term storage in liquid nitrogen 
 
For the long-term storage of all cells, confluent cells were trypsinised and centrifuged as 
above and resuspended in FCS containing 10% DMSO. They were then aliquoted into 
cryotubes and frozen slowly at -80°C for 24 h. After which the vials of cells were stored in 
liquid nitrogen until required. To bring cells up from the liquid nitrogen, the cells were 
thawed rapidly by placing then in a water bath at 37°C. Once thawed, this aliquot was 
diluted in fresh growth medium and cells were pelleted at 1000 g for 5 mins, before which 
they were resuspended in the required growth medium and seeded into a new tissue 
culture flask. The following day, the media was aspirated away and replaced with fresh 
medium to ensure the removal of any traces of remaining DMSO.  
 
2.2.2 Primary fibroblasts 
 
Human primary fibroblasts were maintained in DMEM supplemented with 25 mM glucose, 
15% fetal bovine serum (FBS), 100 U/ ml penicillin and streptomycin 100 U/mL penicillin. 
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While mouse primary fibroblasts were maintained in DMEM supplemented with25 mM 
glucose, 15% heat inactivated FBS (65°C for 30 min), 500 U/ ml penicillin, 500 U/ml 
streptomycin and 25 µg/ ml amphotericin B (PSA). 
 
2.2.2.1 Isolation of primary mouse fibroblasts 
 
Mouse fibroblasts were isolated from 2-3 day old pups. Necks were dislocated following 
with the removal of the head, legs, arms and tail. Starting from the neck, a small incision 
was made and using blunt scissors the skin was peeled away from the body while trying to 
maintain the skin in one piece. Once removed, the skin was washed twice in 5% PBS/PSA, 
and the dermis (the side of the skin on the inside of the mouse) was cleaned to removal 
blood and fat from this layer. The entire dermis was then cut into small pieces (~1 cm2) and 
epidermis side-up, was placed into 1-well of a 6-well plate. Following a brief period of 
attachment, 1 ml of medium containing 5% dispase/medium was gently added to the cells, 
to allow for the gentle dissociated of the epidemis and dermis layers. Tissues were then 
incubated at 37°C for 1-2 hours or overnight at 4°C. After this time, the dermis was removed 
with a scalpel while and the epidermis (dryer and whiter layer) was discarded. The dermis 
was then cut into very small pieces with scissors and a sterile scalpel and placed into a fresh 
1-well of a 6-well plate, were they were then allowed to dry and attach for a brief period of 
no more than 10 mins. Following this fresh medium supplemented with PSA and heat 
inactivated FBS was added to the dermis and incubated for 2-3 days at 37°C in 10% CO2. This 
allowed sufficient time for cells to growing underneath the pieces of attached demise. 
Following this period of incubation, the dermis was detached by the addition of growth 
medium and vortexed vigorously 10-20 times before being centrifuged at 0.8 g for 5 mins.   
Medium was aspirated off and the pelleted cells were placed in a new 10-cm dish for 
regrowth. This allowed the fibroblasts which had attached to the base of the dermis pieces 
to be removed and evenly spread in the 10-cm dish. The following day, the medium 
containing all the dermis and unattached cells were removed and replaced with fresh 
complete medium. Once the cells had reached 80-90% confluency in the first passage cells 
were detached with trypsin-EDTA as described earlier, counted using a haemocytometer 
where they were replated at a density no greater than 5 x 104 cells per flask. This ensured 
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that the cells in the first passage were allowed sufficient space to grow and establish. 
Densities larger or smaller considerably affected the subsequent growth of the cells. 
 
2.2.2.2  Isolation of primary RPE cells 
 
Retinal pigment epithelium (RPE) primary isolations were described previously (Lopes, 
Ramalho et al. 2007). Porcine RPE were harvested in a similar manner with the exception 
that cells were released from the posterior eyecups by treatment with 10x Trypsin 
(Invitrogen).  
 
2.2.3 Preparation of Bacterial Plasmids 
2.2.3.1 Small scale plasmid preparation 
 
For small scale plasmid isolation the QIAGEN Miniprep Kit (Qiagen) was used. Bacterial 
cultures for plasmid preparation were grown from single colonies which were picked from a 
freshly streaked selective plate. A single colony was incubated in 5 ml LB broth containing 
the appropriate antibiotic and grown at 37°C in a shaking incubator (225 rpm) overnight. 
Bacteria were then pelleted by centrifugation at 4 000 rpm for 5 mins in a benchtop 
centrifuge. The pellet was then resuspended and lysed in the provided lysis buffer. The 
solution was neutralised and proteins were precipitated by added neutralisation buffer. 
Debris was spun out by centruifugation at 13 000 g for 15 mins. The resulting supernatant 
was then passed through a Spin Column Assembly to allow binding to the column matrix. 
Following two washes, the pDNA was eluted in 50 µl of elution buffer or sterile water. 
 
2.2.3.2 Large scale plasmid preparation  
 
For the large scale plasmid isolation the Endo-free Plasmid Maxiprep kit (Qiagen) was used 
according to the manufacturer’s recommendations. Briefly, a 5 ml starter culture of E. coli 
strain containing the required plasmid of interest was used to inoculate 500 ml of fresh 
sterile LB broth in a 2 L flask containing the appropriate antibiotic. Bacterial cells were 
subsequently harvested by centrifugation for 15 mins at 6000 rpm using a Sorvall GSA-1500 
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rotor. The pellet was then resuspended in resuspension buffer, before being lysed at room 
temperature for 5 mins followed by neutralisation with neutralization buffer. Lysate was 
then passed over a column with an ion-exchange resin, which binds DNA at a pH of 7 and 
ionic strength of 750 mM NaCl. A medium salt wash was used to remove RNA, proteins and 
low molecular weight impurities. The DNA was eluted followed by precipitation with 
isopropanol and pelleted by centrifugation at 15 000 g for 30 minutes in a Sorvall SA-600 
rotor. The pellet was subsequently washed with 70% ethanol before being resuspended in 
sterile water and stored at -20°C. 
 
2.2.4 Preparation of genomic DNA 
 
For the preparation of genomic DNA from cells and tissues, GenElute Mammalian Genomic 
DNA Miniprep kit (Sigma) was used according to the manufacturer’s recommendations.  
 
2.2.5 Determination of DNA purity and concentration 
 
Ultraviolet absorbance spectrophotometry was used to determine the purity and 
concentration of DNA. The absorbance of nucleic acids at 260 nm was used to calculate the 
concentration of nucleic acid in the sample. The absorbance ratio of A260/A280 provides an 
estimate for the purity of the nucleic acid. Acceptable levels of purity have ratios between 
1.7-1.9. The optical density was measured using a Nanodrop ND1000 Spectrophotometer 
(Thermo Fisher Scientific, Wilmington, Delaware, USA).  
 
2.2.6 Digestion with restriction enzymes 
 
DNA was digested with restriction endonucleases according to the manufacturer’s 
instructions. DNA samples were digested with appropriate enzyme in the compatible buffer 
supplied, with distilled water and bovine serum albumin (BSA) if required. For cloning 
purposes normally 2 μg of vector DNA and 3 μg of insert DNA were digested for 2 hours at 
37˚C in a total volume of 20 μl or 30 μl respectively. The appropriate 10 x Buffer was added 
to the reaction volume (final concentration 1 x) with the remaining volume made up with 
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distilled water. For proceeding steps, all digested vector or insert DNA was heat inactivated 
by incubation at 65˚C for 20 minutes. Double digestions were either performed in one step 
if the enzymes performed optimally in the same buffers or in two steps with DNA 
precipitation between digests. The amount of DNA was reduced to 200 ng if the digestion 
was used as a general check for the correct insertion of a DNA fragment. 
 
2.2.7 Digestion with DNA modifying enzymes 
2.2.7.1 Klenow reaction  
 
Prior to ligations, vector and insert DNAs with incompatible sticky ends were treated with 
Klenow fragment (Invitrogen) in order to blunt end the fragments. The Klenow fragment of 
E. coli DNA polymerase I is a large protein fragment that exhibits 3’ to 5’ exonuclease 
activity as well as 5’ to 3’ polymerase activity. Digestions with restriction enzymes in some 
circumstances leave 5’ overhangs; therefore the subsequent digestion with Klenow enzymes 
is able to create blunt ends in these DNA fragments.  For the enzyme to proceed with the 
filling-in reaction, the entire DNA from a digestion reaction was treated with 1-2 μl of 
Klenow enzyme (0.5U/μl) with the provided buffer and dNTPs (final concentration of 0.1 
mM). The reaction was incubated at room temperature for 30 minutes after which the 
enzyme was heat inactivated at 65˚C for 20 minutes.  
 
2.2.7.2 Ligation  
 
In order to subclone insert DNA fragments into vectors - with either sticky or blunt ends – 
the T4 DNA ligase enzyme (Invitrogen) was used for ligations. Hence DNA fragments 
generated after restriction digestion or after blunt ending were ligated together in a total 
volume of 10 or 20 μl overnight at either 14˚C or room temperature for sticky or blunt end 
ligations respectively. Reactions consisted of 1-2 μl T4 ligase (1U/ μl) in the provided 10 x T4 
ligase buffer. The ratio of vector to insert in the ligation reaction was 1:11 as the vector DNA 
was not dephosphorylated. The ligation mixture was subsequently digested with an 
appropriate enzyme which allowed the cleavage and subsequent inactivation of self-ligated 
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vector DNA as well as other unwanted plasmid or ligation species in the ligation mixture, as 
previously described in (Tolmachov 2009). When using this selection approach, the vector, 
the desired insert sequence as well as their junctions where checked to ensure they did not 
contain any internal sites for the restriction enzyme used to digest the ligation mixture. 
Hence this technique linearises unwanted circular products within the ligation reaction and 
renders them incapable of replicating in bacteria. DNA precipitation was performed on the 
DNA after the overnight ligation reaction and before the subsequent digestion of the 
ligation mixture. From this digested ligation reaction, 5 μl was transformed into competent 
JM109 cells. The quality, quantity and digestion of DNA was analysed after each digestion 
step by agarose gel electrophoresis on gels ranging from 0.8-1.2%. 
 
2.2.8 Transformation of bacteria 
 
For cloning steps JM109 competent cells were used (Promega). This E. coli based strain 
contains the recA mutation was prevents undesirable recombination events and leads to 
plasmid stability. For plasmid isolation 30-100 ng of DNA was transformed into 
ultracompetent E. coli DH5α or XL10-Gold cells (Invitrogen). 
 
2.2.9 Polymerase Chain Reaction (PCR) amplification 
 
Colonies that formed from the transformation of competent cells were amplified and 
screened by PCR analysis using a Robocycler thermal cycler (Stratagene) to check if the 
correct insert was present. The usual PCR reaction mixture contained a 12.5 µl reaction mix 
was prepared containing: 
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Component (concentration) Volume 
(μl) 
Final amount or 
concentration 
10x Taq-Buffer (Invitrogen) 1.25 1 x 
MgCl2 (50mM) 0.375 1.5 x 
DNTP mixture (1mM) 2.5 0.2 mM 
Forward Primer (2.5mM) 2.5 0.5 mM  
Reverse Primer (2.5mM) 2.5 0.5 mM 
Sterile H2O 3.25  
Taq DNA polymerase (5 U/ μl) 0.125  
 12.5  
 
The primers used were: For the PCR analysis of plasmid pEFS-EGFP,  
Forward: F EGFP6 (5’- CGAGAAGCGCGATCACATGG -3’) and  
Reverse: R S/MAR (5’- GCAAAGCATGAGATGTGTGGGGAT -3’).  
This yielded a 450 bp fragment. 
For PCR analysis of plasmid pCAG-EGFP,  
Forward: F CAG F3 (5’- GCAACGTGCTGGTTGTTGTGC -3’) and  
Reverse: R EGFP R1 (5’- CATCTGCACCACCGGCAAG -3’)  
This yielded a 250 bp fragment. 
For PCR analysis of plasmid pEFS-REP1, 
Forward: F RH4 (5’- ATTCGTCAGACATCAGCAGG -3’) and  
Reverse: R S/MAR (5’- GCAAAGCATGAGATGTGTGGGGAT -3’) 
This yielded a 590 bp fragment. 
For PCR analysis of plasmid pCAG-REP1, 
Forward: F CAG F3 (5’- GCAACGTGCTGGTTGTTGTGC -3’) and 
Reverse: R REP1R2 (5’- TATGCCAGTCAGGATTTGCATGAA -3’)  
This yielded a 430 bp fragment. 
For the annealing of MCS2,  
Forward: MCS2 Forward/Upper2 (5’- TCGAAGGATCCTAGCACGCGTGTCGACA -3’) and  
Reverse: MCS2 Reverse/Lower2 (5’- TCGATGTCGACACGCGTGCTAGGATCCT -3’) 
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The specific PCR reaction conditions used were: 
Step pEFS-EGFP & pCAG-EGFP pEFS-REP1 & pCAG-REP1 
(1) Activation  
(2) Denaturation 
(3) Annealing  
(4) Elongation 
(5) Prolonged elongation 
95°C – 3 min 
95°C – 40 min 
59°C – 40 min 
72°C – 1 min 
72°C – 10 min 
95°C – 5 min 
95°C – 40 min 
57°C – 40 min 
72°C – 1 min 
72°C – 10 min 
Repeat of steps (2)-(4) for 32 cycles. 
 
As a positive control, 1 μl of a 1 in 10 dilution of the ligation reaction was included. 
Amplified colonies were checked by running samples on 1.2% agarose gels. Colonies that 
tested positive after PCR amplification were isolated for small-scale plasmid preparation and 
subsequent restriction digestion (described above) to analyse the integrity of restriction 
sites within the newly formed plasmid.  
 
2.2.10 Transfection and gene expression experiments 
2.2.10.1 Cells Transfections  
 
One day prior to transfection B16-F10 and AtT20 cells were seeded in either 10-cm dishes or 
6-well plates at a concentration of 5 x 105 or of 2.5 x 105 per dish or plate for AtT20 and  
B16-F10 cells respectively, while fibroblasts were seeded in 12-well plates at a 
concentration of 5 x 104 cells per well. Transfections were carried out using Lipofectamine 
2000 (Invitrogen), Calcium Phosphate (Promega) or in vivo-jet-Polyethylenimine (PEI) 
(Invivogen) following the manufacturer’s instructions. The following ratios of 
DNA:transfection reagent were used: 0.4 μg DNA: 1 μl Lipofectamine 2000, 1 μg DNA: 3.1 μl 
Calcium Phosphate, 1 μg DNA: 2 μl jet-PEI.  
 
The DNA used in transfections with Lipofectamine 2000 was diluted in OptiMEM 
(Invitrogen), while the DNA in calcium phosphate and PEI transfections was diluted in HBS 
and NaCl respectively. Complexes were allowed to form for 20-30 minutes at room 
temperature. During the incubation time cells were gently washed with PBS prior to the 
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addition of the transfection reagent/DNA complex. The cells were incubated with the 
complexes overnight, at which time the transfection mixture was removed and replaced 
with normal growth medium. Cells were incubated for 48 hours before they were analysed 
for transient transfections.    
 
Primary fibroblasts were transfected with pCAG-REP1 plasmid by nucleofection using the 
AMAXA nucleofector apparatus and the fibroblast kit (Lonza, Cologne). Briefly, 5 x 105 cells 
were pelleted by centrifugation at 200 g for 5 mins and resuspended in 100 µl of 
transfection solution supplied with the kit. Plasmid DNA pCAG-REP1 (20 µg) was added to 
the cells and the suspension was added to cuvettes. Nucleofection was performed in the 
apparatus using the setting programmes P32, P24 and Q32 for human fibroblasts or 
programmes Q32, U23 and W32 for mouse fibroblasts. Following nucleofection, cells were 
taken out of the cuvettes and gently added to 2 ml of pre heated complete medium. Cells 
were incubated overnight prior to analysis.  
 
Primary RPE cells were transfected using Lipofectin reagent (Invitrogen) according to 
manufacturer’s recommendations. Briefly, the transfection medium containing 1 µg of 
plasmid DNA (pDNA) and 6 µl of Lipofectin reagent in serum free medium was incubated for 
15 min at room temperature (RT) and then added to RPE cells overnight. Expression of EGFP 
was analysed 48 hours post transfection by immunofluorescence of transfected cells. 
 
2.2.10.2 Drug-resistance selection  
 
AtT20 cells were seeded in 6-well plates, stably transfected and re-plated into 2 x 10 cm 
dishes 18 hours after transfection. Stably transfected AtT20 cells were selected 24 hours 
after transfection by the addition of Geneticin (G-418) (Invivogen) in DMEM:F-12 medium 
(0.5 mg/ml). G418 selection lasted 2 weeks, with G418-supplemented media being changed 
every 3-4 days. After 2 weeks of selection, isolated cell colonies (containing the neo drug 
resistance gene) were picked and transferred into fresh 24 well plates for re-growth. After 
sufficient growth, half the cells were grown in medium with selection (G418 medium) while 
124 
 
the other half was maintained in normal medium. At different time intervals, GFP 
expression was analysed by FACS analysis.  
 
2.2.11 Flow Cytometry 
 
The long term transfection efficiency as well as EGFP expression of AtT20 stably transfected 
cells was determined by fluorescent activated cell sorter (FACS) analysis at different time 
intervals post transfection. Cells were washed twice with FACS buffer (PBS, 0.5% BSA, 0.01% 
sodium azide) containing TOPRO-3-iodide (Molecular Probes, Paisley, UK) to stain dead cells. 
Fluorescence was analysed using a FACSCalibur system (Becton Dickinson biosciences, San 
Jose, CA), equipped with a 488 nm argon ion laser. Results were analysed using CellQuest 
software (Becton Dickinson biosciences, San Jose, CA). For each sample, a minimum of 
10,000 events were collected. The cells were visualised on an FSC (forward scattering) 
versus SSC (side scattering at 90%) display. The samples were analysed on the cytometer 
and plots of sidescatter (SSC) against EGFP fluorescence (FL1) were plotted. A threshold 
level of fluorescence was set such that 1% of untransfected cells fell about it. The 
percentage of cells fluorescing at a level above this threshold was taken as the percentage 
of cells transfected and this was shown graphically on the histograms obtained for each 
sample by M1. 
 
2.2.12 Antibodies 
 
The following antibodies were used at the dilutions indicated: anti-α-tubulin mouse 
monoclonal (Sigma), 1:5,000; anti-GFP rabbit polyclonal (Abcam, Cambridge, UK), 1:200 for 
immunofluorescence on frozen and whole mount sections; anti-GFP mouse polyclonal 
(Roche), 1:2,000 for immunoblotting and 1:200 for immunofluorescence; anti-RPE65 mouse 
monoclonal antibody (Abcam), 1:200 for immunofluorescence; anti-Rab27a mouse 
monoclonal (4B12) antibody, 1:10,000 for immunoblotting; anti-mouse 2F1 monoclonal 
(Sigma), 1: 500 for immunoblotting and 1:300 for immunofluorescence; anti-rabbit J905 
monoclonal (Sigma), 1:500 for immunoblotting and 1:300 for immunofluorescence; anti-
Rab11 mouse (Sigma), 1:1000 for immunoblotting. Secondary antibodies were conjugated 
to horseradish peroxidase (HRP) were purchased from DAKO (Glostrup, Denmark). Alexa-
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488 and -568 conjugated secondary antibodies were purchased from Molecular Probes 
(Eugene, OR, USA). Anti-rabbit or anti-mouse HRP, 1:10,000 for immunoblotting (DAKO), 
anti-rabbit or anti-mouse Alexa 488 or 568 (Molecular Probes), 1:500 for 
immunofluorescence.  
 
2.2.13 Immunofluorescence and confocal fluorescence microscopy 
 
Cells used for immunofluorescence were grown on glass coverslips, and transfected with 
pDNA where indicated. Cells were washed with phosphate buffered saline (PBS), fixed with 
4% (w/v) paraformaldehyde (PFA) in PBS for 30 min, rinsed twice with PBS, blocked and 
permeabilised with 0.05% (w/v) saponin, 0.5% (w/v) bovine serum albumin (BSA) in PBS 
(PBS/BSA) for 20 min.  Permeabilised cells were incubated with the primary GFP antibody 
for 1 h at room temperature (RT), followed by four washes and incubation with species 
specific Alexa-conjugated secondary antibody for another hour at RT. All incubations and 
washing steps were carried out in PBS/BSA. The coverslips were mounted in immuneO 
mounting medium (MP biomedicals, Solon, Ohio) and visualised using a Zeiss inverted LSM-
510 confocal microscope. Images were processed using Adobe Photoshop software. All 
images shown are single sections in the z-plane and representative of at least 80% of 
transfected cells. 
 
2.2.14 Immunoblot Analysis 
 
Protein extracts were either obtained from transfected cells or injected mouse retinas 
(isolated RPE and neural retinal cells obtained during the process of RPE isolation). Samples 
were lysed in protein lysis buffer (10 mM Tris-HCl (pH 7.5), 2% (w/v) Sodium Dodecyl 
Sulphate (SDS), 1 x protease inhibitor (Roche)) by sonication for 10 second with an 
amplitude of 5 µm (MSE Soniprep 150). The protein concentration was determined using a 
bicinchonic acid (BCA) protein assay kit (Pierce) for the colourimetric detection and 
quantification of total protein, following the manufacturer’s protocol. Samples with 50 µg of 
total protein lysate were resolved by 12% SDS-polyacrylamide gel electrophoresis and 
transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). Membranes were 
blocked in 5% non-fat milk and 0.1% Tween-20 in PBS (PBS-T), incubated with the primary 
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antibody, washed three times, incubated with HRP conjugated species specific secondary 
antibody, and washed as above. All incubations and washing steps were carried out in  
PBS-T. Bound antibody was detected using the ECL Plus Western Blotting detection system 
(GE Healthcare). 
 
2.2.15 Southern Analysis 
 
Protocols for Southern blot analysis have been described previously (Argyros, Wong et al. 
2008; Wong, Argyros et al. 2011). Briefly, for DNA analysis in vitro as well as in vivo, total 
eye DNA (from three to four injected retinas per condition) or cell DNA (from transfected 
cells) was extracted using a GenElute mammalian genomic DNA kit (Sigma-Aldrich). Isolated 
genomic DNA was quantified using a Nanodrop ND1-1000 spectrophotometer (Labtech 
International Ltd., Ringmer, UK). Genomic DNAs (30 µg retinal homogenates or 10 µg 
transfected cells) were digested with a single cutter to all plasmids StuI restriction enzyme 
overnight, separated by agarose gel electrophoresis (30V, 30mA overnight) and transferred 
to Hybond-N+ nylon membranes (Amersham). Membranes were hybridized overnight with 
32P-labeled AlwNI fragment (Rad-Prime labelling kit, Invitrogen) (408-bp DNA fragment of a 
segment of the kanamycin region, which is common to all plasmids). Membranes were 
hybridised in Church buffer (0.25M sodium phosphate buffer (pH 7.2), 1mM EDTA, 1% BSA, 
7% SDS) at 65°C. After 3 washes at 65°C with high stringency buffer (2x saline-sodium citrate 
(SSC)/0.5% SDS for 10 min, 1X SSC/0.5% SDS for 15 min, followed by 0.1x SSC/0.5% SDS 10 
min), specific hybridization signals were detected by exposing the membranes to x-ray film 
with intensifying screens at -80°C. 
 
2.2.16 Subcellular Fractionation 
 
To perform in vitro prenylation on CHM transfected cells as well as CHM injected mouse 
retinas, subcellular fractionation was performed at different time intervals (either 6 months 
or 6 weeks) post transfection or subretinal injection respectively. This enables the 
separation of cellular membranes including membrane associated proteins from cytosolic 
components. Adherent cells were harvested either mechanically or using Trypsin-EDTA as 
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described previously and centrifuged at 1000 x g for 5 minutes at 4°C. The supernatant was 
aspirated and cells were washed with PBS and centrifuged once more. Cells were then 
resuspended in lysis buffer. RPE cells were isolated from CHM mice following subretinal 
injections as described previously.  Samples were then resuspended in protein lysis buffer 
and lysed by sonication. 
Lysates were centrifuged at 800 x g for 10 minutes at 4°C to remove large cell debris obtain 
the post nuclear supernatant (PNS). The PNS was then transferred to a Beckman Centrifuge 
Tube and subjected to ultracentrifugation at 100,000 x g for 1 hour at 4°C using a TLA45 
Beckman rotor. The resulting supernatant (S100, abbreviated to ‘S’) which contained the 
cytosolic fraction was transferred to a fresh tube, while the pellet (P100, abbreviated to ‘P’) 
which contained the membrane fraction was resuspended in an equivalent volume of lysis 
buffer to the S100 fraction. The P100 was then sonicated for 10 seconds and protein 
concentration was determined using BCA as described previously. Both S and P fractions 
were then analysed by immunoblot/Western blot analysis as described previously (probed 
with anti-Rab27a (4B12) or anti-Rab11 antibodies). 
 
2.2.17 RNA isolation and Reverse Transcription PCR (RT-PCR) 
 
To determine the level EGFP or REP1 transcript, reverse transcription-polymerase chain 
reaction (RT-PCR) was performed. Total RNA was extracted from tissues (using three to four 
injected retinas per condition) or cells using TRIzol reagent (Invitrogen) according to 
manufacturer’s recommendations. The concentration of RNA was determined using 
spectrophotometry. First-strand complementary DNAs (cDNAs) were generated from RNA 
using the Superscript III first strand synthesis system (Invitrogen) according to the 
manufacturer’s recommendations. Following this, extracted RNA samples (250 ng for cells 
or 1.5 µg for tissue) were allowed to proceed at 20°C for 10min, 42°C for 30 min, heated at 
99°C for 5 min, then incubated at 3°C for 5 min using the First-Strand cDNA synthesis kit 
(Invitrogen). Amplification of cDNAs was carried out by Polymerase Chain Reaction (PCR) 
using EGFP (as described previously (Chan,Chong et al. 2001)) or REP1 specific primers:  
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For GFP RT-PCR,  
GFP-rtF Forward: (5´-ACGGCAAGCTGACCCTGAAG-3´) and  
GFP-rtR Reverse: (5´- CAACCACTACCTGAGCACCC -3´)  
This yielded a 495 bp fragment. 
 
For REP1 RT-PCR, 
REP-rtF forward primer (5’-GCTGTTCGGGTCATTGAGTTATGT -3’) and 
REP-rtR forward primer (5’-TCAGACATCAGCAGGAGCTGTTAT-3’) 
This yielded a 240 bp fragment. 
 
Primers were designed manually and supplied through Invitrogen. PCR comprised of sterile 
water, -Mg 10x PCR buffer, 25 x MgCl2, 10 mM dNTP mix and primers. This reaction was 
done in a 45 µl reaction and 0.5 µl of Taq polymerase (Invitrogen) was added to the tubes. 
Samples were then inserted into Robocycler thermal cycler (Stratagene). The PCR 
programmes were as follows: initial denaturation at 94°C for 3 min, then 40 cycles of 40 sec 
melting at 94°C, 1 min annealing at 60°C, and 1 min extension at 72°C. After the last cycle, 
the polymerisation step was extended by 10 min at 72°C to ensure that all strands were 
completed.The rt-PCR products were confirmed by agarose gel and showed the specific 
band of predicted size. The primer set GFP-rtF and GFP-rtR yielded a 494-bp amplicon after 
amplification of GFP cDNA, while for REP1 the 240-bp amplicon was seen after amplification 
of REP1 cDNA. For negative controls, no RT products were used as templates in the PCR and 
were verified by the absence of gel-detected bands. Samples were run on 1.5% agarose gels 
and a gel imager was used to view amplified products from cDNA. 
 
2.2.18 Animal work 
 
One-month old C57BL/6 mice (wild-type) (25-30g) were bred and maintained on  
12-h light/dark cycle at the Central Biomedical Services of Imperial College London. MF1 
mice (3-4 month old) were purchased from Charles River Laboratories (UK). All CHM mouse 
lines were bred in house and generated as described previously (Tolmachova, Anders et al. 
2006; Tolmachova, Wavre-Shapton et al. 2010). All animals were maintained in accordance 
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with the rules and regulations of the Home Office. Mice were killed by cervical 
dislocationand eyes immediately enucleated. 
 
2.2.18.1 Preparation of complexes (PEI:DNA)  
 
S/MAR pDNA was complexed with the 22 kDa cationic linear polymer polyethylenimine (PEI) 
(in vivo-JetPEI, Polyplus Transfection, UK) to form stable polyplexes according to the 
manufacturer’s instructions. Briefly, for the subretinal injection of a mouse eye with a 
polyplex at an N/P 8 ratio, 30 µg of pDNA was diluted in 5% isotonic glucose solution to a 
final volume of 30 µl, 4.8 µl of in vivo-jetPEI was diluted in another aliquot of 5% isotonic 
glucose solution to a final volume of 30 µl. Diluted PEI was then added directly to diluted 
pDNA and vortexed briefly prior to injection of 1-2 µl of complexed DNA into the subretinal 
space. 
 
2.2.18.2 Gene transfer to ocular tissues in vivo 
2.2.18.2.1 Topical administration 
 
Protocols for the topical administration of formulations have been described previously 
(Liaw, Chang et al. 2001; Tong, Chang et al 2007). Briefly, for the in vivo eye drop delivery 
studies, the eyes of MF1 mice were initially pre-treated with an enhancer for gene transfer, 
5mM EDTA (10 µl per eye), which was applied as topical eye-drops to the cornea. Mice were 
held such that the eye was held open slightly for a few seconds while the eye drops were 
allowed to penetrate the cornea and be absorbed before the mouse was allowed to blink 
and move freely. This pretreatment occurred 10 minutes before pDNA was applied to the 
eye. The eye was delivered with 0.5 µg/µl of complexed pDNA with PEI (pCAG-Luc)(10 µl per 
mouse eye, three times per day for one day). Formulated pDNA was made fresh each time 
the topical administration was applied to the cornea. One eye would receive drops while the 
other contralateral eye was used as a control and either received plasmid alone or PEI 
formulated pDNA without enhancer pretreatment. To evaluate the gene transfer in vivo, 
mice were imaged for bioluminescence by the IVIS Imaging 50 Series (Xenogen) after 24 and 
48 hours of the first topical administration.   
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2.2.18.2.2 Intravitreal injections 
 
For all intravitreal and subretinal injections, fluid lines, surgical equipment and needles were 
sterilised by repeat rinsing with 70% ethanol and sterile water. Furthermore wild-type mice 
of MF1 strain (3-4 months old) were anesthetised by intraperitoneal injection of 
ketamine/xylazine (ketamine, 80 mg/kg; xylazine, 15 mg/kg, (Sigma-Aldrich). This was 
followed by topical anesthesia in the form of one proparicaine drop (proparacaine 
hydrochloride ophthalmic solution USP 0.5%, Akorn Inc., Buffalo Grove, IL). The pupil was 
then dilated with one drop of tropicamide (tropicamide ophthalmic solution 1%, Falcon 
Pharmaceuticals, Ft. Worth, TX) which usually took 90 s to fully dilate. If the pupil did not 
adequately dilate within this time, another drop of tropicamide was placed on the cornea. 
Following dilation, surgery was usually complete within 30-90 s.     
 
Intravitreal injections were performed under a dissecting microscope with a 10 µl Hamilton 
syringe fitted with a 32 gauge, beveled-tip needle. The needle was inserted through the 
sclera, posterior to the ora serrata in the superotemporal quadrant. Solution was injected 
slowly (1-2 µl) into the vitreous chamber of the eye. The needle was held in place for 5 
seconds to allow for the pressure to equilibrate within the vitreous, before which it was 
withdrawn and the injection was complete. Once the needle had been removed, triple 
antibiotic ophthalmic cream (Taro Pharmaceuticals, Inc., Hawthorne, NY), which contains 
bacitracin, neomycin sulfate, and polymyxin B was applied to the eye. 
 
2.2.18.2.3 Subretinal injections 
 
Injections in C57BL/6 mouse strain were initially performed by Dr Tanya Tolmachova, 
however some injections were also performed by Dr Mariya Moosajee. While all MF1 and 
CHM mouse injections were performed by Dr Mariya Moosajee.    
Subretinal injections were performed using one of two dissecting microscope systems. The 
first was a Leica binocular microscope (Leica Microsystems, Bannockburn, IL) with a fiber-
optic halogen illuminator & dual gooseneck light guide (Dolan-Jenner, Inc., Boxborough, 
MA). This system did not include avideo camera. The second system was an Olympus 
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binocular microscope (Hunt Optics; Pittsburgh, PA). This microscope system contained a 
video attachment module at the top and using a portable Panasonic video camera 
(Panasonic Electronic Devices, Knoxville, TN), recordings or still pictures of the surgical 
techniques were taken. The pictures and video were stored on a HD cardand transferred for 
analysis and editing using Apple Final Cut Pro editing software (version 6; Apple Computer).      
A heating pad was used to maintain the mice at 37°C during the process of anaesthesia 
(T/Pump TP500; Gaymar, Orchard Park, NY). All surgical needles were supplied from 
Hamilton Life Science. 
For the subretinal injections, a glass Hamilton syringe (10 or 50 µl syringe) was fitted with a 
blunt 27 gauge RN (removable) needle with the following details: 10/20 mm in length, PST3 
(blunt –point style 3). Tubing (0.6mm) in the form of intramedic non-radiopaque 
polyethylene tubing (Becton Dickinson, Franklin Lakes, NJ) was attached to this 27 gauge 
needle (50-100 mm but normally no more than 100 mm in length). The remaining free end 
of the tubing was attached to a beveled 33 gauge RN (removable) needle - which was the 
actual needle used to inject the retina – with the following details: 10 mm in length, PST2 
(point style 2), tapN (metal hub).   
The attachment of the tubing meant that while one person was performing the injection 
procedure - insuring the needle was positioned correctly within the retina - another person 
was able to inject the required amount into the retina using the syringe without moving or 
disturbing the needle that was already in the correct position in the retina. Hence this 
meant that once the required pDNA was loaded into the syringe and the mice were 
adequately anesthetized, the actual injection procedure was relatively quick, whereby 
numerous mice could be injected within a short period of time without the need for 
reloading the syringe or additional complications associated with the needle being moved 
unnecessarily within the eye if the person injecting and positioning the needle within the 
retina were the same person.    
 
2.2.19 In vivo luciferase measurements  
 
To measure the luciferase expression in tissue, a luciferase assay was performed. Tissues 
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were removed before being lysed with 250 µl 1 x reporter lysis buffer (Promega). Samples 
were then homogenised manually. From this lysed material, 20 µl was removed and added 
to 50 µl of luciferase substrate-assay buffer in a glass tube which was inserted into a 
luminometer (Berthold Technologies Lumat LB 9507) and relative luciferase units (RLU) per 
second were recorded. Protein concentrations were also determined using BCA as described 
previously and luciferase expression was represented as µg/protein.   
 
2.2.20 In Vivo Bioluminescence Imaging 
 
At regular intervals after subretinal injections, mice were injected intraperitoneally with  
300 µl of luciferin substrate, D-luciferin (Gold Biotechnology, Inc., St Louis, MO, USA)  
(15 mg ml-1 in PBS),  anaesthetized with 2.5% isoflurane and then 10 minutes later, imaged 
for bioluminescence (transgene expression) using the IVIS Imaging 50 Series (Xenogen, 
Caliper Life Sciences Ltd., Runcorn, UK). Bioluminescent imaging (BLI) was performed in a 
light-tight chamber on a temperature-controlled, adjustable stage, while isoflurane was 
administered by means of gas manifold at a flow rate of 2%. Images were acquired at a 
medium binning level (8) and acquisition times were 30-60 seconds, depending on the 
intensity of the luminescence. The Xenogen system reports bioluminescence as  
photons s-1 cm-2 sr-1 in a 0.7-1 cm diameter region of interest encompassing the eye. Data 
were analysed using LivingImage 2.50 software (Xenogen). Background levels of 
bioluminescence were 2 x 104 photons/sec/cm2/sr. 
 
2.2.21 Whole mounting and staining 
 
Mice were subretinally injected with EGFP plasmids and eyes were enucleated at relevant 
times post injection. The eyecup whole mount was prepared by piercing the cornea with a 
27 gauge needle, before immersing in 4% PFA for 1 hour. Using iridectomy scissors, an 
incision was made around the ora serrata, and the eye was separated into anterior and 
posterior segment. The lens and cornea were carefully removed from the posterior segment 
of the eye, and the neural retina was peeled away to expose the RPE. Four radial cuts 
starting from the peripheral edge of the eye cup extending toward the optic nerve were 
made. If necessary, a razor blade was used to extend the initial cuts started with the 
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iridectomy scissors. The flattened eye cups were either analysed immediately for EGFP or 
immunohistochemistry was performed for EGFP expression. Samples were blocked for two 
hours (PBS, 5% non-specific goat serum (Invitrogen), 3% Triton X100), before being 
incubated with GFP antibody in blocking solution overnight at 4°C. After 2 washes in PBS at 
room temperature (RT), sections were incubated with fluorescent-conjugated secondary 
antibodies in blocking solution for two hours at RT and washed with PBS. Eyes were then 
mounted onto glass slides in aqueous mounting medium and covered with glass coverslips 
and viewed using fluorescence microscopy. Controls were made by omitting the primary 
antibody or by carrying out immunohistochemistry on uninjected whole mount eyes. No 
labelling was observed in either control sections. 
 
2.2.22 Histological analysis and Immunohistochemistry 
 
Mouse eyes for histological analysis were fixed in Karnovsky’s Fixative (2% PFA, 2.5% 
glutaraldehyde, 0.1 M cacodylate buffer) for 1 hour. Samples were serially dehydrated in 
alcohol before they were embedded in paraffin wax. Sections were cut at 4 µm thickness 
and stained with haematoxylin and eosin (H&E). Sections were imaged with a camera  
(SIS ColorView IIIU; Olympus, Tokyo, Japan) mounted on a microscope (CKX41; Olympus).  
For frozen section analysis mouse eyes were fixed in 4% PFA in PBS for 1 hour. After removal 
of the lens, eyes were cryoprotected using 10% sucrose in PBS for 30 min, and 20% sucrose 
in PBS over night at 4°C.  Eyes were embedded in optimal cutting temperature compound 
(OCT) (Tissue Tek, Sakura Finetek, Thatcham, UK), frozen in Isopentane on dry ice and stored 
at -80°C until sectioning. Samples were serially sectioned at 10 µm thickness through the 
center of the eye and the optic nerve head in a superior-inferior plane. Sections were cut on 
a Leica CM1850 cryostat set to between 19-23°C (Leica Microsystems), and collected onto 
superfrost microscope slides (Fisher). Slides were stored at -80°C until staining. Frozen 
retinal sections were air dried for at least 30 min before rehydration with PBS. For EGFP 
immunohistochemistry, unspecific binding sites on the sections were blocked for one hour 
with PBS, 1% BSA (Sigma), 0.025% Sodium azide (Sigma), 10% non-specific goat serum 
(Invitrogen) including 0.2% Triton X100 for permeabilisation before being incubated with 
GFP antibody in blocking solution overnight at 4°C. After 2 washes in PBS at RT, sections 
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were incubated with species specific fluorescent-conjugated secondary antibodies for  
40 min at RT, washed again in PBS and either counterstained with propidium iodide (P-4170, 
Sigma) (0.5% in water) or DAPI to visualise nuclei and mounted in aqueous mounting 
medium (ProLONG Gold antifade reagent; Invitrogen) and viewed using confocal 
fluorescence microscopy. Controls were made by omitting the primary antibody or by 
carrying out the immunostaining on uninjected control wild-type eyes. No labelling was 
observed in either control sections. 
 
2.2.23 Apoptosis detection and analysis - TUNEL Assay 
 
Protocols for TUNEL assay have been described previously (Moosajee, Tulloch et al. 2009). 
Briefly, retinal sections that had been processed and analysed for histological analysis were 
dewaxed by two washes in clearing agent Histoclear (National Diagnostics, Atlanta) followed 
by two washes in 100% ethanol and one wash in 70% ethanol before rinsing in deionized 
H2O. After rehydration, retinal sections were digested with proteinase K (10 µg/ml) (Sigma) 
for 15 min, washed twice in H2O, followed by 3% hydrogen peroxide incubation, to block the 
endogenous peroxide activity in the tissue, followed by two final washed with PBS. Levels of 
apoptotic cell death were measured using a detection kit: ApopTag Peroxide In Situ 
Apoptosis Detection Kit (Millipore, Billerica, MA) according to manufacturer’s instructions. 
Retinal sections from various injection groups were compared to negative control wild-type 
uninjected eyes to determine the level of background apoptosis in the mouse retina, as well 
as positive control LPS dosed retinas.    
 
2.2.24 Immunological analysis: Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Levels of TNF-α, MCP1 and IFN-γ cytokines were determined by using enzyme-linked 
immunosorbent assay (ELISA) kits according to manufacturer’s instructions using a 
microplate reader at 450 nm (Molecular Devices, Sunnyvale, CA). Kits were purchased from 
ebioscience (San Diego, CA, USA). Briefly, for ELISA analysis of inflammatory cytokine levels 
in injected retinal homogenates at 1 and 7 days post injection, retinas were enucleated, the 
anterior part of the eye including the lens and cornea were removed, and eyes were 
homogenised on ice in lysis buffer (as described above) for one hour, centrifuged at  
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14,000 rpm/10,000 g for 15 min at 4°C. Protein concentrations from supernatants were 
quantified using the BCA Protein Assay Kit (Pierce), were 50 ng of supernatants were used 
for each sample. Standards were analysed in duplicates, while each sample was analysed in 
triplicates, and each time point as well as treatment was repeated in three to five 
independent experiments. Uninjected eyes or eyes injected subretinally with sterile glucose 
were used as negative controls in this study.  
 
Inflammatory samples to be used as positive controls were described previously (Bonnet, 
Erbacher et al. 2008). Briefly, to induce a strong inflammatory response and to serve as a 
positive inflammatory eye sample, mice were dosed with a lethal dose of ketamine and 
xylazine, before subretinally injecting 2 µl of Escherichia coli (E. coli) Lipopolysaccharides 
(LPS) (Product # L 6143, Sigma/Aldrich), and collecting eyes between 5-15 min post 
subretinal injection.   
 
2.2.25 Statistical analysis 
 
Comparison of inflammatory cytokine levels from pDNA injected retinal homogenates and 
blood serum were analysed by one-way analysis of variance (ANOVA) to access statistical 
significance, with significance level p=0.05 and 0.01. Student t-test was also used where 
appropriate.  
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3 RESULTS 
____________________________________________________________________________ 
 
Experimental outline and rational 
 
We planned to exploit the S/MAR vector technology for the development of novel non-viral 
persistently expressing vectors for Choroideremia (CHM) gene therapy. To this end, we 
created a series of constructs comprising either the reporter gene EGFP or REP1, with 
various promoters, with and without an S/MAR element from the plasmid pEPI. Hence all 
constructs had identical plasmid backbones, with either the reporter gene EGFP or REP1 
with or without the S/MAR element. We performed initial steps to validate the transient 
expression of both transgenes EGFP and REP1 in vitro in a wild-type mouse anterior pituitary 
(AtT20) cell line as well as a melanoma (B16-F10) cell line. The plasmid pEPI, which contains 
the S/MAR element, has been shown to provide long-term EGFP expression in a number of 
cell lines. These include the chinese hamster ovary (CHO-K1) cells (Piechaczek, Fetzer et al. 
1999; Papapetrou, Zoumbos et al. 2005), human cervical cancer (HeLa) cells (Schaarschmidt, 
Baltin et al. 2004), mouse embryonic fibroblasts (NIH 3T3) (Broll, Oumard et al. 2010) as well 
as haematopoietic stem cells (including human haematopoietic progenitor K562 and CD34+ 
cell lines) (Papapetrou, Ziros et al. 2006). Interestingly, control plasmids lacking the S/MAR 
element were not able to sustain EGFP expression in the above mentioned cell lines. Hence 
we sought to demonstrate the principle that the S/MAR containing plasmids we constructed 
can provide long-term transgene expression in vitro as well as in vivo.  We extend and 
demonstrate with the AtT20 cell line we routinely use in our laboratory, the principle that 
S/MAR containing plasmids can provide long-term EGFP and REP1 transgene expression  
in vitro. Furthermore, REP1 long-term expression was also analysed in mouse and human 
CHM primary fibroblasts. Proof-of-principle experiment in these CHM cells in vitro showed 
not only rescue of REP1 protein levels, but also functional rescue of the CHM phenotype. 
Following expression of constructs in vitro, we analysed the expression of constructs in vivo. 
We developed an optimised method for delivering S/MAR containing plasmids in the eye via 
subretinal injections of complexed pDNAs, and showed the utility of S/MAR plasmids in the 
eye. We provide evidence for the first time to show the longitudinal transgene expression of 
luciferase constructs (with the same plasmid backbones as pEPI and EGFP as well as REP1 
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constructs made) as measured using a bioluminescence bioimager. Long-term expression of 
EGFP and REP1 transgenes were also observed (by rt-PCR of mRNA levels, PCR of plasmid 
DNA levels and Western blot analysis of protein levels), as well as evidence for the long 
episomal maintenance of these vectors in the eye. We provide evidence for the superiority 
of an S/MAR containing plasmid in providing long-term expression in the eye. We further 
demonstrate the lack of toxicity within the eye and show that fundus examinations as well 
as detailed histological examinations of retinal sections do not elicit an inflammatory 
response to our plasmids once subretinally injected in the eye. The final part of this project, 
investigates the subretinal injection of CHM mice using an S/MAR based pDNA vector 
expressing the REP1 transgene. We provide evidence for the persistence of transgene 
expression within the retinas of these mice. Following further molecular analysis, we also 
show for the first time the partial correction and rescue of the CHM phenotype in CHMnull/WT 
mice using a plasmid vector.   
 
3.1 Plasmid production and in vitro analysis of EGFP transgene 
 
The first step towards designing a novel non-viral S/MAR plasmid was the development of 
the initial universal S/MAR cloning vector pEPI-MCS1. This was successfully created by Ms 
Azadeh Cheraghchi Bashi as part of her Masters Degree in the Molecular Medicine 
department. The resulting vector, pEPI-MCS1, has the same plasmid backbone as the 
original pioneering plasmid pEPI-EGFP with a few key exceptions. The pEPI-MCS1 vector 
lacked the CMV promoter and EGFP gene upstream of the S/MAR element, while it had the 
insertion of a unique multiple cloning site (MSC) instead. This modified version of the 
original plasmid allowed for easy insertion of various promoter and transgene sequences 
upstream of the S/MAR element and provided the preliminary vector to build upon for 
subsequent cloning strategies (Figure 22). 
 
 
 
 
138 
 
 
 
Figure 22: The original plasmid pEPI-EGFP and the modified pEPI-MCS1 plasmid 
used for subsequent cloning strategies 
 
 
Both plasmids harbour a similar plasmid backbone including similar bacterial components 
and antibiotic selection elements. These include an SV40 ori (SV40 origin), required for 
replication in mammalian cells expressing the SV40 T-antigen, a kanamycin/neomycin 
(kan/neo)   resistance cassette consisting of an SV40 early promoter, the kan/neo resistance 
gene from Tn5 (Aiuti, Slavin et al. 2002) and polyadenylation signals from the Herpes 
simplex virus thymidine kinase (HSV TK) gene which allows stable transfection of eukaryotic 
cells using G418 antibiotic. The bacterial promoter upstream of this cassette expresses 
kanamycin resistance in E. coli. Both plasmids also contain a pUC origin of replication for 
propagation in E. coli and an f1 origin for single-stranded DNA production. The pEPI-EGFP 
plasmid contains the human immediate early cytomegalovirus (CMV) promoter, driving 
transcription of the enhanced green fluorescent gene (EGFP), followed by the SV40 
polyadenylation tail (pA) downstream of the EGFP gene which directs the correct processing 
of the 3’ end of the EGFP mRNA. In contrast the pEPI-MCS1 plasmid has had the insertion of 
a 30 base pair (bp) MCS consisting of unique restriction enzyme sites not found on the 
plasmid including NotI, EcoRV, HindIII and XhoI. The EGFP gene and MCS sequence (and so 
subsequent insertion of other genes of interest in the future) from the pEPI-EGFP and pEPI-
139 
 
MCS1 plasmids respectively, are followed directly by the S/MAR sequence and the SV40 pA 
for mRNA stability. It has been proposed (Stehle, Scinteie et al. 2003) that S/MARs bind to 
components of the nuclear matrix and so plasmids carrying S/MAR elements are able to use 
cellular replication machinery for their replication. However the close association with 
nuclear matrix is not sufficient to initiate replication of the S/MAR plasmid. Episomal DNA 
replication and transcription upstream of the S/MAR is dependent on the active 
transcription of a gene upstream of the S/MAR, with transcription continuing past the gene 
of interest and extending into the S/MAR (Lipps, Jenke et al. 2003; Conese, Auriche et al. 
2004). This in turn may lead to a conformational change of the vector (Mielke, Kohwi et al. 
1990; Zhong,Gulottaet al. 1990) or to a modification of its chromatin structure (Turner 
2002) making the plasmid vector more accessible for the replication enzymes. 
Interestingly, within the 2000 bp S/MAR sequence, there appears to be a cryptic 
termination site at approximately position 1500 -1700 bp (Stehle, Scinteie et al. 2003). 
Furthermore, the orientation of the expression cassette is crucial for correct S/MAR 
function. This is because episomal replication was lost and random vector integration was 
observed when transcription was not able to pass through the S/MAR. This has been 
attributed to the removal of the promoter which drives transcription or the insertion of 
sequences that terminate transcription ahead of the S/MAR element (Lipps, Jenke et al. 
2003; Conese, Auriche et al. 2004).  
While the CMV promoter of the plasmid pEPI-EGFP provides high transgene levels in vitro, 
expression in vivo is often only transient and short lived as viral promoters such as CMV are 
often transcriptionally silenced due to methylation of the promoter (Brooks, Harkins et al. 
2004; Jenke, Stehle et al. 2004; Kachi, Oshima et al. 2005; Kachi, Esumi et al. 2006). Hence to 
minimise the potential for loss of transgene expression in vivo, we developed other plasmids 
harbouring different promoters.While the use of the tissue specific promoters is an option 
when designing plasmid vectors, our ultimate goal was to create plasmid vectors that could 
transfect the cell layers in the eye most affected in our disease of interest, CHM. The two 
cell layers of most interest in the eye for CHM are the retinal pigment epithelium (RPE) and 
photoreceptor cells. The elongation factor-1 promoters (EF1-α and its intronless version 
EFS) and (CMV) early enhancer/chicken beta actin promoter (CAG) have been shown in the 
past to maintain efficient expression in the RPE and photoreceptor cells (Kostic, Chiodini et 
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al. 2003; Cashman, McCullough et al. 2007). Hence as CHM is a disease affecting more than 
one cell type, creating a plasmid vector that utilises a ubiquitously expressed promoter 
based on either the EFS or CAG promoter was deemed more advantageous compared to a 
vector that possessed a tissue specific promoter. Using this approach of a ubiquitous 
promoter we hoped to provide long-term transgene levels in both cell types in the eye.  
Based on this information, our initial approach involved the creation of an S/MAR plasmid 
with the EGFP reporter gene based on the pEPI-MCS1 and pEPI-EGFP plasmids described 
above. We initially wanted to achieve this in a single cloning step; whereby the EGFP with 
the EF1-alpha promoter from the pWPT-GFP plasmid or the CAG promoter from the pCAGGs 
plasmid could be cloned into pEPI-MCS1. However due to the significant problems 
associated with the cloning, it was decided that the cloning process should be done in 
stages. Hence two cloning strategies were employed for the pEFS-EGFP and pCAG-EGFP 
vector series. 
 
3.1.1 Modifying the pEPI-MCS1 vector – Plasmid pEOS 
 
For the initial stage in creating the pEFS-EGFP vector, the universal pEPI-MCS1 vector was 
initially modified by excising a 282 bp fragment from the end of the S/MAR with MluI and 
EcoRI enzymes. The remaining 5084 bp fragment was blunt ended with Klenow and ligated 
overnight. The vector was not dephosphorylated because this was deemed to reduce the 
overall efficiency of cloning (Tolmachov 2009). As the ligation mixture still contained the 
excised fragment from the vector, the mixture was precipitated and digested with SalI. This 
site was only found in the 282 bp insert sequence that we aimed to remove. The ligation 
mixture was then transformed into JM109 competent cells. Of the colonies that grew, 6 
were grown as overnight cultures and the plasmid DNA was isolated and screened for the 
removal of MluI, SalI and BamHI restriction enzymes, as well as restoration of the EcoRI site. 
Correctly ligated plasmids would be undigested with MluI, SalI and BamHI, while digestion 
with EcoRI would be positive giving a linearised vector that would produce a single fragment 
at 5084 bp. All 6 colonies analysed gave the correct digestion patterns (Figure 23D). This 
modified vector was named pEOS plasmid. 
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Figure 23:   Generation of the modified pEOS plasmid 
The cloning strategy for the generation of pEOS plasmid involved the removal of the  
282 bp fragment from the pEPI-MCS1 vector is illustrated in (A) The correct fragment 
sizes of the digested pEPI-MCS1 vector before ligation are shown in (B), where lane 1: 
undigested pEPI-MCS1 vector, lanes 2 and 3: digested pEPI-MCS1 vector with MluI and 
EcoRI restriction enzymes respectively. Successful ligation would result in the pEOS 
plasmid as illustrated in (C). Finally (D) shows the restriction analysis of six clones 
picked after ligation (lanes 3-8) with all clones showing the restoration of the EcoRI site 
(*). Lane 1 and 2 represent undigested and EcoRI digested pEPI-MCS1 vector 
respectively. L: 1 Kb ladder (Invitrogen). 
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3.1.2 Production of an EGFP expressing plasmid driven by EFS – Plasmid pEFS-EGFP 
 
The next step was the insertion of the EFS promoter and EGFP transgene upstream of the 
S/MAR element. The cloning strategy is illustrated in Figure 24. In preparation for the 
insertion of EFS-EGFP, both pEOS and pWPT-GFP plasmids were digested with XhoI. This 
excised the 1.1 kb insert fragment from the pWPT-GFP plasmid (Addgene) which was ligated 
with linearised vector overnight at a molar vector: insert ratio of 1:5. The ligation mixture 
was transformed into JM109 competent cells. Out of the colonies obtained overnight, 70 
colonies were screened by PCR analysis using EGFP and S/MAR specific primers as described 
in the methods. Six clones showed a positive signal from the PCR analysis showing the 
presence of the insert as well as the correct orientation of the insert in the clones. All 6 
clones were selected for plasmid isolation and analysed further for the correct insert 
sequence and orientation using EcoRI and MluI, EcoRI and BamHI or HindIII restriction 
digestion analysis. Correctly ligated plasmids in the 5’ to 3’ orientation would produce three 
fragments when digested with HindIII, 5196 bp, 820 bp and 268 bp. Of the 6 clones, 5 gave 
the expected fragment patterns (Figure 24D).  One colony was selected for isolation with a 
MaxiPrep kit, its quality and quantity was measured using a Nanodrop spectrophotometer. 
This vector was named pEFS-EGFP plasmid. 
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Figure 24:   Generation of pEFS-EGFP plasmid 
The cloning strategy for the generation of pEFS-EGFP plasmid involved inserting the  
1.1 kb EFS-EGFP fragment into the pEOS plasmid is illustrated in (A). The correct 
fragment sizes of the digested pWPT-GFP vector and linearized pEOS vector before 
ligation are shown in (B), where lanes 1 and 3: undigested pEOS and pWPT-GFP vector 
respectively, lanes 2 and 4: digested pEOS and pWPT-GFP vector with XhoI restriction 
enzyme respectively. Successful ligation would result in the pEFS-EGFP plasmid as 
illustrated in (C). Finally (D) shows the restriction analysis of six clones picked after 
ligation (lanes 3-8) with clones 1, 2, 4, 5 and 6 showing the expected three bands (*), 
indicating colonies with the correct restriction pattern, consistent with the successful 
insertion of EGFP and development of pEFS-EGFP. Lane 5 represents the partial 
insertion of the insert with only the EGFP insertion. Lane 1 and 2 represent HindIII 
digested vector and insert pEOS and pWPT-GFP vectors respectively. L: 1 Kb ladder 
(Invitrogen). 
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3.1.3 Production of an EFS control counterpart - Plasmid pEFS-EGFP-Control 
 
The final step in the pEFS-EGFP vector series involved the development of the control 
counterpart to the pEFS-EGFP plasmid. The cloning strategy is illustrated in Figure 25. In 
preparation for the removal of the 2 kb S/MAR element, pEFS-EGFP plasmid was digested 
with HpaI and BglI. This excised the 2 kb S/MAR fragment from the pEFS-EGFP plasmid and 
the linearised vector was blunt ended with Klenow before being ligated overnight. The 
ligation mixture was transformed into JM109 competent cells. Out of the colonies obtained 
overnight, 8 were selected for plasmid isolation and analysis with StuI restriction enzyme. 
Correctly ligated plasmids would give a linearised vector that would produce a fragment at 
4184 bp. All 8 clones had the expected plasmid sizes (Figure 25D).  One colony was selected 
for isolation with a MaxiPrep kit, its quality and quantity was measured using a Nanodrop 
spectrophotometer. As the newly constructed plasmid did not harbour an S/MAR element, 
the plasmid was named pEFS-EGFP-Control plasmid. 
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Figure 25:   Generation of pEFS-EGFP-Control plasmid 
The cloning strategy for the generation of pEFS-EGFP-Control plasmid involved 
removing the 2 kb S/MAR motif from the pEFS-EGFP plasmid is illustrated in (A). The 
correct fragment sizes of the digested pEFS-EGFP plasmid before ligation is shown in 
(B), where lane 1: undigested pEFS-EGFP and lane 2: digested pEFS-EGFP with HpaI and 
BglI restriction enzymes. Successful ligation would result in the pEFS-EGFP-Control 
plasmid as illustrated in (C). Finally (D) shows the restriction analysis of 8 clones picked 
after ligation (lanes 2-10) where all clones showed the correct size of the plasmid (*), 
indicating the successful S/MAR excision and development of pEFS-EGFP-Control. Lane 
1 represents undigested pEFS-EGFP plasmid. L: 1 Kb ladder (Invitrogen). 
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3.1.4 Production of Plasmid pEOS-CAG-S/MAR 
 
The next stage involved the development of the pCAG-EGFP vector series. As an initial step 
in creating the pCAG-EGFP plasmid, the CAG promoter was inserted upstream of the S/MAR 
element. The cloning strategy is illustrated in Figure 26. The CAG promoter was excised from 
the pCAGGs plasmid by digestion with SalI and XhoI, resulting in the removal of the 1.7 kb 
fragment corresponding to the CAG promoter. The vector pEOS was also linearised with 
XhoI, blunt ended with Klenow and ligated overnight with the CAG insert at a molar  
vector:insert ratio of 1:4. Usually a 1:10 ratio of vector:insert is used where the insert is 
added in excess to minimise the chance of the vector or insert re-ligating back on/with 
themselves (as neither were dephosphorylated). However, in this situation the pCAGGS 
plasmid contains the ampicillin resistant gene; hence re-ligated pCAGGs plasmid would not 
grow on kanamycin plates that were used during the cloning process. The ligation mixture 
was then transformed into JM109 competent cells. Out of the colonies obtained overnight, 
70 colonies were screened by PCR analysis using CAG and EGFP specific primers as described 
in the methods. 7 clones showed a positive signal from the PCR analysis showing the 
presence of the insert as well as the correct orientation of the insert in the clones. All 7 
clones were selected for plasmid isolation and analysed further for the correct insert 
sequence and orientation using XhoI and HindIII, XhoI and NotI or XhoI and EcoRI restriction 
digestion analysis. Correctly ligated plasmids in the 5’ to 3’ orientation would produce two 
fragments when digested with XhoI and HindIII, 5084 bp and 1700 bp. Of the 7 clones, 2 
gave the expected fragment patterns (Figure 26D). This vector was named  
pEOS-CAG-S/MAR plasmid.  
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Figure 26:   Generation of pEOS-CAG-S/MAR plasmid 
The cloning strategy for the generation of pEOS-CAG-S/MAR plasmid involved the 
insertion of the 1.7 kb CAG fragment as illustrated in (A). The correct fragment sizes of 
the digested pCAGGs vector and linearized pEOS before ligation are shown in (B), where 
lanes 1 and 2: undigested pEOS and pCAGGs plasmids and lanes 3 and 4: digested pEOS 
and pCAGGs plasmids with XhoI and SalI-XhoI restriction enzymes respectively.  
Successful ligation would result in the pEOS-CAG-S/MAR plasmid as illustrated in (C). 
Finally (D) shows the restriction analysis of 7 clones picked after ligation (lanes 3-9) 
with clones 1 and 2 showing the correct size of the plasmid (*), indicating the successful 
CAG promoter insertion and development of pEOS-CAG-S/MAR. Lanes 1 and 2 
represent XhoI and HindIII digested pEOS and pCAGGs vectors respectively.  
L: 1 Kb ladder (Invitrogen). 
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3.1.5 Production of Plasmid pEOS-CAG-MCS-S/MAR 
 
The next step was the insertion of a pair of complimentary oligonucleotides (MCS2 upper 
and MCS2 lower). These were designed so that after annealing they formed a multiple 
cloning site (MCS) double stranded oligonucleotide (dsOligo) containing the unique 
restriction sites recognised by BamHI, MluI and SalI restriction enzymes, downstream of the 
CAG promoter. The addition of this oligonucleotide would allow relatively easy insertion of 
other genes downstream of the CAG promoter. The cloning strategy is illustrated in Figure 
27. The oligonucleotide primers were annealed at 94 °C as described in the methods and 
ligated overnight with pEOS-CAG-S/MAR vector linearised with XhoI restriction enzyme. The 
ligation mixture was then transformed into JM109 competent cells. Of the colonies that 
grew, 6 were grown as overnight cultures and their plasmids isolated and screened for the 
insertion of the MCS dsOligo in the 5’ to 3’ orientation, with the addition of BamHI, MluI and 
SalI restriction enzyme sites. Correctly ligated plasmids would produce a single linear 
fragment of approximately 6838 bp when digested with BamHI enzyme alone, while 
digestion with EcoRI and BamHI together would produce two fragments of 2000 bp and 
4838 bp. Of the 6 clones, 1 gave the expected fragment patterns (Figure 27D). This modified 
vector was named pEOS-CAG-MCS-S/MAR plasmid.  
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Figure 27:   Generation of pEOS-CAG-MCS-S/MAR plasmid 
The cloning strategy for the generation of pEOS-CAG-MCS-S/MAR plasmid involved the 
insertion of the multiple cloning site double stranded oligonucleotide (MCS dsOligo) as 
illustrated in (A). Successful ligation would result in the pEOS-CAG-MCS-S/MAR plasmid 
as illustrated in (B). The restriction analysis of 6 clones after ligation (lanes 2-7) is 
shown in (C and D) after BamHI digestion alone as shown in (C) or BamHI and EcoRI 
double digestion as shown in (D), with clone 3 showing the correct size of the plasmid 
after both digestions (*), indicating the successful insertion of the MCS and development 
of pEOS-CAG-MCS-S/MAR. Lanes 1 represents digested pEOS-CAG-S/MAR vector.  
L: 1 Kb ladder (Invitrogen). 
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3.1.6 Production of Plasmid pCAG-EGFP 
 
The next step was the insertion of the EGFP transgene downstream of the CAG promoter 
and MCS. The cloning strategy is illustrated in Figure 28. In preparation for the insertion of 
EGFP, both pEOS-CAG-MCS-S/MAR and pEFS-EGFP plasmids were digested with MluI and 
SalI. This excised the 853 bp EGFP insert fragment from the pEFS-EGFP plasmid which was 
ligated with digested pEOS-CAG-MCS-S/MAR vector overnight at a molar vector: insert ratio 
of 1:10. The ligation mixture was transformed into JM109 competent cells. Out of the 
colonies obtained overnight, 70 colonies were picked for PCR analysis using CAG and EGFP 
specific primers as described in the methods. 3 clones showed a positive signal from the PCR 
analysis showing the presence of the insert as well as the correct orientation of the insert. 
All 3 clones were selected for plasmid isolation and analysis with AflIII restriction enzyme. 
Correctly ligated plasmids in the 5’ to 3’ orientation would produce three fragments,  
2015 bp, 2752 bp and 2924 bp. All three clones gave the expected fragment patterns  
(Figure 28D). One colony was selected for isolation with a MaxiPrep kit, its quality and 
quantity was measured using a Nanodrop spectrophotometer. This vector was named 
pCAG-EGFP plasmid. 
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Figure 28:   Generation of pCAG-EGFP plasmid 
The cloning strategy for the generation of pCAG-EGFP plasmid involved the insertion of 
the EGFP transgene as illustrated in (A). The correct fragment sizes of the digested  
pEOS-CAG-MCS-S/MAR vector and pEFS-EGFP before ligation are shown in (B), where 
lanes 1 and 2: undigested pEOS-CAG-MCS-S/MAR and pEFS-EGFP plasmids and lanes 3 
and 4: digested pEOS-CAG-MCS-S/MAR and pEFS-EGFP plasmids. The 853 bp fragment 
from pEFS-EGFP is faint but seen clearer on the digital image. Successful ligation would 
result in the pCAG-EGFP plasmid as illustrated in (C). Finally (D) shows the restriction 
analysis of 3 clones after ligation (lanes 2-4) with all clones showing the correct size of 
plasmid after digestion (*), indicating the successful EGFP transgene insertion and 
development of pCAG-EGFP. Lane 4 represent undigested pEOS-CAG-MCS-S/MAR 
vector. L: 1 Kb ladder (Invitrogen).  
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3.1.7 Production of a CAG control counterpart - Plasmid pCAG-EGFP-Control 
 
The final step in the pCAG-EGFP vector series involved the development of the control 
counterpart to the pCAG-EGFP plasmid. The cloning strategy is illustrated in Figure 29. In 
preparation for the removal of the 2 kb S/MAR element, pCAG-EGFP plasmid was digested 
with NsiI restriction enzyme. This excised the 2 kb S/MAR fragment from the pCAG-EGFP 
plasmid and the linearised vector was ligated overnight. The ligation mixture was 
transformed into JM109 competent cells. Out of the colonies obtained overnight, 8 were 
selected for plasmid isolation and analysis with StuI restriction enzyme. Correctly ligated 
plasmids would produce a single fragment at 5691 bp. Of the 8 clones, 4 gave the expected 
plasmid sizes (Figure 29D).  One colony was selected for isolation with a MaxiPrep kit, its 
quality and quantity was measured using a Nanodrop spectrophotometer. As this plasmid 
did not contain an S/MAR element, the plasmid was named pCAG-EGFP-Control plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
 
Figure 29:   Generation of pCAG-EGFP-Control plasmid 
The cloning strategy for the generation of pCAG-EGFP-Control plasmid involved the 
removal of the 2 kb S/MAR motif from the pCAG-EGFP plasmid as illustrated in (A). The 
correct fragment sizes of the digested pCAG-EGFP plasmid before ligation are shown in 
(B), where lanes 1 and 2: undigested and digested pEOS-CAG-MCS-S/MAR plasmids. The 
2 kb fragment from pCAG-EGFP is faint but seen clearer on the digital image. Successful 
ligation would result in the pCAG-EGFP-Control plasmid as illustrated in (C). Finally (D) 
shows the restriction analysis of 8 clones picked after ligation (lanes 2-9) with clones 3, 
4, 5 and 7 showing the correct size of plasmid after digestion (*), indicating the 
successful S/MAR excision and development of pCAG-EGFP-Control. Lanes 1 represents 
undigested pCAG-EGFP vector. L: 1 Kb ladder (Invitrogen). 
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3.1.8 Transient transfection of AtT20 and B16-F10 cells with  
pEGFP-S/MAR plasmids 
 
To analyse our new sets of pDNA vectors, the pEFS-EGFP and pCAG-EGFP plasmids as well as 
their control counterparts without S/MARs were transfected into AtT20 and B16-F10 cells. 
This was done to ensure the integrity and to confirm expression of the EGFP transgene. 
Furthermore this also allowed one to check any differences in reporter gene expression 
resulting from the EFS and CAG promoters as well as the insertion of the S/MAR sequence. 
For transfections, large scale plasmid preparations were carried out using the Purelink 
HiPure Plasmid Maxiprep Kit (Invitrogen). DNA stock prepared using this kit has reduced 
levels of endotoxins, and should therefore cause less toxicity to cells following transfection.  
Cells were seeded into 24-well plates at a density of 1 x 105 or 5 x 104 for AtT20 and B16-F10 
cell respectively at least 24 hours prior to transfection. After overnight attachment cells 
were 60-70% confluent and were transfected with Lipofectamine 2000 (Invitrogen) 
transfection reagent. Briefly, 0.8 µg of each pDNA was complexed with Lipofectamine 2000 
and added to each well, according to the manufacturer’s recommendations. Complexed 
DNA/Lipofectamine 2000 was left on the cells overnight, and removed the following 
morning, cells were washed with PBS and fresh medium (3:1 ratio of DMEM:F-12 
supplemented with 15% FCS and 100 U/ml penicillin and 100 µg/ml streptomycin (p/s)  for 
AtT20 cells and DMEM supplemented with 15% FCS and p/s for B16-F10 cells) was added. At 
48 hours following transfection, cells were checked under a fluorescent microscope for 
EGFP expression as well as quantification of expression using fluorescence activated cell 
sorting (FACS) analysis. 
Strong levels of EGFP expression were observed in both cell lines at 48 hours post 
transfection from all constructs as shown in Figure 30 and Figure 31. Both pEFS-EGFP and its 
control were able to mediate moderate EGFP levels, with 38.2% ± 0.6 and 34.1% ± 0.27 of 
the total AtT20 cell population, and 27.8% ± 1.27 and 24.2% ± 0.83 of the total B16-F10 cell 
population respectively expressing EGFP. In comparison, pCAG-EGFP and its control were 
able to mediate significantly higher EGFP levels, with 62.7% ± 0.56 and 55.3% ± 0.52 of the 
total AtT20 cell population, and 44.8% ± 0.84 and 43.8% ± 1.32 of the total B16-F10 cell 
population respectively expressing EGFP. When comparing levels of EGFP expression from 
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pEFS-EGFP and pCAG-EGFP, a subtle difference was also evident by immunofluorescent 
analysis of cells. Levels of pEFS-EGFP appeared lower than pCAG-EGFP in both cell lines; 
indeed FACS analysis confirmed this too, as levels of pEFS-EGFP were approximately 1.6 
fold/20% lower in both AtT20 and B16-F10 cells when compared to pCAG-EGFP. This 
reduction in EGFP expression is not surprising, as previous studies show that the CAG 
promoter yields higher transgene levels than most ubiquitous mammalian promoters. The 
differences in expression between pEFS-EGFP and its control, as well as pCAG-EGFP and its 
control are probably due to variation in transfection success. 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
 
Figure 30:   Transfection efficiency of B16-F10 cells 48 hours post transfection 
 
The figure shows representative images of B16-F10 cells 48 hours post transfection 
with plasmids (A) pEFS-EGFP, (B) pEFS-EGFP-Control, (C) pCAG-EGFP or  
(D) pCAG-EGFP-Control. Bright field (left panel), fluorescent (middle) and their merge 
images (right), at 40x magnification are shown. At the same time, EGFP expression 
mediated by each construct was quantified using FACS analysis (far right panel). In all 
cases, histograms show measured events (y axis) against levels of EGFP fluorescence in 
the FL1-H channel (x axis). Untransfected B16-F10 cells appear as a purple graph on the 
left side of the histogram, while cells expressing EGFP appear green (as an overlay). 
Gated cells expressing EGFP are expressed as a percentage (%) of the total 
untransfected population – a threshold of 1% untransfected cells was always set - and 
appear above the bracketed histogram regions. Percentages are mean values from four 
independent experiments ± standard error of the means (s.e.m.). Images are 
representative of three independent experiments.  
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Figure 31:   Transfection efficiency of AtT20 cells 48 hours post transfection 
The figure shows representative images of AtT20 cells 48 hours post transfection with 
plasmids (A) pEFS-EGFP, (B) pEFS-EGFP-Control, (C) pCAG-EGFP or  
(D) pCAG-EGFP-Control. Bright field (left panel), fluorescent (middle) and their merge 
images (right), at 40x magnification are shown. At the same time, EGFP expression 
mediated by each construct was quantified using FACS analysis (far right panel). In all 
cases, histograms show measured events (y axis) against levels of EGFP fluorescence in 
the FL1-H channel (x axis). Untransfected AtT20 cells appear as a purple graph on the 
left side of the histogram, while cells expressing EGFP appear green (as an overlay). 
Gated cells expressing EGFP are expressed as a percentage (%) of the total 
untransfected population – a threshold of 1% untransfected cells was always set - and 
appear above the bracketed histogram regions. Percentages are mean values from four 
independent experiments ± standard error of the means (s.e.m.). Images are 
representative of three independent experiments. 
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Taken together, the fluorescence analysis of EGFP expression on fixed cells as well as the 
FACS analysis shows that AtT20 cells appear to provide higher levels of EGFP expression 
from all constructs compared to B16-F10 cells. Following on from this, both cell lines were 
also used to confirm EGFP protein expression from all constructs by Western blot analysis. 
Briefly, cells were seeded into 10 cm dishes 24 hours prior to Lipofectamine 2000 
transfection, at a density of 5 x 105 cells per dish for AtT20 cells and 2.5 x 105 per dish for  
B16-F10 cells and 24 µg of each pDNA was complexed as described before. At 48 hours 
following transfection, total protein was isolated from AtT20 cells transfected with all four 
pDNAs (pEFS-EGFP, pCAG-EGFP as well as both control plasmids) and electrophoretically 
separated on a 12% Sodium Dodecyl Sulphate (SDS) - polyacrylamide gel before being 
transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were probed with 
an anti-mouse EGFP antibody and secondary horseradish peroxidase (HRP) – conjugated 
anti-mouse IgG (Dako) secondary antibody and visualised by ECL chemiluminescence. Cells 
transfected with pEPI-EGFP served as positive control for EGFP expression. Untransfected 
cells as well as cells transfected with empty vector, pEOS plasmid, were used as negative 
controls. Both pEFS-EGFP and pCAG-EGFP as well as the control plasmids showed expression 
of EGFP protein at the correct molecular weight expected for the EGFP protein (~ 50 kDa), as 
shown in Figure 32.     
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Figure 32:   Western blot analysis of EGFP protein levels in AtT20 and B16-F10 
cells 48 hours post transfection 
The figure shows (A) AtT20 and (B) B16-F10 cells transfected with plasmids  
pEFS-EGFP, pEFS-EGFP-Control, pCAG-EGFP and pCAG-EGFP-Control (lanes 2, 3, 4 and 
5 respectively). Expression of GFP was analysed by Western analysis of cell pellets  
(50 µg) 48 hours post-transfection using an anti-mouse EGFP antibody. Untransfected 
cells as well as cells transfected with (an empty expression cassette) the original pEOS 
vector served as negative controls (lane 1 and 6; (-)), while pEPI-EGFP served as a 
positive control (lane 7; (+)) and α-tubulin was used as a loading control. Results are 
representative of three independent experiments.  
 
During the cloning process of the pCAG-EGFP plasmid, we were also able to get a  
pCAG-EGFP plasmid from Professor Hans Lipps, University of Witten, Germany who 
originally provided us with the pEPI-EGFP plasmid. This pCAG-EGFP plasmid was based on 
the pEPI-EGFP plasmid; therefore it had the CAG promoter inserted in place of the CMV 
promoter upstream of the S/MAR region. Interestingly, this plasmid did not have the 
removal of the 283 bp fragment at the end of the S/MAR sequence, described in the earlier 
section 3.1.1. Previously the 5’-end of the S/MAR sequence has been shown to be most 
important and crucial sequence for the correct function of S/MAR sequences (Stehle, 
Scinteie et al. 2003). Hence one would predict that the removal of the 283 bp fragment from 
the 3’-end should not affect the overall function of the EGFP transgene or corresponding 
pDNA vectors. To analyse this, both pCAG-EGFP plasmids (for this section plasmids will be 
referred to as pCAG-EGFP (EOS) (currently made) and pCAG-EGFP (HL) (from Professor 
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Lipps) respectively for ease of identification), were transfected into AtT20 cells and the 
transfection efficiency of both plasmids was compared by FACS analysis. As can be seen in 
Figure 33, both pCAG-EGFP plasmids were able to transfect AtT20 cells at a similar level 
57.7% for pCAG-EGFP (HL) and 55.6% for pCAG-EGFP (EOS).  
Considering this, one can confidently say that the removal of the 283 bp fragment from the 
original pEPI-MCS1 plasmid and the creation of the pEOS vector (see section 3.1.1 for 
details) did not affect the overall EGFP transgene expression levels. Indeed constructs made 
based on the pEOS vector (pEFS-EGFP and pCAG-EGFP as well as the corresponding control 
plasmids), were also able to produce EGFP protein of the correct size. Furthermore one can 
be confident that the EGFP-S/MAR constructs made as well as S/MAR constructs to be made 
in the future based on these plasmids are not hindered in any way and provide sufficient 
transgene expression levels as analysed by EGFP. 
 
 
 
Figure 33:   FACS analysis of EGFP expression levels 48 hours post transfection in 
AtT20 cells transfected with both pCAG-EGFP plasmid vectors (pCAG-EGFP (HL) 
and pCAG-EGFP (EOS)) 
ATt20 cells were transfected with either (A) pCAG-EGFP (HL) or (B) pCAG-EGFP (EOS) 
plasmids and EGFP expression of each construct was quantified using FACS analysis. 
Histograms show measured events (y axis) against levels of EGFP fluorescence in the 
FL1-H channel (x axis). Untransfected AtT20 cells appear as a purple graph on the left 
side of the histogram, while cells expressing EGFP appear green (as an overlay). Gated 
cells expressing EGFP are expressed as a percentage (%) of the total untransfected 
population – a threshold of 1% untransfected cells was always set - and appear above 
the bracketed histogram regions. Levels of EGFP expression for both pCAG-EGFP HL and 
EOS plasmid vectors were similar at 57.7% ± 0.89 and 55.6% ± 0.35 respectively. 
Percentages are mean values from five independent experiments ± standard error of the 
means (s.e.m.).  
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3.1.9 Transient EGFP transfection in RPE cells in situ 
 
While AtT20 and B16-F10 transfections are important for confirming the expression of  
pEFS-EGFP and pCAG-EGFP plasmid constructs, it was also deemed advantageous to show 
the EGFP transgene expression in cells more relevant to the eye. As one of the target cells in 
this project is RPE cells, primary mouse and porcine RPE cells were selected for the 
subsequent transfections. These experiments would help investigate the behaviour of the 
new EGFP plasmids under conditions more closely resembling those found in vivo. Primary 
RPE cells were isolated from adult C57BL/6 mouse eyes (wild-type) as described previously 
(Lopes, Ramalho et al. 2007), as well as from porcine eyes. RPE cells were plated onto glass 
coverslips in 24-well plates where they were approximately 80-90% confluent after 
overnight attachment. Cells were subsequently transfected with 1 µg of pEFS-EGFP or pCAG-
EGFP plasmid, and 6 µl of Lipofectin reagent (Invitrogen) as described previously (Faure, 
Hecquet et al. 1999). One day following transfection, cells were visualised for EGFP 
expression under a fluorescent microscope, as shown in Figure 34. The gene transfer of RPE 
cells in situ has been shown to be difficult to achieve, thus while transfection was achieved, 
the efficiency observed was low. Despite this were gene transfer was observed both 
constructs were able to mediate strong EGFP expression in primary RPE cells.     
 
162 
 
 
Figure 34:   Expression of pEFS-EGFP and pCAG-EGFP following transfection of 
primary RPE cells 
Primary RPE cells were isolated from mouse and porcine eyes, plated onto 24-well 
plates and transfected with 1 µg of plasmid pEFS-EGFP or pCAG-EGFP and 6 µl 
Lipofectin transfection reagent. Twenty fours hours post transfection cells were 
visualised for EGFP expression, and representative images are shown with plasmids 
pCAG-EGFP (A & C) and pEFS-EGFP (B & D). Fluorescent (left panel) bright field 
(middle) and their merge images (right), at 40x magnification are shown. Panels A & B 
represent porcine primary RPE cells, while panels C & D represent mouse primary RPE 
cells. Images are representative of two independent experiments. 
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3.1.10 Long-term EGFP expression in AtT20 cells 
 
As AtT20 cells appear to provide higher levels of EGFP expression from all constructs (see 
Figure 30 - Figure 32), these transfected cells were also used for the long-term analysis of 
EGFP expression levels from all constructs. Primary RPE cells were not used for the long-
term studies because although they closely resemble in vivo conditions, they are not an 
immortal cell line. Primary RPE cells only survive under optimal conditions for a short period 
of time. They have limited cell divisions once cells are split a few times in culture as well as 
reduced viability over time; hence their use in long-term analysis is unfortunately limited 
and inappropriate.  
 
AtT20 cells were seeded into 6-well plates and transfected as described previously (see 
section 3.1.8), with plasmids pEFS-EGFP, pCAG-EGFP as well as the corresponding control 
plasmids. Plasmid pEPI-EGFP and its control were used as a positive and negative control in 
experiments. Forty eight hours post transfection, cells were transferred to a 10 cm dish and 
G418 antibiotic was applied at a concentration of 0.5 mg/ml for a period of two weeks, with 
medium being changed every 3 days. This allows for the selection of cells that express the 
neo gene present on all plasmids and so these plasmids would confer resistance to the G418 
antibiotic applied and should survive the selection period. On the contrary non-transfected 
cells as well as cells that may have been transfected, but the plasmid has not been 
maintained during cell division will die away. Previous studies have shown that this two 
week period of selection is necessary for the selection of the pEPI plasmid in other 
eukaryotic cells (Baiker, Maercker et al. 2000; Jenke, Stehle et al. 2004) and is sufficient to 
eliminate all cells that do not express the neo gene. 
At the end of the two week selection process, six well-formed, antibiotic-resistant AtT20 
colonies expressing EGFP were isolated and split into medium with and without G418 
antibiotic. Although the EGFP expression from some cells (such as CHO-K1 cells) has been 
shown to be stable even in the absence of a selection pressure (Piechaczek, Fetzer et al. 
1999), this has yet to be shown in AtT20 cells. Therefore it was deemed necessary for our 
AtT20 cells to be cultured under the two different conditions, in medium with and without 
G418.  
164 
 
At regular time intervals, EGFP expression was quantified by FACS analysis, where a 
minimum of 10,000 cells/events were collected from each sample. The samples were 
analysed on the cytometer and histogram plots of measured events (y axis) against EGFP 
fluorescence (FL-1 – x axis) were plotted. A threshold level of fluorescence was set such that 
1% of untransfected cells fell above it. The percentage of cells expressing EGFP at a level 
above this threshold was taken as the percentage of the total cells expressing EGFP, and this 
was shown graphically on histograms obtained for each sample by M1 or a bracketed region 
with the percentage indicated. Representative plots are shown in Figure 35- Figure 37. For 
each plasmid analysed (pEFS-EGFP, pCAG-EGFP and positive control pEPI-EGFP) 4 colonies 
were picked for long-term FACS analysis of EGFP expression as shown in Table 2. For 
illustrative purposes, a representative colony is used in the text and figures (expression of 
clone 3 from all plasmids over time). 
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Table 2: Percentage of EGFP expression in isolated AtT20 cell colonies transfected 
with pEFS-EGFP, pCAG-EGFP and pEPI-EGFP over time 
AtT20 cells were transfected with plasmid pEFS-EGFP (top four columns), pCAG-EGFP 
(middle four columns) or pEPI-EGFP positive control (bottom four columns) and 
maintained in G418 medium for 2 weeks. Colonies were then picked and cultured for a 
period of 12 weeks either in the presence of a selection pressure (+G418), or no 
selection pressure (-G418). Each week cells were passaged and a representative portion 
of each colony was analysed by FACS analysis to determine the percentage of each 
individual colony expressing EGFP over time. Colony 3 (red font) from each plasmid 
group was selected as a representative colony for that plasmid over time. Numbers are 
given as percentages of EGFP expressing cells in the total cell population of each colony 
at time points 2, 4, 8 and 12 weeks post transfection.   
 
 
 
                     Weeks        
 Clone              PT 
2 4 8 12 
+ 
G418 
- 
G418 
+ 
G418 
- 
G418 
+ 
G418 
- 
G418 
+ 
G418 
- 
G418 
pEFS-EGFP   1  28.1 - 83.4 74.5 75.6 70.2 77.9 74.7 
2 32.7 - 59.1 55.8 40.0 37.6 39.2 38.4 
3 34.1 - 49.4 47.7 72.9 67.7 83.4 74.5 
4 38.4 - 52.8 47.2 63.3 54.3 70.5 63.4 
 pCAG-EGFP   1  30.8 - 52.3 48.6 68.6 65.8 82.6 80.0 
2 35.6 - 55.6 49.5 67.9 62.3 78.3 72.2 
3 40.0 - 83.4 74.5 86.5 75.8 90.9 85.3 
4 27.2 - 45.2 42.0 56.7 52.6 76.1 70.8 
   pEPI-EGFP   1  17.6 - 49.4 47.7 48.3 42.6 50.8 45.2 
2 26.2 - 34.1 32.8 37.6 27.5 28.3 29.4 
3 36.9 - 50.6 46.0 68.1 53.3 75.7 70.2 
4 38.1 - 56.1 45.9 64.4 58.1 70.1 65.3 
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As can be seen for all plasmids analysed in Figure 35, 36 and 37, there is a steady and stable 
increase in the expression of EGFP in AtT20 cells up to 12 weeks following transfection. For 
colony 3 stable AtT20 cells transfected with pCAG-EGFP, there is a stable increase of EGFP 
expression in transfected cells. Levels of EGFP start at 40% at week two post transfection 
and reach 90.9% and 85.3% in cells maintained in G418 medium (+ G418) and normal 
medium (- G418) respectively, at 12 weeks post transfection. A similar level was also 
obtained for the colony 3 stable pEFS-EGFP transfected cells, with EGFP expression starting 
at 34.1% after two weeks of selection and increase to 83.4% and 74.5% in cells maintained 
with and without selection (+ and – G418) respectively, at 12 weeks post transfection. The 
positive control colony 3 for pEPI-EGFP also performed similarly, providing a stable increase 
in EGFP levels starting at 36.9% two weeks post transfection, and reaching 75.7% and 70.2% 
in G418 + and G418 – cells respectively at 12 weeks post transfection. Overall the highest 
level of EGFP expression were observed in cells transfected with pCAG-EGFP, then pEFS-
EGFP and finally pEPI-EGFP stable AtT20 cells at 12 weeks post transfection. Importantly, 
EGFP expression was stable for all plasmids analysed irrespective of whether cells were 
maintained in selection or not. Levels of EGFP expression were similar in the other three 
pCAG-EGFP, pEFS-EGFP and pEPI-EGFP colonies analysed as seen in Table 2. 
One might have expected to observe a more uniform population close to 100% of the 
population expressing EGFP after the initial two weeks of G418 selection was applied to 
transfected cells. However due to the limitations of the colony isolation method, whereby 
isolated clones may have been picked and included cells that may not have expressed EGFP, 
this would have meant that these cells would not have been killed off during the G418 
selection process due to the presence of the neo gene in their nucleus, and so would have 
survived alongside EGFP expressing cells (throughout the entire experiment). Importantly, 
resistant colonies that grew from At20 cells transfected with control plasmids lacking the 
S/MAR element (pCAG-EGFP-Control, pEFS-EGFP-Control and pEPI-EGFP-Control) were also 
maintained in G418 or normal medium for up to 12 weeks post transfection. In all control 
plasmids, levels of EGFP expression were similar to background levels of untransfected 
AtT20 cells; reaching levels no higher than 3.1% (Figure 35B, Figure 36B and Figure 37B). 
This result verifies results seen by others in other cells (Piechaczek, Fetzer et al. 1999; 
Schaarschmidt, Baltin et al. 2004; Papapetrou, Zoumbos et al. 2005).    
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Figure 35:   FACS analysis of EGFP expression levels over time in AtT20 cells 
transfected with pEFS-EGFP and pEFS-EGFP-Control plasmid vectors 
(A) AtT20 cells were transfected with plasmids pEFS-EGFP or pEFS-EGFP-Control and 
analysed by FACS analysis 48 hours post transfection (PT) (top panel). EGFP expression 
levels from both plasmids showed good levels of transfection after 48h PT (42.5% and 
37.3% of the total population respectively). Selection pressure with G418 antibiotic was 
applied to both cell populations for a period of 2 weeks at which point cells were 
analysed for EGFP expression at the end of the 2 week selection period (middle). Levels 
of EGFP expression were sustained in cells transfected with pEFS-EGFP (34.1% of the 
initial population) while EGFP expression was lost in pEFS-EGFP-Control transfected 
cells (4.4% of the initial population). Individual colonies that had formed from cells 
transfected with pEFS-EGFP were picked, where half were maintained under selection 
while the other half was maintained in normal medium (+G418 and –G418 
respectively). Cells transfected with pEFS-EGFP and maintained for 6 weeks with and 
without G418 selection were analysed for EGFP expression by FACS analysis (bottom). 
Levels of EGFP expression were maintained for both cell populations with and without 
G418 selection (49.4% and 47.7% respectively). 
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Figure 35:   FACS analysis of EGFP expression levels over time in AtT20 cells 
transfected with pEFS-EGFP and pEFS-EGFP-Control plasmid vectors 
(B) EGFP expression levels from pEFS-EGFP transfected cells at 8 weeks PT with and 
without selection pressure (top panel); levels of EGFP were maintained (72.9% and 
67.7% respectively). Levels of EGFP expression were also measured at 12 weeks PT 
with and without selection pressure from pEFS-EGFP, as well as from cells transfected 
with pEFS-EGFP-Control maintained with G418 selection pressure (bottom). At 12 
weeks PT, levels of EGFP expression in cells from pEFS-EGFP maintained with and 
without selection pressure were sustained (83.4% and 74.5% respectively), while EGFP 
expression from cells transfected with pEFS-EGFP-Control was lost (3.1%). 
 
In all cases, histograms show measured events (y axis) against levels of EGFP 
fluorescence in the FL1-H channel (x axis). Untransfected AtT20 cells appear as a pink 
graph on the left side of the histogram, while cells expressing EGFP appear green (as an 
overlay). Gated cells expressing EGFP are expressed as a percentage (%) of the total 
untransfected population – a threshold of 1% untransfected cells was always set - and 
appear above the bracketed histogram regions.    
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Figure 36:   FACS analysis of EGFP expression levels over time in AtT20 cells 
transfected with pCAG-EGFP and pCAG-EGFP-Control plasmid vectors 
(A) AtT20 cells were transfected with plasmids pCAG-EGFP or pCAG-EGFP-Control and 
analysed by FACS analysis 48 hours post transfection (PT) (top panel). EGFP expression 
levels from both plasmids showed good levels of transfection after 48h PT (69.9% and 
60.6% of the total population respectively). Selection pressure with G418 antibiotic was 
applied to both cell populations for a period of 2 weeks at which point cells were 
analysed for EGFP expression at the end of the 2 week selection period (middle). Levels 
of EGFP expression were sustained in cells transfected with pCAG-EGFP (40.0% of the 
initial population) while EGFP expression was lost in pCAG-EGFP-Control transfected 
cells (3.7% of the initial population). Individual colonies that had formed from cells 
transfected with pCAG-EGFP were picked, where half were maintained under selection 
while the other half was maintained in normal medium (+ G418 and – G418 
respectively). Cells transfected with pCAG-EGFP and maintained for 6 weeks with and 
without G418 selection were analysed for EGFP expression by FACS analysis (bottom). 
Levels of EGFP expression were maintained for both cell populations with and without 
G418 selection (83.4% and 74.5% respectively).  
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Figure 36:   FACS analysis of EGFP expression levels over time in AtT20 cells 
transfected with pCAG-EGFP and pCAG-EGFP-Control plasmid vectors 
(B) EGFP expression levels from pCAG-EGFP transfected cells at 8 weeks PT with and 
without selection pressure (top panel); levels of EGFP were maintained (86.5% and 
75.8% respectively). Levels of EGFP expression were also measured at 12 weeks PT 
with and without selection pressure from pCAG-EGFP, as well as from cells transfected 
with pCAG-EGFP-Control maintained with G418 selection pressure (bottom). At 12 
weeks PT, levels of EGFP expression in cells from pCAG-EGFP maintained with and 
without selection pressure were sustained (90.9% and 85.3% respectively), while EGFP 
expression from cells transfected with pCAG-EGFP-Control was lost (2.1%). 
In all cases, histograms show measured events (y axis) against levels of EGFP 
fluorescence in the FL1-H channel (x axis). Untransfected AtT20 cells appear as a pink 
graph on the left side of the histogram, while cells expressing EGFP appear green (as an 
overlay). Gated cells expressing EGFP are expressed as a percentage (%) of the total 
untransfected population – a threshold of 1% untransfected cells was always set - and 
appear above the bracketed histogram regions. 
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Figure 37:   FACS analysis of EGFP expression levels over time in AtT20 cells 
transfected with (+ control) pEPI-EGFP and pEPI-EGFP-Control plasmid vectors 
(A) AtT20 cells were transfected with plasmids pEPI-EGFP or pEPI-EGFP-Control and 
analysed by FACS analysis 48 hours post transfection (PT) (top panel). EGFP expression 
levels from both plasmids showed good levels of transfection after 48h PT (53.8% and 
44.8% of the total population respectively). Selection pressure with G418 antibiotic was 
applied to both cell populations for a period of 2 weeks at which point cells were 
analysed for EGFP expression at the end of the 2 week selection period (middle). Levels 
of EGFP expression were sustained in cells transfected with pCAG-EGFP (36.9% of the 
initial population) while EGFP expression was lost in pEPI-EGFP-Control transfected 
cells (5.4% of the initial population). Individual colonies that had formed from cells 
transfected with pEPI-EGFP were picked, where half were maintained under selection 
while the other half was maintained in normal medium (+ G418 and –G418 
respectively). Cells transfected with pEPI-EGFP and maintained for 6 weeks with and 
without G418 selection were analysed for EGFP expression by FACS analysis (bottom). 
Levels of EGFP expression were maintained for both cell populations with and without 
G418 selection (50.6% and 46.0% respectively). 
172 
 
 
Figure 37:   FACS analysis of EGFP expression levels over time in AtT20 cells 
transfected with (+ control) pEPI-EGFP and pEPI-EGFP-Control plasmid vectors 
(B) EGFP expression levels from pEPI-EGFP transfected cells at 8 weeks PT with and 
without selection pressure (top panel); levels of EGFP were maintained (68.1% and 
53.3% respectively). Levels of EGFP expression were also measured at 12 weeks PT 
with and without selection pressure from pEPI-EGFP, as well as from cells transfected 
with pEPI-EGFP-Control maintained with G418 selection pressure (bottom). At 12 
weeks PT, levels of EGFP expression in cells from pEPI-EGFP maintained with and 
without selection pressure were sustained (70.7% and 75.7% respectively), while EGFP 
expression from cells transfected with pEPI-EGFP-Control was lost (2.4%). 
In all cases, histograms show measured events (y axis) against levels of EGFP 
fluorescence in the FL1-H channel (x axis). Untransfected AtT20 cells appear as a pink 
graph on the left side of the histogram, while cells expressing EGFP appear green (as an 
overlay). Gated cells expressing EGFP are expressed as a percentage (%) of the total 
untransfected population – a threshold of 1% untransfected cells was always set - and 
appear above the bracketed histogram regions.    
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PCR analysis was also performed on total DNA isolated from short and long-term AtT20 cells 
transfected with both pDNA vector sets (pEFS-EGFP and pCAG-EGFP as well as the 
corresponding control plasmids) without G418 selection pressure (Figure 38). PCR analysis 
of both vectors revealed the presence of pDNA in AtT20 cells up to 12 weeks post 
transfection, consistent with the FACS data observed above for the vectors.  
Results from the FACS and PCR analysis of pDNA was further verified by rt-PCR analysis of 
EGFP mRNA levels from short and long-term AtT20 cells transfected with each pDNA vector 
set (Figure 39). Long-term EGFP mRNA transcript was observed in AtT20 cells transfected 
with both vectors pEFS-EGFP and pCAG-EGFP. No bands were observed for the PCR analysis 
of RNA samples using the same primers to amplify pDNA in AtT20 cells (data not shown), 
verifying that the EGFP mRNA expression observed in Figure 389 is true and not a 
contamination of genomic DNA.      
 
Figure 38:   PCR detection of pEFS-EGFP and pCAG-EGFP pDNA vectors in AtT20 
cells extracted short term and long-term post transfection without G418 selection 
pressure 
PCR analysis of (A) pEFS-EGFP and pEFS-EGFP-Control and (B) pCAG-EGFP and  
pCAG-EGFP-Control pDNA vectors at 48 hours (lanes 1-4) and 12 weeks (lanes 5-8) post 
transfection (PT) without G418 selection pressure. PCR samples were separated by 
agarose gel electrophoresis and a positive PCR band was observed using EFS-EGFP or 
CAG-EGFP specific primer sets yielding a product size of 450 bp or 250 bp respectively. 
The arrowhead indicates the size corresponding to pDNA 450 bp on (A) and 250 bp on 
(B). Results are representative of three independent experiments. L= 100 bp ladder 
(Invitrogen). 
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Figure 39:   RT-PCR analysis of EGFP mRNA from AtT20 cells transfected with 
EGFP-S/MAR plasmids at 48 hours and 12 weeks post transfection without G418 
selection pressure 
Total RNA was extracted from AtT20 cells transfected with (A) pEFS-EGFP and  
pEFS-EGFP-Control and (B) pCAG-EGFP and pCAG-EGFP-Control pDNA vectors at 48 
hours (lanes 1-4) and 12 weeks (lanes 5-8) post transfection, without G418 selection 
pressure.  Total RNA was isolated and used to generate cDNA. PCR was performed with 
two EGFP specific primers to yield a product size of 494 bp, as indicated by the 
arrowhead on (A) and (B). Untransfected cells as well as no RNA product/water served 
as a negative control (lanes 9 and 10). Results are representative of three independent 
experiments. L= 100 bp ladder (Invitrogen). 
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3.1.11 Replication analysis of pEGFP-S/MAR vectors in AtT20 cells 
 
To assess whether plasmids pEFS-EGFP and pCAG-EGFP were able to replicate in AtT20 cells, 
long-term transfected cells were analysed by DpnI and MboI restriction digestion analysis. 
The DpnI enzyme recognises bacterial DNA sequences, while MboI enzyme recognises 
mammalian DNA sequences. Total genomic DNA was extracted from cells and was digested 
with both enzymes independently followed by analysis by PCR for the presence or absence 
of a band using plasmid specific primers. Hence sequences of DNA that had not been cut by 
the restriction enzyme would also not be able to be PCR amplified and so no detectable PCR 
band would be observed. In contrast, samples that had been digested with either enzyme 
would cause the DNA to become linearised and so PCR analysis would yield a PCR band.  
Figure 40 shows the representative PCR analysis of pEFS-EGFP, pCAG-EGFP and pEPI-EGFP 
plasmids following MboI and DpnI digestion of AtT20 cells 12 weeks following transfection 
with and without G418 medium. The results show that all the plasmids analysed in the 
AtT20 cells were able to replicate during the 12 weeks post transfection. Therefore all 
plasmids were transform from pDNAs of bacterial origin - which they all would have been 
when pDNAs were originally amplified and purified - to pDNAs of mammalian origin after 
being cultured with the AtT20 cells at the end of the 12 week period. Noteworthy is the fact 
that the replication of the plasmids was unaffected regardless of whether the cells were 
maintained in G418 selection medium or normal medium. Hence both pEFS-EGFP and  
pCAG-EGFP pDNA vectors were able to replicate and mediate long expressing levels of the 
EGFP transgene in AtT20 cells.       
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Figure 40:   Long-term PCR analysis of MboI or DpnI digested AtT20 cells 
transfected with EGFP-S/MAR plasmids 12 weeks post transfection with and 
without G418 selection pressure 
Genomic DNA was extracted from AtT20 cells 48 hours (lanes 1 and 2) and 12 weeks 
(lanes 3-14) post transfection (PT) with (A) pEFS-EGFP (B) pCAG-EGFP and (C) pEPI-
EGFP pDNA vectors. Long-term cells (at 12 wks PT) were maintained either with or 
without G418 selection pressure (+/-). Genomic DNA was digested with either MboI 
(lanes 1, 6-8, 12-14 in (A) and (B) or lanes 1, 4 and 6 in (C)) or DpnI (lanes 2, 3-5, 9-11 
in (A) and (B) or lanes 2, 3 and 5 in (C)) (M or D respectively) and assessed by PCR 
analysis using EFS-EGFP, CAG-EGFP or CMV-EGFP specific primer sets yielding a 
product size of 450 bp, 250 bp or 350bp for pEFS-EGFP, pCAG-EGFP or pEPI-EGFP 
plasmids respectively. PCR samples were separated by agarose gel electrophoresis and 
a positive PCR band was observed using the correct corresponding pDNA and primer 
set, yielding product sizes above. The arrowhead indicates the size 450 bp on (A), 250 
bp on (B) and 350 bp on (C). For the PCR reaction, pDNA (25 ng) pEFS-EGFP, pCAG-
EGFP or pEPI-EGFP (in the case of (A), (B) or (C) respectively) digested with MboI 
served as a positive control (lane 15 in (A) and (B) or lane 7 in (C)), while pDNA 
digested with DpnI served as a negative control (lane 16 in (A) and (B) or lane 8 in (C)). 
Results are representative of four independent experiments. L= 100 bp ladder 
(Invitrogen). 
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3.1.12 Episomal maintenance of pEGFP-S/MAR vectors in AtT20 cells 
 
To trace the presence and localisation of the EGFP pDNA vector series at the end of the 
experiment (12 weeks PT), plasmid rescue experiments were performed. As such E.coli 
bacterial cells were transformed with 1 µg of total DNA isolated from 1 x 106 cells at 12 
weeks PT with either pEFS-EGFP, pCAG-EGFP or pEPI-EGFP plasmids. Kanamycin resistant 
bacterial colonies were obtained 24 hours after transformation at a rate of approximately  
2-5 colonies per plate, irrespective of the plasmid DNA being analysed, which indicates a low 
copy number of all plasmids in AtT20 cells. This is in agreement with previous reports which 
indicate that S/MAR plasmids transfected in cells such as CHO-K1 or HeLa cells also have low 
plasmid copy numbers (Piechaczek, Fetzer et al. 1999; Schaarschmidt, Baltin et al. 2004). 
Plasmid DNA extracted from these clones were digested with various restriction enzymes 
and analyzed by gel electrophoresis.  
Clones isolated from AtT20 cells transfected with pEFS-EGFP vector were analysed by 
digestion with XhoI and BamHI restriction enzyme. The digestion fragments from these 
clones where compared to the positive control of digested pEFS-EGFP plasmid, giving the 
fragments 5104 bp and 1080 bp when digested with XhoI and linearised plasmid of 6184 bp 
when digested with BamHI. Clones from the AtT20 pCAG-EGFP cells were analysed by NdeI 
and HindIII restriction analysis. The digestion fragments from these clones were also 
compared to the positive control of digested pCAG-EGFP plasmid, giving the fragments  
3500 bp, 2410 bp and 1781 bp when digested with NdeI and giving the fragments 3142 bp 
and 4549 bp when digested with HindIII. Finally the colonies from the AtT20 pEPI-EGFP cells 
were digested with the AflIII and NdeI restriction enzymes. The digestion fragments from 
pDNA isolated from these clones were also compared to the positive control of digested 
pEPI-EGFP plasmid, giving the fragments 3700 bp and 3000 bp when digested with AflIII and 
5100 bp and 1600 bp when digested with NdeI. The restriction digestion fragments 
observed from all three EGFP pDNA vectors (pEFS-EGFP, pCAG-EGFP and pEPI-EGFP) 
extracted from AtT20 cells is shown in Figure 43. The digested pDNA from 4 antibiotic 
resistant bacterial clones was identical to the restriction fragments observed in the 
corresponding original pDNA. This confirms the presence of an intact episomal  
pEFS-EGFP, pCAG-EGFP and pEPI-EGFP plasmid in the AtT20 cells. 
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Figure 41:   Plasmid rescue of pEFS-EGFP, pCAG-EGFP and pEPI-EGFP vectors 
isolated from AtT20 cells 
Plasmid rescue analysis of pDNA isolated from 4 randomly chosen clones (lanes 1-4) 
after transformation of E.coli bacteria with 1 µg of total DNA isolated from AtT20  
(A) pEFS-EGFP (B) pCAG-EGFP and (C) pEPI-EGFP stable cell lines, as described in the 
text. Undigested plasmid served as a negative control (lane 5; (-)), while all bands show 
identical sizes with the positive control of original pEFS-EGFP, pCAG-EGFP and  
pEPI-EGFP plasmids respectively (lane 6; (+)), demonstrating that pEFS-EGFP,  
pCAG-EGFP and pEPI-EGFP vectors are retained episomally in AtT20 cells. Results are 
representative of four independent experiments. L: 1 kb Ladder (Invitrogen). 
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The episomal state was further confirmed by Southern blot analysis. The highest expressing 
two clones from AtT20 pEFS-EGFP and pCAG-EGFP transfected cells and one clone from 
pEPI-EGFP at 12 weeks post transfection were isolated from 1x106 cells for each clone as 
described in the methods, and subjected to Southern blot analysis. Total cellular DNA  
(10 µg) was isolated from each clone and digested with a single cutter to all plasmids StuI 
restriction enzyme, which linearises all three plasmids pEFS-EGFP, pCAG-EGFP and  
pEPI-EGFP. Digested DNA was then analysed by Southern hybridisation with a 32P-labelled 
AlwNI fragment - a 408 bp DNA fragment of a segment of the kanamycin region, which is 
common to all plasmids - as a probe. As shown in Figure 42 the hybridisation pattern clearly 
confirms the episomal state of all three plasmids, pEFS-EGFP, pCAG-EGFP pEPI-EGFP vectors. 
In all clones analysed, irrespective of whether the clones were maintained in G418 medium 
or not, a distinct band identical in size to the original pEFS-EGFP, pCAG-EGFP and pEPI-EGFP 
plasmids (+) is seen. 
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Figure 42:   Southern blot analysis of the episomal status of pEFS-EGFP,  
pCAG-EGFP and pEPI-EGFP vectors isolated from AtT20 cells 
Southern blots of total DNA isolated from two clones of AtT20 cells transfected with  
(A) pEFS-EGFP and (B) pCAG-EGFP and (C) pEPI-EGFP vectors and cultured for 12 
weeks in medium with or without G418. DNA (10 µg) was separated on 0.8% agarose 
gels and hybridized with 32P-labelled AlwNI probe. In (A) and (B) lanes 1-2, StuI 
digested total DNA from AtT20 cells maintained in G418 medium, while lanes 3-4, the 
same clones digested with StuI maintained in normal medium. In (C) lane 1, clone 
maintained in G418 medium, lane 2, the same clone maintained in normal medium. All 
clones produced a clear distinct band after StuI digestion, identical to the band arising 
after digestion of 8 ng of corresponding positive control original pDNAs (pEFS-EGFP on 
(A); lane 5 (+), pCAG-EGFP on (B); lane 5 (+) or pEPI-EGFP on C; lane 3 (+)). Results are 
representative of three independent experiments. L: 1 Kb ladder (Invitrogen).  
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In conclusion, at the end of the in vitro analysis of pEFS-EGFP, pCAG-EGFP and pEPI-EGFP 
vectors, all vectors were able to maintain the active long-term expression of the EGFP 
transgene (and EGFP mRNA) located upstream of the S/MAR element in the absence of 
selection pressure in the AtT20 cell line, as demonstrated by FACS, PCR and rt-PCR analysis. 
Perhaps more importantly, all vectors were also able to be maintained as an active episome 
during the many cycles of replication and cell divisions, as shown by plasmid rescue and 
Southern blot analysis. These results are in agreement with previously published reports 
(Piechaczek, Fetzer et al. 1999; Schaarschmidt, Baltin et al. 2004; Papapetrou, Zoumbos et 
al. 2005). 
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3.2 Plasmid production and in vitro analysis of REP1 transgene 
 
The ultimate goal of this project was the development of a unique non-viral plasmid vector 
suitable for the gene therapy of CHM. Similar to the cloning process of the EGFP transgene, 
our initial aims were to achieve this in a single cloning step; whereby the REP-1 gene driven 
by the EF1-α promoter from the pWPI-REP-1 or the CAG promoter from the pCAGGs 
plasmid could be cloned into pEPI-MCS1. However, due to significant problems associated 
with the cloning, it was decided that the cloning process should be done in stages. Hence as 
with the EGFP transgene cloning process, two cloning strategies were employed for the 
pEFS-REP1 and pCAG-REP1 vector series.  
 
3.2.1 Production of an expression plasmid with EFS alone – Plasmid pEOS-EFS-S/MAR 
 
The initial cloning step involved the creation of a plasmid vector expressing only the EFS 
promoter. The cloning strategy is illustrated in Figure 43. Hence the 800 bp EGFP transgene 
from the pEFS-EGFP plasmid (see section 3.1.2 and Figure 24) was excised by MluI and SalI 
restriction digestion. This was in preparation for cloning a plasmid with an EFS promoter and 
S/MAR sequence, to allow the insertion of REP1 cDNA downstream of the promoter. 
Digested vector was blunt ended and ligated overnight. The ligation mixture was 
transformed into JM109 competent cells. Out of the colonies obtained overnight, 3 were 
selected for plasmid isolation and screened for correct ligation in the 5’ to 3’ orientation, 
with the restoration of SalI and MluI sites, as well as the analysis with XhoI restriction 
enzyme. Correctly ligated plasmids would produce two fragments of 268 bp and 5116 bp 
when digested with XhoI enzyme. Of the 3 clones, all clones gave the expected plasmid sizes 
(Figure 43D). This vector was named pEOS-EFS-S/MAR plasmid. 
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Figure 43:   Generation of pEOS-EFS-S/MAR plasmid 
The cloning strategy for the generation of pEOS-EFS-S/MAR plasmid involved the 
removal of the EGFP gene from the pEFS-EGFP plasmid as illustrated in (A). The correct 
fragment sizes of the digested pEFS-EGFP plasmid before ligation are shown in (B), 
where lanes 1 and 2: undigested and digested pEFS-EGFP vector respectively. 
Successful ligation would result in the pEOS-EFS-S/MAR plasmid as illustrated in (C). 
Finally (D) shows the restriction analysis of 3 clones picked after ligation and digested 
with XhoI (lanes 8-10) with all clones showing correct size of plasmid after digestion (*), 
indicating the successful removal of the EGFP transgene and development of  
pEOS-EFS-S/MAR. The 268 bp fragment from pEFS-EGFP-S/MAR is faint but seen 
clearer on the digital image. Lanes 1-5: undigested DNA, lane 6-10: XhoI digested DNA, 
lane 1 and 6: pEOS vector, lane 2 and 7: pEFS-EGFP-S/MAR, lane 3-5 & 8-10: colonies 1-
3. L: 1 Kb ladder (Invitrogen). 
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3.2.2 Production of a REP-1 expressing plasmid driven by EFS – Plasmid pEFS-REP-1 
 
The next step involved the insertion of REP1 cDNA into pEOS-EFS-S/MAR. The cloning 
strategy is illustrated in Figure 44.  Initially both vector pEOS-EFS-S/MAR and insert  
pBC-REP1 (Stratagene) plasmids were digested with MluI and BamHI. The excised 2 kb REP1 
cDNA from pBC was ligated with digested vector overnight at a molar vector: insert ratio of 
1:10. The ligation mixture was transformed into JM109 competent cells. Out of the colonies 
obtained overnight, 72 colonies were picked for PCR analysis using EFS and REP1 specific 
primers as described in the methods. Of the colonies picked for PCR analysis and that gave a 
positive signal on the PCR for the insertion and correct orientation of the insert, 5 clones 
were selected for plasmid isolation and analysis with XhoI and EcoRI restriction digestion 
analysis. Correctly ligated plasmids in the 5’ to 3’ orientation would produce 3 fragments 
3600 bp, 2300 bp and 1600 bp. All 5 clones analysed gave the expected fragment patterns 
(Figure 44D). One colony was selected for isolation with a MaxiPrep kit, its quality and 
quantity was measured using a Nanodrop spectrophotometer. This vector was named  
pEFS-REP1 plasmid. 
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Figure 44:   Generation of pEFS-REP1 plasmid 
The cloning strategy for the generation of pEFS-REP1 plasmid involved the insertion of 
the REP1 cDNA from the pBC-REP1 plasmid is illustrated in (A). The correct fragment 
sizes of the digested pEOS-EFS-S/MAR and pBC-REP1 plasmids before ligation are 
shown in (B), where lanes 1 and 2: undigested pEOS-EFS-S/MAR and pBC-REP1 and 
lanes 3 and 4: digested pEOS-EFS-S/MAR and pBC-REP1 vectors respectively. Successful 
ligation would result in the pEFS-REP1 plasmid as illustrated in (C). Finally (D) shows 
the restriction analysis of 5 clones picked after ligation and digested with EcoRI (lanes 
5-9) with all clones showing correct size of plasmid (*), indicating the successful 
insertion of the REP1 transgene and development of pEFS-REP1. Lanes 1 and 2 show 
undigested pEOS-EFS-S/MAR and pBC-REP1 DNA, lane 3 and 4 show EcoRI digested 
pEOS-EFS-S/MAR and pBC-REP1, lane 5-9 show EcoRI digested colonies 1-5. L: 1 Kb 
ladder (Invitrogen). 
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3.2.3 Production of EFS control counterpart - Plasmid pEFS-REP1-Control 
 
The final step in the pEFS-REP1 vector series involved the development of the control 
counterpart to the pEFS-REP1 plasmid. The cloning strategy is illustrated in Figure 45. In 
preparation for the removal of the 2 kb S/MAR element, pEFS-REP1 plasmid was digested 
with HpaI and BglI. This excised the 2 kb S/MAR fragment from the pEFS-REP1 plasmid and 
the linearised vector was ligated overnight. The ligation mixture was transformed into 
JM109 competent cells. Out of the colonies obtained overnight, 4 clones were selected for 
plasmid isolation and analysis with StuI restriction enzyme. Correctly ligated plasmids would 
give a linearised vector that would produce a fragment 5352 bp. All of the clones gave the 
expected plasmid sizes (Figure 45D).  One colony was selected for isolation with a MaxiPrep 
kit, its quality and quantity was measured using a Nanodrop spectrophotometer. As the 
newly constructed plasmid did not harbour an S/MAR element, the plasmid was named  
pEFS-REP1-Control plasmid.    
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Figure 45:   Generation of pEFS-REP1-Control plasmid 
The cloning strategy for the generation of pEFS-REP1-Control plasmid involved the 
removal of the 2 kb S/MAR motif from the pEFS-REP1 plasmid as illustrated in (A). The 
correct fragment sizes of the digested pEFS-REP1 plasmid before ligation are shown in 
(B), where lanes 1 and 2: undigested and digested pEFS-REP1 vector respectively. The  
2 kb fragment from pEFS-REP1 is faint but seen clearer on the digital image. Successful 
ligation would result in the pEFS-REP1-Control plasmid as illustrated in (C). Finally (D) 
shows the restriction analysis of 4 clones picked after ligation (lanes 2-5) with all clones 
showing correct size of plasmid (*), indicating the successful S/MAR excision and 
development of pEFS-REP1-Control. Lane 1 represents undigested pEFS-REP1 vector.  
L: 1 Kb ladder (Invitrogen). 
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3.2.4 Production of Plasmid pCAG-REP1 
 
The next stage involved the development of the pCAG-REP1 vector series. The vector 
created previously pEOS-CAG-MCS-S/MAR plasmid (see section 3.1.5) was used to insert the 
REP1 cDNA from the pEFS-REP1 plasmid downstream of the CAG promoter. The cloning 
strategy is illustrated in Figure 46. Both pEOS-CAG-MCS-S/MAR and pEFS-REP1 plasmids 
were digested with BamHI and MluI, resulting in the removal of the 2 kb REP1 cDNA 
fragment from the pEFS-REP1 plasmid. Digested vector and insert were ligated overnight at 
a molar vector: insert ratio of 1:10. The ligation mixture was then transformed into JM109 
competent cells. Out of the colonies obtained overnight, 72 colonies were picked for PCR 
analysis using CAG and REP1 specific primers as described in the methods. Of the colonies 
picked for PCR analysis and that gave a positive signal on the PCR for the insertion and 
correct orientation of the insert, 5 clones were selected for plasmid isolation and analysis 
with XhoI and NotI, BamHI and EcoRV or EcoRV (alone) restriction enzymes. Correctly ligated 
plasmids in the 5’ to 3’ orientation would produce 2 fragments at 2110 bp and 6720 bp 
when digested with EcoRV restriction enzyme. Of the 5 colonies analysed, 4 clones gave the 
expected fragment patterns (Figure 46D). One colony was selected for isolation with a 
MaxiPrep kit, its quality and quantity was measured using a Nanodrop spectrophotometer. 
This vector was named pCAG-REP1 plasmid. 
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Figure 46:   Generation of pCAG-REP1 plasmid 
The cloning strategy for the generation of pCAG-REP1 plasmid involved the insertion of 
the 2 kb REP1 cDNA fragment as illustrated in (A). The correct fragment sizes of the 
digested pEFS-REP1 and pEOS-CAG-MCS-S/MAR vectors before ligation are shown in 
(B), where lanes 1 and 2: undigested pEOS-CAG-MCS-S/MAR and pEFS-REP1, while 
lanes 3 and 4: digested pEOS-CAG-MCS-S/MAR and pEFS-REP1 vector respectively. 
Successful ligation would result in the pCAG-REP1 plasmid as illustrated in (C). Finally 
(D) shows the restriction analysis of 5 clones picked after ligation (lanes 3-7) with 
clones 1-4 showing the correct size of plasmid (*), indicating the successful REP1 
transgene insertion and development of pCAG-REP1. Lanes 1 and 2 represent digested 
pEOS-CAG-MCS-S/MAR and pEFS-REP1 vectors respectively. L: 1 Kb ladder 
(Invitrogen). 
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3.2.5 Production of CAG control counterpart - Plasmid pCAG-REP1-Control 
 
The final step in the pCAG-REP1 vector series involved the development of the control 
counterpart to the pCAG-REP1 plasmid. The cloning strategy is illustrated in Figure 47. In 
preparation for the removal of the 2 kb S/MAR element, pCAG-REP plasmid was digested 
with NotI and DraIII restriction enzymes. This excised the 2 kb S/MAR fragment from the 
pCAG-REP1 plasmid and the linearised vector was ligated overnight. The ligation mixture 
was transformed into JM109 competent cells. Out of the colonies obtained overnight, 8 
were selected for plasmid isolation and analysis with StuI restriction enzyme. Correctly 
ligated plasmids would give a linearised vector that would produce a fragment at 6830 bp. 
Of the 8 clones, 1 gave the expected plasmid sizes (Figure 47D). One colony was selected for 
isolation with a MaxiPrep kit, its quality and quantity was measured using a Nanodrop 
spectrophotometer. As the newly constructed plasmid did not harbour an S/MAR element, 
the vector was named pCAG-REP1-Control plasmid.    
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Figure 47:   Generation of pCAG-REP1-Control plasmid 
The cloning strategy for the generation of pCAG-REP1-Control plasmid involved the 
removal of the 2 kb S/MAR motif from the pCAG-REP1 plasmid as illustrated in (A). The 
correct fragment sizes of the digested pCAG-REP1 plasmid before ligation are shown in 
(B), where lanes 1 and 2: undigested and digested pCAG-REP1 vector respectively. The 
2 kb fragment from pCAG-REP1 is faint but seen clearer on the digital image. Successful 
ligation would result in the pCAG-REP1-Control plasmid as illustrated in (C). Finally (D) 
shows the restriction analysis of 8 clones picked after ligation (lanes 2-9) with 1 clone 
showing the correct size of plasmid (*), indicating the successful S/MAR excision and 
development of pCAG-REP1-Control. Lanes 1 undigested pCAG-REP1 vector. L: 1 Kb 
ladder (Invitrogen). 
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3.2.6 Transient transfection of AtT20 cells with pREP1-S/MAR plasmids 
 
To analyse the new REP1 vectors pEFS-REP1 and pCAG-REP1 as well as their control 
counterparts without S/MARs, plasmids were separately transfected with Lipofectamine 
2000 into AtT20 cells (0.8 µg of each pDNA). This experiment aimed to confirm the 
expression of the REP1 transgene, in a similar strategy used for the analysis of the EGFP 
transgene from the pEFS-EGFP and pCAG-EGFP as well as the control plasmids.   
At 48 hours following transfection, cell pellets were collected for REP1 protein expression by 
Western blot analysis. Briefly, cells were lysed and protein lysates (50 µg) were separated on 
a 7% SDS-polyacrylamide gel and blots were probed with anti-mouse REP1 antibody 2F1 
(Santa Cruz Technology, Santa Cruz, California) which recognises human Rep1 protein. 
Strong REP1 expression levels were observed in AtT20 cells 48 hours post transfection from 
all constructs as shown in Figure 48.  
 
Figure 48:   Western blot analysis of REP1 protein expression levels in AtT20 cells 
48 hours post transfection 
The figure shows expression of REP1 protein levels by Western analysis of AtT20 cell 
pellets (50 µg) 48 hours post-transfection using anti-mouse REP1 antibody 2F1 which 
recognises human Rep1 protein. Cells were transfected with plasmids pEFS-REP1, 
pEFS-REP1-Control, pCAG-REP1 and pCAG-REP1-Control pDNA vectors (lanes 1-4 
respectively), where all plasmids show expression of REP1 protein. Untransfected cells 
served as negative control (lane 5; (-)), human Rep1 protein (hREP1) served as a 
positive control (lane 6; (+)) and α-tubulin was used as a loading control. Results are 
representative of three independent experiments.  
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Expression of REP1 transgene was further confirmed in these cells by immunofluorescence 
analysis of fixed AtT20 cells. Briefly, 48 hours following transfection, AtT20 cells were rinsed 
in phosphate buffered saline (PBS), fixed in 4% paraformaldehyde (PFA) before being 
incubated with the REP1 antibody 2F1. As shown in Figure 49, immunofluorescent analysis 
of transfected cells shows both pEFS-REP1 and pEFS-REP1-Control plasmids mediate 
moderate levels of REP1 protein, while pCAG-REP1 and pCAG-REP1-Control plasmids were 
able to mediate higher REP1 levels.   
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Figure 49:   Expression of REP1 in AtT20 cells as analysed by immunofluorescence 
analysis of REP1 protein levels 48 hours post transfection 
AtT20 cells were transfected with plasmids (A) pEFS-REP1, (B) pEFS-REP1-Control,  
(C) pCAG-REP1 or (D) pCAG-REP1-Control. Expression of REP1 was observed within the 
cells at 48 hours post transfection by incubating with mouse anti-2F1 antibody (which 
recognises human REP1 protein) followed by anti-mouse 488 conjugated secondary 
antibody. Representative images are shown with all four plasmids where bright field 
(left panel), fluorescent (middle) and their merge images (right), at 40x magnification 
are shown. Images are representative of three independent experiments. 
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3.2.7 Transient REP1 transfection in RPE cells in situ 
 
To provide proof of principle testing of pEFS-REP1 and pCAG-REP1 plasmid constructs, 
primary RPE cells were also isolated from mouse and porcine eyes, and transfected with 
Lipofectin reagent (Invitrogen). This was done in order to assess the ability of REP1 plasmids 
to express in cells more relevant to the eye (compared to AtT20 and B16-F10 cells) as well as 
to transfect cells closely resembling those found in vivo in the eye. Briefly, RPE cells were 
transfected with 1 µg of pEFS-REP1 or pCAG-REP1 plasmid complexed with 6 µl of Lipofectin 
reagent in serum free medium overnight. One day post transfection, cells were rinsed with 
PBS and fixed in 4% PFA before being incubated with a REP1 antibody (2F1) which 
specifically recognizes human REP1 protein. Similar to the EGFP observations described in 
the earlier section 3.1.9, the efficiency of gene transfer in RPE cells with both REP1 plasmids 
was low. Despite this, were gene transfer was observed, both constructs were able to 
provide strong levels of REP1 expression in isolated RPE cells. Representative 
immunofluorescence pictures of pEFS-REP1 and pCAG-REP1 transduced RPE cells are shown 
in Figure 50. 
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Figure 50:   Expression of pEFS-REP1 and pCAG-REP1 following transfection of 
primary RPE cells – in situ 
Primary RPE cells were isolated from mouse and porcine eyes, plated onto 24-well 
plates and transfected with 1 µg of plasmid pEFS-REP1 or pCAG-REP1 and 6 µl 
Lipofectin transfection reagent. Twenty four hours post transfection to detect REP1 
expression, cells were incubated with mouse anti-2F1 antibody (which recognising 
human REP1 protein) followed by anti-mouse 488 conjugated secondary antibody. 
Representative images are shown with plasmids pCAG-REP1 (A & C) and pEFS-REP1 (B 
& D). Fluorescent (left panel), bright field (middle) and their merge images (right), at 
40x magnification are shown. Panels A & B represent porcine primary RPE cells, while 
panels C & D represent mouse primary RPE cells. Images are representative of two 
independent experiments. 
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3.2.8 Long-term REP1 expression in AtT20 cells 
 
AtT20 cells were also used for the long-term analysis of REP1 expression level from all 
constructs. Utilising a similar approach to that performed for the new EGFP pDNA vector 
series, AtT20 cells were transfected with plasmids pEFS-REP1, pCAG-REP1 or the 
corresponding control plasmids, G418 selection was applied 48 hours post transfection, and 
isolated clones were maintained in selection for up to 2 weeks, at which time cells were split 
into medium with or without G418. At regular time intervals, stable AtT20 cells transfected 
with either REP1 plasmids (pEFS-REP1, pCAG-REP1), were collected for Western blot analysis 
to observe the expression of REP1 protein in the isolated cells. Three colonies were picked 
for the stable and long-term REP1 expression analysis, where colonies were maintained in 
normal or G418 medium (Figure 51).  
Similar to the EGFP pDNA vector series, both pEFS-REP1 and pCAG-REP1 plasmids were able 
to maintain stable REP1 protein expression in all colonies analysed. Noteworthy was the fact 
that by 12 weeks post transfection, the Western blot analysis of AtT20 cells transfected with 
control non-S/MAR plasmids (pEFS-REP1-Control and pCAG-REP1-Control) could not be 
performed because there were insufficient cells to collect for analysis. This was most likely 
due to the fact that cells transfected with either of the control plasmids did not survive the 
long selection process with the presence of G418 in the culture medium, showing that only 
transient antibiotic resistance was initially observed, however this was not maintained 
persistently.   
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Figure 51:   Western blot analysis of REP1 protein expression levels over time in 
three stable AtT20 cells transfected with pEFS-REP1 and pCAG-Rep1 plasmid 
vectors 
AtT20 cells transfected with either (A) pEFS-REP1 or (B) pCAG-REP1 plasmids show 
good transfection efficiency 48 hours after transfection. G418 selection pressure was 
applied for a period of two weeks at which point three colonies (clones 1-3) for each 
plasmid were picked and split into medium with and without G418 antibiotic (+ G418 
and – G418 respectively). Cells were analysed for REP1 expression at regular time 
intervals post transfection (PT) (50 µg). 
On (A) lane 1: 48 hours transient transfection; lane 2 and 3: clone 1 at 12 weeks PT + 
and – G418 respectively; lane 4, 5 and 6: clone 2 at 4 weeks, and 12 weeks PT + and – 
G418 respectively; lane 7 and 8: clone 3 at 12 weeks PT + and – G418 respectively.  
On (B) lanes 2, 3-4, 5-6 and 7-8: 48 hours transient transfection and clones 1-3 at 12 
weeks PT + and – G418 respectively. 
Untransfected cells served as a negative control (-), human Rep1 protein (hREP1) 
served as a positive control (+) and α-tubulin was used as a loading control. Control 
plasmids without the S/MAR were not able to survive the selection process. Results are 
representative of three independent experiments.  
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Total DNA was also isolated from AtT20 cells at 48 hours and 12 weeks post transfection 
with either pEFS-REP1 or pCAG-REP1 vectors without G418 selection pressure and analysed 
for the PCR detection of the appropriate vector (Figure 52). As seen with the EGFP pDNA 
vectors, PCR analysis revealed the persistence of pEFS-REP1 and pCAG-REP1 pDNA in 
transfected AtT20 cells for up to 12 weeks post transfection, confirming the similar long-
term REP1 protein expression levels also observed in the stably transfected AtT20 cells.  
To further verify the Western blot and PCR analysis results, REP1 RNA was also analysed in 
transient and long-term pEFS-REP1 or pCAG-REP1 transfected AtT20 cells by rt-PCR analysis 
(Figure 53). Indeed REP1 mRNA transcript was observed in AtT20 cells for up to 12 weeks 
post transfection, regardless of pDNA (pEFS-REP1 or pCAG-REP1 vectors). Noteworthy is the 
fact that pDNA levels as well as REP1 mRNA were observed in AtT20 cells maintained in 
normal medium lacking G418 selection (although an initial selection process of two weeks 
was required and standard practice).  
 
Figure 52:   PCR detection of pDNA in AtT20 cells extracted short-term and long- 
term post transfection without G418 selection pressure 
PCR analysis of (A) pEFS-REP1 and pEFS-REP1-Control and (B) pCAG-REP1 and  
pCAG-REP1-Control pDNA vectors at 48 hours (lanes 1-4) and 12 weeks (lanes 5-8) 
following transfection. PCR samples were separated by agarose gel electrophoresis and 
a positive PCR band was observed using EFS-REP1 or CAG-REP1 specific primer sets 
yielding product sizes 590 bp and 430 bp respectively. The arrowhead indicates the size 
corresponding to pDNA 590 bp on (A) or 430 bp on (B). Results are representative of 
three independent experiments. L= 100bp ladder (Invitrogen). 
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Figure 53:   RT-PCR analysis of REP1 mRNA from AtT20 cells transfected with 
REP1-S/MAR plasmids at 48 hours and 12 weeks post transfection without G418 
selection pressure 
Total RNA was extracted from AtT20 cells transfected with (A) pEFS-REP1 and  
pEFS-REP1-Control and (B) pCAG-REP1 and pCAG-REP1-Control pDNA vectors at 48 
hours (lanes 1-4) and 12 weeks (lanes 5-8) post transfection, without G418 selection 
pressure. Total RNA was isolated and used to generate cDNA. PCR was performed with 
two REP1 specific primers to yield a product size of 240 bp, as indicated by the 
arrowhead on (A) and (B). Untransfected cells as well as no RNA product/water served 
as a negative control (lanes 9 and 10). Results are representative of three independent 
experiments. L= 100bp ladder (Invitrogen). 
 
 
3.2.9 Replication analysis of pREP1-S/MAR vectors in AtT20 cells 
 
Experiments to confirm that the plasmids pEFS-REP1 and pCAG-REP1 were able to replicate 
in AtT20 cells, were similar to the experiments performed for the pEGFP-S/MAR vectors. 
Cellular pDNA was isolated from AtT20 cells at 12 weeks post transfection of both plasmids 
where cells were maintained either in G418 medium or normal medium without antibiotic. 
Plasmid DNAs were then digested with enzymes DpnI and MboI and analysed by PCR 
analysis for the presence or absence of a PCR band when amplified using plasmid specific 
primers. Figure 54 shows representative PCR results demonstrating that both REP1 plasmids 
pEFS-REP1 and pCAG-REP1 were able to replicate in AtT20 cells after 12 weeks post 
transfection, shifting from pDNA of bacterial origin to producing the restriction digestion 
pattern of pDNA of mammalian origin. 
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Figure 54:   Long-term PCR analysis of MboI and DpnI digested AtT20 cells 
transfected with REP1-S/MAR plasmids at 12 weeks post transfection with and 
without G418 selection pressure 
Genomic DNA was extracted from AtT20 cells 48 hours (lanes 1 and 2) and 12 weeks 
(lanes 3-14) post transfection (PT) with (A) pEFS-REP1 and pEFS-EGFP-Control and  
(B) pCAG-REP1 and pCAG-EGFP-Control pDNA vectors. Long-term cells (at 12 wks PT) 
were maintained either with or without G418 selection pressure (+/-). Genomic DNA 
was digested with either MboI (lanes 1, 6-8, 12-14) or DpnI (lanes 2, 3-5, 9-11) (M or D 
respectively) and assessed by PCR analysis using EFS-REP1 or CAG-REP1 specific 
primer sets yielding a product size of 650 bp and 430 bp for pEFS-REP1 or pCAG-REP1 
plasmids respectively. PCR samples were separated by agarose gel electrophoresis and 
a positive PCR band was observed using the correct corresponding pDNA and primer 
set, yielding product sizes above. The arrowhead indicates the size 650 bp on (A) and 
430 bp on (B). For the PCR reaction, pDNA (25 ng) pEFS-REP1 (in the case of (A)) or  
pCAG-REP1 (in the case of (B)) digested with MboI served as a positive control (lane 
15), while pDNA digested with DpnI served as a negative control (lane 16). Results are 
representative of four independent experiments. L= 100 bp ladder (Invitrogen). 
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3.2.10 Episomal maintenance of pREP1-S/MAR vectors in AtT20 cells 
 
To trace pEFS-REP1 and pCAG-REP1 at 12 weeks post transfection, different AtT20 clones 
were selected and the total DNA was isolated from 1x106 cells for each clone as described in 
the methods. These were then subjected to Southern blot analysis to determine the 
episomal state of pEFS-REP1 and pCAG-REP1 AtT20 clones. To ensure that the selection 
pressure applied to AtT20 pEFS-REP1 and pCAG-REP1 clones had not forced the pDNAs to 
integrate into the genomic DNA, total cellular DNA was isolated from two of the strongest 
expressing clones that were either maintained in normal or G418 medium. As with the 
analysis of the EGFP pDNA vectors, DNAs were then digested with StuI enzyme. Linearized 
pEFS-REP1 and pCAG-REP1 plasmids were subsequently hybridized with the 32P-labeled 
AlwNI fragment that was used as a probe for the Southern blot. As shown in Figure 55, the 
hybridisation patterns clearly demonstrate the episomal nature of both pEFS-REP1 and 
pCAG-REP1 vectors. In all clones analysed, there was a distinct band identical in size to the 
original pEFS-REP1 and pCAG-REP1 plasmids (that were used as positive controls). 
Importantly, clones remained episomal regardless of whether they were maintained in G418 
selective medium or not. 
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Figure 55:   Southern blot analysis of the episomal status of pEFS-REP1 and  
pCAG-REP1 vectors isolated from AtT20 cells 
Southern blots of total DNA isolated from two clones of AtT20 cells transfected with 
(A) pEFS-REP1 and (B) pCAG-REP1 vectors at 12 weeks post transfection, cultured 
either in normal or G418 selection medium. DNA (10 µg) was separated on 0.8% 
agarose gels and hybridized with 32P-labelled AlwNI probe. Lanes 3-4, StuI digested total 
DNA, from AtT20 cells maintained in G418 medium, while lanes 1-2, the same clones 
digested with StuI maintained in normal medium. All clones produced a clear distinct 
band after StuI digestion, identical to the band arising after digestion of 8 ng of 
corresponding positive control original pDNAs (pEFS-REP1 in (A) and pCAG-REP1 in 
(B); (+)). Results are representative of three independent experiments. L: 1 Kb ladder 
(Invitrogen). 
 
The episomal state was further confirmed by plasmid rescue experiments similar to the 
experiments carried out for the EGFP pDNA vectors. E.coli bacterial cells were transformed 
with 1 µg of total DNA isolated from 1 x 106 cells at 12 weeks post transfection with either 
pEFS-REP1 or pCAG-REP1 plasmids. 24 hours after transformation, four colonies were 
isolation with a MiniPrep kit and plasmid DNA extracted from these clones was digested 
with various restriction enzymes and analysed by gel electrophoresis.  
Clones that arose from AtT20 cells transfected with pEFS-REP1 vector were analysed by 
digestion with XhoI and EcoRI restriction enzymes, while pCAG-REP1 transfected AtT20 
clones were digested with EcoRV and EcoRI restriction enzymes. The digestion patterns of all 
clones were compared to digested original plasmid DNA, pEFS-REP1 or pCAG-REP1 vectors. 
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Clones from the AtT20 pEFS-REP1 cells digested with XhoI, give the fragments  
4902 bp, 1300 bp and 1150 bp, as well as the fragments 1651 bp, 2301 bp and 3400 bp 
when digested with EcoRI. While colonies from the AtT20 pCAG-REP1 cells digested with 
EcoRV gave the fragments 2110 bp and 6720 bp, as well as the fragments 4830 bp, 2300 bp 
and 1700 bp when digested with EcoRI. As can be seen from Figure 56 all digestion patterns 
of isolated colonies were identical to the corresponding original pDNA. This further validates 
the episomal status of pEFS-REP1 and pCAG-REP1 plasmids in AtT20 cells.  
 
Figure 56:   Plasmid rescue of pEFS-REP1 and pCAG-REP1 vectors isolated from 
AtT20 cells 
Plasmid rescue analysis of pDNA isolated from 4 randomly chosen clones (lanes 1-4), 
after transformation of E.coli bacteria with 1 µg of total DNA isolated from AtT20 (A) 
pEFS-REP1 and (B) pCAG-REP1 stable cell lines, as described in the text. Undigested 
plasmid served as a negative control (lane 5 (-)), while all bands show identical sizes 
with the positive control of original pEFS-REP1 and pCAG-REP1 plasmid respectively 
(lane 6 (+)), demonstrating the episomal status of pEFS-REP1 and pCAG-REP1 vectors 
in AtT20 cells. Results are representative of four independent experiments. L: 1 kb 
Ladder (Invitrogen). 
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3.2.11 Functional studies in human and mouse fibroblasts (CHM4 and ChmFlox cells) 
 
Our previous experiments involved the transfection of wild-type cells in vitro and the 
examination of EGFP as well as REP1 transgene expression within these transfected cells. 
Since our research is mainly orientated around the eye disease CHM; we were also eager to 
carry out similar experiments with the pEFS-REP1 and pCAG-REP1 vectors in CHM knock-out 
(KO) cell lines to show functionality of the vectors in knockout cells. Previous in vitro 
experiments for CHM assessed the rescue and delivery of REP1 to defective lymphocytes 
and fibroblasts through protein and enzymatic activities (Seabra, Brown et al. 1993; Anand, 
Barral et al. 2003). Hence as a proof-of-principle for the development of a novel non-viral 
genetic modification of RPE cells, initial experiments were carried out in vitro as before 
using either lymphocyte or fibroblast cells from CHM patient or CHM mice. To this end, 
primary human fibroblasts isolated from CHM affected patients (CHM4 cells) were obtained 
from a collaborator Dr Ian Macdonald at the National Eye Institute (NIH). These CHM4 cells 
were entirely devoid of REP1 protein and were a full REP1 knockout cell line.  
 
3.2.11.1 Isolation and KO of mouse fibroblasts  
 
Primary mouse fibroblasts were also isolated from a mouse CHM cell line (ChmFlox) as 
described in the methods. As CHM KO in mice is embryonically lethal, various CHM mouse 
models have been created to analyse the pathogenesis of the disease including mice with 
ChmFlox alleles, expressing the Cre protein under the control of a tamoxifen (TM) inducible 
promoter (MerCreMer - MCM)(Tolmachova, Anders et al. 2006). This mouse model was 
created using the Cre/loxP system of site specific recombination, whereby two loxP sites 
were inserted either side of exon 4 in the murine CHM gene. This allows for the conditional 
deletion of exon 4 (upon TM treatment), which in turn causes a frameshift mutation and 
ultimately the appearance of an early stop codon in the CHM gene. Hence this mouse model 
was chosen as an ideal candidate to use for the isolation of primary fibroblasts and 
subsequent treatment with TM to induce a CHM null/KO cell line similar to the CHM KO 
human fibroblast cell line.  
 
Briefly, CHM pups were culled 2-3 days after birth from a breeding cage of a heterozygous 
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ChmFlox/Y MCM + male and ChmFlox/Flox female breeding pair. All pups from this breeding pair 
were screened by PCR analysis for the presence of the Cre transgene using the 4B primer 
pair as described in the methods (Figure 57Ai). This breeding scheme was required to 
produce offspring which were homozygous for the ChmFlox allele and carried the Cre 
transgene under the control of the MCM promoter. Fibroblasts were derived directly from 
excised skin explants from the above breeding cage. As this procedure of dermal fibroblast 
isolation from the mouse skin requires isolation prior to the development of pigment and 
hair follicles around day 4 after birth, this meant that all isolations were initially done on 
each pup individually. However once the PCR analysis was performed the fibroblasts were 
grouped into ChmFlox Cre+ or ChmFlox Cre- fibroblasts and will be referred to as Flox, Cre+ and 
Flox, Cre-  fibroblasts respectively from this stage onwards.  
The knockout of exon 4 and subsequent creation of a Chmnull cell line was the next 
experiment that was needed once the primary fibroblasts had been isolated from the 
ChmFlox mice. This was achieved by treating the isolated Flox, Cre+ cells with various 
concentrations of TM to induce the CHM KO genotype. Briefly, primary mouse fibroblasts 
were plated into 10 cm dishes at a density of 5x104 cells along with varying concentrations 
of TM. Cells were cultured for 48 hours in the presence of TM which catalyses the 
recombination between the loxP sites and subsequent induction of the null genotype.  As 
the cell doubling time was fast, cells were plated such that they were sparse enough to 
divide to prevent reintegration of the excised fragment. After 24 hours only a partial 
knockout was seen – data not shown. The KO event was analysed by PCR analysis using 
primers to identify the ChmWT, ChmFlox and ChmNull alleles as shown in Figure 57Aii. The cells 
treated with 5-10 µM TM (dissolved in EtOH) showed the most effective conversion from 
flox to null genotype, while cells treated with 20 µM were not as viable due to the toxicity of 
the high TM concentration. Importantly, after the 48 hours of TM treatment, cells were 
maintained in normal fibroblast medium, and it was shown that the treatment of TM is also 
non-reversible or permanent as the null genotype was maintained in TM induced cells 
despite a number of cell divisions in vitro (Figure 57Bi). As a negative control Flox, Cre- 
fibroblasts were also isolated and treated with TM, however as expected no change in the 
genotype of the cells was observed (Figure 57Aiii). 
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Figure 57:   PCR analysis of the ChmWT, ChmFlox and ChmNull alleles following 
tamoxifen induction of isolated primary fibroblasts (Generation of KO CHM 
fibroblasts) 
(A) Primary fibroblasts were isolated from CHM pups and analysed by (i) PCR analysis 
using primers to specifically amplify the Cre gene, yielding a product size of 350 bp as 
indicated by the arrowhead on (i). Initially 8 CHM primary fibroblast cultures were 
established from 8 individual pups (lanes 1-8) with 4 pups showing the presence of the 
Cre gene (lanes 1, 3, 4, and 8 (*)). These fibroblasts were labelled ChmFlox Cre+ (Flox, 
Cre+) and pooled, while the remaining fibroblasts which were absent for the Cre gene 
(lanes 2, 5, 6 and 7) were also pooled and labelled ChmFlox Cre- (Flox, Cre-). Lane 9 and 
10 served as a negative and positive control respectively for the PCR reaction. 
Subsequently isolated (ii) Flox, Cre+ and (iii) Flox, Cre- fibroblasts (at passage 3) were 
treated with 0-20 µM Tamoxifen (TM) dissolved in either DMSO (lanes 1-6) or EtOH 
(lanes 8-13) for 48 hours, and analysed for the conversion to the ChmNull allele after Cre-
recombination. Lanes 1 and 8 were untreated cells, while lanes 2 and 9 were DMSO and 
EtOH treated cells (without TM); which served as a control for the TM treatment and 
dosage. Lanes 14 and 15 served as positive and negative control for the PCR reaction. 
Lane 7 is empty. Results are representative of five independent experiments. L: 100bp 
ladder (Invitrogen). 
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Figure 57:   PCR analysis of the ChmWT, ChmFlox and ChmNull alleles following 
tamoxifen induction of isolated primary fibroblasts (Generation of KO CHM 
fibroblasts) 
(B)(i) The same ChmFlox Cre+ (Flox, Cre+) cells at passage 3 (from Figure 57Aii) were also 
maintained in normal medium (after the initial 48 hours of TM treatment) and analysed 
again at passage 11 for the permanent conversion to the ChmNull  allele. Results are 
representative of five independent experiments. L: 100bp ladder (Invitrogen). 
 
The TM-treated ChmFlox cells were also analysed by Western analysis at 48 hours after TM 
treatment to further validate the extent of the null genotype / KO of mouse REP1 protein 
levels in these cells. Briefly, total protein was isolated from TM treated mouse fibroblasts 
and analysed by Western blot using an anti-rabbit J905 antibody which recognises human 
and mouse REP1, and secondary conjugated anti-rabbit IgG.  
Figure 58 validates the PCR analysis of TM treated Flox, Cre+ cells, and shows that cells 
treated with either 5 or 10 µM TM (dissolved in EtOH) have the most effective knockdown 
of mouse REP1 protein levels. When the percentage of REP1 protein in the TM treated cells 
was compared to the untreated Flox, Cre+ cells, approximately 37.9% and 25.2% 
(corresponding to 5 or 10 µM TM respectively regardless of whether TM was dissolved in 
EtOH or DMSO) of REP1 protein was still present in the ChmFlox cells. Repeated treatments 
with TM reduce this percentage further to make even better substantial knockout cells (data 
not shown). 
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Figure 58:   Western analysis of REP1 protein knockdown in ChmFlox Cre+ and 
ChmFlox Cre- cells by tamoxifen treatment (Generation of KO CHM fibroblasts) 
Primary fibroblasts (A) ChmFlox+ Cre+  (Flox, Cre+) or (B) ChmFlox- Cre- (Flox, Cre-) cells 
were treated with 0-10 µM Tamoxifen (TM) dissolved in either EtOH (lanes 2-4) or 
DMSO (lanes 5-7). The reduction of endogenous (mouse) REP1 protein levels were 
analysed by Western analysis of cell pellets (50 µg) 48 hours post-TM treatment, using 
anti-REP1 antibody J905, which recognises both human and mouse Rep1 as well as 
Rep2 protein. Levels of REP1 protein were quantified in the analysed cell pellets 
comparing untreated and TM-treated cells (right graph). Error bars represent the 
standard error of the means (s.e.m.). REP1 protein levels were approximately reduced 
to 37.9% ± 13.4 and 25.2% ± 9.7 when treated 5 and 10 µM TM respectively. Untreated 
cells (lane 1) as well as cells treated with DMSO or EtOH alone (lanes 4 and 7 
respectively) served as negative controls as did the Flox, Cre- cells. Human Rep1 protein 
(50 ng) (lane 8) served as a positive control and α-tubulin was used as a loading control. 
Results are representative of three independent experiments.  
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3.2.11.2 Transient transfection of human and mouse fibroblasts  
 
Once we had established an effective method of isolating and creating knockout mouse 
fibroblasts, we hoped to use the human and mouse KO cell lines in parallel experiments to 
show the functionality of the pCAG-REP1 vector in restoring the expression of REP1 protein 
levels in these cells. The pCAG-REP1 vector was chosen (rather than pEFS-REP1) as this 
plasmid has higher REP1 transgene expression levels, as shown in Figure 49.     
Initial experiments involved the transfection optimisation of CHM4 cells with pEPI-GFP 
vector. Previously published reports show efficient transfection of primary fibroblasts with 
the chemical transfection reagents including: Fugene, Lipofectamine, Lipofectamine 2000, 
Calcium Phosphate and linear polyethylenimine (PEI). Therefore based on this, human 
CHM4 cells were initially plated onto either 6 or 12-well plates and individually transfected 
with the transfection reagents mentioned above according to the manufacturers 
recommendations. The expression of EGFP was analysed in transfected cells after 48 hours 
by FACS analysis. Figure 59 shows that conventional transfection reagents such as Fugene, 
Lipofectamine 2000 and Calcium Phosphate did not efficiently transfect human CHM4 cells 
with only 7.2% ± 0.45, 5.8 % ± 0.26 and 8.4% ± 0.32 of cells showing EGFP expression levels 
respectively. The highest levels of EGFP expression were seen in cells transfected with the 
cationic polymer PEI; with 12.2% ± 0.29 of cells showing EGFP expression (Figure 59D). 
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Figure 59:   FACS analysis of EGFP expression in CHM4 human fibroblast cells 48 
hours post transfection with pEPI-EGFP vector 
CHM4 cells were transfected with pEPI-EGFP using the following transfection reagents:  
(A) Fugene, (B) Lipofectamine 2000, (C) Calcium Phoshate or (D) PEI and showed 7.2%, 
5.8%, 8.4% and 12.2% EGFP expression levels respectively by FACS analysis after 48 
hours. PEI transfection of CHM4 cells resulted in the highest EGFP expression levels.     
In all cases, histograms show measured events (y axis) against levels of EGFP 
fluorescence in the FL1-H channel (x axis). Untransfected CHM4 cells served as a 
negative control and appear as a pink graph on the left side of the histogram, while cells 
expressing EGFP appear green (as an overlay). Gated cells expressing EGFP are 
expressed as a percentage (%) of the total untransfected population – a threshold of 1% 
untransfected cells was always set - and appear above the bracketed histogram regions.  
AtT20 and/or B16-F10 cells were included as positive controls with all transfection 
reagents (data not shown). Percentages are mean values from four (or three for (B)) 
independent experiments ± standard error of the means (s.e.m.).   
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Similar disappointing and low levels of transfection were also observed in the mouse Flox, 
Cre+ cells (data not shown). As these low levels of transfection were deemed unacceptable, 
mechanical transfection in the form of AMAXA nucleofection was employed to efficiently 
transfect the mouse (Flox, Cre+) and human (CHM4) cells. AMAXA transfection is a non-viral 
approach to transfect difficult-to-transfect cell lines using a combination of specific electrical 
pulses as well as cell-type specific solutions to transfect DNA directly into the nucleus of 
cells. Furthermore AMAXA transfection does not require cell division for the transfer of DNA 
into the nucleus. This was deemed particularly important for CHM4 cells as they appeared 
to have a very slow doubling rate (personal observations). Hence perhaps this slow growth 
rate could account for the low transfection efficiency observed with the normal 
chemical/non-viral transfection methods employed above, which rely on cell division for the 
transfer of DNA into the nucleus.  
AMAXA transfections were optimised using the basic fibroblast AMAXA kit. During the 
optimisation process a range of programmes were used as well as varying the concentration 
of pDNA and cell density. Optimisation was based on viability and transgene expression 
levels. In summary 5x105 cells were used per reaction, with 20 µg pCAG-REP1 vector, using 
programmes P32, P24 and Q32 for CHM4 KO cells and programmes Q32, U23 and W32 for 
of Flox, Cre+ KO cells. Only low passaged cells were transfected as this minimised cell death 
following AMAXA transfection. One day following transfection, cells were fixed and stained 
for REP1 expression by FACS analysis. Figure 60 shows representative expression observed 
at 24 hours for REP1 in CHM4 and Flox, Cre+ cells transfected with pCAG-REP1 vector. 
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Figure 60:   Efficient FACS analysis of REP1 expression in human and mouse CHM 
KO fibroblasts 24 hours post transfection with pCAG-REP1 vector 
Both KO (A) Human CHM4 cells and (B) Mouse Flox, Cre+ (+TM) cells were transfected 
with 20 µg of pCAG-REP1 vector using AMAXA nucleofection. Cells were fixed and REP1 
expression levels were analysed by FACS analysis after 24 hours using an anti-Rep1 
antibody 2F1 which recognises human Rep1 protein. Levels of REP1 expression varied 
from 30.7 % (for programme P32 – top left histogram) and 26.7% (for programme P24- 
top right histogram) for human fibroblasts and 25.7% (for programme Q32 – bottom left 
histogram) and 22.1% (for programme U23 – bottom left histogram) for mouse 
fibroblasts depending on the transfection programme chosen. Programme P32 and Q32 
resulted in the highest REP1 expression levels in human and mouse fibroblasts 
respectively.  
In all cases, histograms show measured events (y axis) against levels of REP1 
fluorescence in the FL4-H channel (x axis). Untransfected CHM4 (top histograms) or  
Flox + (bottom histograms) cells served as a negative control and appear as a purple 
graph on the left side of the histogram, while cells expressing REP1 appear green (as an 
overlay). Gated cells expressing REP1 are expressed as a percentage (%) of the total 
untransfected population – a threshold of 1% untransfected cells was always set - and 
appear above the bracketed histogram regions. Percentages are mean values from four 
independent experiments ± standard error of the means (s.e.m.). +TM= Treatment with 
tamoxifen (TM). 
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After 24 hours following AMAXA transfection with the pCAG-REP1 vector, cells were also 
fixed and REP1 expression was further confirmed by immunofluorescence of transfected 
cells using the REP1 antibody 2F1 which recognises only human REP1 protein. Untransfected 
Flox, Cre+ fibroblasts were also stained with J905 antibody which recognises both human 
and mouse REP1 protein. This was carried out to show the extent of mouse REP1 which was 
still present in the cells despite TM treatment. Figure 61A and B show representative images 
of pCAG-REP1 transfected CHM4 cells and mouse TM-treated Flox, Cre+ fibroblasts 
respectively. This shows that pCAG-REP1 was able to mediate strong levels of REP1 
expression in both cell lines following transfections with two different AMAXA programmes 
(programmes P32 and P24 for human cells, or Q32 and U23 for mouse cells). Importantly, 
Flox, Cre+ fibroblasts stained with J905 antibody showed limited staining (Figure 61B (iii)) 
confirming that the TM treatment and the subsequent KO event was successful and that 
limited mouse REP1 protein was still present in these cells.  
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Figure 61:   Expression from pCAG-REP1 following AMAXA transfection of human 
and mouse CHM KO cells 
(A) Human CHM4 cells were AMAXA transfected with 20 µg of pCAG-REP1 vector. After 
24 hours, cells were fixed and to detect REP1 expression, cells were incubated with 
mouse REP1 antibody (2F1) which recognises human REP1 protein only, followed by 
anti-mouse 488 conjugated secondary antibody. Dapi was also added to stain the nuclei 
blue for easier distinction of cells. Representative images are shown for AMAXA 
transfections with programmes (i) P32 and (ii) P24 as well as (iii) untransfected cells. 
Bright field (left panel), fluorescent (middle) and merge images with Dapi (right) at 40x 
magnification are shown. Images are representative of three independent experiments. 
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Figure 61:   Expression from pCAG-REP1 following AMAXA transfection of human 
and mouse CHM KO cells  
(B) Mouse fibroblasts were isolated from Flox, Cre+ pups between 1-4 days after birth. 
Once confluent, cells were treated with 10 µM TM to induce the knock-down/KO of 
REP1 protein in the cells. Following successful knock-down/KO, mouse CHM KO cells 
were AMAXA transfected with 20 µg of pCAG-REP1 vector. After 24 hours, cells were 
fixed and to detect REP1 expression, cells were incubated with mouse REP1 antibody 
(2F1) which recognises human REP1 protein only or J905 antibody for untransfected 
cells, which recognises both mouse and human REP1 protein. This was followed by 
either anti-mouse or rabbit Alexa 488-conjugated secondary antibody. Dapi was also 
added to stain the nuclei blue for easier distinction of cells. Representative images are 
shown for AMAXA transfections with programmes (i) Q32 and (ii) U23 as well as (iii) 
untransfected TM+ cells. Bright field (left panel), fluorescent (middle) and merge images 
with Dapi (right) at 40x magnification are shown. Images are representative of three 
independent experiments. +TM= Treatment with tamoxifen (TM). 
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3.2.11.3 Long-term expression of REP1 in human and mouse fibroblasts  
 
To investigate if the pCAG-REP1 vector could maintain extra-chromosomal stability similar 
to the results shown for the same plasmids (as well as the pEFS-EGFP and pCAG-EGFP 
vectors) in AtT20 cells, long-term analysis was also carried out in the mouse and human KO 
fibroblasts. Hence cells were AMAXA transfected with pCAG-REP1 vector and 48 hours 
following transfection cells were placed in G418 selective medium for 2 weeks. Antibiotic 
resistant clones were then isolated and cultured in normal medium for a further 4 weeks 
after which Western blot analysis was performed. This showed whether the expression of 
REP1 was sustained and as colonies were not maintained in G418 antibiotic medium, the 
expression of REP1 was also analysed for mitotic stability in the absence of selection 
pressure. No clear colonies grew following the transfected with pCAG-REP1-Control vector. 
Similar results were also seen with the long-term analysis of pCAG-REP1 and its control 
counterpart in AtT20 cells. Hence as before, control plasmids did not survive the prolonged 
selection procedure as these cells lacked the S/MAR element, and so were only transiently 
resistant to the G418 antibiotic and so were not able to be permanently established.   
Western blot analysis was performed to confirm REP1 expression at 6 weeks post 
transfection. Briefly, total protein lysates were isolated from 2 colonies after transfection 
with pCAG-REP1 vector and analysed by Western blotting, probing with antibodies for REP1; 
2F1 (for the human CHM4 cells ) or J905 (for the mouse Flox cells). Figure 62 shows 
representative Western blots showing that REP1 protein expression was maintained for up 
to 6 weeks in both human and mouse KO cell lines. In a complimentary experiment, in 
parallel with Western analysis at 6 weeks post transfection, cells were also analysed by FACS 
analysis for REP1 expression. Indeed as shown by Figure 63, levels of REP1 protein are 
undiminished in both cell lines at 6 weeks post transfection.   
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Figure 62:   Western analysis of long-term pCAG-REP1 vector expression in CHM 
KO cells 
Primary KO fibroblasts from (i) Human CHM4 cells and (B)(i) Mouse TM-treated  
ChmFlox+ Cre+ cells (CHM KO) were AMAXA transfected with 20 µg of pCAG-REP1 vector. 
48 hours following transfection, cells were maintained in G418 selection medium for 2 
weeks, after which isolated clones were picked and grown for a following 4 weeks in 
normal medium without G418 antibiotic. Cell lysates (50 µg) were collected from two 
isolated clones each for human and mouse KO cells at 24 hours and 6 weeks after 
transfection. Lysates were then analysed by Western analysis for the expression of 
REP1 protein using anti-Rep1 antibody J905 for mouse cell lysates – as this antibody 
recognises both human and mouse Rep1 – or 2F1 antibody for human cell lysates – as 
this antibody specifically recognises only human REP1. Lanes 1 and 3 as well as lanes 2 
and 4 on (i) represent clone 1 and 2 respectively. Lanes 1-5 as well as lanes 6-9 on (ii) 
represent clone 1 and 2 respectively. Untransfected fibroblasts served as a negative 
control in human KO cells (lane 5), while untransduced/WT cells not dosed with TM 
and cells treated with tamoxifen but not transfected with pCAG-REP1 served as negative 
controls in mouse KO cells (lanes 1, 3, 5, 6 and 8). Human Rep1 protein was used as a 
positive control and α-tubulin was used as a loading control. Results are representative 
of three independent experiments. +TM= Treatment with tamoxifen (TM). 
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Figure 63:   FACS analysis of long-term pCAG-REP1 vector expression in CHM KO 
cells 
At 6 weeks post transfection (i) Human CHM4 cells and (ii) Mouse TM-treated ChmFlox+ 
Cre+ cells (CHM KO) cells were also fixed and REP1 expression levels were analysed by 
FACS analysis using an anti-Rep1 antibody 2F1 which recognises human Rep1 protein. 
Levels of REP1 expression varied from 22.2% and 21.3% for human fibroblasts 
(corresponding to transfection with AMAXA programmes P32 and P24 - top left and 
right histograms respectively) and  20.2% and 18.2% for mouse fibroblasts 
(corresponding to transfection with AMAXA programmes Q32 and U23 - bottom left and 
right histograms respectively). This showed that levels of REP1 were not diminished 
after 6 weeks in vitro.  
In all cases, histograms show measured events (y axis) against levels of REP1 
fluorescence in the FL4-H channel (x axis). Untransfected CHM4 (top histograms) or  
Flox + (bottom histograms) cells served as a negative control and appear as a purple 
graph on the left side of the histogram, while cells expressing REP1 appear green (as an 
overlay). Gated cells expressing REP1 are expressed as a percentage (%) of the total 
untransfected population – a threshold of 1% untransfected cells was always set - and 
appear above the bracketed histogram regions. Percentages are mean values from three 
independent experiments ± standard error of the means (s.e.m.). +TM= Treatment with 
tamoxifen (TM). 
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Total DNA was also isolated from CHM KO cells transfected with pCAG-REP1 vector. This was 
used to perform analysed by PCR analysis for the presence of pCAG-REP1 pDNA in 
transfected cells up to 6 weeks post transfection. Figure 64 shows the long-term presence of 
pCAG-REP1 pDNA in both mouse and human KO cell lines.  
The persistence of REP1 transcript was also verified in transfected CHM KO cells by the 
isolation of RNA from cell pellets and subsequent rt-PCR analysis. Figure 65 shows that REP1 
mRNA levels were maintained for up to 6 weeks in both cell lines.  
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Figure 64:   PCR detection over time of pCAG-REP1 pDNA in CHM KO cells after 
AMAXA transfection with pCAG-REP1 vector 
PCR analysis of pCAG-REP1 in (A) Human (CHM4 cell line) and (B) Mouse (ChmFlox+ Cre+  
+TM) cells following AMAXA transfection with 20 µg of pCAG-REP1 vector at 24 hours 
and 6 weeks following transfection. AMAXA programmes P24, P32 and Q32 were used 
for human cells, while programmes Q32, U23 and W32 were used for mouse cells. Lanes 
5 and 9 on (A) and lanes 6 and 10 on (B) represent cells transfected with pCAG-REP1-
Control vector at 24 hours and 6 weeks following transfection respectively. PCR 
samples were separated by agarose gel electrophoresis and a positive PCR band was 
observed using CAG-REP1 specific primer set yielding a product size of 430 bp. The 
arrowhead indicates the size 430 bp on (A) and (B). Untransfected cells, untransfected 
and TM dosed as well as no PCR product/water served as a negative control (lane 1 in A 
and B, lanes 2 and 11 in B respectively), while pCAG-REP1 pDNA (25 ng) served as a 
positive control (lane 10 in A, lane 11 in B) for the PCR reaction. Results are 
representative of three independent experiments. +TM= Treatment with tamoxifen 
(TM), L= 100bp ladder (Invitrogen). 
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Figure 65:   RT-PCR analysis over time of REP1 mRNA from CHM KO cells after 
AMAXA transfection with pCAG-REP1 vector 
Total RNA was extracted from (A) Human (CHM4 cell line) and (B) Mouse (ChmFlox+ Cre+  
+TM) cells following AMAXA transfection (with three different programmes) with 20 µg 
of pCAG-REP1 vector at 24 hours and 6 weeks following transfection. AMAXA 
programmes P24, P32 and Q32 were used for human cells, while programmes Q32, U23 
and W32 were used for mouse cells. Lanes 5 and 9 on (A) and lanes 6 and 10 on (B) 
represent cells transfected with pCAG-REP1-Control vector at 24 hours and 6 weeks 
following transfection respectively. Total RNA was isolated and used to generate cDNA. 
PCR was performed with human REP1 specific primers to yield a product size of 240 bp 
as indicated by the arrowhead on (A) and (B). RNA from untransfected cells, 
untransfected and TM dosed as well as no RNA product/ water served as a negative 
control (lane 1 in A and B, lanes 2 and 11 in B respectively), while RNA isolated from 
AtT20 cells transfected with pCAG-REP1 after 48 hours served as a positive control 
(lane 10 in A, lane 12 in B) for the rt-PCR reaction. Results are representative of three 
independent experiments. +TM= Treatment with tamoxifen (TM), L= 100bp ladder 
(Invitrogen). 
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3.2.11.4 Episomal status of stable human and mouse cell lines   
 
To trace the presence of pCAG-REP1 at 6 weeks post transfection in both mouse and human 
CHM KO cells, plasmid rescue was performed whereby E.coli bacterial cells were 
transformed with 1 µg of total DNA isolated from 5x105 cells, at 6 weeks post-transfection. 
Cells showing the highest levels of pCAG-REP1 after transfection of mouse and human cells 
were picked; human cells transfected with P32 programme, and mouse cells transfected 
with Q32 programme. Kanamycin resistant colonies were obtained after 24 hours at a rate 
of 4-5 colonies per plate, which indicates a low plasmid copy number of pCAG-REP1 plasmid 
in both KO cell lines. Plasmid DNA was extracted from 6 antibiotic resistant clones and 
digested with EcoRV restriction enzyme and analysed by gel electrophoresis (Figure 66). All 
clones have the same bands as the original pCAG-REP1, confirming the presence of an intact 
episomal plasmid in both CHM KO cell lines.  
In a complimentary approach, the episomal state of pCAG-REP1 was also analysed by 
Southern blot analysis. Total cellular DNA (10 µg) was isolated from the two long-term 
clones from both cell lines and digested with StuI restriction enzyme - which linearises  
pCAG-REP1 plasmid - and hybridised with a 32P-labelled AlwNI fragment as a probe. As 
shown in Figure 67 the hybridisation pattern clearly confirms the episomal state of  
pCAG-REP1 vector in the CHM KO cell lines. In all clones analysed, a distinct band identical in 
size to the original pCAG-REP1 plasmids (+) is seen. 
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Figure 66:   Plasmid rescue of pCAG-REP1 vector isolated from CHM KO cells 
Plasmid rescue analysis of pDNA isolated from 6 randomly chosen clones (lanes 1-6). 
Clones were generated following the transformation of E.coli bacteria with 1 µg of total 
DNA isolated from CHM (A) Mouse (ChmFlox+ Cre+ TM+) cells and (B) Human (CHM4 cell 
line) KO cells 6 weeks following transfection with pCAG-REP1 vector, as described in 
the text. Undigested plasmid served as a negative control (-), while all bands show 
identical sizes with the positive control of original pCAG-REP1 plasmid respectively (+), 
demonstrating the episomal status pCAG-REP1 vector in CHM KO cells. Results are 
representative of four independent experiments. +TM= Treatment with tamoxifen (TM), 
L: 1 kb Ladder (Invitrogen). 
 
 
 
 
 
 
 
 
 
 
 
Figure 67:   Southern blot analysis of the episomal status of pCAG-REP1 vector 
isolated from CHM KO cells 
Southern blots of total DNA isolated from two clones of CHM Mouse (ChmFlox+ Cre+ TM+) 
and Human (CHM4 cell line) KO cells transfected with pCAG-REP1 vector at 6 weeks 
following transfection, cultured in normal medium. DNA (10 µg) was separated on 0.8% 
agarose gels and hybridized with 32P-labelled AlwNI probe. Lanes 1-2, StuI digested total 
DNA, from Human KO cells, while lanes 3-4, StuI digested total DNA, from Mouse KO 
cells. All clones produced a clear distinct band after StuI digestion, identical to the band 
arising after digestion of 8 ng of corresponding positive control original pDNA  
pCAG-REP1; (+). Results are representative of three independent experiments. L: 1 Kb 
ladder (Invitrogen). 
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3.2.11.5 Correction and in vitro prenylation analysis of stable human and mouse cell 
lines   
 
Previously it has been reported that the lack of REP1 function in (cells isolated from) CHM 
patients caused defects in Rab prenylation in isolated cells from these patients; namely 
Rab27a prenylation defects (Seabra, Ho et al. 1995). Hence we were eager to analyse if by 
transfecting pCAG-REP1 vector into the CHM KO cells – both human and mouse KO cells 
described earlier - we were able to provide correction for the prenylation defect seen in 
these cells. In order to analyse the maximum amount of prenylation correction, CHM KO 
stable cells expressing the highest amounts of REP1 transgene levels at 6 weeks post 
transfection were used, as described in the previous section 3.2.11.3 and Figure 63 (Human 
and Mouse KO cells transfected with P32 and Q32 AMAXA programmes).  
To this end, CHM stable KO human and mouse cells at 6 weeks post transfection with  
pCAG-REP1 vector were analysed for the prenylation status of Rab27a in these cells by 
subcellular fractionation and subsequent Western blot analysis as previously described 
(Seabra, Ho et al. 1995; Anand, Barral et al. 2003; Tolmachova, Anders et al. 2006). Briefly, 
CHM KO cells were transfected with pCAG-REP1 vector and total protein lysates from 
transfected cells at 6 weeks post transfection were subjected to subcellular fractionation.  
This allowed the separation of soluble (S) and pellet (P) fractions from the cells were 
analysed by Western blot probing with an anti-Rab27a antibody 4B12. In wild-type cells one 
would expect normally prenylated Rab27a protein to be found in the pellet fraction of cells. 
In contrast CHM cells which have a defect in Rab27a prenylation should have approximately 
50% of the protein in the cytosolic fraction. This is because without prenyl groups, Rabs 
cannot associate with membranes and so remain cytosolic and dysfunctional. Upon 
transfection of CHM KO cells with pCAG-REP1, one would expect to observe a similar 
pattern to that of wild-type cells if the CHM KO cells have been rescued by the transfection 
of pCAG-REP1 plasmid. 
Figure 68 shows the corresponding Western blot carried out on long-term expressing CHM 
KO cells transfected with pCAG-REP1 vector. The blot shows higher levels of Rab27a protein 
in the pellet fraction compare to cytosolic fraction of untransfected Flox, Cre+ cells prior to 
TM treatment (lanes 1 and 2 respectively in Figure 68B). Hence these cells closely resemble 
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wild-type cells. In contrast, when the untransfected Flox, Cre+ cells are treated with TM 
(10 µM), a shift in the expression levels of Rab27a is seen, where approximately 50% of the 
protein is now in the pellet fraction as well as the cytosolic fraction (lanes 3 and 4 
respectively in Figure 68B). This confirms the knock-down of REP1 in the cells by TM 
treatment, where cells now show the expected defect in prenylation of Rab27a observed in 
CHM cells. Similarly untransfected human KO cells also show an equal amount of Rab27a 
protein in both cytosolic and pellet fractions analysed reminiscent of the CHM KO 
phenotype (lanes 1 and 2 respectively in Figure 68A). Excitingly, when one compares the 
pellet and cytosolic fractions of transfected human KO cells, a clear reduction of Rab27a 
protein levels is observed in the cytosolic fraction (lanes 3 and 4 respectively in Figure 68A). 
Similarly reduced levels of Rab27a protein are also observed when comparing the pellet and 
cytosolic fractions of transfected mouse Flox, Cre+ (+TM dosed) KO cells (lanes 5 and 6 
respectively in Figure 68B).  
Both these shifts in the cytosolic fraction of Rab27a protein expression shows that Rab27a is 
able to be correctly prenylated in these cells following the transfection of pCAG-REP1 
plasmid. Hence within these cells, Rab27a protein is able to be correctly targeted to 
intracellular membranes and in turn the phenotypic (functional) rescue of this protein is 
observed. 
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Figure 68:   Western analysis showing the phenotypic rescue of Rab27a protein 
function in CHM KO cells transfected with pCAG-REP1 vector 
Total protein lysates were isolated from (A) Human (CHM4 cell line) and (B) Mouse  
(ChmFlox+ Cre+ TM+) cells 6 weeks following AMAXA transfection with pCAG-REP1 
vector (corresponding to transfection with programmes P32 and Q32 for human and 
mouse cells respectively). Lysates (25 µg) were subjected to subcellular fractionation, 
where soluble (S) and pellet (P) fractions were analysed by Western analysis and 
probed with anti-Rab27a antibody 4B12. Untransfected human cells (lanes 1 and 2) as 
well as untransfected mouse cells (- TM and +TM lanes 1-2 and 3-4 respectively) were 
used as a control for the subcellular fractionation. Rab11 was used as a loading control.  
+TM= Treatment with tamoxifen (TM). Results are representative of one experiment.  
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In conclusion after the 6 weeks of cultivation and long-term analysis of pCAG-REP1 vector in 
CHM KO cells, it is clear that pCAG-REP1 was not only able to maintained active 
transcription of the REP1 gene in wild-type cells, but also in human and mouse CHM KO 
cells. Indeed REP1 protein and mRNA levels as well as pCAG-REP1 pDNA levels remained 
stable during this period as analysed by Western blot, PCR and rt-PCR analysis. Furthermore 
pCAG-REP1 vector was also able to maintain itself as an active episome, as shown by 
plasmid rescue experiments. Despite both mouse and human KO cells only expressing 
moderate levels of REP1 protein (~ 20% transfection efficiency at 6 weeks post transfection), 
we were able to show the correction of the CHM phenotype. Specifically we observed 
considerable correction of the Rab27a prenylation defect in these cells following the 
transfection of pCAG-REP1 plasmid.  
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3.3 Optimisation of EGFP and Luc plasmid delivery in vivo 
 
During the period of vector cloning and optimisation we were also able to obtain an S/MAR 
plasmid vector containing the Luciferase gene driven by either the Ubiquitin-C, 
cytomegalovirus (CMV) or cytomegalovirus (CMV) early enhancer/chicken beta actin (CAG) 
promoter from Professor Hans Lipps, University of Witten, Germany, pUbiqC-Luc, pEPI-Luc 
and pCAG-Luc plasmids respectively. All plasmids were based on the pEPI-EGFP plasmid, 
hence there was either an Ubiquitin-C or CAG promoter inserted in place of the CMV 
promoter upstream of the S/MAR region followed by a luciferase transgene instead of the 
EGFP transgene.  
While the two plasmids pCAG-Luc and pCAG-EGFP are comparable, both plasmids were 
used for in vivo experiments to infer results that complemented one another. Hence for 
monitoring of long-term transgene expression within the same mouse it was deemed that 
the luciferase expressing plasmid pCAG-Luc would be most appropriate. This was because 
bioluminescent imaging of the same mouse could be done non-invasively as described 
previously for many organs within the mouse including the eye (Chalberg, Genise et al. 
2005). Similarly the EGFP expressing plasmid pCAG-EGFP would be most appropriate where 
histological analysis of EGFP transgene expression within the retina could be done. This was 
because standardised protocols have been established within our laboratory for EGFP 
expressing viral vectors (Tolmachova, Wavre-Shapton et al. 2010). Furthermore one could 
also draw upon experimental outcomes of the pCAG-EGFP and pEFS-EGFP plasmids as they 
both possessed similar plasmid backbones to the pCAG-REP1 plasmid. Hence any limitations 
or successes of either plasmid in vivo in WT mice could be corroborated and one could 
assume a similar fate for the pCAG-REP1 plasmid in vivo in WT and CHM mice.  
The pUbiqC-Luc plasmid also offered us the opportunity to test an additional plasmid 
harbouring a ubiquitously expressing mammalian/eukaryotic promoter in vivo. This allows 
us to draw upon the possibility of differences in transgene expression levels between 
commonly used ubiquitous eukaryotic/mammalian promoters. Such promoters included the 
elongation factor-1 short (EFS) and UbiqC – as well as promoters of a viral origin – including 
immediate early cytomegalovirus (CMV) and CAG.  
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Previously, Argyros et al. in 2008 found that the long-term luciferase transgene expression 
of an S/MAR plasmid in vivo was due to the synergy between a tissue specific promoter 
(alpha-1 antitrypsin - AAT) and the S/MAR element (Argyros, Wong et al. 2008). We were 
interested to see if this synergistic effect was exclusive to tissue specific promoters or 
indeed non-tissue specific promoters could also yield such long-term expression levels  
in vivo.  
 
3.3.1 Injection strategy for gene delivery to the eye – Subretinal injections 
 
Within the eye one of the most appropriate delivery routes to the RPE and photoreceptor 
cells is arguably through subretinal injections; whereby vector suspensions are placed in the 
(potential) space/plasma membrane between the photoreceptors and RPE cells. While this 
technique has been successfully employed for delivery in numerous animal models of ocular 
diseases (Liu,Tuo et al. 2011), the actual procedure within the literature remains varied.  
Numerous approaches have been described including injections via a transcorneal/ 
transvitreal route (Timmers, Zhang et al. 2001; Johnson, Berglin et al. 2008), transscleral 
route (Price, Turner et al. 1987) as well as transscleral-transchoroidal-Bruch’s membrane 
route (Gekeler, Kobuch et al. 2004; Gerding 2007).  
During our initial experimental set up for our in vivo subretinal injections (in WT/MF1 mice), 
we developed an optimised and improved method. We found this method the most 
consistent; whereby we standardized the method of Timmers et al as well as Johnson et al 
(Timmers, Zhang et al. 2001; Johnson, Berglin et al. 2008). Figure 69 shows images of the 
single as well as double subretinal injection technique. A video of the single surgical 
procedure is also submitted with this study (found on the back cover of this thesis). 
Throughout the results injections in the C57BL/6 mouse strain were initially performed by 
Dr Tanya Tolmachova; however some injections were also performed by Dr Mariya 
Moosajee. While all MF1 and CHM mouse injections were performed by Dr Mariya 
Moosajee.    
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Figure 69: Illustrations of the subretinal injection procedure/technique 
Illustrated above are representative pictures (as well as accompanying videos) of the 
single and double subretinal injections carried out in MF1 mice. Mice were anesthetized 
and the subretinal injections were performed using a dissecting microscope. (A) The 
pupil was dilated with tropicamide. Inset shows the pupil prior to dilation. (B) A drop of 
VidisicR carbomer eye gel was place on the eye and (C) a microscope coverslip was 
placed onto the gel such that the fundus including its blood vessels were readily seen 
and examined. (D) The limbus of the eye was grasped gently with forceps and a 33 
gauge bevelled needle was used to cut through the cornea near the limbus. This panel 
shows the positioning of the 33 gauge needle in the centre of the anterior chamber. (E) 
The needle tip was then advanced to the retina opposite the puncture site where it 
penetrates the neural retina into the subretinal space. (F) The needle was removed after 
the injection procedure and the fundus was examined immediately following the 
subretinal injection. For illustrative purposes a blue dye was used to subretinally inject 
into the retina and the fundus image clearly show the presence of a single bleb or (G) 
using the same technique a picture of a single bleb following injection of formulated 
pDNA is also shown. The mouse was also injected again at the opposite site of the first 
injection; representative fundus images illustrating the presence of two blebs following 
the double subretinal injection of (H) blue dye and (I) pDNA are also shown. The imaged 
mouse eyes are approximately 3 mm in diameter. Blood vessels and fundus images are 
seen clearer on digital images.     
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3.3.1.1 Signs of a successful procedure 
 
One of the easiest and quickest methods employed to monitor a successful subretinal 
injection procedure was the careful fundus examination directly through a dissecting 
microscope. This was done prior to the start of the injection procedure, to monitor any 
abnormalities within the retina but more importantly the fundus of all the mice was also 
evaluated immediately following the injection. The presence of a clear single or double bleb 
underlying the neural retina was often the best indication of a successful single or double 
subretinal injection. The presence of a clear bleb showed that the injected formulated pDNA 
had successfully inflated the subretinal space as well as showing that the pDNA was 
confined within this region of the eye. Mice which did not observed a clear bleb where not 
included in any experimental groups, and were often observed to have a damaged retina 
either prior to the injection procedure due to a genetic abnormality or through a 
complication during the actual procedure. All blebs raised by injection into the subretinal 
space regressed with 24-48 hours following injection. As a result of the method of 
anaesthesias employed during the injection procedure (injectable anaesthesia as opposed 
to inhalation anaesthesia), mice were observed to be more prone to bleeding (personal 
observations when comparing procedure outcomes using the different anaesthesias above). 
Hence where the bleeding in the retina was confined to the small site of needle insertion, 
these mice were still classed as a successful and included within experiments. However 
when the bleeding was more comprehensive - spanning into the vitreous body - or if the 
lens was nicked during the injection procedure, these mice were not included in 
experimental groups.    
 
3.3.1.2 Potential problems during the procedure 
 
While the video (accompanying this thesis) and illustrations in Figure 69 highlight the 
successes and correct technique used for the subretinal injection procedure, a number of 
potential problems were also encountered during the optimisation process. The common 
problems we met are highlighted within Table 3 where potential solutions and approaches 
we employed to combat these problems are also shown.  
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Table 3: Potential problems associated with the subretinal injection procedure.  
The table below summarises the main problems encountered during the optimisation 
process and techniques developed for the subretinal injection of the adult mouse eye. 
Problem Potential causes Potential solutions 
Difficulty with 
injection 
procedure  
-Technically demanding 
procedure to achieve alone – 
positioning needle accurately & 
stably in retina while pressing 
down on the syringe to release 
the delivery solution into the 
subretinal space, without moving 
the needle out of position 
-Needle mounted onto tubing to 
allow surgeon to advance it into 
place & assistant to inject the 
correct amount of material from 
the syringe when surgeon ready –
minimised movement & damage  
-Purchase of a foot-pedal 
operated microinjector pump 
Haemorrhage 
or significant 
blood in the 
eye 
- Blunt needle used during the 
procedure - retina nicked causing 
a hole in the retina 
- In house sharp needles were 
made. While tips were sharp, they 
were also fragile & prone to 
bending after a few injections 
- Needles were monitored before 
injection & discarded if sharpness 
was compromised 
- Sharp custom ordered needles 
were purchased from Hamilton 
insuring tips were equally sharp & 
had standardised bevels 
Limited blood 
in the eye 
- Needle penetrated through the 
retina into the choroid 
- Ciliary body nicked 
- Advance the needle less into the 
retina 
- Inject closer to the lens 
No clear bleb 
observed 
- Needle did not penetrate 
correctly -injected material leaked 
into the vitreous 
- Retina was torn during the 
insertion of the needle 
- Advance the needle tip further 
into the retina before injecting 
the material 
- Penetrate in a single motion 
without moving once in place 
Bleb poorly 
inflated or  
becomes 
deflated 
- Fluid in the subretinal space 
leaked into the vitreous  
- Volume injected too high 
causing leakage into vitreous 
- Fluid in subretinal space leaked 
out through the first injection site 
- Hold needle in place for 5 sec 
after injection so pressure 
equilibrium reached in retina 
- Inject a maximum of 2 µl per 
eye, <2 µl if mouse is small 
- Ensure the two injection sites 
are far enough apart 
Air bubbles - Injection tubing or solutions not 
efficiently degassed 
- Spin prior to loading syringe 
- Prime tubing & syringe with 
water before loading material 
Lens cloudy - Lens nicked - Avoid the lens 
Cornea cloudy - Cornea was not kept moist 
during the procedure 
- Apply lubrication to eye 
between anaesthesia as well as 
before & after injection 
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3.3.2 Optimisation of luciferase expression in the eye using the bioluminescent 
technique 
 
The cationic polymer polyethylenimine (PEI) has been successfully used for the 
complexation of pDNA and has been shown to efficiently condense pDNA (Dunlap, Maggiet 
al. 1997). Specifically it has been used as a gene transfer agent (GTA) in cell culture as well 
as in vivo using in vivo-jetPEI in a wide variety of tissues including the retina (Liao and Yau 
2007; Boussif, Lezoualc'h et al. 1995). Hence once the procedure for subretinal injections 
was standardised within the mouse retina, the next stage involved the optimisation of 
complexed pDNA with PEI (PEI/DNA) in vivo and the efficient delivery of complexes into the 
retina. 
The amount of in vivo-jetPEI one can use to form a stable cationic complex between itself 
and pDNA is determined by the N/P ratio. This is a measure of the ionic balance of 
complexes; i.e. the number of nitrogen residues of in vivo-jetPEI per phosphate in the 
nucleic acid/DNA. Previously DNA/PEI polyplexes of varying N/P ratio from 8 and 10 have 
been successfully used for gene transfer in vivo. This includes delivery via systemic gene 
transfer in neonatal mice and subsequent transfection in the spleen, liver, lung, heart, brain 
and kidney (Wong, Argyros et al. 2011) as well as transfection of ganglion cells within the 
eye following intravitreal injections in adult mice (Liao and Yau et al 2007). Furthermore 
DNA/PEI polyplexes were also used to aid transfection in vitro in human corneal epithelial 
cells (HCE) (Hornof, Fuente et al. 2008). Despite these studies, to date and to the best of our 
knowledge, subretinal injection of PEI/DNA (or PEI/S/MAR pDNA) to the adult mouse retina 
has not been previously reported using non-viral vectors. Hence to comprehensively 
optimise the expression of pDNA within the retina using in vivo-jetPEI, various N/P ratios of 
PEI/DNA were examined.  
The luciferase expressing plasmid pCAG-Luc was complexed (30 µg) with in vivo-jetPEI at 
N/P ratios varying from 5-9 (based on the manufacturers recommendations for in vivo 
experiments ranging between N/P ratios 6-8), in a 30 µl volume of sterile 5% isotonic 
glucose solution. The PEI/DNA polyplexes were then separately injected (2 µl) into the retina 
of MF1 mice following a single subretinal injection (1 µg of PEI:pCAG-Luc delivered to the 
retina). Luciferase activity in retinal samples was determined 48 hours post injection using a 
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luminometer. Untreated retinas were included as a negative control to determine the 
background levels of luciferase expression in the retina. Results from this experiment are 
shown in Figure 70.  
Luciferase expression from all N/P ratios analysed showed substantially higher levels of 
luciferase expression when compared to control uninjected retinas. This indicates the 
successful transduction of the retina (at 48 hours) following subretinal injections in MF1 
mice. Indeed the success rate of luciferase transduction - irrespective of the N/P ratio used - 
and in turn success rate of the subretinal injection technique was approximately 70% across 
all the groups analysed. Optimal levels of luciferase expression were observed for N/P 8 
injected retinas (3299 ± 37.69 µg/protein). Levels of luciferase expression were 
approximately 73% and 65% lower in N/P 5 (887 ± 82.29 µg/protein) and 6 (1160 ± 196.11 
µg/protein) injected retinas respectively, when compared to N/P 8 retinas (p<0.0001 and 
p<0.001 respectively). In comparison levels of luciferase expression in N/P 7 and 9 injected 
retinas were more similar to one another (2048 ± 140.13 µg/protein and 2141 ± 82.77 
µg/protein respectively); however expression was still approximately 38% and 35% lower 
respectively when compared to N/P 8 retinas (p<0.05).   
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Figure 70: Evaluation of the optimal luciferase expression within the retina 48 
hours following single subretinal injections of PEI/pDNA polyplexes of varying 
N/P ratios 
Plasmid DNA pCAG-Luc (30 µg) was complexed with polyethylenimine (PEI)  
(PEI:pCAG-Luc) at varying N/P ratios of polyplexes (N/P 5-9), and 2 µl (1 µg) of each 
formulation was subretinally injected into the retina of MF1 mice. Retinal homogenates 
were subsequently lysed and analysed using a luminometer 48 hours following 
injection. The bar chart illustrates the quantification of luciferase expression 
represented as µg/protein. Optimal expression was observed in the following order of 
highest expression: N/P 8, 9, 7, 6 and finally 5 (3299 ± 37.69, 2141 ± 82.77, 2048 ± 
140.13, 1160 ± 196.11 and 887 ± 82.29 µg/protein respectively). Uninjected retinas as 
well as retinas from mice not expressing luciferase were used as negative controls. *, ** 
and *** represent statistical significance compared to N/P 8 injected retinas with 
P<0.05, P<0.001 or P<0.0001 respectively, Student’s t test. Results are mean values 
from four to eight independent experiments. Error bars represent the standard error of 
the means (s.e.m.).  
 
We were also eager to investigate the optimal S/MAR pDNA vector that expressed the 
highest levels of Luciferase transgene within the retina following subretinal injections of 
formulated PEI:DNA/ S/MAR polyplexes. Hence we were interested in analysing and 
comparing the luciferase expression from pCAG-Luc pDNA with the expression from other 
S/MAR pDNA vectors containing the Luciferase gene driven by either the Ubiquitin-C or CMV 
promoter. To investigate this, in vivo-jetPEI was formulated with 30 µg of each plasmid 
pCAG-Luc, pUbiqC-Luc and pCMV-Luc, respectively, at an N/P 8 ratio,  in a 30 µl volume as 
described earlier, and separately injected into MF1 mice by a single subretinal injection (1 
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µg of each pDNA was delivered to the retina). Luciferase activity in retinal samples was 
determined 48 hours post injection as performed previously using a luminometer, where 
untreated retinas were included as a negative control. Luciferase expression results are 
shown in Figure 71. 
 
Figure 71: Evaluation of luciferase expression within the retina 48 hours 
following the single subretinal injection of pDNAs with various promoters - UbiqC, 
CMV and CAG – formulated with PEI 
Plasmid DNA pCAG-Luci, pCMV-Luci or pUbiqC-Luci (30 µg) was complexed with PEI 
(N/P 8) and delivered to the retina of MF1 mice following a single subretinal injection 
(2 µl / 1 µg per eye). Retinal homogenates were subsequently lysed and analysed using 
a luminometer 48 hours following injection. The bar chart illustrates the quantification 
of luciferase expression represented as µg/protein. The highest levels of luciferase 
expression were observed in pCAG-Luc, then pCMV-Luc and finally pUbiqC-Luc injected 
retinas (2033 ± 88.6, 1746 ± 36.43 and 803 ± 42.61 µg/protein respectively). Uninjected 
retinas as well as retinas from mice not expressing luciferase were used as negative 
controls. The expression of luciferase within the retina is significantly different between 
pCAG-Luc and pCMV-Luc (* p<0.05, Student’s t test) as well as being highly significantly 
different between pCAG-Luc and pUbiqC-Luc or pCMV-Luc and pUbiqC-Luc (*** 
p<0.0001, Student’s t test). Results are mean values from four to five independent 
experiments. Error bars represent the s.e.m.  
 
We observed that the levels of luciferase expression with all three pDNAs (pCAG-Luc, pCMV-
Luc and pUbiqC-Luc) were clearly higher than the levels of uninjected control samples. 
Where mice were injected but not observed to be expressing luciferase, levels of expression 
were comparable to uninjected control samples. Furthermore the levels of luciferase 
expression between pCAG-Luc and pCMV-Luc injected retinas (2033 ± 88.6 and 1746 ± 36.43 
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µg/protein respectively) were the most similar where levels were approximately 14% lower 
in the pCMV-Luc injected retinas (803 ± 42.61 µg/protein) compared to pCAG-Luc injected 
retinas (p<0.05). In contrast, the luciferase expression from both pDNA (pCAG-Luc and 
pCMV-Luc) injected retinas was considerable higher than the pUbiqC-Luc injected retinas. 
Furthermore approximately 60% lower luciferase expression level was observed in pUbiqC-
Luc injected retinas when compared to pCAG-Luc injected retinas (p<0.0001). Similarly 54% 
lower luciferase expression was observed when pUbiqC-Luc injected retinas were compared 
to pCMV-Luc injected retinas (p<0.0001). Hence the highest levels of luciferase expression 
were observed for formulated pDNAs in the following order: pCAG-Luc > pCMV-Luc > 
pUniqC-Luc.  
 
3.3.3 Standardising the bioluminescent imaging technique for obtaining luciferase 
expression in the eye 
 
To monitor the long-term expression of luciferase within the mouse eye, the in vivo 
bioluminescent imaging (BLI) technique was utilised. BLI is a highly sensitive technique 
which offers an invaluable approach to visualise, measure and monitor over a time course 
transgene expression in vivo of the same animal non-invasively. The mechanism of 
bioluminescence used for in vivo studies is based on the reaction which occurs when a 
luciferase substrate, such as luciferin, is oxidised by the enzyme luciferase, in the presence 
of oxygen, ATP and magnesium ions, to produce an oxidised substrate, such as oxyluciferin, 
and energy in the form of light as shown in Figure 72. This process is very different from 
fluorescence, where an external light is absorbed and then remitted at another wavelength. 
In contrast with BLI, there is no external light source to excite the chemical reaction; hence 
it has very low levels of background as well as the ability to detect weak signals with high 
sensitivity.  
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Figure 72: The mechanism of bioluminescence 
The luciferin substrate is provided externally and is oxidised in the presence of oxygen 
and ATP by the luciferase protein produced from the plasmid DNA. This process results 
in the emission of light photons that are detected by a cooled charged coupled device 
(CCD) camera, as described in the text.  
 
For in vivo studies in mice, in order to observe luciferase expression, the luciferase substrate 
D-luciferin is delivered intraperitoneally (i.p.) into mice and anesthetized animals are 
subsequently imaged for bioluminescence in a light-tight chamber by a cooled, charge-
coupled device (CCD) camera.  
In our studies, luciferase expression was monitored using Xenogen Living Image software 
that allows detection and quantification of expression level as photons/sec/cm2/seradian 
(sr). This software is used broadly due to its simplicity in quantifying photons of light 
emitted and displaying the intensity of luciferase expression from high to low as red to 
purple (seen in Figure 73).  
To obtain reproducible BLI data, we were initially required to standardise the imaging 
protocol we used in our mice following subretinal injections, including the delay between 
injections and imaging as well as the position of the mice during imaging. To optimise 
luciferase expression, we subretinally injected a standard luciferase expressing plasmid  
(pCAG-Luc) into the retina of an adult MF1 mouse. At 24 hours following injection, a dose of 
300 µl D-luciferin (150 mg/ml) substrate was administered and mice were placed 
immediately onto the warm stage and monitored for expression every two minutes for up 
to 45 minutes after the delivery of luciferin. The results are shown in the Figure 73.  
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Figure 73: Investigating the maximal luciferase expression within the eye 
following subretinal injections 
To determine the maximum luciferase activity in the eye, luciferin was administered i.p. 
to an MF1 mouse at 24 hours following the subretinal injection of formulated pCAG-Luc 
plasmid with PEI (30 µg DNA complexed with PEI (N/P 8)). Bioluminescence was 
measured every 2 minutes as described in the text and quantified using the Xenogen 
Living Image software (given as photons/sec/cm2/sr). (A) The chart shows the 
luciferase activity against time after D-luciferin delivery. Maximum luciferase 
expression was observed between 14-18 minutes after i.p. delivery of Luciferin (n=1). 
(B) The picture shows the MF1 mouse expressing luciferase 24 hours after subretinal 
injection of formulated pCAG-Luc, with the red circle representing the region of interest 
and the area of measurement (seradian). The intensity of luciferase expression is shown 
from high to low (red to purple) as seen on the scale.  
 
We observed maximum luciferase expression at approximately 14-18 minutes after  
D-luciferin administration. Furthermore the maximum expression was observed when mice 
where either laid on their front or the respected side that the eye had been injected on. 
Laying the mice on their backs sometimes caused the position of the retina to become 
obscured. Based on this study, we kept measurements under consistent conditions by 
monitoring luciferase expression at a constant between 14-18 minutes following injection of 
300 µl D-luciferin (150 mg/ml) throughout the project to prevent any irregularities. 
Furthermore during the imaging process, mice were laid on the uninjected side, so that 
injected eyes were above the body, in order to maximise luciferase expression. 
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3.3.4 S/MARs provide long-term luciferase expression in vivo in the eye – BL6 mice 
 
While injections and optimisation of the subretinal injection technique were performed in 
the MF1 mouse strain, we were also interested in performing a longitudinal study to 
measure the expression of luciferase from S/MAR containing pDNAs within the retina of the 
C57BL/6 mouse strain. This was the ultimate strain of interest as all CHM mouse strains 
were also on the C57BL/6 mouse background. Hence longitudinal expression of S/MAR 
pDNAs in the C57BL/6 mouse strain, following subretinal injections, could also imply that 
similar longitudinal REP1 transgene expression were possible in the CHM mouse strains 
using pCAG-REP1 and/or pEFS-REP1 pDNAs. 
As an initial experiment, we were interested in assessing the longitudinal expression of 
S/MAR pDNAs within the retina; hence we chose to use a luciferase expressing pDNA as the 
expression can be easily and non-invasively monitored long term. The pUbiqC-Luc pDNA as 
well as its control pUbiqC-Luc-Control pDNA without an S/MAR element was formulated 
with in vivo-jetPEI (N/P 8) as described earlier, and subretinally injected into the eyes of 
C57BL/6 mice. The longitudinal expression was then monitored at 48 hours and for a total of 
six months at regular intervals using the Xenogen in vivo bioluminometer. Longitudinal 
results from these mice are illustrated for both pUbiqC-Luc and as well pUbiqC-Luc-Control 
pDNA vectors. As a control, mice were also subretinally injected with pEPI-Luc and  
pEPI-Luc-Control (Figure 74A and B).  
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Figure 74: Illustration of luciferase (distribution and) expression in the eye 
following single subretinal injections in C57BL/6 mice over time 
(A) Plasmid DNA pUbiqC-Luci, pUbiqC-Luci-Control, pEPI-Luc and pEPI-Luc-Control (30 
µg) was complexed with PEI (N/P 8) and delivered to the retina of C57BL/6 mice 
following a single subretinal injection (1-2 µl / 0.5-1 µg per eye). All four groups of mice 
were visualised at regular intervals (from 48 hours post subretinal injection) using a 
Xenogen bioimager after intraperitoneal (i.p.) injection of D-Luciferin (15 mg/ml). High 
to low intensity of luciferase expression is graphically shown exclusively within the eye 
area by red to violet colouring. The colour bar indicates relative signal intensity (as 
photons/sec/cm2/sr). The expression of luciferase from pUbiqC-Luc injected mice show 
prolonged expression of luciferase within the retina, while pUbiqC-Luc-Control injected 
mice also show loss of luciferase expression within a month of injection. Luciferase 
expression seen clearer on digital images.   
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Figure 74: Illustration of luciferase (distribution and) expression in the eye 
following single subretinal injections in C57BL/6 mice over time  
(B) The expression promoted by pEPI-Luc and pEPI-Luc-Control is initially considerably 
higher within the retina compared to all other groups of injected mice at one day post 
injection. However, importantly this level of expression drops precipitously over time 
whilst that driven by pUbiqC-Luc is maintained long-term. Thus the S/MAR element 
within this plasmid does not sustain pEPI-Luc expression in the retina.  
 
All pDNA constructs were able to mediate high levels of luciferase transgene expression 
within the retina at 24 hours following subretinal injection. Importantly, no luciferase 
expression was detected outside of the retina. The highest levels of expression at this early 
time point were observed from the pEPI-Luc and pEPI-Luc-Control injected mice. 
Interestingly, thereafter, a rapid decline in transgene expression within the first week of 
injection brings the levels of luciferase from pEPI-Luc and its control to almost background 
levels (uninjected retinas). This rapid decline in expression is not surprising and has been 
observed previously within the retina when the CMV promoter is used. This is primarily due 
to this viral promoter often being subjected to substantial methylation and hence becomes 
switched off in vivo. 
In contrast, while the expression from the pEPI-Luc plasmid was rapidly lost within the first 
week, the remaining non-S/MAR plasmid, pUbiqC-Luc-Control, did not show such an abrupt 
decline in expression immediately after injection. Instead a gradual decline was seen and by 
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1 month following subretinal injections, expression levels in this group had also dropped to 
background levels (uninjected retinas). Finally, pUbiqC-Luc injected mice were the only 
group to be able to mediate stable and persistent levels of transgene expression up to 6 
months following a single subretinal injection. This shows that the absence of the S/MAR 
moiety causes a dramatic difference in expression levels between pUbiqC-Luc and pUbiqC-
Luc-Control plasmids.  
Importantly, this long term expression in C57BL/6 mice after a single subretinal injection of 
an S/MAR plasmid that contains a ubiquitously expressing promoter - pUbiqC-Luc - in vivo 
has never been shown before. This result arguable brings into question the synergy 
observed by Argyros et al. between plasmids containing tissue specific promoters and the 
S/MAR moiety to provide continuous levels of transgene expression in vivo (Argyros, Wong 
et al. 2008). 
While luciferase expression was observed in all groups of C57BL/6 mice examined, 
expression levels were lower than previously published reports showing luciferase 
expression in vivo (Argyros, Wong et al. 2008). Hence we were unable to accurately quantify 
the luciferase expression (using the Xenogen Living Image software) observed in the mice 
examined in Figure 74 as levels appeared to be close to the limit for quantification. The 
combination of low luciferase expression as well as the fact that the C57BL/6 mouse strain is 
highly pigmented within the retina, may have contributed to the limitations of this mouse 
strain at this stage within our experimental optimisation.  
 
3.3.4.1 S/MARs provide expression in the RPE cells of injected retina 
 
While the distribution of luciferase within all subretinally injected mice appears to be 
limited primarily to the eyes - as seen by Figure 74 - we were also eager to analyse the 
specific tissue distribution of luciferase transgene expression within the eye by 
immunohistochemistry. Eyes were enucleated 1 week following the subretinal injection of 
pUbiqC-Luc, where mice were shown to be expressing luciferase by imaging on the Xenogen 
bioimager prior to enucleating. This length of time allowed the bleb within the retina to 
reabsorb and the neural retina to re-attach to the RPE layer. Both paraffin-imbedded as well 
as frozen sections were collected and stained for luciferase detection using a rabbit 
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monoclonal luciferase antibody (Santa Cruz). While all mice prior to histology analysis 
showed clear luciferase expression when imaged on the Xenogen in vivo bioluminometer, 
no luciferase positive staining was observed in any sections analysed by 
immunohistochemistry (data not shown).  
In a similar approach, C57BL/6 mice were also subretinally injected with pEFS-EGFP plasmid. 
At 1 week post injection, frozen as well as paraffin-imbedded sections were also analysed by 
immunohistochemistry detection of EGFP using a rabbit polyclonal EGFP primary antibody 
(Abcam). Similar to the luciferase immunohistochemistry analysis, no difference in the 
expression of EGFP was seen between the analysed injected and control sections (data not 
shown).  
One possible explanation for the difficulties in luciferase and EGFP transgene detection 
could be due to the highly pigmented retina of the C57BL/6 mice, particularly within the RPE 
cell layer. Furthermore, as luciferase expression was observed prior to sample histological 
analysis (on the Xenogen bioimager), it appears the difficulty of luciferase detection may 
also have been accentuated due to the fact that the expression levels of luciferase from the 
pUbiqC-Luc plasmid were too low to observe on histological sections. Indeed, in Figure 71 
we showed that in the three plasmids analysed within the retina, expression levels of 
luciferase from the pUbiqC-Luc plasmid - while higher than control uninjected samples - was 
significantly lower than pCAG-Luc or pCMV-Luc injected retinas. One could speculate that 
perhaps the same could be true for the pEFS-EGFP plasmid and that low EGFP expression 
levels from the EFS promoter are not sufficient enough to be observed using 
immunohistochemistry. 
As an alternative more sensitive strategy for the detection of the EGFP transgene in the 
C57BL/6 mice, RPE cells were isolated from the retinas of 10 mice subretinally injected with 
pEFS-EGFP plasmid as described in the methods. Briefly, eyes were enucleated 1 week 
following injection of pEFS-EGFP and incubated with Papain solution (1 U) (Sigma), where 
patches of RPE cells were manually removed with pulses of growth media. As a positive 
control isolated RPE cells were also analysed from mice 1 month post subretinal injection 
with Lentivirus pWPT-EGFP (positive samples provided by Dr Tanya Tolmachova), while 
uninjected RPE cells were used as a negative control. All isolated RPE cells were 
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subsequently analysed by FACS analysis for EGFP expression. For FACS analysis, cells in each 
sample were plotted according to side-scatter (SSC-H) - which is a rough measure of cell 
complexity/granularity - as well as fluorescence in the FL-1 channel – which indicates the 
level of EGFP fluorescence. We observed low but noticeable levels of EGFP in RPE cells 
isolated from pEFS-EGFP mice eyes when compared to RPE cells from control uninjected 
eyes, 6.9% and 1% respectively, as shown in Figure 75A and B. The RPE cells isolated from 
positive control pWPT-EGFP Lentiviral injected mouse eyes had 10.9% EGFP expression, as 
show in Figure 75C.  
The same RPE cells as well as the neural retina isolated from the pEFS-EGFP injected and 
control uninjected mice were also lysed and subjected to Western blot analysis for EGFP 
protein expression. No EGFP protein expression was observed in the RPE cells as well as NR 
from the pEFS-EGFP injected retinas. These results further emphasise the importance of 
using a strong and highly expressing promoter in order to successfully monitor robust 
transgene expression levels in vivo. 
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Figure 75: FACS analysis of EGFP expression in RPE cells isolated from pEFS-EGFP 
injected retinas of C57BL/6 mice 1 week post subretinal injection 
The expression of EGFP observed by FACS analysis in RPE cells isolated from (A) Negative 
control – uninjected eyes, (B) pEFS-EGFP injected eyes (n=10)and (C) Positive control lentivirus 
pWPT-GFP injected eyes (positive samples provided by Dr Tanya Tolmachova at 1 month post 
injection). Levels of EGFP expression in isolated RPE cells from both pEFS-EGFP and positive 
control pWPT-GFP injected eyes both show similar levels of EGFP expression (6.9% and 10.9% 
respectively). In all cases, histograms (left panel) show measured events (y axis) against levels 
of EGFP fluorescence in the FL1-H channel (x axis). RPE cells are shown as a purple graph on the 
left side of all histogram, where gated cells expressing EGFP are expressed as a percentage (%) 
of the total untransfected population - a threshold of 1% untransfected RPE cells was always set 
- and appear above the bracketed histogram regions, to ensure that low-level positive events 
were also included. While all dot plots (right panel) show side-scatter (SSC-Height) which is a 
measure of complexity /granularity (y axis) against levels of EGFP fluorescence in the FL1-H 
channel (x axis). Each RPE cell analysed is shown as an individual dot on the plot, where 
untransfected RPE cells appear as a dense crescent on the left hand side of the plot. In contrast 
transfected cells from both vectors produce a smear across the plot and appear further to the 
right of each plot - showing higher levels of EGFP expression in these cells. 
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3.3.5 S/MARs provide long-term expression in vivo – MF1 mice 
 
Due to the difficulties encountered with analysis of transgene expression in C57BL/6 mice, 
we decided to progress in vivo experiments using another WT mouse strain, MF1 mice. 
These mice have a normal retina with the exception that the RPE layer which is normally 
pigmented within the retina of C57BL/6 mice is unpigmented in MF1 mice. We hoped that 
by using this new mouse strain, we could observe expression within the retina and dissect 
better the pattern and distribution of expression from our S/MAR constructs.   
In a similar experiment to the one carried out in C57BL/6 mice, we also assessed the 
longitudinal luciferase expression of a number of S/MAR plasmids including: pCAG-Luc, 
pCAG-Luc-Control, pUbiqC-Luc, pUbiqC-Luc-Control and pEPI-CMV pDNAs. Each of the pDNA 
expression systems under investigation was formulated with in vivo-jetPEI (N/P 8) as 
described earlier and separately administered to each group of mice by subretinal injection. 
As a control group, mice were also injected with naked pCAG-Luc (un-complexed). The 
longitudinal expression was followed up to 6 months (and one year for pCAG-Luc) post 
injection by in vivo bioluminescent imaging (BLI) (Figure 76 and Figure 77). 
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Figure 76: Illustration of luciferase (distribution and) expression in MF1 mice 
over time following single subretinal injections in the eye of PEI:pCAC-Luc, 
PEI:pCAG-Luc-Control and naked pCAG-Luc plasmid 
 
Plasmid DNA pCAG-Luci and pCAG-Luci-Control (30 µg) was complexed with PEI (N/P 
8) and delivered to the retina of MF1 mice following a single subretinal injection (2 µl / 
1 µg per eye). A final group of mice where were also subretinally injected with un-
complexed /naked pCAG-Luc pDNA. All mice were visualised at regular intervals (from 
24 hours post subretinal injection) using a Xenogen bioimager after intraperitoneal 
injection of D-Luciferin (15 mg/ml). High to low intensity of luciferase expression is 
graphically shown exclusively within the eye area by red to violet colouring. The colour 
bar indicates relative signal intensity (as photons/sec/cm2/sr). Initially, expression of 
luciferase is observed in all groups of mice analysed, however levels of expression are 
only short term in PEI:pCAG-Luc-Control as well as naked pCAG-Luc injected mice, 
where loss of expression is observed by 1 month and 1 week post injection respectively. 
In contrast PEI:pCAG-Luc injected mice (as well as PEI:pUbiqC-Luc injected mice – data 
not shown) have persistent luciferase expression within the retina up to 6 months and 1 
year post injection. Luciferase expression seen clearer on digital images.   
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Figure 77: Long-term luciferase expression of formulated pUbiqC-Luc, pCAG-Luc, 
their control plasmids as well as naked pCAG-Luc 
The figure shows the longitudinal luciferase expression up to 6 months and 1 year (for 
pCAG-Luc) following a single subretinal injection. Luciferase expression was measured 
using the Xenogen Living Image software and is represented as photons/sec/cm2/sr. 
Only the formulated pUbiqC-Luc and pCAG-Luc plasmids are able to persistently 
express luciferase levels for up 6 months and 1 year respectively. Background levels of 
light emission from uninjected retinas is 2 x 104 photons/sec/cm2/sr. Results are mean 
values from six to seven independent experiments (per group). Error bars represent the 
s.e.m.  
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One day after the subretinal injection of all five groups of MF1 mice, all plasmid constructs 
mediated high levels of luciferase expression. However a rapid decline in transgene 
expression was observed within the first few days following subretinal injections particularly 
in both control groups, pCAG-Luc-Control, pUbiqC-Luc-Control as well as naked  
un-complexed pCAG-Luc. While an abrupt decline in transgene expression was observed 
within a week following injection, expression levels of luciferase transgene were seen to 
reduce even further over time and we found these levels to decline to above baseline levels 
within one month post-injection (p<0.05). In contrast, thereafter, we observed high levels of 
transgene expression mediated by the plasmids pCAG-Luc and pUbiqC-Luc in the retinas of 
injected mice over the 6 months and 1 year - for pCAG-Luc and pUbiqC-Luc respectively - 
period of this study (p<0.01 on day 168 for pUbiqC-Luc and p<0.01 on day 365 for pCAG-
Luc).  
By way of illustration, transgene levels after one month mediated by pCAG-Luc-Control,  
pUbiqC-Luc-Control as well as naked pCAG-Luc plasmids were all approximately 15-20% of 
those determined at 24 hours post injection. In contrast, transgene levels after one month 
mediated by pCAG-Luc and pUbiqC-Luc were still 70% and 60% of the levels determined 24 
hours after injection. While a small decline in transgene levels were observed for both 
plasmids pCAG-Luc and pUbiqC-Luc over the first 100 days, which later stabilised, expression 
levels are still 5 times higher at 6 months post injection than that of the other plasmids at 
one week. This vast difference between the expression of pCAG-Luc and pUbiqC-Luc 
compared to their corresponding control plasmids, shows the importance of the S/MAR 
moiety in providing a continuous high level of transgene expression in vivo within the retina 
(as seen previously in Figure 74). 
In a complimentary experiment, to further measure the kinetics of (short and long term) 
transgene expression in vivo, total DNA was isolated from retinal homogenates of MF1 mice 
at 1 week and 6 months post subretinal injection of formulated pEFS-EGFP, pCAG-EGFP and 
the corresponding control plasmids. Total retinal DNA was then analysed for the PCR 
detection of the appropriate pDNA (Figure 78). PCR analysis revealed the persistent 
expression of pEFS-EGFP and pCAG-EGFP pDNA within retinal homogenates up to 6 months 
post injection. Notably however, the expression of both controls, pEFS-EGFP-Control and 
pCAG-EGFP-Control, was transient and lost within the retina by 6 months post injection.To 
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further verify these PCR results, total RNA was also extracted from injected retinal 
homogenates at 1 and 6 months following injection and EGFP RNA levels were analysed in 
by rt-PCR analysis (Figure 79). Indeed EGFP mRNA transcript levels were undiminished from 
both groups of S/MAR pDNAs injected retinas, while control samples only showed transient 
EGFP RNA levels. Considered together, these results from the PCR as well as rt-PCR analyses 
are in good correspondence with the longitudinal luciferase expression analysis determined 
by in situ bioluminescent imaging (Figure 74, Figure 76 and Figure 77). As observed 
previously the long term expression of control non-S/MAR pDNAs were also lost in the 
retina following subretinal delivery (while in contrast long term expression of the same 
luciferase pDNAs containing an S/MAR moiety was seen).  
 
Figure 78: Short and long-term PCR detection of pEFS-EGFP and pCAG-EGFP pDNA 
vectors in eye homogenates following subretinal injections of WT MF1 mice 
PCR analysis of formulated (A) pEFS-EGFP and pEFS-EGFP-Control and (B) pCAG-EGFP 
and pCAG-EGFP-Control pDNA vectors at 1 week (lanes 1-3) and 6 months (lanes 4-6) 
post injection (PI). PCR samples were separated by agarose gel electrophoresis and a 
positive PCR band was observed using EFS-EGFP or CAG-EGFP specific primer sets 
yielding a product size of 450 bp or 250 bp respectively. The arrowhead indicates the 
size corresponding to pDNA 450 bp on (A), 250 bp on (B). Uninjected eyes as well as no 
PCR product/water served as a negative control (lanes 7 and 9 respectively), while 
pDNA (25ng) pEFS-EGFP (in the case of A) or pCAG-EGFP (in the case of B) served as a 
positive control (lane 8) for the PCR reaction. Results are representative of three 
independent experiments. L= 100bp ladder (Invitrogen). 
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Figure 79: RT-PCR analysis of short and long-term EGFP mRNA from tissue 
homogenates following subretinal injections of WT MF1 mice with pEFS-EGFP and 
pCAG-EGFP pDNA vectors 
Total RNA was extracted from MF1 mice following single subretinal injections of 
formulated (A) pEFS-EGFP and pEFS-EGFP-Control and (B) pCAG-EGFP and  
pCAG-EGFP-Control pDNA vectors at 1 week (lanes 1-3) and 6 months (lanes 4-6) post 
injection (PI). Total RNA was isolated and used to generate cDNA. PCR was performed 
with EGFP specific primers to yield a product size of 494 bp, as indicated by the 
arrowhead on (A) and (B). RNA from uninjected eyes, untransfected AtT20 cells, as well 
as no RNA product/water served as a negative control (lanes 7, 9 and 11), while AtT20 
cells transfected with pEFS-EGFP (in the case of (A)) or pCAG-EGFP (in the case of (B)) 
served as a positive control (lane 10 and 12). Lane 8 is empty. Results are 
representative of three independent experiments. L= 100 bp ladder (Invitrogen). 
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3.3.6 Immunohistochemical detection of luciferase expressing cells in the retina 
 
To analyse the tissue distribution of luciferase transgene expression within the eye as well 
as to localise the luciferase signal to a particular cell type, eyes were enucleated and 
paraffin-embedded sections were made and analysed by immunohistochemistry. At 1 week 
post injection, a significant amount of positive luciferase staining was observed in the RPE 
cell layer following transduction of pUbiqC-Luc pDNA (Figure 80). The presence of luciferase 
expression (within this retinal sample) is in agreement with the luciferase expression 
determined by in situ BLI analysis - prior to the sample being harvested (Figure 80A). In 
contrast, no staining was detected in the retinas of control uninjected samples which were 
incubated with primary and secondary antibody to determine the levels of background 
luciferase expression in retinal tissues (data not shown). Furthermore additional negative 
controls included pUbiqC-Luc injected retinal sections incubated without primary antibody 
and only secondary antibody to further analyse the level of background luciferase staining 
from the luciferase antibody (Figure 80D). The presence of luciferase expression within the 
RPE cells correlates with the positive EGFP staining of RPE cells isolated from pEFS-EGFP 
injected retinal samples (see Figure 75).  
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Figure 80: Immunohistochemistry analysis showing the (tissue) distribution of 
luciferase expression within retinal sections of a pUbiqC-Luc injected mouse 
retina following subretinal injection at 1 week post injection (single injection) 
Luciferase expression from formulated pUbiqC-Luc (30 µg of pDNA, N/P 8) subretinally 
injected mouse as analysed by (A) in situ bioluminescent imaging (BLI). Mice were 
visualised at 1 week post injection (PI) using a Xenogen bioimager. The retina from the 
injected pUbiqC-Luc mouse was subsequently harvested and also analysed by 
immunohistochemistry. (B) H&E analysis reveals normal morphology of the injected 
eye. (C) Paraffin-embedded retinal sections were stained for luciferase expression 
(n=1); sections were probed with a rabbit monoclonal luciferase antibody (Santa Cruz), 
and a secondary Alexa 568. Nuclei were also stained blue using 4’, 6-diamidino-2-
phenylindole (DAPI). Luciferase expression (red) was observed within the RPE layer of 
injected eyes, (D) while no expression is observed in the negative control. Fluorescent 
(left panel) and Dapi images (right), at 40x magnification are shown. Negative controls 
included uninjected retinal sections with both primary and secondary antibody (data 
not shown) as well as positively expressing retinal section incubated with secondary 
antibody only.    
C, choroid; RPE, retinal pigment epithelium; OS, photoreceptor outer segments; IS, 
photoreceptor inner segments; ONL, outer nuclear layer; OPL, outer plexiform layer; 
INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. 
256 
 
3.3.7 Single vs Double Subretinal injections (-Tissue distribution) 
 
The results presented thus far have shown promisingly that single subretinal injections 
provide sustainable levels of EGFP and Luciferase transgenes in vivo within the retina. While 
these results are novel and encouraging, one must also bear in mind that by delivering more 
pDNA into the subretinal space, one could also in theory provide higher levels of transgene 
expression within the retina. Indeed many gene therapy trials in mice to-date have involved 
the double subretinal injection of therapeutic genes into the subretinal space (where viral 
injections have shown considerable retinal transduction). Such double injections result in 
half the retina being transduced from the first injection, the mouse is then injected again at 
another site within the retina – usually opposite the original site, hoping to transduce the 
remaining half of the retina and maximising transduction. Hence single and double 
injections allow the required injected material to be placed between the photoreceptors 
and RPE cells, this causes a retinal bleb between the two layers leading to potentially 
around half or the entire area of the retina to be reached and in turn transduced. 
Importantly, further repeat injections, can have incremental risks within the mouse retina, 
and will undoubtedly not be well tolerated by the mouse eye, where the eye would no 
longer be able to regress back on itself and hence cause irreparable damage. We were 
interested in analysing if a similar difference in transduction of the mouse retina could also 
be observed following the single and double subretinal injections of formulated non-viral 
S/MAR pDNA. 
Mice were injected either by single or double subretinal injection of formulated pCAG-Luc 
(30 µg of pDNA, N/P 8, 1 µg/2 µl in total per eye) as described earlier. The luciferase 
expression in retinal samples was determined 48 hours post injection using a luminometer. 
The comparison of luciferase expression from this experiment is shown in Figure 81. 
While the levels observed for the double injected retinas were not double the amount from 
the single injected retinas, the difference is still significantly higher; levels were 
approximately 62% lower in single injected retinas compared to double retinas (2033 ± 88.6 
and 3299 ± 37.69 µg/protein respectively) (p<0.0001).  
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Figure 81: A comparison of luciferase expression at 48 hours within the retina 
following single and double subretinal injections 
Plasmid DNA pCAG-Luc (30 µg) was complexed with PEI (N/P 8) and delivered to the 
retina of MF1 mice following a single or double subretinal injection  
(2 µl / 1 µg per eye). Retinal homogenates were subsequently lysed and analysed using 
a luminometer 48 hours following injection. The bar chart illustrates the quantification 
of luciferase expression represented as µg/protein. Levels of expression were 
approximately 1.6 fold higher in double subretinal injected retinas compared to single 
injected retinas (2033 ± 88.6 µg/protein compared to 3299 ± 37.69 µg/protein 
respectively). Uninjected retinas as well as retinas from mice not expressing luciferase 
were used as negative controls. The difference in expression of luciferase between 
single and double subretinally injected retinal samples is highly significant (*** 
p<0.0001, Student’s t test). Results are mean values from four to five independent 
experiments. Error bars represent the s.e.m.  
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In a complimentary experiment, mice were also injected either by single or double 
subretinal injection of formulated pCAG-EGFP (30 µg of pDNA, N/P 8, 1 µg/2 µl in total per 
eye). The amount of EGFP expression was observed 1 week post injection in retinal whole 
mounts as described in the methods. Briefly, enucleated eyes were fixed in 4% PFA, cut into 
flat mounts using iridectomy scissors. Immunohistochemistry was then performed on flat 
mounts for the expression of EGFP (following both injections/groups of mice), where 
samples were incubated with an anti-GFP rabbit polyclonal primary antibody (Abcam) and 
an Alexa-488 conjugated secondary antibody. Controls were made by analysing injected 
retinas omitting the primary antibody (results not shown) or by carrying out 
immunohistochemistry on uninjected as well as sham/vehicle alone injected (PBS) whole 
mount eyes. These controls allowed us to assess the background EGFP expression from the 
secondary antibody as well as the background EGFP expression in uninjected and sham 
injected whole eyes respectively. Representative retinal whole mounts are shown in  
Figure 82.  
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Figure 82: Expression of EGFP transgene in the RPE cells (of mouse retinas) from 
whole mounts of pCAG-EGFP injected retinas following single and double 
subretinal injections 
The expression of EGFP from formulated pCAG-EGFP (30 µg pDNA N/P 8) subretinally 
injected into the mouse retina and analysed by retina whole mounts 1 week following 
injection. Shown is the whole mount of the eye following the (A) single or (B) double 
subretinal injection of pDNA. Control whole mount samples include (C) sham/vehicle 
(PBS) or (D) uninjected retinas. To detect EGFP expression, all retinal whole mounts 
were incubated with anti-rabbit polyclonal EGFP primary antibody and Alexa 488 
secondary antibody. Fluorescent images at 2.5x (for A and B) and 1.25 x (for C and D) 
magnification are shown. Images are representative of four-five independent 
experiments. EGFP expression seen clearer on digital images.   
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Whole mount analysis from both single and double subretinal injections showed a focus of 
expression within less than half of the retina or a more dispersed expression throughout the 
whole retina respectively.  
From both analyses performed with pCAG-Luc as well as pCAG-EGFP (Figure 81 and Figure 
82) it appears clear that double injections provide higher levels of Luciferase and EGFP 
transgenes in vivo. One could explain the reason for not observing double the amount of 
luciferase and EGFP expression within the retina due a number of reasons. One potential 
problem/limitation of the double injection procedure is the possibility of the vector leaking 
through both injection sites after removal of the injection needle in the retina. Furthermore 
leakage through the first injection site during the second injection procedure could also 
occur. Difficulty in injecting the retina efficiently once it has been pierced after the initial 
subretinal injection, causing it to no longer be rigid and easy to manipulate into the correct 
position with a needle is also a potential problem that could be encountered during the 
double injection procedure.  
Despite these problems, the maximum amount of expression observed within the retina 
using a non-viral vector appears to be following the double subretinal injection of PEI 
formulated S/MAR pDNAs within the retina. Hence in all subsequent in vivo experiments in 
MF1 mice we used double subretinal injections.    
 
3.3.8 Immunohistochemical detection of EGFP expressing cells in the retina 
 
As well as analysis of whole mount retinas to show the presence of EGFP expression within 
the RPE cells following subretinal injections of pCAG-EGFP into the retinas, EGFP expression 
was also investigated by Western analysis. RPE and neural retinal cells were isolated from 
the retinas of 10 C57BL/6 mice (3-4 months old) 48 hours following the double subretinal 
injection of pCAG-EGFP and pCAG-Luc-Control plasmids. Samples were lysed and 50 µg of 
total protein lysates were resolved by 12% SDS-polyacrylamide gel electrophoresis and 
transferred to a PVDF membrane. The membrane was then probed with an anti-GFP mouse 
polyclonal antibody (Roche). A representative blot is shown in Figure 83. The Western blot 
analysis revealed strong expression of EGFP within the RPE cell layer of injected mouse 
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retinas from both pDNA groups (pCAG-EGFP and pCAG-Luc-Control), while expression was 
absent in the neural retina of these mice.  
 
 
Figure 83: Western blot analysis of RPE and neural retinal cells isolated following 
the subretinally injected pCAG-EGFP and pCAG-EGFP-Control pDNA vectors 
The figure shows the Western blot analysis of EGFP protein levels upon partitioning of 
the RPE and neural retina (NR) cells (50 µg) from C57BL/6 mice (n=10) 48 hours 
following the double subretinal injection of plasmids pCAG-EGFP and  
pCAG-EGFP-Control. Untransfected cells as well as cells transfected with pEPI-EGFP 
served as a positive and negative control respectively, while α-tubulin was used as a 
loading control. EGFP expression is exclusively observed in the isolated RPE cells of 
both injected plasmid groups. 
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To further complement the EGFP expression observed within the RPE cells by whole mount 
immunohistochemistry (Figure 82) and Western blot analysis (Figure 83), we also analysed 
the long term tissue expression of EGFP by immunohistochemistry analysis of retinal 
sections (Figure 84). At 1 and 6 months post injection, eyes were enucleated and frozen 
sections were obtained and analysed by confocal microscopy. By examining the whole eye 
at 1 and 6 months post injection, the blebs that had arisen by the injection procedure 
appear to have regressed and limited retinal detachment is observed throughout the 
sections. Furthermore, EGFP transgene expression levels appear to be persistent, however 
expression is limited to the sites of injection (Figure 84A). As such two clear regions of EGFP 
expression are evident both sides of the retina at 1 and 6 months post injection. Limited 
regions of the neural retina also show some EGPF expression, however this is probably 
caused by residual plasmid within the retina from the injection procedure (specifically the 
insertion and removal of the needle into the retina). Importantly, in the regions were EGFP 
expression is observed, the outer nuclear layer, inner nuclear layer and ganglion cell layers 
all exhibit relatively normal thickness. Closer examination of the retina at 1 and 6 months 
shows the most detectable EGFP expression was localized to the RPE cell layer, where 
considerable co-localisation with an RPE cell marker protein - Rpe65 - was observed (Figure 
84B). No EGFP staining was seen in control uninjected retinas. Notable was the lack of DAPI 
staining on the nuclei of RPE cells, in injected and control uninjected retinas. This may have 
been due to the fact that the RPE cells are a single cell layer within the retina, as such are a 
sparse cell layer which could result in inconsistent DAPI staining within these cells.       
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Figure 84: Immunofluorescence detection of EGFP expression in the mouse retina 
at 1 and 6 months following the double subretinal injection of pCAG-EGFP 
(A) The figure shows a collage/composite of the whole retina, where numerous images 
were taken with 40x objective. Immunofluorescence labelling using an anti-GFP rabbit 
antibody was performed on frozen sections. Shown are representative images of EGFP 
immunolabeling on whole retinas from MF1 mice following the double subretinal 
injection of pCAG-EGFP at (A) 1 month and (B) 6 months post injection. Levels of EGFP 
transgene are persistent at both 1 and 6 months post injection, however expression is 
limited to the sites of injection. Nuclei were also stained using Propidium Iodide (red). 
Images are representative of three-four independent experiments. EGFP expression 
seen clearer on digital images.    
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Figure 84: Immunofluorescence detection of EGFP expression in the mouse retina 
at 1 and 6 months following the double subretinal injection of pCAG-EGFP 
(B) The figure shows a collage/composite of the whole retina, where numerous images 
were taken with 40x objective. Immunofluorescence labelling using an anti-GFP rabbit 
antibody was performed on frozen sections. Shown are representative images of EGFP 
immunolabeling on whole retinas from MF1 mice following the double subretinal 
injection of pCAG-EGFP at (A) 1 month and (B) 6 months post injection. Levels of EGFP 
transgene are persistent at both 1 and 6 months post injection, however expression is 
limited to the sites of injection. Nuclei were also stained using Propidium Iodide (red). 
The figure shows representative close-up regions of the retina at 1 month (panels a-d, i-
n) and 6 months (panels e-h) post injection. The retina was examined for the expression 
of EGFP transgene (green) (a, e, i, l) and the localization of Rpe65 protein (red) (b, f, j, m) 
within the RPE cells of injected WT MF1 mice. Control samples included injected sample 
without primary antibody (i-k) and showed no EGFP staining. Considerable co-
localisation (yellow) of Rpe65 and EGFP is observed within the RPE cell layer of injected 
retinas at 1 and 6 months post injection. Nuclei were also stained with DAPI (blue) (d, h, 
k). Fluorescent images (a-d) (e-k) and (l-n) are shown at 20x, 40x and 63x magnification 
respectively.  
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In a complimentary experiment, EGFP expression was also examined in situ (within the 
retina) following fundus as well as SLO examinations of the retina 1 week following the 
single subretinal injection of formulated pEFS-EGFP (Figure 85). Control retina images were 
obtained for fundus examinations however this was not the case for the SLO examinations. 
While it is unlikely that the fluorescence observed was background fluorescence caused 
solely due to the injection procedure, this cannot be ruled out as a source or contributor for 
the fluorescence seen in the SLO images. Thus although the expression appears promising in 
Figure 85B one must be cautious in the interpretation of the images.        
 
Figure 85: Fundus examination following injection of EGFP/S/MAR plasmids 
shows the presence of EGFP fluorescence within the retina 
Mice were imaged at 1 week following the subretinal injection of formulated  
pEFS-EGFP pDNA. The fundus was examined in situ by either (A) fundus examination 
using a fluorescent microscope or (B) SLO examination. Shown is the representative 
EGFP fluorescence observed within the retina of an injected mouse (left panel), while no 
expression is seen in the control uninjected eye of the same mouse (right panel). 
Representative SLO examination of an injected mouse also shows intense fluorescence 
signal represented by the areas of white (signal). Shown are SLO images with the 
central view of the retina - where the centre is on the optic nerve (left panel), as well as 
the peripheral image of the same retina (right panel). (All SLO examinations were 
carried out at Oxford University by Professor Robert MacLaren and Dr Peter Issa). 
Digital images may be clearer.  
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3.3.9 Histological examinations following subretinal injections 
 
While it is important that we assess and observe the long term EGFP and Luciferase 
transgene expression within the retina, specifically in the RPE cell layer of the retina, it is 
equally important that the area of the injection site as well as surrounding tissue of the 
retina should also remain normal. Hence detailed histological analysis of retinal sections 
following subretinal injections of WT MF1 mice was also carried out.  
 
3.3.9.1 Ophthalmoscopic analysis of fundi 
 
To assess potential inflammation or abnormalities within the retina following the subretinal 
delivery of S/MAR plasmids, we performed fundus examinations (in situ) of various groups 
of MF1 mice that had been double subretinally injected with complexed pCAG-Luc at 1 week 
and 1 month post injected (PI). We analysed the various groups of MF1 mice by indirect 
opthalmoscopy. We also assessed the fundi from the following control retinas: naked 
(uncomplexed) pCAG-Luc pDNA, sterile Glucose alone, PEI-Glucose alone and uninjected 
WT. Fundus analysis of naked pCAG-Luc injected retinas would reveal if the mice were 
reacting to the actual pDNA, while Glucose and PEI-Glucose injected retinas would show if 
the mice were reacting to the injection procedure or the gene delivery agent/vehicle PEI 
respectively. This length of time was chosen as it allowed the bleb within the retina to be 
reabsorbed and the neural retina to return contact with the RPE layer.  
Representative fundi of all groups of mice analysed are shown in Figure 86. The fundus 
examinations reveal that all retinas appear normal in all 4 quadrants of the eye (superior, 
inferior, temporal and nasal) at 1 week and 1 month (for pCAG-Luc) post injection. The 
retinas appear to show limited inflammation as evident by the healthy colour and clear 
organised blood vesicles in the eye.  Furthermore, all subretinal blebs have regressed and 
minimal signs of the injections procedure are evident.  
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Figure 86: Ophthalmic examinations of fundi following the double subretinal 
injection of formulated pCAG-Luc mice at 1week and 1 month post injection 
MF1 WT mice were double subretinally injected with formulated pCAG-Luc (30 µg 
pDNA N/P 8) and analysed by fundus examination (in situ) at (A) 1 week and (B) 1 
month post injection (PI). As negative control the fundus examination was also included 
of mice double subretinally injected with (C) un-complexed pDNA (Naked DNA),  
(D) Glucose alone, (E) PEI-Glucose as well as (F) WT uninjected mice. Injected retinas 
were analysed in the superior, inferior, temporal and nasal regions. All retinas appear 
health, with clear blood vessels and no evidence of inflammation or abnormality.  
Images are representative of four-five independent experiments. Digital images may be 
clearer.   
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3.3.9.2 Analysis of retinal sections – H&E and TUNEL 
 
To assess whether there was a local inflammatory response within the retinas to S/MAR 
plasmids, we also examined paraffin-embedded retinal sections of eyes that had been single 
and double subretinally injected with complexed pCAG-Luc. Furthermore the sections of the 
same control samples used in the fundus examination were also analysed: naked pCAG-Luc 
pDNA, sterile Glucose and PEI alone.  
We performed haematoxylin and eosin (H&E) staining and examined retinal sections for 
infiltration and activation of inflammatory cells such as polymorphonuclear leukocytes 
(PMN), which would indicate an adverse and toxic response present in the retina (Giese, 
Sumner et al. 1998; Ramadan, Ramirez et al. 2006). Such an inflammation would be mainly 
localised near or at the site of injection, hence identifying the precise injection site in retinal 
sections is vastly advantageous and informative. Indeed subretinal injections cause a 
localised detachment at the site of injection; however retinal detachment can also occur 
during histology processing. As the site of retinal detachment cannot be the ultimate mark 
for the site of injection, in our subsequent analyses of retinal sections, we choose to analyse 
numerous sections taken throughout the entire eye either side of the optic nerve, with the 
idea to include sections near and far from the site of injection. 
 
Figure 87 shows representative H&E stained whole retinas as well as higher magnification of 
areas throughout the entire retina. Encouragingly, we did not observed evidence of a 
cellular inflammatory reaction as judged by an absence of PMN or round cell infiltration 
with H&E staining of eye sections (Figure 87A).   
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Figure 87: Histological (H&E) examination of inflammatory cell infiltrations in 
MF1 mouse retinas following the single and double subretinal injections of 
formulated pCAG-Luc at 1 month post injection 
(A) Shown are representative haematoxylin and eosin (H&E) stained retinal sections of 
MF1 mice subretinally injected with formulated pCAG-Luc at 1 month post injection. As 
a negative control, retina sections from injected naked (un-complexed) pCAG-Luc 
(Naked DNA) mice were also analysed. No evidence of a cellular inflammatory reaction 
is observed within the H&E stained sections. All cell layers exhibit relatively normal 
thickness and morphology.     
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Figure 87: Histological (H&E) examination of inflammatory cell infiltrations in 
MF1 mouse retinas following the single and double subretinal injections of 
formulated pCAG-Luc at 1 month post injection    
(B) Shown are representative H&E stained retinal sections of negative control MF1 mice 
subretinally injected with: Glucose, PEI-Glucose alone and uninjected. As a positive 
control, mice were also injected with E. coli Lipopolysaccharides (LPS), where 
substantial infiltrations of polymorphonuclear leukocytes (PMN), and damage at the site 
of injection is observed (indicated by the black arrows in the LPS retina - far bottom 
right panel). H&E staining of the whole retina (left panels) and highlighted sections as 
indicated by the black boxes (right panels) are shown at 4x and 20x magnification 
respectively. Images are representative of four-five independent experiments. 
 
RPE, retinal pigment epithelium; OS, photoreceptor outer segments; ONL, outer nuclear 
layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. 
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Within the cell, numerous barriers can prevent the efficient and persistent transport of 
pDNA into the nucleus. We have previously shown that through the formulation of S/MAR 
pDNA and subsequent subretinal injections, persistent expression within the RPE cells is 
observed; showing that this technique circumvents a number of these barriers. However, as 
a last resort to the delivery of drugs or pDNA, some cells have been shown to undergo 
apoptosis (Yew, Zhao et al. 2000). Hence tissue death under these optimised conditions was 
also examined in the same retinal sections as above using terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) analysis.  
Figure 88 shows representative TUNEL staining of whole retinas as well as higher 
magnification of the same areas analysed by H&E analysis (Figure 87) throughout the entire 
retina. Analyse of tissue cell death in retinal sections showed no apoptotic events within the 
retina of any of the groups of mice analysed (Figure 88A).  
As a positive control mice were also subretinally injected with Escherichia. Coli (E. coli) 
Lipopolysaccharides (LPS) and eyes were collected between 5-15 min post subretinal 
injection.We observed thinning of the nuclear layers of the retina, cellular infiltrations of 
PMN, retinal detachment and damage at the site of injection in most sections examined as 
well as cell death induced apoptosis of cells in the retina (Figure 87B and Figure 88B). As a 
negative control uninjected retinas were also analysed and showed no inflammation or 
infiltration of cells as well as no apoptotic cells in the retina (Figure 87B and Figure 88B). 
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Figure 88: Cell death (TUNEL) examination in MF1 mouse retinas following the 
single and double subretinal injections of formulated pCAG-Luc at 1 month post 
injection 
(A) Shown are representative TUNEL stained retinal sections of MF1 mice subretinally 
injected with formulated pCAG-Luc at 1 month post injection. As a negative control, 
retina sections from injected naked (un-complexed) pCAG-Luc (Naked DNA) mice were 
also analysed. No evidence of apoptotic cell death was observed within the TUNEL 
stained sections.   
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Figure 88: Cell death (TUNEL) examination in MF1 mouse retinas following the 
single and double subretinal injections of formulated pCAG-Luc at 1 month post 
injection   
(B) Shown are representative TUNEL stained retinal sections of negative control MF1 
mice subretinally injected with: Glucose, PEI-Glucose alone and uninjected. As a positive 
control, mice were also injected with E. Coli Lipopolysaccharides (LPS), where 
substantial apoptotic cell death as shown by black cell staining is observed (indicated by 
the black arrows in the LPS retina - far bottom right panel). TUNEL staining on the 
whole retina (left panels) and highlighted sections as indicated by the black boxes (right 
panels) are shown at 4x and 20x magnification respectively. Images are representative 
of four-five independent experiments. 
RPE, retinal pigment epithelium; OS, photoreceptor outer segments; ONL, outer nuclear 
layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer.     
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3.3.9.3 Analysis of inflammatory Chemokines - ELISA 
 
The retina is often considered an immune privileged organ, however it can present immune 
activity when put under environmental stress (Wakefield and Lloyd 1992; Jo, Wu et al. 2003; 
Yeh, Song et al. 2003; Powers, Davies et al. 2005; Chintakuntlawar, Astley et al. 2007) and so 
is prone to environmental alterations. Specifically, there is evidence for immune-based 
inflammation in the eye caused by increases in inflammatory cytokines: tumor necrosis 
factor-α (TNF-α) (Wakefield and Lloyd 1992; Limb, Chignell et al. 1996; Limb, Hollifield et al. 
2001; Nakazawa, Matsubara et al. 2006; Nakazawa, Kayama et al. 2011), monocyte 
chemotactic protein-1 (MCP-1) (Jo, Wu et al. 2003; Yoshida, Yoshida et al. 2003; Nakazawa, 
Matsubara et al. 2006), interferon-γ (IFN-γ) (Wakefield and Lloyd 1992; Chen, Chauhan et al. 
2011; Hooks, Chan et al. 1988; Cathcart, Zheng et al. 2011), as well as potential proapoptotic 
factors (Brignole, De Saint-Jean et al. 1998; Gao, Schwalb et al. 1998; Brignole, Pisella et al. 
2000; Brignole, Pisella et al. 2001; Yang, Elner et al. 2011), TNF and IFN induced apoptosis 
(Zhang, Covar et al. 2011). Hence we examined the levels of these cytokines by Enzyme-
linked immunosorbent assay (ELISA) of retinal homogenates that had been subretinally 
injected with complexed S/MAR pDNA (pCAG-EGFP), Glucose and PEI alone at 1 and 7 days 
post injection (Figure 89A). At day one post injection, limited inflammation was observed in 
retinas injected with pCAG-EGFP by analysis of MCP-1 and IFN-γ  protein expression (77 ± 
1.54 and 64 ± 2.4 pg/ml respectively) (Figure 89B and C), while a transient increase of TNF-α 
protein was observed (78 ± 5.24 pg/ml, p<0.05)(Figure 89A). Levels of TNF-α protein were 
also elevated in glucose and PEI-Glucose injected retinas (p<0.05 and p<0.001 respectively) 
at the same time point (65 ± 0.69 and 88 ± 7.26 pg/ml respectively). Importantly, despite 
this by day 7 post injection protein expression levels of all cytokines had returned to control 
uninjected levels. In contrast, LPS positive control tissues showed significantly elevated 
levels of all cytokines. Due to the presence of a tight blood-retinal barrier within the eye, 
one would not expect to find elevated levels of cytokines within the serum of injected mice. 
However, as bleeding was occasionally observed following subretinal injections, as a control, 
serum levels of injected mice were analysed for the expression of all three cytokines at the 
same time points (Figure 90). As expected, no elevated levels of cytokines were observed. In 
contrast, LPS positive control mice showed significantly high levels of all cytokines.  
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Figure 89: Examination of inflammatory cytokines TNF-α, MCP-1 and IFN-γ 
expression in mouse retinal homogenates following the subretinal injections of 
formulated pCAG-EGFP at 1 and 7 days post injection 
ELISA was performed to determine the levels of (A) TNF-α, (B) MCP-1 and (C) IFN-γ in 
the retinas of eyes following the double subretinal injection of pCAG-EGFP at 1 and 7 
days post injection (PI). As a negative control Glucose, PEI-Glucose and uninjected 
retinas were used. As a positive control, E. coli LPS was subretinally injected into the 
retina and significantly high levels of all three cytokines where observed compared to 
uninjected control levels at day 7 PI. Levels of TNF-α protein were significantly elevated 
in pCAG-EGFP, Glucose and PEI-Glucose injected retinas (78 ± 5.24, 65 ± 0.69, 88 ± 7.26 
pg/ml respectively) (* p<0.05, *p<0.05 and **p<0.01 respectively, Student’s t test) at 
day 1 PI with respect to control uninjected retinas, however levels returned to control 
uninjected levels by day 7 PI. Percentages are mean values from four-five independent 
experiments. Error bars represent the s.e.m.  
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Figure 90: Examination of inflammatory cytokines TNF-α, MCP-1 and IFN-γ 
expression in the blood serum of mice following the subretinal injections of 
formulated pCAG-EGFP at 1 and 7 days post injection 
ELISA was performed to determine the blood serum levels of (A) TNF-α, (B) MCP-1 and 
(C) IFN-γ in mice following double subretinal injection of pCAG-EGFP at 1 and 7 days 
post injection (PI). As a negative control Glucose, PEI-Glucose and uninjected retinas 
were used. As a positive control, E. coli LPS was injected via intraperitoneal (i.p.) 
injection and significantly high levels of all three cytokines where observed compared to 
all other groups analysed. No elevated levels of any cytokines were observed at day 1 
and 7 PI in all groups analysed. Percentages are mean values from three independent 
experiments (Student’s t test). Error bars represent the s.e.m.  
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3.3.10 Episomal status of EGFP and Luciferase S/MAR plasmids in vivo 
 
In the final analysis of S/MAR pDNA safety in vivo, we were also eager to show that S/MAR 
plasmids were not only persistently expressed within the RPE cells, but also maintained as a 
passive episome within the RPE cells as well as the entire retina as a whole.  
The episomal maintenance in vivo was examined by plasmid rescue of pEFS-EGFP and  
pCAG-EGFP isolated from kanamycin resistant E.coli after transformation with total DNA 
from retinal homogenates of MF1 mice 6 months post subretinal injection. The restriction 
pattern of the pEFS-EGFP plasmid was analysed using XhoI and BamHI; giving the fragments 
5104 bp and 1080 bp when digested with XhoI and linearised plasmid of 6184 bp when 
digested with BamHI. While HindIII and AflIII were used for pCAG-EGFP plasmid analysis; 
giving the fragments 3142 bp and 4549 bp when digested with HindIII and fragments  
2015 bp, 2752 bp and 2924 bp when digested with AflIII. The restriction patterns of these 
plasmids were compared to positive controls which were the corresponding original pDNAs 
and were consistent with unmodified non-integrating plasmid constructs (Figure 91). 
Further evidence for episomal maintenance was provided by Southern blot analysis. DNA 
was isolated from mouse retinas injected with of pEFS-EGFP, pCAG-EGFP, pCAG-Luc and 
pUbiqC-Luc, as well as all corresponding control non-SMAR plasmids. DNA was digested with 
StuI restriction enzyme, which has a single restriction site in all 8 pDNAs (pEFS-EGFP, pCAG-
EGFP, pCAG-Luc, pUbiqC-Luc and controls), and then subjected to Southern blot analysis. 
Representative blots showing the analysis of the EGFP and luciferase plasmids can be seen 
in Figure 92 and Figure 93 respectively. All blots show the band of the expected size in all 
pDNAs analysed, confirming the presence of an intact episomal pEFS-EGFP, pCAG-EGFP, 
pCAG-Luc, pUbiqC-Luc plasmid in the mouse retina. Encouragingly, despite the lack of long-
term EGFP expression  (Figure 78 and Figure 79) as well as the lack of long-term luciferase 
expression, were levels of luciferase had declined to near-background levels in all control 
plasmids (Figure 74, Figure 76 and Figure 77) at 6 months post injection, all control plasmids 
were still maintained as an episome within the retina. 
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Figure 91: Plasmid rescue analysis of pEFS-EGFP and pCAG-EGFP vectors isolated 
at 6 months post subretinal injections in MF1/WT mice. 
Plasmid rescue analysis of pDNA isolated from 2 randomly chosen clones (lanes 1-2), 
after transformation of E.coli bacteria with 1 µg of total DNA isolated from eye 
homogenates of MF1 mice 6 months post subretinal injection of (A) pEFS-EGFP and  
(B) pCAG-EGFP pDNA vectors, performed as described in methods. Undigested plasmid 
served as a negative control (lane 4 (-)), while all bands show identical sizes with the 
positive control of original pEFS-EGFP on (A) or pCAG-EGFP on (B) (lane 3 (+)), 
demonstrating that pEFS-EGFP and pCAG-EGFP vectors are retained episomally in the 
retinas of injected MF1 mice. Results are representative of two independent 
experiments. L: 1 kb Ladder (Invitrogen). 
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Figure 92: Representative Southern blot of isolated EGFP plasmids isolated at 6 
months post subretinal injections in MF1/WT mice 
Southern blots of total pDNA isolated from eye homogenates of MF1 mice 6 months post 
subretinal injection of (A) pEFS-EGFP and pEFS-EGFP-Control and (B) pCAG-EGFP and  
pCAG-EGFP-Control pDNA vectors, performed as described in methods. DNA (30 µg) 
was separated on 0.8% agarose gels and hybridized with 32P-labelled AlwNI probe.  
Lanes 1-2, pEFS-EGFP or pCAG-EGFP isolated from eye homogenates (4-5 eyes per lane) 
by sacrifice 6 months post injection. Lane 3, pEFS-EGFP-Control or pCAG-EGFP-Control 
isolated from eye homogenates (4-5 eyes per lane) by sacrifice 6 months post injection. 
All clones produced a clear distinct band after StuI digestion, identical to the band 
arising after digestion of 8 ng of corresponding positive control original pDNAs. This 
shows that at 6 months post injections, S/MAR plasmids as well as the corresponding 
control non-S/MAR plasmids are maintained as an episome within the retina  
(pEFS-EGFP and pEFS-EGFP-Control on (A) or pCAG-EGFP and pCAG-EGFP-Control on 
(B); lanes 4 and 5 respectively (+)). Results are representative of two-three 
independent experiments. L: 1 Kb ladder (Invitrogen). 
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Figure 93: Representative Southern blot of isolated luciferase plasmids isolated at 
3 or 6 months post subretinal injections in MF1/WT mice 
Southern blots of total pDNA isolated from eye homogenates of MF1 mice 6 months post 
subretinal injection of (A) pUbiqC-Luc and pUbiqC-Luc-Control and (B) pCAG-Luc and  
pCAG-Luc-Control pDNA vectors, performed as described in methods. DNA (30 µg) was 
separated on 0.8% agarose gels and hybridized with 32P-labelled AlwNI probe. In (A) 
lanes 1-2, pUbiqC-Luc isolated from eye homogenates (4-5 eyes per lane expressing 
luciferase) by sacrifice 6 months post injection. Lane 3, pUbiqC-Luc-Control isolated 
from eye homogenates (4-5 eyes per lane not expressing luciferase) by sacrifice 6 
months post injection. In (B) lanes 1-2, pCAG-Luc isolated from eye homogenates (4-5 
eyes per lane expressing luciferase) by sacrifice 3 months post injection. Lane 3,  
pCAG-Luc isolated from eye homogenates (4-5 eyes per lane expressing luciferase) by 
sacrifice 6 months post injection, Lane 4 pCAG-Luc-Control isolated from eye 
homogenates (4-5 eyes per lane not expressing luciferase) by sacrifice 6 months post 
injection. All clones produced a clear distinct band after StuI digestion, identical to the 
band arising after digestion of 8 ng of corresponding positive control original pDNAs. 
This shows that at 6 months post injections, S/MAR plasmids as well as the 
corresponding control non-S/MAR plasmids are maintained as an episome within the 
retina (pUbiqC-Luc and pUbiqC-Luc-Control on (A); lanes 4 and 5 respectively (+) or 
pCAG-Luc and pCAG-Luc-Control on (B); lanes 5 and 6 on (B) respectively (+)). Results 
are representative of two-three independent experiments. L: 1 Kb ladder (Invitrogen). 
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In summary, as well as providing long-term expression, SMAR plasmids are able to be 
maintained episomally within the retina, showing no signs of vector integration seen with 
other viral vectors as well as further validating the safety of our plasmids in vitro as well as 
in vivo.  
 
3.3.11 Limitations of PEI as a gene transfer agent 
 
While we have shown no adverse effects within the retinas of injected mice following the 
subretinal injections of formulated S/MAR pDNA, on the rare occasion, white precipitate 
was observed following the fundus examination of injected retinas. Representative images 
are shown in Figure 94. Noteworthy is the fact that mice showing such precipitates were not 
used for subsequent analyses – particularly transgene analysis of frozen sections.  
One could explain this occurrence because of the limited stability of PEI/pDNA complexes in 
solution. Indeed complexes at concentration exceeding 0.5 µg/µl have been associated with 
considerable precipitation and in-turn loss of biological efficacy (Davies, McLachlan et al. 
2008). During all our subretinal injections, the preparation of complexes was done using 
freshly prepared, recently quantified pDNA stocks that had been delivered at 0.5 µg/µl - in 
order to deliver the highest concentrations of formulations to the retina without 
compromising on stability. Despite this one cannot exclude the possibility that on limited 
occasions following the subretinal injection of complexes, concentration levels exceeded  
0.5 µg/µl.  
Regardless of these obvious limitations of PEI as a gene delivery agent within the retina, we 
can confidently state that when S/MAR vectors are compacted with PEI – at the maximum 
threshold of 0.5 µg/µl - and injected into the correct or appropriate region of the eye long-
term episomal expression as well as limited toxicity is observed.  
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Figure 94: Representative ophthalmic examinations of fundi revealing the 
presence of precipitate following the subretinal injection of formulated PEI/pDNA 
Shown are the fundus examination (in situ) of two MF1 WT mice following the 
subretinally injection of formulated pDNA. On rare occasions, precipitate was observed 
within the retina as evident by white plaques encompassing the site of the subretinal 
injection (as indicated by the arrows). Pronounced precipitate is seen in the image on 
the left while less precipitate as well as a retinal detachment is seen in the image on the 
right. Such mice were not included in any subsequent analyses. Digital images may be 
clearer.   
 
3.3.12 Alternative administration routes in the eye - topical instillations and intravitreal 
injections 
 
Subretinal injections can be arguable considered as the ultimate delivery route to be 
considered for administration in the eye, specifically to the retina and RPE cells. Indeed we 
have shown in previous sections that the subretinal delivery of formulated pDNA is able to 
reach our target RPE cells efficiently. However, we were also eager to analyse alternative 
administration and delivery routes for gene delivery in the eye. Topical instillations have 
until recently been considered to have limited efficiencies. Despite this, previous reports 
show expression in various ocular tissues including corneal epithelium and RPE cells after 
topical administration of polymer micelles (PM)-formulated pDNA via EDTA enhancer 
treatment followed by eye drop delivery of pDNA (Liaw, Chang et al. 2001). 
Hence utilising a similar principle, briefly as described in the methods, the outbred MF1 
mouse strain was used, where eyes were pretreated with 5 mM EDTA (10 µL per mouse eye) 
which was applied as topical eye-drops to the cornea. Ten minutes following pretreatment, 
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mice were then delivered with 0.5 µg/µl of formulated pCAG-Luc pDNA with PEI (10 µl per 
mouse eye, three times per day). As a control the other eye either received plasmid alone or 
PEI formulated pCAG-Luc pDNA without enhancer pretreatment. At 24 and 48 hours 
following the first topical administration, the mice were assessed for gene transfer and 
imaged for luciferase expression using a Xenogen in vivo bioluminometer. 
Despite this we were unable to achieve any expression in the retina when topical 
instillations of EDTA enhancer and formulated PEI: pCAG-Luc pDNA, formulated pDNA 
without enhancer or plasmid alone was applied to the animals (data not shown). 
Another alternative method of vector delivery in the retina is through intravitreal injections. 
Intravitreal injections would deliver injected vectors into the vitreous of the eye, however to 
be of interest to us, the vectors would need to reach the target RPE cells; hence they would 
need to diffuse through the vitreous as well as the neural retina before reaching the RPE 
(Maurice and Mishima 1984; Bishop 2000). We were interested in analysing whether 
through intravitreal injections – we could observe gene expression within the retina, ideally 
in the RPE cells and also whether any other cells within the retina could also be transfected 
too.       
Hence in an approach identical to the initial stages of the subretinal injection technique 
described in section 3.3.1 and Figure 69A-D, MF1 mice were anesthetized and injected with 
a 32 gauge needle inserted through the sclera into the vitreous chamber of the eye. Mice 
were injected with 0.5 µg/µl of formulated/complexed pCAG-Luc pDNA with PEI (1-2 µl per 
mouse eye) as described in the methods. As a control the other contralateral eye remained 
uninjected, was injected with PBS alone or was injected with naked plasmid alone 
(uncomplexed). 24 and 48 hours following injection, mice were imaged for bioluminescent 
expression of luciferase as described earlier. Similar to the outcome seen for the topical 
instillations, no expression was observed in any of the groups of mice analysed following 
intravitreal injections of compelxed pCAG-Luc pDNA or naked pCAG-Luc pDNA with the 
retina (data not shown).  
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3.4 In vivo performance of REP1 plasmids (in WT and CHM mice) 
 
3.4.1 Tissue expression of REP1 in MF1/WT mice 
 
In an approach comparable to the RPE cell analysis of EGFP expression in vivo, the 
expression of REP1 protein was investigated. This was done by Western blot analysis of 
isolated RPE and neural cells from 10 C57BL/6 mice (3-4 months old) 48 hours following the 
double subretinal injection of formulated pCAG-REP1 and pCAG-REP1-Control plasmids. 
Samples were lysed and protein lysates (50 µg) were resolved on a 7% SDS-polyacrylamide 
gel. After this they were transferred to a PVDF membrane and probed with an anti-mouse 
REP1 antibody 2F1 which specifically recognises human Rep1 protein. A representative blot 
is shown in Figure 95. As expected, the Western analysis shows no expression within the 
neural retina while strong REP1 expression is seen within the isolated RPE cell layer from 
mouse retinas injected with both pCAG-REP1 and pCAG-REP1-Control pDNAs.  
Noteworthy, is the fact that the similar Western blot experiment involving the subretinal 
injection of formulated pEFS-REP1 plasmid was unsuccessful; showing no expression within 
either of the two isolated cell layers.    
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Figure 95: Western analysis of RPE and neural retinal cells isolated following the 
subretinal injection of pCAG-REP1 and pCAG-REP1-Control pDNA vectors 
The figure shows the expression of REP1 protein levels by Western analysis after 
separation of the RPE and neural retina (NR) cells (50 µg) from C57BL/6 mice (n=10) 
48 hours following the double subretinal injection of plasmids pCAG-REP1 and  
pCAG-REP1-Control. The expression of REP1 was observed using anti-mouse REP1 
antibody 2F1 which specifically recognises human Rep1 protein. Strong REP1 protein 
levels are observed exclusively in the isolated RPE cells of both injected plasmid groups. 
Untransfected RPE cells served as a negative control. Human Rep1 protein (hREP1) 
served as a positive control (40 ng), while α-tubulin was used as a loading control.  
 
While the expression of REP1 was confirmed in the RPE cells of injected C57BL/6 mice, we 
also wanted to show this localised expression by immunohistochemistry analysis of retinal 
sections. As we encountered considerable problems with the immunohistochemistry 
detection of EGFP S/MAR plasmids in C57BL/6 mice (described in the previous section 
3.3.4.1), we performed immunohistochemical analysis of REP1 transgene levels in MF1 
mice. Mice were subretinally injected with pCAG-REP1 plasmid and at 1 week post injection 
eyes were enucleated and frozen sections were obtained. Sections were then analysed by 
immunohistochemistry for the detection of REP1 transgene levels using the 2F1 anti-mouse 
monoclonal REP1 antibody which recognises only human Rep1 protein. Unfortunately, no 
difference in the expression of REP1 was seen between the analysed injected and control 
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sections; where considerable background staining was observed in both sections (data not 
shown).  
A possible explanation for the difficulties in detecting REP1 transgene levels in these 
sections could be due to the lack of specificity of the 2F1 antibody, potentially due to the 
fact that this antibody is a mouse antibody which is being used on mouse tissue. While the 
2F1 antibody is a mouse monoclonal antibody raised against recombinant human REP1 
(Santa Cruz), the immunohistochemical analysis of mouse retinal samples, shows that as a 
monoclonal antibody, the 2F1 antibody, is not specific for a single epitope of the human 
REP1 protein, but rather when used on mouse tissue it also recognising the mouse REP1 
epitope. Similar problems were also reported by others within our group when analysing 
retinal sections for REP1 expression levels using the 2F1 anti-mouse antibody.          
 
3.4.2 Long-term expression of REP1 plasmids in vivo in WT/ MF1 mice 
 
To analyse the long term transgene expression of REP1 in vivo in WT MF1 mice, total DNA 
was isolated from retinal homogenates at 1 week and 6 months following the subretinal 
injection of pEFS-REP1, pCAG-REP1 and control plasmids and analysed by PCR (Figure 96). 
PCR analysis of pEFS-REP1 and pCAG-REP1 pDNA revealed the long-term persistence of both 
plasmids within retinal homogenates. In contrast both control plasmids were absent at 6 
months post injection. These long term pDNA results are in agreement with previous 
analyses of EGFP and luciferase S/MAR plasmids in vivo. 
Total RNA was also extracted and REP1 RNA levels were analysed in retinal homogenates at 
1 and 6 months post injection by rt-PCR analysis (Figure 97). Similar to the pDNA PCR results 
above, REP1 mRNA analysis shows the long-term mRNA levels of REP1 from both pEFS-REP1 
and pCAG-REP1 injected retinas. The control injected samples in comparison loose REP1 
mRNA levels by 6 months following injection.     
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Figure 96: Short and long-term PCR detection of pEFS-REP1 and pCAG-REP1 pDNA 
vectors from eye homogenates following subretinal injections of MF1/ WT mice 
PCR analysis of (A) pEFS-REP1 and pEFS-REP1-Control and (B) pCAG-REP1 and  
pCAG-REP1-Control pDNA vectors at 1 week (lanes 1-3) and 6 months (lanes 4-6) post 
injection (PI). PCR samples were separated by agarose gel electrophoresis and a 
positive PCR band was observed using EFS-REP1 or CAG-REP1 specific primer sets 
yielding a product size of 650 bp or 430 bp respectively. The arrowhead indicates the 
size corresponding to pDNA 650 bp on (A), 430 bp on (B). Uninjected eyes as well as no 
PCR product/water served as a negative control (lanes 7 and 9 respectively), while 
pDNA (25ng) pEFS-REP1 (in the case of A) or pCAG-REP1 (in the case of B) served as a 
positive control (lane 8) for the PCR reaction. Results are representative of three 
independent experiments. L= 100bp ladder (Invitrogen). 
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Figure 97: RT-PCR analysis of short and long-term REP1 mRNA from tissue 
homogenates following subretinal injections of MF1/ WT mice with pEFS-REP1 
and pCAG-REP1 pDNA vectors 
Total RNA was extracted from MF1/WT mice following single subretinal injections of  
(A) pEFS-REP1 and pEFS-REP1-Control and (B) pCAG-REP1 and pCAG-REP1-Control 
pDNA vectors at 1 week (lanes 1-3) and 6 months (lanes 4-6) post injection (PI). Total 
RNA was isolated and used to generate cDNA. PCR was performed with human REP1 
specific primers to yield a product size of 240 bp as indicated by the arrowhead on (A) 
and (B). RNA from untransfected AtT20 cells as well as no RNA product/water served 
as a negative control (lanes 9 and 11), while AtT20 cells transfected with pEFS-REP1 (in 
the case of (A)) or pCAG-REP1 (in the case of (B)) served as a positive control (lane 10 
and 12). Lane 8 is empty/blank. Results are representative of three independent 
experiments. L= 100 bp ladder (Invitrogen). 
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3.4.3 Episomal status of REP1 S/MAR plasmids in vivo 
 
To confirm the episomal state of both REP1 constructs in the RPE cells of the retina, total 
DNA was isolated from retinal homogenates at 6 months post injection. Following this 
plasmid rescue analysis was performed on the pEFS-REP1 and pCAG-REP1 isolated from 
E.coli bacterial cells after transformation with 1 µg of total DNA. The restriction pattern of 
the pEFS-REP1 plasmid was analysed using EcoRI and XhoI; giving the fragments 3400 bp, 
2301 bp and 1651 bp with EcoRI and fragments 1150 bp, 1300 bp and 4902 bp with XhoI. In 
contrast, the digestion pattern of pCAG-REP1 plasmid was analysed using EcoRI and EcoRV; 
giving the fragments 4830 bp, 2300 bp and 1700 bp with EcoRI and 2110 bp and 6720 bp 
with EcoRV. In all cases the restriction pattern was identical to those observed with the 
positive control of the digested original pDNA - pEFS-REP1 and pCAG-REP1 (Figure 98).  
The episomal state was further confirmed by Southern analysis. Total retinal DNA was also 
isolated from non-S/MAR control plasmids of both REP1 constructs. Isolated DNA (30 µg) 
was digested with StuI restriction enzyme and analysed by Southern hybridization with a 
32P-labeled AlwNI fragment - common to all S/MAR plasmids - that was used as a probe for 
the Southern blot. The hybridisation pattern clearly shows the episomal state of both  
pEFS-REP1 and pCAG-REP1 plasmids with distinct bands identical to the size of the original 
plasmids (Figure 99). Importantly, both control plasmids are still maintained episomally 
within the retina, although expression is observed to be only transient (Figure 96 and  
Figure 97).  
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Figure 98: Plasmid rescue analysis of the episomal status of REP1 plasmids 
isolated at 6 months post subretinal injections in MF1/WT mice 
Plasmid rescue analysis of pDNA isolated from 2 randomly chosen clones (lanes 1-2), 
after transformation of E.coli bacteria with 1 µg of total DNA isolated from eye 
homogenates of MF1 mice 6 months post subretinal injection of (A) pEFS-REP1 and  
(B) pCAG-REP1 pDNA vectors, performed as described in methods. Undigested plasmid 
served as a negative control (-), while all bands show identical sizes with the positive 
control of original pEFS-REP1 on (A) or pCAG-REP1 on (B) (+), demonstrating that 
pEFS-REP1 and pCAG-REP1 vectors are retained episomally in the retinas of injected 
MF1 mice. Results are representative of two independent experiments. Some fragments 
may be faint but seen clearer on the digital image. L: 1 kb Ladder (Invitrogen). 
 
 
291 
 
 
Figure 99: Southern blot analysis of the episomal status of REP1 plasmids isolated 
at 6 months post subretinal injections in MF1/WT mice. 
Southern blots of total pDNA isolated from eye homogenates of MF1 mice 6 months post 
subretinal injection of (A) pEFS-REP1 and pEFS-REP1-Control and (B) pCAG-REP1 and  
pCAG-REP1-Control pDNA vectors, performed as described in methods. DNA (30 µg) 
was separated on 0.8% agarose gels and hybridized with 32P-labelled AlwNI probe.  
Lanes 1-2, pEFS-REP1 or pCAG-REP1 isolated from eye homogenates (4-5 eyes per lane) 
by sacrifice 6 months post injection. Lane 3, pEFS-REP1-Control or pCAG-REP1-Control 
isolated from eye homogenates (4-5 eyes per lane) by sacrifice 6 months post injection. 
All clones produced a clear distinct band after StuI digestion, identical to the band 
arising after digestion of 8 ng of corresponding positive control original pDNAs  
(pEFS-REP1 and pEFS-REP1-Control on (A) or pCAG-REP1 and pCAG-REP1-Control on 
(B); lanes 4 and 5 respectively (+)). Results are representative of two independent 
experiments. L: 1 Kb ladder (Invitrogen). 
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3.4.4 Tissue expression of REP1 in CHM mice 
 
The ultimate aim of this study is to develop a non-viral S/MAR plasmid harbouring the REP1 
transgene, to be used as a potential novel therapeutic option for treating CHM mice in vivo. 
As shown in Section 3.3.4.1, S/MAR plasmids harbouring the EFS promoter show 
considerably lower plasmid expression in vivo. Hence despite both plasmids (pEFS-REP1 and 
pCAG-REP1) showing persistent expression in WT MF1 mice, only the pCAG-REP1 plasmid 
and its control were used for injections in CHM mice. We were eager to analyse the ability 
of pCAG-REP1 to mediate long-term REP1 transgene levels in CHM mice, as well as to assess 
the episomal status and any potential phenotypic or genotypic functional rescue within the 
retina following injections.  
The CHM mouse models chosen for analysis where: CHMFlox, Tyr-Cre+ mice and Chmnull/WT. In 
male and female mice, the CHM null alleles cause embryonic lethality; hence various CHM 
mouse models have been created to overcome these problems (Tolmachova, Anders et al. 
2006). As CHM is X-linked, one such mouse model chosen is the CHMnull/WT mice where 
heterozygous-null females are chimeras; approximately 50% of cells are expected to be 
knockout (KO) cells, showing no REP1 function, while the remaining cells are normal with 
normal REP1 function. As CHMnull/WT mice show progressive degeneration of the retina by  
4-8 months – as evident by patchy degeneration seen in both RPE and photoreceptor cells – 
these mice are the ‘true’ CHM mouse model to use for long term analyses. Hence 1 month 
old mice would be injected with formulated pCAG-REP1 prior to the onset of disease, and 
would be assess at 6 months post injection for the phenotypic rescue of degeneration 
within the retina - via detailed ophthalmic examination (using a scanning laser 
ophthalmoscope-SLO for detailed fundus examination), electroretinographic analysis (using 
an electroretinogram-ERG for detailed analysis of retinal function particularly in various cell 
types within the retina including the photoreceptors and ganglion cells) as well as 
histological analysis of injected retina sections.   
In contrast, the CHMFlox, Tyr-Cre+ mice are a tissue specific KO mouse model, showing 
complete KO within the RPE and other pigmented cells only, while the photoreceptors and 
remaining neural retina are normal. These mice were used for all short term experiments 
for genotypic rescue, where the assessment of REP1 transgene levels as well as the rescue 
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of the prenylation defect, particularly rescue of Rab27a prenylation which is known to be 
defective in CHM mice would be assessed.  
 
3.4.4.1 Long term expression in CHM mice  
 
To assess the persistence of REP1 transgene expression following the subretinal injection of 
formulated pCAG-REP1 and pCAG-REP1-Control in CHM injected mice, total DNA and RNA 
was isolated from retinal homogenates injected with both plasmids. For short-term 
expression, CHMFlox, Tyr-Cre+mouse homogenates were analysed 1 month post injection 
(PI), while CHMnull/WT mouse homogenates were assessed for long-term expression at 6 
months PI. Representative PCR analysis shows expression of both plasmids (pCAG-REP1 and  
pCAG-REP1-Control) at 1 month PI in CHMFlox, Tyr-Cre+analysed retinas. By 6 months PI only 
expression of pCAG-REP1 was observed in the CHMnull/WT analysed retina, while expression 
of pCAG-REP1-Control was lost (Figure 100A).  
Similarly rt-PCR shows high levels of REP1 mRNA from pCAG-REP1 plasmid at 1 and 6 
months PI corresponding to the CHMFlox, Tyr-Cre+and CHMnull/WT retinas respectively, while 
REP1 mRNA levels were lost by 6 months PI from the retina of a CHMnull/WT mouse injected 
with pCAG-REP1-Control plasmid (Figure 100B).  
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Figure 100: Analysis of short and long-term pCAG-REP1 pDNA and REP1 mRNA 
from tissue homogenates following subretinal injections of CHM mice with pCAG-
REP1 pDNA vector 
CHMFlox, Tyr-Cre+ (Flox, Tyr) and CHMnull/WT (null/wt) mice were subretinally injected 
with pCAG-REP1 and pCAG-REP1-Control pDNA vectors, performed as described in 
methods. (A) Isolated DNA was extracted from injected retinas at 1 month (lanes 1-2) 
and 6 months (lanes 3-4) post injection (1M and 6M PI respectively). PCR samples were 
separated by agarose gel electrophoresis and a positive PCR band was observed using 
CAG-REP1 specific primer sets yielding a product size of 430 bp as indicated by the 
arrowhead. Uninjected retinas from CHMFlox, Tyr-Cre+ mice, as well as no PCR 
product/water were included as a negative control (lanes 5 and 7), while pDNA (25ng) 
pCAG-REP1 served as a positive control (lane 6) for the PCR reaction.  
(B) Total RNA was isolated and used to generate cDNA. PCR was performed with human 
REP1 specific primers to yield a product size of 240 bp as indicated by the arrowhead. 
As a negative control no RNA product/water was used (lane 6), while RNA from human 
CHM4 KO cells transfected with pCAG-REP1 served as a positive control (lane 5). Each 
lane represents one retina analysed. L= 100 bp ladder (Invitrogen). 
 
 
 
 
 
 
 
295 
 
3.4.5 Episomal status in CHM mice 
 
In order to investigate the status of the pCAG-REP1 plasmid in the retina at 1 and 6 months 
PI, total DNA from the corresponding CHMFlox, Tyr-Cre+ and CHMnull/WT mice were obtained 
and analysed by plasmid rescue for episomal maintenance. E.coli cells were transformed 
with 1 µg of total DNA and kanamycin-resistant colonies were obtained the next day at a 
rate of between 3-5 colonies per plate. This low number signifies that the pCAG-REP1 
plasmid is maintained at a low plasmid copy number within the retina, as shown previously 
for pCAG-REP1 and pEFS-REP1 in WT mice. Plasmids isolated from two colonies for the 
pCAG-REP1 plasmid (using a MiniPrep kit) were digested with EcoRI and EcoRV restriction 
enzymes. The fragments 4830 bp, 2300 bp and 1700 bp were observed with EcoRI and 
2110 bp and 6720 bp with EcoRV. The restriction patterns of this plasmid are consistent with 
an unmodified non-integrating plasmid construct (Figure 101).  
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Figure 101:   Plasmid rescue analysis of the episomal status of pCAG-REP1 vector 
isolated at 1 month and 6 months post subretinal injections in CHM mice 
Plasmid rescue analysis of total DNA isolated from eye homogenates of  
CHMFlox, Tyr-Cre+ (Flox, Tyr) and CHMnull/WT (null/wt) mice at 1 and 6 months post 
injection (PI) of pCAG-REP1 plasmid. The left panel shows the EcoRI restriction pattern 
of pDNA isolated from 2 randomly chosen clones after transformation of E.coli bacteria 
with 1 µg of total DNA isolated from eye homogenates of CHMFlox, Tyr-Cre+ mice at 1 
month PI (lanes 1-2) and CHMnull/WT mice at 6 months PI (lanes 3-4). The right panel 
shows the EcoRV analysis of the same 2 clones at 1 and 6 PI. Undigested plasmid served 
as a negative control (lane 5; -), while all bands show an identical size to the positive 
control pCAG-REP1 (lane 6; +), verifying the episomal status of pCAG-REP1 vector in the 
retinas of injected CHM mice. L: 1 kb Ladder (Invitrogen). 
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3.4.6 Functional long-term rescue in CHM mice 
To determine if the long-term expression of REP1 protein within the retinas of injected CHM 
mice was able to provide functional rescue of the CHM phenotype, we analysed the 
prenylation status of Rab27a protein within the RPE cells of injected CHMnull/WT mice at 6 
months post injection (PI). We have shown previously that following subretinal injections of 
S/MAR pDNAs into the retina, RPE cells are transduced. Hence, RPE cells were isolated from 
4 injected retinas as described previously. RPE cells were isolated and used for subsequent 
analysis rather than intact retinal homogenates, as we wanted to increase the chances of 
seeing a functional phenotypic effect. Thus this was most likely to be within the cells we 
know we have been able to transfect in the past. Isolated RPE cells were also collected from 
uninjected retinas of the same mouse. Briefly, we isolated the RPE cells from these mice and 
analysed the Rab27a prenylation status by subjecting cells to subcellular fractionation and 
subsequent immunoblot analysis probing with an anti-Rab27a antibody 4B12.  
Figure 102 shows the Western blot performed on the RPE cells isolated from the long-term 
expressing CHMnull/WT mice at 6 months post injection (PI) with pCAG-REP1 plasmid. The blot 
shows the presence of Rab27a protein in both the cytosolic and pellet fractions in the RPE 
cells isolated from uninjected CHMnull/WT mice. This expression pattern shows that the 
Rab27a protein within these cells is not correctly prenylated and so remains in the cytosol 
and in turn is dysfunctional. Excitingly, when this expression pattern is compare to that of 
isolated RPE cells from injected CHMnull/WT mice at 6 months PI, a clear shift and subsequent 
reduction in the expression of Rab27a protein levels in the cytosolic fraction is observed. 
This shows that after 6 months following the subretinal injection of pCAG-REP1 pDNA vector 
in CHMnull/WT mice, we were able to observe the functional phenotypic rescue of Rab27a 
protein expression within the RPE cells isolated from injected retinas.  
Despite the clear Rab27a rescue observed, many reports have also indicated that a number 
of other as yet unidentified Rab proteins may also be defective in CHM cells (Tolmachova, 
Anders et al. 2006, Seabra 1996; Seabra, Ho et al. 1995). Hence while these results are 
extremely exciting, one cannot rule out that other Rab proteins (which have not been 
analysed in these samples) may not have been functionally rescued and indeed the defect of 
prenylation in these other Rab proteins may not be observed.  
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Figure 102: Western analysis showing the phenotypic rescue of Rab27a protein 
function in CHMnull/WT mice at 6 months post subretinal injection of pCAG-REP1 
vector 
RPE cells were isolated from CHMnull/WT mice at 6 months following the subretinal 
injection of pCAG-REP1 pDNA vector. Cells were lysed (25 µg) and subjected to 
subcellular fractionation where soluble (S) and pellet (P) fractions were analysed by 
Western analysis and probed with anti-Rab27a antibody 4B12. RPE cells from injected 
CHMnull/WT mice at 6 months PI show a clear shift and reduction of Rab27a protein 
expression in the soluble fraction compared to the pellet fraction, indicating that these 
isolated RPE cells have less unprenylated Rab27a protein in the cytosol, and so a 
functional rescue of Rab27a protein is observed. Rab11 was used as a loading control. 
Results are representative of one experiment.  
 
Out of 9 CHMnull/WT mice injected in total, by 6 months following injection, 6 mice had 
developed dense iatrogenic cataracts; i.e. these cataracts were induced inadvertently 
following the subretinal injection procedure.  This was most probably due to the lens being 
touched during the injection procedure. At the stage of injection, all 9 CHM mice were 
extremely small as they were only 1 month old, thus these mice were probably more 
vulnerable to iatrogenic cataracts, due to the small size of all retinas. Unfortunately all 
iatrogenic cataracts were too dense to allow subsequent fundus examinations. Furthermore 
the remaining 3 CHM mice, while all had milder iatrogenic cataracts, only partial fundus 
examinations were possible. Despite this, we decided to analyse these three mice for 
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additional functional rescue, where the mice were transferred to a collaborator Prof Robert 
MacLaren at Oxford University for further analysis (SLO and ERG analysis). Due to time 
restraints, these experiments were still ongoing at the end of this study and so were not 
included in this project. 
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4 DISCUSSION 
____________________________________________________________________________ 
 
4.1 The ideal gene therapy vector – Summary of project 
 
Viral vectors have long been the preferred system in the majority of experimental and 
clinical studies for ocular gene therapy. However, several safety issues have been 
highlighted in recent times (Provost, Le Meur et al. 2005; Stieger, Colle et al. 2008), paving 
the way for alternative delivery routes. Despite this, alternative non-viral vectors have often 
been plagued by low transfection efficiencies and transient transgene expression in vivo. 
These problems have rendered them unacceptable as gene delivery options for the clinic. 
The exception to the rule has possibly been the development of nanoparticles and their 
successful long-term expression in vivo (Farjo, Skaggs et al. 2006; Cai, Nash et al. 2009). We 
hoped to utilise vectors harbouring scaffold/matrix attachment regions (S/MARs) as an 
alternative non-viral delivery tool. To this end, the aim of this study was to develop a novel, 
non-viral, episomal gene therapy vector for stable, long-term gene expression in vitro with 
ocular applications. Specifically, we aimed towards the development of a non-viral gene 
therapy strategy for Choroideremia (CHM).  
The ideal non-viral vector for human gene therapy must be able to mediate long-term levels 
of therapeutic transgene expression as well as having no detrimental effect on the host at 
the cellular or somatic level. The recently described pEPI vector possesses key features of 
replication and episomal retention. This appears to be solely through the use of an S/MAR 
which functions as a cis-acting element for episomal retention (Jackson, Juranek et al. 2006). 
Of particular interest are the mammalian S/MAR elements, the human β-interferon gene 
cluster. This class of S/MAR elements has been shown in vitro to prevent S/MAR-containing 
pDNA vectors from integration (Piechaczek, Fetzer et al. 1999), epigenetic transgene 
silencing while also promoting extra-chromosomal and mitotic stability (Jenke, Stehle et al. 
2004). Noteworthy is the fact that these key characteristics are provided without the need 
for viral encoded proteins (Piechaczek, Fetzer et al. 1999; Papapetrou, Ziros et al. 2006). The 
ability to provide mitotic stability is thought to be due to the direct interaction of the S/MAR 
element with the components of the nuclear matrix (Jenke, Fetzer et al. 2002; de Jong 
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2006). In particular, the S/MAR element from the pEPI plasmid was found to preferentially 
associate with the scaffold attachment factor A (SAF-A) protein which is a principle 
component of chromatin and chromosomes (Kipp, Gohring et al. 2000). This interaction 
most likely brings pEPI into contact with the host replication machinery, which is located on 
the nuclear matrix, hence facilitating pEPI replication once per cell cycle.  
Furthermore, S/MAR pDNAs have also recently been shown to provide persistent transgene 
expression in vivo following hydrodynamic delivery to the murine liver (Argyros, Wong et al. 
2008). However the precise mechanism by which S/MAR elements provide this key 
sustainability in vivo has not been investigated. 
 
The CMV promoter of the pEPI plasmid has been shown to provide high transgene levels  
in vitro. However, in vivo expression is transient. This is primarily due to viral promoters 
such as CMV, becoming transcriptionally silenced due to methylation of the promoter 
(Jenke, Stehle et al. 2004; Brooks, Harkins et al. 2004; Kachi, Esumi et al. 2006; Kachi, 
Oshima et al. 2005). Hence to minimise the potential loss of transgene expression we 
developed other plasmids harbouring different promoters.  
Previous studies for targeted delivery to specific cell types within the retina have utilised 
tissue specific promoters. The promoters of interphotoreceptor retinoid binding protein 
(IRBP) (Semple-Rowland, Eccles et al. 2007) as well as rhodopsin (RHO) genes (Bemelmans, 
Bonnel et al. 2005) have been effectively used for delivery to the photoreceptor cells. In 
contrast, the vitelliform macular dystrophy (VMD2) and tyrosinase related protein-1 (Tyrp1) 
or tyrosinase (Murisier, Guichard et al. 2006) promoters have been shown to selectively 
express in RPE cells (Kachi, Oshima et al. 2005; Kachi, Esumi et al. 2006). However as CHM is 
a disease primarily of both these cell layers, we chose to create plasmids with ubiquitously 
expressed promoters based on the elongation factor-1 (EF1-α and its intronless version EFS) 
and (CMV) early enhancer/chicken beta actin (CAG) promoters. Both promoters have been 
shown in the past to maintain efficient expression in the RPE and photoreceptor cells 
(Kostic, Chiodini et al. 2003; Cashman, McCullough et al. 2007). We show that the inclusion 
of an S/MAR element into an EFS and CAG promoter-driven plasmid is able to provide 
persistent transgene expression in vitro. However, perhaps more importantly, following the 
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subretinal delivery into the mouse retina, we show the unparalleled long-term transgene 
expression from both these S/MAR vectors in ocular tissue. To our knowledge this is the first 
attempt with pDNA to correct for CHM, where we showed a partial correction of the 
phenotype in vitro as well as in vivo.  
While this is extremely exciting, the results provided in this study have some limitations. 
Furthermore improvements can be made to our current episomal plasmids to enhance and 
stabilise gene expression. 
 
4.2 Experimental Limitations 
 
A substantial limitation to the experiments described throughout this thesis has been the 
lack of appropriate ‘negative rt’ controls in all rt-PCR experiments. During RNA preparations, 
it is virtually impossible to completely eliminate genomic DNA. Therefore it is important to 
include a minus-reverse transcriptase control in all rt-PCR experiments; typically this would 
include a mock reverse transcription containing all rt-PCR reagents, except the reverse 
transcriptase. If a product is observed with the negative rt control, this would indicate that 
contaminating DNA is present in the sample. As this important control is missing from all rt-
PCR experiments, and thus genomic DNA contamination cannot be ruled out, one must be 
cautious with the interpretation of these results.  
 
An additional limitation due to time restraints was the fact that all prenylations experiments 
were only performed once. While long term Western analysis showing phenotypic rescue of 
Rab27a protein function in vitro as well as in vivo with the pCAG-REP1 vector was 
demonstrated clearly, further repeat experiments would add confidence to these 
experiments. 
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4.3 Long-term expression in vitro 
4.3.1 Immortalised cell lines 
 
Following the generation of stable pEGFP-S/MAR and pREP1-S/MAR vectors in AtT20 cells, 
we were able to show that both plasmid vectors were able to mediate persistent transgene 
expression in vitro. This is in agreement with previously published reports for pEPI plasmid 
in cell lines including the Chinese hamster ovary (CHO-K1) cells (Piechaczek, Fetzer et al. 
1999; Papapetrou, Zoumbos et al. 2005), human cervical cancer (HeLa) cells (Schaarschmidt, 
Baltin et al. 2004) and mouse embryonic fibroblast (NIH 3T3) (Broll, Oumard et al. 2010). 
Furthermore efficient replication and episomal maintenance was observed in these cells. 
We show that all plasmids were maintained at a low-copy number (vector molecules/cell)  
in vitro. Similar finding were seen in previous studies where less than 10 copies/cell have 
been reported for the pEPI plasmid (Piechaczek, Fetzer et al. 1999; Baiker, Maercker et al. 
2000).  
Interestingly we show that in vitro the promoter is not the principle requirement for  
long-term transgene expression. Indeed the active transcription of the promoter upstream 
of the S/MAR and then continuation past the promoter and extending part of the way into 
the S/MAR is believed to be crucial for long-term expression in vitro (Stehle, Scinteie et al. 
2003). 
While long-term expression was observed, an initial selection pressure in the form of 
antibiotic (G418) was required. This was because without this selection pressure, expression 
was readily lost in vitro (personal observations). Suggestions have been made that following 
G418 selection, pEPI is able to be maintained in nuclear compartments called ‘replication 
factories’. These factories aid in the ability of pEPI to persistently express transgenes (Cook, 
Gattone et al. 1983; Zaidi, Young et al.2005). This hypothesis suggests that several 
molecules of DNA polymerase are located and only active within the nucleus at these 
replication factories. Therefore one can propose that following the transcription of the 
neo/kan gene within these plasmids, as well as the treatment with the G418 antibiotic, 
these cells were able to be maintained within these replication factories. If the maintenance 
of plasmids in these factories is a rare event, the necessity for this initial selection pressure 
becomes clear. Furthermore our plasmids are maintained extra-chromosomally possibly due 
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to the binding the S/MAR elements within our plasmids to the SAF-1 protein. This theory 
could also explain the reason why we were able to observe episomal maintenance of all 
S/MAR and non-S/MAR plasmids in vitro, despite the lack of persistent transgene expression 
from the non-S/MAR plasmids. 
 
4.3.2 Primary fibroblasts 
 
We were also able to perform the novel proof-of-principle experiments were we showed 
long-term expression of pCAG-REP1 in CHM KO human (CHM4 fibroblasts) and mouse (Flox, 
MerCreMer+, tamoxifen-induced) cells. Both primary KO cell lines expressed moderate levels 
of the human REP1 protein up to 6 weeks in vitro. The lack of REP1 function in CHM is 
thought to be caused by Rab prenylation defects, in particular Rab27a (Seabra, Ho et al. 
1995). Therefore in order to assess the ability to rescue the function of these cells in vitro, 
we assessed the prenylation status of Rab27a within our long-term expressing cells. We 
were able to observe a shift in the pattern of Rab27a protein, from the cytosolic to the 
pellet fraction. This suggested that following transfection with the pCAG-REP1 plasmid, 
these KO cells are able to correctly prenylate Rab27a and subsequently correctly target 
Rab27a to intracellular membranes. These novel experiments highlighted the utility of 
S/MAR vectors for CHM therapy. 
 
4.4 Long-term expression in vivo 
4.4.1 Effective Subretinal injections and formulations 
 
We have also shown unparalleled long-term transgene expression and efficient delivery of 
our S/MAR vectors within the retinas of injected mice for up to 1 year following a single 
subretinal injection. Furthermore, we also showed the episomal maintenance within the 
RPE cells of the retina for up to 6 months following injections of pDNA. Noteworthy is the 
observation that there was minimal adverse effect from the subretinal injection of S/MAR 
pDNA into the mouse eye. This was analysed by H&E analysis, TUNEL staining, fundus 
imaging as well as ELISA analysis showing normal morphology as well as limited levels of 
inflammatory cytokines in the retina. 
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Interestingly, we observed for that upon comparison of complexed vector DNA from both 
S/MAR and control (non-S/MAR) plasmids, transgene expression levels were diminished in 
all control plasmids as early as one month post injection. This was seen regardless of 
whether the pDNA expressed luciferase or EGFP. Indeed this pattern of transient expression 
is in agreement with previously published studies where non-S/MAR plasmids showed a 
sharp decline in transgene levels within one week of injection in the liver (Argyros, Wong et 
al. 2008; Wong, Argyros et al. 2011). The authors suggested this was due to extensive 
methylation of the promoter sequence in these non-S/MAR plasmids (Argyros, Wong et al. 
2008). However, there are also numerous other reasons for transcriptional silencing within 
the eye following injections of vectors including histone deacetylation (Fedor and Daniell 
1980) as well as cytokine-induced suppression (Fiorentini and Maffei 1976). One can 
elucidate that the latter is unlikely to be attributed to transcription silencing in our study, as 
no elevated levels of cytokines were detected in subretinally injected retinas. However 
additional work is needed to clearly establish the mechanism of the transcriptional silencing 
of control plasmids in the retina.  
Regardless of this, we have shown that pDNA vectors harbouring an S/MAR moiety with a 
ubiquitously expressing promoter are indeed protected from silencing in the eye. 
Interestingly, this is contrary to previous reports that show synergy between S/MAR 
elements and tissue specific promoters (Argyros, Wong et al. 2008). One can speculate that 
the within the retina as the cells are non-dividing, ultimately, if one is able to direct pDNA 
efficiently with an S/MAR plasmid containing a strong promoter - regardless of whether this 
is a tissue specific promoter or not - one can obtain long-term expression. Therefore the 
need for tissue specific promoters may only apply to rapidly dividing tissues such as the 
liver. Within the retina, we are able to effectively complex our pDNAs with the cationic 
polymer polyethylenimine (PEI) and subsequently, this together with the efficient delivery 
to the retina via a subretinal injection is able to mediate long-term transgene level in vivo.  
In our study, we observed that the luciferase expression following administration of 
naked/un-complexed pDNA (pCAG-Luci-S/MAR) was initially similar to the expression of 
complexed pDNA (PEI: pCAG-Luci-S/MAR). In first light this appears puzzling, however this 
may be explained by the low nuclease activity in the eye (Napirei, Ricken et al. 2004; Kurreck 
2009). Hence after a brief period of expression, naked pDNA is either shed away by 
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nucleases or switched off by a number of ways indicated previously, due to the lack of a PEI 
protective barrier surrounding the pDNA upon subretinal injection in the eye. 
 
4.4.2 Lack of expression following alternative routes 
 
During this study, we were also eager to analyse whether by utilising different delivery 
routes in the eye we could potentially target transgene expression to different regions of 
the eye. Previously, polymer micelles (PM) have been formulated with pDNA and delivered 
efficiently to the eye via topical instillations (Liaw, Chang et al. 2001). Interestingly, this 
report showed successful delivery to the cornea as well as other cells of the eye (at a lower 
level) using an enhancer treatment of EDTA prior to pDNA delivery. Utilising a similar 
approach, we found no expression in the cornea or retina after EDTA enhancer and 
formulated PEI:S/MAR pDNA was applied to the corneas of mice. While the mechanism of 
EDTA transport is largely unclear in the cornea, it has been proposed that internalisation is 
influenced by endocytosis and the opening of the tight junctions at the corneal epithelium 
(Liaw, Chang et al. 2001; Tong, Chang et al 2007). It is important however to note that, the 
transport mechanism of complexed PEI is known to be through the proton-sponge 
mechanism (Boussif, Lezoualc'h et al. 1995; Behr 1997) and indeed the escape from the 
endocytic pathway. Hence as the transport mechanism of PEI is not through endocytosis, it 
perhaps is not surprising that no expression was observed in corneal tissues or other areas 
of the retina following eye drop delivery of S/MAR formulated pDNA. Importantly the fact 
that naked/un-complexed DNA also showed no expression in the eye perhaps highlights the 
limitations of this approach in reaching not only corneal cells but also cells of the inner 
retina.  
As an alternative method, we also attempted to deliver pDNA formulations to the retina via 
intravitreal injections; however this also resulted in no expression within the retina. This 
may be explained by studies which have looked into the complex network within the 
vitreous, namely the negatively charged glycosaminoglycans (GAGs). Within the vitreous, 
GAGs bind to positively charged complexes such as cationic lipids if delivered to the vitreous 
without shielding their surface with polyethylenegylcol (PEG; named ‘pegylation’) (Peeters, 
Sanders et al. 2005; Pitkanen, Ruponen et al. 2003). Hence one can explain the lack of 
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expression following the intravitreal injections of formulated pDNA with PEI due to the lack 
of pegylation of these pDNAs prior to injection. Indeed as GAGs are negatively charged, they 
have a high affinity for positively charged lipids whereby they bind and form aggregates 
within the retina if delivered unpegylated (Peeters, Sanders et al. 2005; Peeters, Sanders et 
al. 2007). Furthermore, the neural retina - in particular the inner limiting membrane (ILM) - 
is also poorly permeable to unpegylated complexes including PEI polyplexes we used within 
our study, as shown previously (Pitkanen, Ruponen et al. 2004). 
While we observed no expression following intravitreal injection of PEI/DNA polyplexes at a 
nitrogen/phosphate ratio of 8:1 (N/P 8), we did not optimise the transfection efficiencies 
using this approach. Indeed others have found that following the intravitreal injection of 
PEI/DNA polyplexes at N/P 10, transgene expression was evident in the ganglion cell layer of 
the retina (Liao and Yau 2007). Our current formulations are efficient at delivering 
transgenes to the subretinal space, specifically well suited to targeting the RPE cell layer. 
However future optimisation of formulations coupled with intravitreal injections could allow 
the expression of transgenes to other cell types such as ganglion cells. This is seen in recent 
studies which have shown the restoration of photosensitivity in mice that have degenerated 
rod and cone cells. In these studies following intravitreal injections, virus-mediated 
expression of channel rhodopsin, which is a photosensitive ion channel, was observed in 
ganglion cells (Bi, Cui et al. 2006). Thus future developments of this approach could have 
considerable implications for targeting other cell types in the retina.  
 
4.4.3 Improvements in the gene delivery vehicle 
 
PEI has been shown to efficiently condense pDNA in vitro as well as in vivo (Boussif, 
Lezoualc'h et al. 1995). Furthermore the significant expression observed in the retinas of 
injected mice also shows that PEI has considerable utility for ocular gene therapy. 
Unfortunately however, the ultimate development of clinically viable formulation of PEI, 
appear to be limited. This is mainly due to the limited stability as well as the low 
concentration of PEI/pDNA complexes (0.5 µg/ µl) in solution prior to the loss of stability – 
normally in the form of precipitate.  
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Indeed in some rare situations we saw the presence of precipitates within the retinas of 
injected mice. However noteworthy is the fact that, despite the observation of precipitate, 
luciferase expression was still seen within the eye. One could argue that the occurrence of 
precipitates within the retina may not have been solely due to the instability of PEI/DNA 
complexes in solution. It may be likely that the vector which was injected into the retina 
may not have completely entered the subretinal space, while small amounts of vector could 
also have entered the vitreous. As mentioned previously, GAGs found in the vitreous have 
been shown to cause severe aggregation of lipoplexes within the vitreous (Peeters, Sanders 
et al. 2005; Pitkanen, Ruponen et al. 2003). Interestingly the aggregation of nanoparticles in 
the vitreous is overcome by shielding their surface through pegylation (Peeters, Sanders et 
al. 2005; Peeters, Sanders et al. 2007). Hence in the future perhaps pegylation of S/MAR 
pDNA vectors could be examined as a route to avoid aggregation of the vectors in the 
vitreous. 
The problem of low concentrations of PEI/DNA complexes is heightened by the limited size 
of the retina. This is particularly evident in the mouse retina, as following stable complex 
formulations a maximum volume of 1-2 µl can be injected into the retina before which 
irreparable damage is observed. Davies et al. recently introduced a method of concentrating 
pDNA/PEI complexes using ultracentrifugation, whereby concentration levels of pDNA/PEI 
formulations were dramatically increased from 0.2 to >8 mg/ml pDNA (Davies, McLachlan et 
al.2008). For future experiments one could take these results forward and potentially 
enhance the concentration of pDNA/PEI complexes delivered to the retina using 
ultracentrifugation. 
 
4.5 A therapeutic option for Choroideremia 
 
The ultimate aim of this project was the development of non-viral vectors for CHM gene 
therapy. Hence we hoped to apply the success of our preliminary proof-of-principle 
experiments in CHM KO cells to show that our plasmids were able to also provide 
phenotypic correction in vitro. To this end, we initially showed the transient and long-term 
expression of pCAG-REP1 in the RPE cells of two CHM models: Tyr-Cre+ and CHMnull/WT mice. 
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Furthermore we also showed that pDNA in the retinas of injected mice was maintained as 
an episome. However our ultimate intereste was to analyse whether long-term REP1 
protein within injected retinas of CHM mice could provide functional rescue of the CHM 
phenotype in the CHMnull/WT mice. Tolmachova et al. have previously shown this mouse 
model to have prenylation defects, namely defects of Rab27a (Tolmachova, Anders et al. 
2006). We were able to observe a shift in the cytosolic fraction of Rab27a protein which 
showed that Rab27a was able to be correctly prenylated in the RPE cells of these mice 
following the subretinal injection of pCAR-REP1 plasmid. Hence a partial phenotypic rescue 
in the RPE cells of the CHMnull/WT mice was observed. While these results in vitro as well as  
in vivo are extremely promising, many reports have indicated that a subset of Rabs underlay 
the CHM phenotype or at least are responsible for its appearance (Tolmachova, Anders et 
al. 2006, Seabra 1996; Seabra, Ho et al. 1995). Interestingly, Rab27a deficiency mice (ashen 
mice) do not show signs of retinal degeneration (Gibbs, Azarian et al. 2004); hence one 
cannot rule out other Rab proteins that may be defective within these cells that have not 
been analysed. 
Despite this, as virtually no functional REP1 is produced in CHM, the presence of a low level 
of functional REP1 protein localised within the eye, could potentially prenylate enough 
critical Rab proteins within the eye, resulting in the normal function and in turn potentially 
also preventing or arresting disease development and progression. 
 
4.5.1 Future work for CHM gene therapy 
4.5.1.1 Further development of the current construct 
 
The current pREP1-S/MAR vectors created during this project can be modified by a number 
of ways. The REP1 expressing S/MAR plasmids could be modified to containing reporter 
gene such as EGFP or Luciferase which would be advantageous and allow easier detection of 
REP1 transgene levels in vivo. This could be done using a bicistronic cassette (with an 
internal ribosome entry site (IRES)) would allow translation of two proteins under the 
control of a single promoter. Hence this would enable the simple monitoring of our protein 
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of interest (REP1) through the observation of an easily detectable reporter gene either EGFP 
or Luciferase.      
It may also be interesting to explore the idea of subretinally injecting two pREP1-S/MAR 
vectors with two different tissue specific promoters for the treatment of CHM. As CHM is a 
disease primarily of photoreceptor and RPE cells, the use of tissue specific promoters for 
both these cell types could be an interesting alternative approach for CHM therapy. A 
combination of RHO or IRBP promoter alongside a VMD2 or Tyrp1 promoter would allow 
the targeting of both photoreceptor and RPE cells as shown previously (Semple-Rowland, 
Eccles et al. 2007; Bemelmans, Bonnel et al. 2005; Kachi, Oshima et al. 2005; Kachi, Esumi et 
al. 2006). Using this approach one would make formulations of both vectors and subretinally 
inject equal amounts of each vector into the subretinal space of CHM mice. This approach 
could efficiently allow transfection of both tissues in the retina. Furthermore, one would 
hypothesis that if CHM mice are treated early enough before the onset of deterioration, 
phenotypic correction may also be observed in both tissues. This could lead to the 
prevention of progressive retinal degeneration as well as the potential for the restoration of 
sight. Indeed these experiments could unravel many new and exciting therapeutic options 
that if successful in CHM mice, could also be clinically applicable to CHM patients.   
 
4.5.1.2 Improvements in transcriptional levels 
 
We have shown long-term transgene expression levels in vivo for all our S/MAR pDNA 
vectors. However upon immunohistological analysis, the spread of transgene expression 
within the retina appears to be limited primarily to the site of injection. One could utilise 
alternative approaches to improve the transcriptional levels of REP1 within the retina, 
thereby increasing the chances of profound visual rescue in these mice.  
As plasmids used for in vivo experiments are produced in E. coli, their cytidine-phosphate-
guanosine (CpG) sequences are often unmethylated, which in turn cause immune responses 
through the host defense mechanism. However, the reduction of CpG sequences on plasmid 
vectors has been shown to reduce the inflammatory responses from these vectors. 
Furthermore plasmid vectors have been shown to have significantly increase levels of 
expression in vivo while also increasing the persistence of expression (Ehrhardt, Peng et al. 
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2003; Le Hir, Gatfield et al. 2001). Therefore one could hypothesis that reducing or 
preferably removing all CpG sequences from the bacterial backbone of our pCAG-REP1 
plasmid could provide even higher REP1 transgene expression levels in the retina.  
One such approach appears to be the creation of minicircles which consist of a minimal DNA 
vector that has had all the bacterial control regions from the pDNA vector removed from it 
including the origin of replication as well as the antibiotic resistance marker. In an 
interesting study by Riu et al. minicircle plasmids with transgene under the control of the  
α 1-anti trypsin (AAT), EF1-α and UbC promoters were shown in all cases to have 
considerably higher levels of expression compared to the original plasmids with bacterial 
sequences (Riu, Chen et al. 2007). In another study minimally sized S/MAR minicircles were 
also shown to provide higher and more substantial transgene expression in vitro as well as 
in vivo (Wong, Argyros et al. 2011). These promising results demonstrate the possibility of 
creating an ideal REP1 minicircle for CHM disease. Ultimately, such a novel S/MAR minicircle 
may represent the ideal gene therapy vector for CHM therapy, as the S/MAR moiety would 
lack a bacterial backbone and one would hypothesise would provide higher and persistent 
atoxic REP1 gene expression.  
 
4.5.1.3 Further analyses in CHM mice  
 
Unfortunately due to time constraints the CHMnull/WT mice which were injected with  
pCAG-REP1 while they showed partial prenylation correction, ultimately this does not mean 
that the retinal degeneration or indeed that the sight of these mice was corrected. 
Numerous behavioural tests on these mice could help elucidate these remain unanswered 
questions. These can include the use of relatively crude tests of visual system function by 
measuring the optokinetic reflex from mice by manually scoring the reflexive head turning 
which is elicited when an animal is placed in the center of a slow turning drum (Douglas, 
Alam et al. 2005; Thaung, Arnoldet al. 2002). Furthermore detailed scanning laser 
ophthalmic (SLO) and electroretinographic (ERG) examinations could also reveal invaluable 
insights into the retinas of these injected mice as performed previously (Tolmachova, 
Anders et al. 2006). 
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Hence one can compare the progression of retinopathy within the control eye to that of the 
injected eye. While our formulations have shown been shown to successfully transfect and 
potentially rescue the RPE cells of these mice, it would also be interesting to analyse if by 
treating one cell type this would be sufficient to stop degeneration of the another cell type, 
namely the photoreceptor cells. Hence the analysis of the outer retina, including the 
separate contributions of rod and cone systems, as quantified by ERG could potentially 
prove to be an extremely interesting analysis.  
Furthermore, histological analysis of injected retinas could also provide valuable insight into 
the potential rescue of the retinal outer nuclei layer (ONL) which has been shown to 
deteriorate considerably in old CHMnull/WTmice (Tolmachova, Anders et al. 2006). 
 
4.6 Concluding remarks 
 
In this current study we have presented extremely encouraging results that show how 
naturally occurring S/MAR elements can be exploited for the efficient non-viral gene 
therapy of ocular tissue. The ability to effectively compact S/MAR vectors as well as the 
combination of utilising an effective delivery route has proven crucial to this success. We 
have shown unparalleled phenotypic correction of CHM by the pCAG-REP1 pDNA vector  
in vitro as well as in vivo. However, our results also highlight some limitations of this vector 
system. Indeed the ability to overcome these limitations could potentially pave the way to a 
successful non-viral therapeutic approach for CHM. Importantly future experiments need 
not be limited to CHM alone. Our current experiments support the use and application of 
non-viral S/MAR-mediated therapy for the treatment of numerous inherited retinal 
diseases. These including diseases affecting the RPE, as well as other areas of the eye by 
either using tissue specific promoters directed towards specific cell types such as 
photoreceptors, or by delivering S/MAR vectors to different regions of the eye such as 
ganglion cells via intravitreal injections or corneal cells via intracameral injections. 
Cumulatively at this stage in biological research, realistic improvements to S/MAR-based 
vectors will undoubtedly place these vector systems along the path of future ocular gene 
therapy. 
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